2023 Retiree Pharmacy Prescription Drug Plan (PDP) Formulary

Medicare Part D: Compass Formulary 2023

Please click here.

For Medicare Part D: Prior Authorization Criteria

Please click here.

For Medicare Part D: Step Therapy Criteria

Please click here.

For more recent information or other questions, please contact:

Retiree Pharmacy PDP

Important Message About What You Pay for Vaccines – Our plan covers most Part D vaccines at no cost to you, even if you haven't paid your deductible (if applicable). Call Member Services for more information.

Important Message About What You Pay for Insulin – You won't pay more than $35 for a one-month supply of each Part D insulin product covered by our plan, no matter what cost-sharing tier it's on, even if you haven't paid your deductible (if applicable).

For more recent information or other questions, please contact Customer Service at 1-877-461-9218.

For TTY users, 711 National Relay Service, Oct. 1 – March 31, 8 a.m. – 8 p.m. EST, seven days a week, and April 1 – Aug. 30, 8 a.m. – 8 p.m. EST, Monday – Friday.

Visit **medicare.highmark.com**.

Formulary ID: 23029 Version: 21

Updated: 12/2023

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this drug list (formulary) refers to “we,” “us,” or “our,” it means Highmark Blue Cross Blue Shield of Western New York or Highmark Blue Shield of Northeastern New York.

When it refers to “plan” or “our plan,” it means 2023 Retiree Pharmacy PDP.

This document includes a list of the drugs (formulary) for our plan which is current as of January 1, 2023. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2023, and from time to time during the year.

What is the 2023 Retiree Pharmacy PDP Formulary?

A formulary is a list of covered drugs selected by our plans in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Our plans will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at one of our plan’s network pharmacies, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the 2023 Retiree Pharmacy PDP Formulary (drug list) change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
    - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Retiree Pharmacy PDP Formulary?”

- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.

- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug or move it to a different cost-sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 31-day supply of the drug.

  - If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled "How do I request an exception to the Retiree Pharmacy PDP Formulary?"

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2023 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2023 coverage year except as described above. This means these drugs will remain available at the same cost-sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of January 1, 2023. To get updated information about the drugs covered by our plans, please contact us. Our contact information appears on the front and back cover pages. In the event of mid-year non-maintenance formulary changes, members will be notified by mail and prospective members will receive an update with this formulary. The most up-to-date formulary is available on our website, medicare.highmark.com.

How do I use the 2023 Retiree Pharmacy PDP Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 9. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, "Cardiovascular – Hypertension & Lipids." If you know what your drug is used for, look for the category name in the list that begins on page 9. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins at the end of this document. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Our plans cover both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs cost less than brand name drugs.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** Our plans require you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plans before you fill your prescriptions. If you don't get approval, our plans may not cover the drug.

- **Quantity Limits:** For certain drugs, our plans limit the amount of the drug that is covered. For example, our plans provide 31 tablets, per 31 days, per prescription for 100mg losartan. This may be in addition to a standard one-month or three-month supply.

- **Step Therapy:** In some cases, our plans require you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, our plans may not cover Drug B unless you try Drug A first. If Drug A does not work for you, our plans will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 9. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online document(s) that explain(s) our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask our plans to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the Retiree Pharmacy PDP Formulary?" on page 5 for information about how to request an exception.

What if my drug is not on the 2023 Retiree Pharmacy PDP Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Customer Service and ask if your drug is covered.

If you learn that our plan does not cover your drug, you have two options:

- You can ask Customer Service for a list of similar drugs that are covered by our plans. When you receive the list, show it to your doctor and ask your doctor to prescribe a similar drug that is covered by our plan.
- You can ask our plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the 2023 Retiree Pharmacy PDP Formulary?

You can ask our plan to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at a lower cost-sharing level if this drug is not on the specialty tier. If approved, this would lower the amount you must pay for your drug.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, our plans limit the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, our plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug or additional utilization restrictions, would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, or utilization restriction exception. **When you request a formulary or utilization restriction exception, you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan, you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first *90* days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 31-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 31-day supply of medication. After your first *31*-day supply, we will not pay for these drugs, even if you have been a member of the plan less than *90* days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

The above transition process will be implemented to accommodate you if you have an immediate need for a non-formulary drug or a drug that requires prior authorization due to a change in your level of care while you are waiting for an exception request to be processed.

For more information

For more detailed information about your plan's prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about your plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day / 7 days a week. TTY users should call 1-877-486-2048. Or visit http://www.medicare.gov.

2023 Retiree Pharmacy PDP Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by your plan. If you have trouble finding your drug in the list, turn to the Index at the end of this document.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., ABELCET) and generic drugs are listed in lowercase italics (e.g., *abacavir*).

The information in the Requirements/Limits column tells you if your plan has any special requirements for coverage of your drug.

The following is a Formulary Format Example Only:

Drug Name	Compass Drug Tier	Requirements/ Limits
Anti - Infectives		
XYZ DRUG	NF	QL- 28

Table of Contents

Anti - Infectives 5
Antineoplastic / Immunosuppressant Drugs 17
Autonomic / Cns Drugs, Neurology / Psych 26
Cardiovascular, Hypertension / Lipids 57
Dermatologicals/Topical Therapy 69
Diagnostics / Miscellaneous Agents 78
Ear, Nose / Throat Medications 81
Endocrine/Diabetes 82
Gastroenterology 90
Immunology, Vaccines / Biotechnology 96
Miscellaneous Supplies 100
Musculoskeletal / Rheumatology 100
Obstetrics / Gynecology 103
Ophthalmology 110
Respiratory And Allergy 113
Urologicals 119
Vitamins, Hematinics / Electrolytes 121

List of Abbreviations

T1: Cost-Sharing Tier 1 includes preferred generic drugs. This is the lowest cost-sharing tier.

T2: Cost-Sharing Tier 2 includes generic drugs.

T3: Cost-Sharing Tier 3 includes preferred brand name drugs and may include some single-sourced drugs (those generic drugs made by a single manufacturer).

T4: Cost-Sharing Tier 4 includes non-preferred brand name drugs and may include some single-sourced generic drugs (those generic drugs made by a single manufacturer).

T5: Cost-Sharing Tier 5 includes specialty drugs. This is the highest cost-sharing tier.

LA: Limited access

PA: Prior authorization required

PA-BvD: This drug may be covered under Medicare part B or D depending on the circumstance. Information may need to be submitted describing the use and setting of the drug to make the determination.

PA-NS: Prior authorization required for new starts only

QL: Quantity limit applies. The quantity limit is noted for each drug. For example, if the quantity limit is QL (90 EA per 180 days), the quantity limit would be 90 units per 180-day supply.

ST: Step therapy applies

ST-NS: Step therapy applies to new starts only

Below is a list of drug name formatting patterns that may appear in the following pages.

List of Patterns

lowercase italics: Generic drugs

UPPERCASE BOLD: Brand name drugs

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
Anti - Infectives		
abacavir	T2	
abacavir-lamivudine	T3	
ABELCET	T4	PA-BvD
acyclovir oral capsule	T2	
acyclovir oral suspension 200 mg/5 ml	T2	
acyclovir oral tablet	T2	
acyclovir sodium intravenous solution	T4	PA-BvD
adefovir	T4	
AEMCOLO	T4	QL (12 EA per 3 days)
albendazole	T5	
amantadine hcl oral capsule	T2	QL (124 EA per 31 days)
amantadine hcl oral solution	T2	
amantadine hcl oral tablet	T2	
AMBISOME	T5	PA-BvD
amikacin injection solution 500 mg/2 ml	T4	
amoxicillin oral capsule	T2	
amoxicillin oral suspension for reconstitution	T2	
amoxicillin oral tablet	T2	
amoxicillin oral tablet,chewable 125 mg, 250 mg	T2	
amoxicillin-pot clavulanate oral suspension for reconstitution	T2	
amoxicillin-pot clavulanate oral tablet	T2	
amoxicillin-pot clavulanate oral tablet extended release 12 hr	T4	
amoxicillin-pot clavulanate oral tablet,chewable	T2	
amphotericin b	T4	PA-BvD
amphotericin b liposome	T5	PA-BvD
ampicillin oral capsule 500 mg	T2	
ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg	T4	
ampicillin-sulbactam injection	T4	
ANCOBON	T5	
APTIVUS	T5	
ARIKAYCE	T5	PA
atazanavir	T4	
atovaquone	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
atovaquone-proguanil	T2	
AUGMENTIN ES-600	T4	
AUGMENTIN ORAL SUSPENSION FOR RECONSTITUTION 125-31.25 MG/5 ML	T4	
AVYCAZ	T5	
AZACTAM	T4	
azithromycin intravenous	T4	
azithromycin oral	T2	
aztreonam	T4	
BACTRIM	T4	
BACTRIM DS	T4	
BARACLUDE	T5	
BAXDELA	T5	
benznidazole	T3	PA
BETHKIS	T5	PA
BICILLIN C-R	T3	
BICILLIN L-A	T4	
BIKTARVY	T5	QL (31 EA per 31 days)
BILTRICIDE	T4	
CANCIDAS	T5	
caspofungin intravenous recon soln 50 mg	T5	
caspofungin intravenous recon soln 70 mg	T4	
CAYSTON	T5	PA
cefaclor oral capsule	T2	
cefaclor oral suspension for reconstitution 250 mg/5 ml	T2	
cefaclor oral tablet extended release 12 hr	T4	
cefadroxil oral capsule	T2	
cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml	T2	
cefadroxil oral tablet	T2	
cefazolin injection recon soln 1 gram, 10 gram, 500 mg	T4	
cefdinir	T2	
cefepime injection	T4	
cefixime	T4	
cefotetan injection	T4	
cefoxitin	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
cefpodoxime	T2	
cefprozil	T2	
ceftazidime	T4	
ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg	T4	
cefuroxime axetil oral tablet	T2	
cefuroxime sodium injection recon soln 750 mg	T4	
cefuroxime sodium intravenous recon soln 1.5 gram	T4	
cephalexin oral capsule 250 mg, 500 mg	T2	
cephalexin oral capsule 750 mg	T4	
cephalexin oral suspension for reconstitution	T2	
cephalexin oral tablet	T4	
chloroquine phosphate oral tablet 250 mg	T2	QL (50 EA per 30 days)
chloroquine phosphate oral tablet 500 mg	T2	QL (25 EA per 30 days)
CIMDUO	T5	QL (31 EA per 31 days)
CIPRO ORAL SUSPENSION,MICROCAPSULE RECON	T4	
CIPRO ORAL TABLET 250 MG, 500 MG	T4	
ciprofloxacin hcl oral tablet 100 mg, 750 mg	T2	
ciprofloxacin hcl oral tablet 250 mg, 500 mg	T1	
ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml	T4	
clarithromycin	T2	
CLEOCIN HCL	T4	
CLEOCIN INJECTION	T4	
CLEOCIN PEDIATRIC	T4	
clindamycin hcl	T2	
clindamycin in 5 % dextrose	T4	
CLINDAMYCIN PEDIATRIC	T2	
clindamycin phosphate injection	T4	
clindamycin phosphate intravenous	T4	
clotrimazole mucous membrane	T2	
COARTEM	T4	
colistin (colistimethate na)	T4	
COMBIVIR	T5	
COMPLERA	T5	
CRESEMBA ORAL	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
CUBICIN RF	T5	
DALVANCE	T5	
dapsone oral	T3	
daptomycin intravenous recon soln 350 mg	T5	
daptomycin intravenous recon soln 500 mg	T4	
darunavir ethanolate	T5	
DELSTRIGO	T5	QL (31 EA per 31 days)
demeclocycline	T4	
DESCOVY	T5	QL (31 EA per 31 days)
dicloxacillin	T2	
DIFICID ORAL SUSPENSION FOR RECONSTITUTION	T5	QL (136 ML per 12 days)
DIFICID ORAL TABLET	T5	QL (20 EA per 10 days)
DIFLUCAN ORAL SUSPENSION FOR RECONSTITUTION	T4	
DIFLUCAN ORAL TABLET 100 MG, 150 MG, 200 MG	T4	
DORYX MPC ORAL TABLET,DELAYED RELEASE (DR/EC) 120 MG	T4	
DORYX MPC ORAL TABLET,DELAYED RELEASE (DR/EC) 60 MG	T5	
DORYX ORAL TABLET,DELAYED RELEASE (DR/EC) 50 MG	T4	
DOVATO	T5	QL (31 EA per 31 days)
DOXY-100	T4	
doxycycline hyclate oral capsule	T2	
doxycycline hyclate oral tablet 100 mg, 150 mg, 50 mg, 75 mg	T4	
doxycycline hyclate oral tablet 20 mg	T2	
doxycycline hyclate oral tablet,delayed release (dr/ec)	T4	
doxycycline monohydrate oral capsule 100 mg, 50 mg	T2	
doxycycline monohydrate oral capsule 150 mg, 75 mg	T4	
doxycycline monohydrate oral capsule,ir - delay rel,biphase	T4	
doxycycline monohydrate oral suspension for reconstitution	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
doxycycline monohydrate oral tablet 100 mg, 50 mg, 75 mg	T2	
doxycycline monohydrate oral tablet 150 mg	T4	
E.E.S. 400 ORAL TABLET	T4	
E.E.S. GRANULES	T4	
EDURANT	T5	
efavirenz oral capsule 200 mg	T4	
efavirenz oral capsule 50 mg	T2	
efavirenz oral tablet	T4	
efavirenz-emtricitabin-tenofov	T5	
efavirenz-lamivu-tenofov disop	T5	QL (31 EA per 31 days)
emtricitabine	T2	
emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg	T5	
emtricitabine-tenofovir (tdf) oral tablet 200-300 mg	T4	
EMTRIVA ORAL CAPSULE	T4	
EMTRIVA ORAL SOLUTION	T3	
EMVERM	T5	
entecavir	T4	
EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG	T5	PA; QL (28 EA per 28 days)
EPCLUSA ORAL PELLETS IN PACKET 200-50 MG	T5	PA; QL (56 EA per 28 days)
EPCLUSA ORAL TABLET	T5	PA; QL (28 EA per 28 days)
EPIVIR	T4	
EPZICOM	T5	
ERAXIS(WATER DILUENT) INTRAVENOUS RECON SOLN 100 MG	T5	
ERAXIS(WATER DILUENT) INTRAVENOUS RECON SOLN 50 MG	T4	
ertapenem	T4	
ERYPED 200	T4	
ERYPED 400	T4	
ERY-TAB	T4	
ERYTHROCIN (AS STEARATE) ORAL TABLET 250 MG	T4	
ERYTHROCIN INTRAVENOUS RECON SOLN 500 MG	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
erythromycin ethylsuccinate oral suspension for reconstitution	T4	
erythromycin ethylsuccinate oral tablet	T4	
erythromycin oral	T4	
ethambutol	T2	
etravirine	T5	
EVOTAZ	T5	
famciclovir	T2	
FIRVANQ	T4	
FLAGYL ORAL CAPSULE	T4	
fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml	T4	
fluconazole oral suspension for reconstitution	T3	
fluconazole oral tablet	T2	
flucytosine	T5	
fosamprenavir	T5	
fosfomycin tromethamine	T4	
FUZEON SUBCUTANEOUS RECON SOLN	T5	
gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml	T4	
gentamicin injection solution 40 mg/ml	T4	
GENVOYA	T5	
griseofulvin microsize	T4	
griseofulvin ultramicrosize	T4	
HARVONI ORAL PELLETS IN PACKET	T5	PA; QL (28 EA per 28 days)
HARVONI ORAL TABLET 90-400 MG	T5	PA; QL (28 EA per 28 days)
HIPREX	T4	
HUMATIN	T4	
hydroxychloroquine oral tablet 100 mg	T4	QL (93 EA per 31 days)
hydroxychloroquine oral tablet 200 mg	T2	QL (93 EA per 31 days)
hydroxychloroquine oral tablet 300 mg	T4	QL (62 EA per 31 days)
hydroxychloroquine oral tablet 400 mg	T4	QL (31 EA per 31 days)
imipenem-cilastatin	T4	
IMPAVIDO	T5	
INTELENCE ORAL TABLET 100 MG, 200 MG	T5	
INTELENCE ORAL TABLET 25 MG	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
INVANZ INJECTION	T4	
ISENTRESS HD	T5	
ISENTRESS ORAL POWDER IN PACKET	T5	
ISENTRESS ORAL TABLET	T5	
ISENTRESS ORAL TABLET,CHEWABLE 100 MG	T5	
ISENTRESS ORAL TABLET,CHEWABLE 25 MG	T3	
isoniazid oral	T2	
itraconazole	T4	PA
ivermectin oral	T2	PA
JULUCA	T5	
KALETRA ORAL SOLUTION	T5	
KALETRA ORAL TABLET 100-25 MG	T4	
KALETRA ORAL TABLET 200-50 MG	T5	
ketoconazole oral	T2	
KITABIS PAK	T4	PA
KRINTAFEL	T4	
lamivudine	T3	
lamivudine-zidovudine	T3	
LAMPIT	T4	PA
ledipasvir-sofosbuvir	T5	PA; QL (28 EA per 28 days)
levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml	T3	
levofloxacin oral	T2	
LEXIVA ORAL SUSPENSION	T4	
LEXIVA ORAL TABLET	T5	
linezolid in dextrose 5%	T4	
linezolid oral suspension for reconstitution	T5	
linezolid oral tablet	T4	
LIVTENCITY	T5	PA; QL (124 EA per 31 days)
lopinavir-ritonavir oral solution	T4	
lopinavir-ritonavir oral tablet 100-25 mg	T3	
lopinavir-ritonavir oral tablet 200-50 mg	T5	
MACROBID	T4	QL (90 EA per 365 days)
MACRODANTIN ORAL CAPSULE 100 MG	T4	QL (90 EA per 365 days)
MACRODANTIN ORAL CAPSULE 25 MG	T4	QL (360 EA per 365 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
MACRODANTIN ORAL CAPSULE 50 MG	T4	QL (180 EA per 365 days)
MALARONE	T4	
MALARONE PEDIATRIC	T4	
maraviroc	T5	
MAVYRET ORAL PELLETS IN PACKET	T5	PA; QL (140 EA per 28 days)
MAVYRET ORAL TABLET	T5	PA; QL (84 EA per 28 days)
mefloquine	T2	
MEPRON	T5	
meropenem intravenous recon soln 1 gram, 500 mg	T4	
methenamine hippurate	T2	
metronidazole in nacl (iso-os)	T4	
metronidazole oral capsule	T4	
metronidazole oral tablet	T2	
micafungin	T5	
minocycline oral capsule	T2	
minocycline oral tablet	T4	
minocycline oral tablet extended release 24 hr	T4	
MINOLIRA ER	T4	
moxifloxacin oral	T2	
moxifloxacin-sod.chloride(iso)	T4	
MYAMBUTOL ORAL TABLET 400 MG	T4	
MYCAMINE INTRAVENOUS RECON SOLN 50 MG	T5	
MYCOBUTIN	T4	
nafcillin injection recon soln 1 gram, 2 gram	T4	
nafcillin injection recon soln 10 gram	T5	
NEBUPENT	T4	PA-BvD; QL (1 EA per 28 days)
neomycin	T2	
nevirapine oral suspension	T4	
nevirapine oral tablet	T3	
nevirapine oral tablet extended release 24 hr 400 mg	T4	
nitazoxanide	T5	
nitrofurantoin macrocrystal oral capsule 100 mg	T3	QL (90 EA per 365 days)
nitrofurantoin macrocrystal oral capsule 25 mg	T4	QL (360 EA per 365 days)
nitrofurantoin macrocrystal oral capsule 50 mg	T3	QL (180 EA per 365 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
nitrofurantoin monohyd/m-cryst	T3	QL (90 EA per 365 days)
nitrofurantoin oral suspension 25 mg/5 ml	T5	QL (1800 ML per 365 days)
NORVIR ORAL POWDER IN PACKET	T4	
NORVIR ORAL TABLET	T4	
NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON	T5	QL (32 EA per 31 days)
NOXAFIL ORAL SUSPENSION	T5	
NOXAFIL ORAL TABLET,DELAYED RELEASE (DR/EC)	T5	
NUZYRA	T5	
nystatin oral	T2	
ODEFSEY	T5	QL (31 EA per 31 days)
ofloxacin oral tablet 300 mg, 400 mg	T4	
ORACEA	T4	
oseltamivir oral capsule 30 mg	T2	QL (170 EA per 365 days)
oseltamivir oral capsule 45 mg, 75 mg	T2	QL (90 EA per 365 days)
oseltamivir oral suspension for reconstitution	T3	QL (1080 ML per 365 days)
oxacillin in dextrose(iso-osm)	T4	
oxacillin injection	T4	
paromomycin	T4	
penicillin g pot in dextrose intravenous piggyback 2 million unit/50 ml, 3 million unit/50 ml	T4	
penicillin g potassium injection recon soln 20 million unit	T4	
penicillin g sodium	T5	
penicillin v potassium	T2	
PENTAM	T4	
pentamidine inhalation	T4	PA-BvD; QL (1 EA per 28 days)
pentamidine injection	T4	
PIFELTRO	T5	QL (62 EA per 31 days)
piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram	T4	
PLAQUENIL	T4	QL (93 EA per 31 days)
polymyxin b sulfate	T4	
posaconazole oral	T5	
praziquantel	T4	
pretomanid	T4	PA; QL (31 EA per 31 days)
PREVYMIS ORAL	T5	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PREZCOBIX	T5	
PREZISTA ORAL SUSPENSION	T5	
PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG, 800 MG	T5	
PRIFTIN	T3	
primaquine	T3	
PRIMAXIN IV INTRAVENOUS RECON SOLN 500 MG	T4	
pyrazinamide	T4	
pyrimethamine	T5	PA
QUALAQUIN	T4	PA; QL (42 EA per 28 days)
quinine sulfate	T4	PA; QL (42 EA per 28 days)
RELENZA DISKHALER	T4	
RETROVIR ORAL CAPSULE	T4	
RETROVIR ORAL SYRUP	T4	
REYATAZ ORAL CAPSULE 200 MG, 300 MG	T5	
REYATAZ ORAL POWDER IN PACKET	T5	
ribavirin oral capsule	T3	
ribavirin oral tablet 200 mg	T3	
rifabutin	T4	
rifampin intravenous	T4	
rifampin oral	T3	
rimantadine	T2	
ritonavir	T3	
RUKOBIA	T5	QL (62 EA per 31 days)
SELZENTRY ORAL SOLUTION	T5	
SELZENTRY ORAL TABLET 150 MG, 300 MG, 75 MG	T5	
SELZENTRY ORAL TABLET 25 MG	T4	
SEYSARA	T5	
SIRTURO	T5	
SITAVIG	T4	
SIVEXTRO INTRAVENOUS	T5	
SIVEXTRO ORAL	T5	QL (6 EA per 31 days)
sofosbuvir-velpatasvir	T5	PA; QL (28 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
SOLODYN ORAL TABLET EXTENDED RELEASE 24 HR 105 MG, 115 MG, 55 MG, 65 MG, 80 MG	T4	
SOLOSEC	T4	
SOVALDI	T5	PA; QL (28 EA per 28 days)
SPORANOX	T4	PA
streptomycin	T5	
STRIBILD	T5	
STROMECTOL	T4	PA
sulfadiazine	T4	
sulfamethoxazole-trimethoprim oral suspension	T2	
sulfamethoxazole-trimethoprim oral tablet	T1	
SUNLENCA ORAL	T5	
SUPRAX ORAL CAPSULE	T4	
SUPRAX ORAL SUSPENSION FOR RECONSTITUTION 200 MG/5 ML, 500 MG/5 ML	T4	
SUPRAX ORAL TABLET,CHEWABLE	T4	
SYMFI	T5	QL (31 EA per 31 days)
SYMFI LO	T5	QL (31 EA per 31 days)
SYMTUZA	T5	QL (31 EA per 31 days)
TAMIFLU ORAL CAPSULE 30 MG	T4	QL (170 EA per 365 days)
TAMIFLU ORAL CAPSULE 45 MG, 75 MG	T4	QL (90 EA per 365 days)
TAMIFLU ORAL SUSPENSION FOR RECONSTITUTION	T4	QL (1080 ML per 365 days)
TARGADOX	T4	
TAZICEF INJECTION	T4	
TEFLARO	T5	
tenofovir disoproxil fumarate	T3	
terbinafine hcl oral	T2	QL (90 EA per 180 days)
tetracycline	T4	
tigecycline	T5	
tinidazole	T2	
TIVICAY ORAL TABLET 10 MG	T4	
TIVICAY ORAL TABLET 25 MG, 50 MG	T5	
TIVICAY PD	T5	
TOBI	T5	PA
TOBI PODHALER	T5	PA; QL (224 EA per 56 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
tobramycin in 0.225 % nacl	T5	PA
tobramycin inhalation	T5	PA
tobramycin sulfate injection solution	T4	
TOLSURA	T5	PA; QL (130 EA per 31 days)
TRECATOR	T4	
trimethoprim	T2	
TRIUMEQ	T5	
TRIUMEQ PD	T5	QL (186 EA per 31 days)
TRIZIVIR	T5	
TRUVADA	T5	
TYBOST	T4	
TYGACIL	T5	
UNASYN INJECTION RECON SOLN 15 GRAM, 3 GRAM	T4	
VABOMERE	T4	
valacyclovir	T2	
VALCYTE	T5	
valganciclovir oral recon soln	T5	
valganciclovir oral tablet	T3	
VALTREX	T4	
VANCOCIN ORAL CAPSULE 125 MG	T4	PA; QL (124 EA per 31 days)
VANCOCIN ORAL CAPSULE 250 MG	T4	PA; QL (248 EA per 31 days)
vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg	T4	
vancomycin oral capsule 125 mg	T4	PA; QL (124 EA per 31 days)
vancomycin oral capsule 250 mg	T4	PA; QL (248 EA per 31 days)
vancomycin oral recon soln	T4	
VEMLIDY	T5	QL (31 EA per 31 days)
VFEND IV	T4	PA
VFEND ORAL SUSPENSION FOR RECONSTITUTION	T5	
VFEND ORAL TABLET	T4	
VIBRAMYCIN (CALCIUM)	T3	
VIBRAMYCIN (MONO)	T4	
VIBRAMYCIN ORAL CAPSULE 100 MG	T4	
VIRACEPT ORAL TABLET	T5	
VIREAD	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
VIVJOA	T4	PA; QL (18 EA per 84 days)
voriconazole intravenous	T5	PA
voriconazole oral suspension for reconstitution	T5	
voriconazole oral tablet	T4	
VOSEVI	T5	PA; QL (28 EA per 28 days)
XENLETA ORAL	T5	
XIFAXAN ORAL TABLET 200 MG	T5	QL (27 EA per 365 days)
XIFAXAN ORAL TABLET 550 MG	T5	PA; QL (62 EA per 31 days)
XIMINO	T4	
XOFLUZA ORAL TABLET 40 MG, 80 MG	T3	QL (9 EA per 365 days)
ZEMDRI	T5	
ZEPATIER	T5	PA; QL (28 EA per 28 days)
ZERBAXA	T5	
ZIAGEN	T4	
zidovudine	T2	
ZITHROMAX INTRAVENOUS	T4	
ZITHROMAX ORAL PACKET	T4	
ZITHROMAX ORAL SUSPENSION FOR RECONSTITUTION	T4	
ZITHROMAX ORAL TABLET 250 MG, 500 MG	T4	
ZITHROMAX TRI-PAK	T4	
ZITHROMAX Z-PAK	T4	
ZOSYN IN DEXTROSE (ISO-OSM) INTRAVENOUS PIGGYBACK 2.25 GRAM/50 ML	T4	
ZYVOX INTRAVENOUS PIGGYBACK 600 MG/300 ML	T4	
ZYVOX ORAL	T5	
Antineoplastic / Immunosuppressant Drugs		
abiraterone oral tablet 250 mg	T5	PA-NS; QL (124 EA per 31 days)
abiraterone oral tablet 500 mg	T5	PA-NS; QL (62 EA per 31 days)
AFINITOR	T5	PA-NS; QL (31 EA per 31 days)
AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 5 MG	T5	PA-NS; QL (62 EA per 31 days)
AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 3 MG	T5	PA-NS; QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ALECENSA	T5	PA-NS; QL (248 EA per 31 days)
ALUNBRIG ORAL TABLET 180 MG, 90 MG	T5	PA-NS; QL (31 EA per 31 days)
ALUNBRIG ORAL TABLET 30 MG	T5	PA-NS; QL (186 EA per 31 days)
ALUNBRIG ORAL TABLETS,DOSE PACK	T5	PA-NS; QL (60 EA per 365 days)
anastrozole	T2	
ARIMIDEX	T5	
AROMASIN	T5	
ASTAGRAF XL	T4	PA-BvD
AYVAKIT	T5	PA-NS; QL (31 EA per 31 days)
AZASAN	T4	PA-BvD
azathioprine oral tablet 100 mg, 75 mg	T4	PA-BvD
azathioprine oral tablet 50 mg	T2	PA-BvD
BALVERSA	T5	PA-NS
bexarotene oral	T5	PA-NS
bexarotene topical	T5	PA-NS; QL (60 GM per 28 days)
bicalutamide	T2	
BOSULIF ORAL TABLET 100 MG	T5	PA-NS; QL (93 EA per 31 days)
BOSULIF ORAL TABLET 400 MG, 500 MG	T5	PA-NS; QL (31 EA per 31 days)
BRAFTOVI ORAL CAPSULE 75 MG	T5	PA-NS; QL (186 EA per 31 days)
BRUKINSA	T5	PA-NS; QL (124 EA per 31 days)
CABOMETYX	T5	PA-NS; QL (31 EA per 31 days)
CALQUENCE	T5	PA-NS; QL (62 EA per 31 days)
CALQUENCE (ACALABRUTINIB MAL)	T5	PA-NS; QL (62 EA per 31 days)
CAPRELSA ORAL TABLET 100 MG	T5	PA-NS; QL (62 EA per 31 days)
CAPRELSA ORAL TABLET 300 MG	T5	PA-NS; QL (31 EA per 31 days)
CASODEX	T4	
CELLCEPT ORAL CAPSULE	T4	PA-BvD
CELLCEPT ORAL SUSPENSION FOR RECONSTITUTION	T5	PA-BvD
CELLCEPT ORAL TABLET	T5	PA-BvD
COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1)	T5	PA-NS; QL (56 EA per 28 days)
COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3)	T5	PA-NS; QL (112 EA per 28 days)
COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY)	T5	PA-NS; QL (84 EA per 28 days)
COPIKTRA	T5	PA-NS; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
COTELLIC	T5	PA-NS; LA; QL (63 EA per 28 days)
cyclophosphamide oral	T3	PA-BvD
cyclosporine modified	T2	PA-BvD
cyclosporine oral capsule	T2	PA-BvD
DAURISMO ORAL TABLET 100 MG	T5	PA-NS; QL (31 EA per 31 days)
DAURISMO ORAL TABLET 25 MG	T5	PA-NS; QL (62 EA per 31 days)
DROXIA	T3	
ELIGARD	T4	
ELIGARD (3 MONTH)	T4	
ELIGARD (4 MONTH)	T4	
ELIGARD (6 MONTH)	T4	
EMCYT	T5	
ENSPRYNG	T5	PA; QL (1 ML per 28 days)
ENVARSUS XR	T4	PA-BvD
ERIVEDGE	T5	PA-NS; QL (31 EA per 31 days)
ERLEADA ORAL TABLET 240 MG	T5	PA-NS; QL (31 EA per 31 days)
ERLEADA ORAL TABLET 60 MG	T5	PA-NS; QL (124 EA per 31 days)
erlotinib	T5	PA-NS; QL (31 EA per 31 days)
everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 7.5 mg	T5	PA-NS; QL (31 EA per 31 days)
everolimus (antineoplastic) oral tablet 5 mg	T5	PA-NS; QL (62 EA per 31 days)
everolimus (antineoplastic) oral tablet for suspension 2 mg, 5 mg	T5	PA-NS; QL (62 EA per 31 days)
everolimus (antineoplastic) oral tablet for suspension 3 mg	T5	PA-NS; QL (93 EA per 31 days)
everolimus (immunosuppressive)	T5	PA-BvD
exemestane	T4	
EXKIVITY	T5	PA-NS; QL (124 EA per 31 days)
FARESTON	T5	
FEMARA	T4	
FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG	T5	
FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG	T4	
FOTIVDA	T5	PA-NS; QL (21 EA per 28 days)
GAVRETO	T5	PA-NS; QL (124 EA per 31 days)
gefitinib	T5	PA-NS; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
GENGRAF	T2	PA-BvD
GILOTRIF	T5	PA-NS; QL (31 EA per 31 days)
GLEEVEC ORAL TABLET 100 MG	T5	PA-NS; QL (93 EA per 31 days)
GLEEVEC ORAL TABLET 400 MG	T5	PA-NS; QL (62 EA per 31 days)
GLEOSTINE ORAL CAPSULE 10 MG, 40 MG	T4	PA-NS
GLEOSTINE ORAL CAPSULE 100 MG	T5	PA-NS
HYDREA	T4	
hydroxyurea	T2	
IBRANCE	T5	PA-NS; QL (21 EA per 28 days)
ICLUSIG	T5	PA-NS; QL (31 EA per 31 days)
IDHIFA ORAL TABLET 100 MG	T5	PA-NS; QL (31 EA per 31 days)
IDHIFA ORAL TABLET 50 MG	T5	PA-NS; QL (62 EA per 31 days)
imatinib oral tablet 100 mg	T5	PA-NS; QL (93 EA per 31 days)
imatinib oral tablet 400 mg	T5	PA-NS; QL (62 EA per 31 days)
IMBRUVICA ORAL CAPSULE 140 MG	T5	PA-NS; QL (124 EA per 31 days)
IMBRUVICA ORAL CAPSULE 70 MG	T5	PA-NS; QL (31 EA per 31 days)
IMBRUVICA ORAL SUSPENSION	T5	PA-NS; QL (216 ML per 25 days)
IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG	T5	PA-NS; QL (31 EA per 31 days)
IMURAN	T4	PA-BvD
INLYTA	T5	PA-NS; QL (124 EA per 31 days)
INQOVI	T5	PA-NS; QL (5 EA per 28 days)
INREBIC	T5	PA-NS; QL (124 EA per 31 days)
IRESSA	T5	PA-NS; QL (31 EA per 31 days)
JAKAFI	T5	PA-NS; QL (62 EA per 31 days)
JAYPIRCA ORAL TABLET 100 MG	T5	PA-NS; QL (62 EA per 31 days)
JAYPIRCA ORAL TABLET 50 MG	T5	PA-NS; QL (31 EA per 31 days)
KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG	T5	PA-NS; QL (49 EA per 28 days)
KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG	T5	PA-NS; QL (70 EA per 28 days)
KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG	T5	PA-NS; QL (91 EA per 28 days)
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1)	T5	PA-NS; QL (21 EA per 28 days)
KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2)	T5	PA-NS; QL (42 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3)	T5	PA-NS; QL (63 EA per 28 days)
KLISYRI	T5	PA
KOSELUGO ORAL CAPSULE 10 MG	T5	PA-NS; QL (279 EA per 31 days)
KOSELUGO ORAL CAPSULE 25 MG	T5	PA-NS; QL (124 EA per 31 days)
KRAZATI	T5	PA-NS; QL (186 EA per 31 days)
lapatinib	T5	PA-NS; QL (186 EA per 31 days)
lenalidomide	T5	PA-NS; QL (21 EA per 28 days)
LENVIMA	T5	PA-NS
letrozole	T2	
leucovorin calcium oral	T3	
LEUKERAN	T5	
leuprolide (3 month)	T4	ST
leuprolide subcutaneous kit	T5	
LONSURF	T5	PA-NS
LORBRENA ORAL TABLET 100 MG	T5	PA-NS; QL (31 EA per 31 days)
LORBRENA ORAL TABLET 25 MG	T5	PA-NS; QL (93 EA per 31 days)
LUMAKRAS ORAL TABLET 120 MG	T5	PA-NS; QL (248 EA per 31 days)
LUMAKRAS ORAL TABLET 320 MG	T5	PA-NS; QL (93 EA per 31 days)
LUPKYNIS	T5	PA; QL (186 EA per 31 days)
LUPRON DEPOT	T5	ST
LUPRON DEPOT (3 MONTH)	T5	ST
LUPRON DEPOT (4 MONTH)	T5	ST
LUPRON DEPOT (6 MONTH)	T5	ST
LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG	T5	PA
LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED)	T5	PA
LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT	T5	PA
LYNPARZA	T5	PA-NS; QL (124 EA per 31 days)
LYSODREN	T3	
LYTGOBI ORAL TABLET 4 MG	T5	PA-NS; QL (93 EA per 31 days)
LYTGOBI ORAL TABLET 4 MG (4X 4 MG TB)	T5	PA-NS; QL (124 EA per 31 days)
LYTGOBI ORAL TABLET 4 MG (5X 4 MG TB)	T5	PA-NS; QL (155 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
MATULANE	T5	
megestrol oral suspension 400 mg/10 ml (40 mg/ml)	T3	PA
megestrol oral suspension 625 mg/5 ml (125 mg/ml)	T4	PA
megestrol oral tablet	T3	PA-NS
MEKINIST ORAL RECON SOLN	T5	PA-NS; QL (1260 ML per 31 days)
MEKINIST ORAL TABLET 0.5 MG	T5	PA-NS; QL (93 EA per 31 days)
MEKINIST ORAL TABLET 2 MG	T5	PA-NS; QL (31 EA per 31 days)
MEKTOVI	T5	PA-NS; QL (186 EA per 31 days)
mercaptopurine	T2	
MESNEX ORAL	T5	
methotrexate sodium	T2	PA-BvD
methotrexate sodium (pf) injection solution	T2	PA-BvD
MYCAPSSA	T5	PA; QL (124 EA per 31 days)
mycophenolate mofetil oral capsule	T3	PA-BvD
mycophenolate mofetil oral suspension for reconstitution	T5	PA-BvD
mycophenolate mofetil oral tablet	T3	PA-BvD
mycophenolate sodium	T4	PA-BvD
MYFORTIC	T4	PA-BvD
NEORAL	T4	PA-BvD
NERLYNX	T5	PA-NS; QL (186 EA per 31 days)
NEXAVAR	T5	PA-NS; QL (124 EA per 31 days)
NILANDRON	T5	
nilutamide	T5	
NINLARO	T5	PA-NS; QL (3 EA per 28 days)
NUBEQA	T5	PA-NS; QL (124 EA per 31 days)
octreotide acetate injection solution 1,000 mcg/ml, 500 mcg/ml	T5	PA
octreotide acetate injection solution 100 mcg/ml, 200 mcg/ml, 50 mcg/ml	T4	PA
ODOMZO	T5	PA-NS; LA; QL (31 EA per 31 days)
ONUREG	T5	PA-NS; QL (14 EA per 28 days)
ORGOVYX	T5	PA-NS; QL (31 EA per 31 days)
ORSERDU ORAL TABLET 345 MG	T5	PA-NS; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ORSERDU ORAL TABLET 86 MG	T5	PA-NS; QL (93 EA per 31 days)
PEMAZYRE	T5	PA-NS; QL (14 EA per 21 days)
PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1)	T5	PA-NS; QL (28 EA per 28 days)
PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)	T5	PA-NS; QL (56 EA per 28 days)
POMALYST	T5	PA-NS; QL (21 EA per 28 days)
PROGRAF ORAL CAPSULE 0.5 MG, 1 MG	T4	PA-BvD
PROGRAF ORAL CAPSULE 5 MG	T5	PA-BvD
PROGRAF ORAL GRANULES IN PACKET	T4	PA-BvD
PURIXAN	T5	
QINLOCK	T5	PA-NS; QL (93 EA per 31 days)
RAPAMUNE ORAL SOLUTION	T5	PA-BvD
RAPAMUNE ORAL TABLET 0.5 MG	T4	PA-BvD
RAPAMUNE ORAL TABLET 1 MG, 2 MG	T5	PA-BvD
RETEVMO ORAL CAPSULE 40 MG	T5	PA-NS; QL (186 EA per 31 days)
RETEVMO ORAL CAPSULE 80 MG	T5	PA-NS; QL (124 EA per 31 days)
REVLIMID	T5	PA-NS; QL (21 EA per 28 days)
REZLIDHIA	T5	PA-NS; QL (62 EA per 31 days)
REZUROCK	T5	PA; QL (62 EA per 31 days)
ROZLYTREK ORAL CAPSULE 100 MG	T5	PA-NS; QL (155 EA per 31 days)
ROZLYTREK ORAL CAPSULE 200 MG	T5	PA-NS; QL (93 EA per 31 days)
RUBRACA	T5	PA-NS; QL (124 EA per 31 days)
RYDAPT	T5	PA-NS; QL (248 EA per 31 days)
SANDIMMUNE ORAL	T4	PA-BvD
SANDOSTATIN INJECTION SOLUTION 100 MCG/ML	T5	PA
SANDOSTATIN INJECTION SOLUTION 50 MCG/ML, 500 MCG/ML	T4	PA
SCEMBLIX ORAL TABLET 20 MG	T5	PA-NS; QL (62 EA per 31 days)
SCEMBLIX ORAL TABLET 40 MG	T5	PA-NS; QL (310 EA per 31 days)
SIGNIFOR	T5	PA
SIKLOS ORAL TABLET 1,000 MG	T5	
SIKLOS ORAL TABLET 100 MG	T4	
sirolimus oral solution	T5	PA-BvD
sirolimus oral tablet	T4	PA-BvD
SOLTAMOX	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
sorafenib	T5	PA-NS; QL (124 EA per 31 days)
SPRYCEL	T5	PA-NS; QL (31 EA per 31 days)
STIVARGA	T5	PA-NS; QL (84 EA per 28 days)
sunitinib malate	T5	PA-NS; QL (31 EA per 31 days)
SUTENT	T5	PA-NS; QL (31 EA per 31 days)
SYNRIBO	T5	
TABLOID	T4	
TABRECTA	T5	PA-NS; QL (124 EA per 31 days)
tacrolimus oral	T2	PA-BvD
TAFINLAR ORAL CAPSULE	T5	PA-NS; QL (124 EA per 31 days)
TAFINLAR ORAL TABLET FOR SUSPENSION	T5	PA-NS; QL (930 EA per 31 days)
TAGRISSO	T5	PA-NS; LA; QL (31 EA per 31 days)
TALZENNA	T5	PA-NS; QL (31 EA per 31 days)
tamoxifen	T2	
TARGRETIN ORAL	T5	PA-NS
TARGRETIN TOPICAL	T5	PA-NS; QL (60 GM per 28 days)
TASIGNA	T5	PA-NS; QL (124 EA per 31 days)
TAZVERIK	T5	PA-NS; QL (248 EA per 31 days)
TEPMETKO	T5	PA-NS; QL (62 EA per 31 days)
THALOMID ORAL CAPSULE 100 MG, 150 MG, 50 MG	T5	PA-NS; QL (28 EA per 28 days)
THALOMID ORAL CAPSULE 200 MG	T5	PA-NS; QL (56 EA per 28 days)
TIBSOVO	T5	PA-NS; QL (62 EA per 31 days)
toremifene	T5	
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION	T5	ST
tretinoin (antineoplastic)	T5	
TREXALL	T4	PA-BvD
TUKYSA ORAL TABLET 150 MG	T5	PA-NS; QL (124 EA per 31 days)
TUKYSA ORAL TABLET 50 MG	T5	PA-NS; QL (248 EA per 31 days)
TURALIO ORAL CAPSULE 125 MG	T5	PA-NS; QL (124 EA per 31 days)
TYKERB	T5	PA-NS; QL (186 EA per 31 days)
VANFLYTA	T5	PA-NS; QL (62 EA per 31 days)
VENCLEXTA ORAL TABLET 10 MG	T3	PA-NS; QL (62 EA per 31 days)
VENCLEXTA ORAL TABLET 100 MG	T5	PA-NS; QL (186 EA per 31 days)
VENCLEXTA ORAL TABLET 50 MG	T5	PA-NS; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
VENCLEXTA STARTING PACK	T5	PA-NS; QL (84 EA per 365 days)
VERZENIO	T5	PA-NS; QL (62 EA per 31 days)
VIJOICE ORAL TABLET 125 MG, 50 MG	T5	PA-NS; QL (28 EA per 28 days)
VIJOICE ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1)	T5	PA-NS; QL (56 EA per 28 days)
VITRAKVI ORAL CAPSULE 100 MG	T5	PA-NS; QL (62 EA per 31 days)
VITRAKVI ORAL CAPSULE 25 MG	T5	PA-NS; QL (186 EA per 31 days)
VITRAKVI ORAL SOLUTION	T5	PA-NS; QL (310 ML per 31 days)
VIZIMPRO	T5	PA-NS; QL (31 EA per 31 days)
VONJO	T5	PA-NS; QL (124 EA per 31 days)
VOTRIENT	T5	PA-NS; QL (124 EA per 31 days)
WELIREG	T5	PA-NS; QL (93 EA per 31 days)
XALKORI	T5	PA-NS; QL (124 EA per 31 days)
XATMEP	T4	PA-BvD
XERMELO	T5	PA; QL (93 EA per 31 days)
XGEVA	T5	PA-NS
XOSPATA	T5	PA-NS; QL (124 EA per 31 days)
XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2)	T5	PA-NS; QL (8 EA per 28 days)
XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1)	T5	PA-NS; QL (4 EA per 28 days)
XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK)	T5	PA-NS; QL (24 EA per 28 days)
XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK)	T5	PA-NS; QL (32 EA per 28 days)
XTANDI ORAL CAPSULE	T5	PA-NS; QL (124 EA per 31 days)
XTANDI ORAL TABLET 40 MG	T5	PA-NS; QL (124 EA per 31 days)
XTANDI ORAL TABLET 80 MG	T5	PA-NS; QL (62 EA per 31 days)
YONSA	T5	PA-NS; QL (124 EA per 31 days)
ZEJULA ORAL CAPSULE	T5	PA-NS; QL (93 EA per 31 days)
ZEJULA ORAL TABLET	T5	PA-NS; QL (31 EA per 31 days)
ZELBORAF	T5	PA-NS; QL (248 EA per 31 days)
ZOLINZA	T5	PA-NS
ZORTRESS	T5	PA-BvD
ZYDELIG	T5	PA-NS; QL (62 EA per 31 days)
ZYKADIA	T5	PA-NS; QL (93 EA per 31 days)
ZYTIGA ORAL TABLET 250 MG	T5	PA-NS; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ZYTIGA ORAL TABLET 500 MG	T5	PA-NS; QL (62 EA per 31 days)
Autonomic / Cns Drugs, Neurology / Psych		
ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML	T5	QL (2.4 ML per 56 days)
ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 960 MG/3.2 ML	T5	QL (3.2 ML per 56 days)
ABILIFY MAINTENA	T5	QL (1 EA per 28 days)
ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET WITH SENSOR AND STRIP 15 MG, 2 MG, 20 MG, 30 MG, 5 MG	T5	PA-NS
ABILIFY MYCITE STARTER KIT ORAL TABLET WITH SENSOR, STRIP, POD 10 MG	T5	PA-NS
ABILIFY ORAL TABLET	T5	PA-NS
acetaminophen-caff-dihydrocod oral capsule	T2	PA; QL (372 EA per 31 days)
acetaminophen-codeine oral solution 120-12 mg/5 ml	T2	PA; QL (5167 ML per 31 days)
acetaminophen-codeine oral tablet	T2	PA; QL (403 EA per 31 days)
ADDERALL ORAL TABLET 20 MG	T4	ST; QL (93 EA per 31 days)
ADDERALL ORAL TABLET 5 MG, 7.5 MG	T4	ST; QL (62 EA per 31 days)
ADDERALL XR	T4	ST; QL (31 EA per 31 days)
ADLARITY	T4	PA; QL (4 EA per 28 days)
ADZENYS XR-ODT	T4	ST; QL (31 EA per 31 days)
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML	T3	PA; QL (1 ML per 28 days)
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 70 MG/ML	T3	PA; QL (2 ML per 28 days)
AJOVY AUTOINJECTOR	T3	PA; QL (1.5 ML per 28 days)
AJOVY SYRINGE	T3	PA; QL (1.5 ML per 28 days)
ALLZITAL	T4	QL (372 EA per 31 days)
almotriptan malate oral tablet 12.5 mg	T4	QL (8 EA per 28 days)
almotriptan malate oral tablet 6.25 mg	T4	QL (16 EA per 28 days)
ALPRAZOLAM INTENSOL	T4	PA
alprazolam oral tablet 0.25 mg, 0.5 mg	T4	PA; QL (93 EA per 31 days)
alprazolam oral tablet 1 mg, 2 mg	T4	PA; QL (155 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg	T4	PA; QL (31 EA per 31 days)
alprazolam oral tablet extended release 24 hr 2 mg	T4	PA; QL (155 EA per 31 days)
alprazolam oral tablet extended release 24 hr 3 mg	T4	PA; QL (93 EA per 31 days)
alprazolam oral tablet,disintegrating 0.25 mg, 0.5 mg	T4	PA; QL (93 EA per 31 days)
alprazolam oral tablet,disintegrating 1 mg, 2 mg	T4	PA; QL (155 EA per 31 days)
AMBIEN	T4	PA; QL (31 EA per 31 days)
AMBIEN CR	T4	PA; QL (31 EA per 31 days)
amitriptyline	T2	PA-NS
amitriptyline-chlordiazepoxide	T4	PA-NS
amoxapine	T3	
amphetamine sulfate	T4	PA
AMPYRA	T5	PA; QL (62 EA per 31 days)
AMRIX	T5	QL (31 EA per 31 days)
ANAFRANIL	T4	PA-NS
APLENZIN	T4	QL (31 EA per 31 days)
APOKYN	T5	PA; QL (60 ML per 30 days)
apomorphine	T5	PA; QL (60 ML per 30 days)
APTENSIO XR	T4	ST; QL (31 EA per 31 days)
APTIOM ORAL TABLET 200 MG	T5	QL (186 EA per 31 days)
APTIOM ORAL TABLET 400 MG	T5	QL (93 EA per 31 days)
APTIOM ORAL TABLET 600 MG, 800 MG	T5	QL (62 EA per 31 days)
ARICEPT	T4	
aripiprazole oral solution	T4	PA-NS
aripiprazole oral tablet	T2	PA-NS
aripiprazole oral tablet,disintegrating	T5	PA-NS
ARISTADA INITIO	T5	QL (4.8 ML per 365 days)
ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 1,064 MG/3.9 ML	T5	QL (3.9 ML per 28 days)
ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 441 MG/1.6 ML	T5	QL (1.6 ML per 28 days)
ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 662 MG/2.4 ML	T5	QL (2.4 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 882 MG/3.2 ML	T5	QL (3.2 ML per 28 days)
armodafinil	T4	PA; QL (31 EA per 31 days)
ARTHROTEC 50	T4	
ARTHROTEC 75	T4	
ASCOMP WITH CODEINE	T4	PA; QL (372 EA per 31 days)
asenapine maleate	T4	QL (62 EA per 31 days)
ATIVAN ORAL TABLET 0.5 MG	T5	QL (124 EA per 31 days)
ATIVAN ORAL TABLET 1 MG	T5	QL (186 EA per 31 days)
ATIVAN ORAL TABLET 2 MG	T5	QL (155 EA per 31 days)
atomoxetine oral capsule 10 mg, 25 mg, 40 mg	T4	QL (62 EA per 31 days)
atomoxetine oral capsule 100 mg, 60 mg, 80 mg	T4	QL (31 EA per 31 days)
atomoxetine oral capsule 18 mg	T4	QL (124 EA per 31 days)
AUBAGIO	T5	PA; QL (31 EA per 31 days)
AUSTEDO ORAL TABLET 12 MG, 6 MG	T5	PA; QL (124 EA per 31 days)
AUSTEDO ORAL TABLET 9 MG	T5	PA; QL (155 EA per 31 days)
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG	T5	PA; QL (93 EA per 31 days)
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 24 MG	T5	PA; QL (62 EA per 31 days)
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG	T5	PA; QL (217 EA per 31 days)
AUSTEDO XR TITRATION KT(WK1-4)	T5	PA; QL (84 EA per 365 days)
AUVELITY	T4	PA-NS; QL (62 EA per 31 days)
AZILECT ORAL TABLET 0.5 MG	T4	
AZILECT ORAL TABLET 1 MG	T5	
AZSTARYS	T4	ST; QL (31 EA per 31 days)
baclofen oral suspension	T4	PA; QL (496 ML per 31 days)
baclofen oral tablet	T2	
BAFIERTAM	T5	PA; QL (124 EA per 31 days)
BANZEL	T5	PA-NS
BELBUCA BUCCAL FILM 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG	T3	PA; QL (62 EA per 31 days)
BELBUCA BUCCAL FILM 750 MCG, 900 MCG	T5	PA; QL (62 EA per 31 days)
BELSOMRA	T4	ST; QL (31 EA per 31 days)
benztropine oral	T1	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
BRIVIACT ORAL SOLUTION	T5	QL (620 ML per 31 days)
BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 75 MG	T5	QL (62 EA per 31 days)
BRIVIACT ORAL TABLET 50 MG	T4	QL (62 EA per 31 days)
bromocriptine	T4	
BUPAP	T4	QL (403 EA per 31 days)
buprenorphine	T4	PA; QL (4 EA per 28 days)
buprenorphine hcl sublingual tablet 2 mg	T2	QL (93 EA per 31 days)
buprenorphine hcl sublingual tablet 8 mg	T2	QL (62 EA per 31 days)
buprenorphine-naloxone sublingual film 12-3 mg, 4-1 mg, 8-2 mg	T3	QL (62 EA per 31 days)
buprenorphine-naloxone sublingual film 2-0.5 mg	T3	QL (93 EA per 31 days)
buprenorphine-naloxone sublingual tablet	T2	QL (93 EA per 31 days)
bupropion hcl oral tablet	T1	
bupropion hcl oral tablet extended release 24 hr 150 mg	T2	QL (93 EA per 31 days)
bupropion hcl oral tablet extended release 24 hr 300 mg	T2	QL (31 EA per 31 days)
bupropion hcl oral tablet extended release 24 hr 450 mg	T4	QL (31 EA per 31 days)
bupropion hcl oral tablet sustained-release 12 hr	T2	QL (62 EA per 31 days)
buspirone	T2	
butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg	T4	PA; QL (403 EA per 31 days)
butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg	T4	PA; QL (372 EA per 31 days)
butalbital-acetaminophen oral capsule	T4	QL (403 EA per 31 days)
butalbital-acetaminophen oral tablet 50-300 mg	T4	QL (403 EA per 31 days)
butalbital-acetaminophen oral tablet 50-325 mg	T4	QL (372 EA per 31 days)
butalbital-acetaminophen-caff oral capsule 50-300-40 mg	T4	QL (403 EA per 31 days)
butalbital-acetaminophen-caff oral capsule 50-325-40 mg	T4	QL (372 EA per 31 days)
butalbital-acetaminophen-caff oral tablet	T4	QL (372 EA per 31 days)
butalbital-aspirin-caffeine oral capsule	T4	
butorphanol nasal	T2	QL (5 ML per 28 days)
BUTRANS TRANSDERMAL PATCH WEEKLY 10 MCG/HOUR, 15 MCG/HOUR, 5 MCG/HOUR, 7.5 MCG/HOUR	T4	PA; QL (4 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
BUTRANS TRANSDERMAL PATCH WEEKLY 20 MCG/HOUR	T5	PA; QL (4 EA per 28 days)
CAMBIA	T5	
CAPLYTA	T5	PA-NS; QL (31 EA per 31 days)
carbamazepine oral capsule, er multiphase 12 hr	T2	
carbamazepine oral suspension 100 mg/5 ml	T2	
carbamazepine oral tablet	T2	
carbamazepine oral tablet extended release 12 hr	T2	
carbamazepine oral tablet,chewable	T2	
CARBATROL	T4	
carbidopa	T2	
carbidopa-levodopa	T2	
carbidopa-levodopa-entacapone	T4	
carisoprodol	T4	PA
CELEBREX	T4	ST; QL (62 EA per 31 days)
celecoxib	T2	ST; QL (62 EA per 31 days)
CELEXA ORAL TABLET	T4	
CELONTIN ORAL CAPSULE 300 MG	T4	
chlordiazepoxide hcl	T4	
chlorpromazine oral	T4	
chlorzoxazone oral tablet 250 mg	T5	PA
chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg	T4	PA
citalopram oral capsule	T4	PA-NS; QL (31 EA per 31 days)
citalopram oral solution	T3	
citalopram oral tablet	T1	
clobazam oral suspension	T4	PA-NS; QL (496 ML per 31 days)
clobazam oral tablet	T3	PA-NS; QL (62 EA per 31 days)
clomipramine	T4	PA-NS
clonazepam oral tablet 0.5 mg	T2	QL (93 EA per 31 days)
clonazepam oral tablet 1 mg	T2	QL (124 EA per 31 days)
clonazepam oral tablet 2 mg	T2	QL (310 EA per 31 days)
clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg	T2	QL (93 EA per 31 days)
clonazepam oral tablet,disintegrating 1 mg	T2	QL (124 EA per 31 days)
clonazepam oral tablet,disintegrating 2 mg	T2	QL (310 EA per 31 days)
clonidine hcl oral tablet extended release 12 hr	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
clorazepate dipotassium oral tablet 15 mg	T2	QL (186 EA per 31 days)
clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg	T2	QL (93 EA per 31 days)
clozapine oral tablet 100 mg, 25 mg	T3	QL (279 EA per 31 days)
clozapine oral tablet 200 mg	T3	QL (124 EA per 31 days)
clozapine oral tablet 50 mg	T3	QL (93 EA per 31 days)
clozapine oral tablet,disintegrating 100 mg, 25 mg	T4	QL (279 EA per 31 days)
clozapine oral tablet,disintegrating 12.5 mg	T4	QL (93 EA per 31 days)
clozapine oral tablet,disintegrating 150 mg	T4	QL (186 EA per 31 days)
clozapine oral tablet,disintegrating 200 mg	T4	QL (124 EA per 31 days)
CLOZARIL ORAL TABLET 100 MG	T5	QL (279 EA per 31 days)
CLOZARIL ORAL TABLET 200 MG	T5	QL (124 EA per 31 days)
CLOZARIL ORAL TABLET 25 MG	T4	QL (279 EA per 31 days)
CLOZARIL ORAL TABLET 50 MG	T4	QL (93 EA per 31 days)
codeine sulfate	T4	PA; QL (186 EA per 31 days)
codeine-butalbital-asa-caff	T4	PA; QL (372 EA per 31 days)
COMTAN	T4	
CONCERTA	T4	ST; QL (31 EA per 31 days)
CONZIP	T4	PA; QL (30 EA per 30 days)
COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML	T5	QL (31 ML per 31 days)
COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML	T5	QL (12 ML per 28 days)
COTEMPLA XR-ODT	T4	ST; QL (62 EA per 31 days)
cyclobenzaprine oral capsule,extended release 24hr	T4	QL (31 EA per 31 days)
cyclobenzaprine oral tablet 10 mg, 7.5 mg	T4	QL (93 EA per 31 days)
cyclobenzaprine oral tablet 5 mg	T4	QL (155 EA per 31 days)
CYMBALTA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 20 MG, 60 MG	T4	QL (62 EA per 31 days)
CYMBALTA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 30 MG	T4	QL (31 EA per 31 days)
dalfampridine	T5	PA; QL (62 EA per 31 days)
DANTRIUM ORAL CAPSULE 25 MG	T4	
dantrolene oral	T2	
DAYBUE	T5	PA; QL (3600 ML per 30 days)
DAYPRO	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
DAYTRANA	T4	PA; QL (30 EA per 30 days)
DAYVIGO	T4	ST; QL (31 EA per 31 days)
DEMEROL (PF) INJECTION SYRINGE 25 MG/ML	T4	PA; QL (824 ML per 31 days)
DEMEROL INJECTION SOLUTION 50 MG/ML	T4	PA; QL (412 ML per 31 days)
DEPAKOTE	T4	
DEPAKOTE ER	T4	
DEPAKOTE SPRINKLES	T4	
desipramine	T2	
desvenlafaxine oral tablet extended release 24 hr 100 mg	T4	QL (124 EA per 31 days)
desvenlafaxine oral tablet extended release 24 hr 50 mg	T4	QL (31 EA per 31 days)
desvenlafaxine succinate	T2	QL (31 EA per 31 days)
DEXEDRINE SPANSULE ORAL CAPSULE, EXTENDED RELEASE 10 MG	T4	ST; QL (155 EA per 31 days)
DEXEDRINE SPANSULE ORAL CAPSULE, EXTENDED RELEASE 15 MG	T5	ST; QL (124 EA per 31 days)
dexmethylphenidate oral capsule,er biphasic 50-50	T2	QL (31 EA per 31 days)
dexmethylphenidate oral tablet 10 mg	T2	QL (62 EA per 31 days)
dexmethylphenidate oral tablet 2.5 mg, 5 mg	T2	QL (93 EA per 31 days)
dextroamphetamine sulfate oral capsule, extended release 10 mg	T4	QL (155 EA per 31 days)
dextroamphetamine sulfate oral capsule, extended release 15 mg	T4	QL (124 EA per 31 days)
dextroamphetamine sulfate oral capsule, extended release 5 mg	T4	QL (186 EA per 31 days)
dextroamphetamine sulfate oral solution	T4	
dextroamphetamine sulfate oral tablet 10 mg	T4	QL (186 EA per 31 days)
dextroamphetamine sulfate oral tablet 15 mg, 20 mg, 30 mg	T4	QL (62 EA per 31 days)
dextroamphetamine sulfate oral tablet 5 mg	T4	QL (341 EA per 31 days)
dextroamphetamine-amphetamine oral capsule,extended release 24hr	T4	QL (31 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 30 mg, 5 mg, 7.5 mg	T3	QL (62 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 20 mg	T3	QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
DHIVY	T4	ST
DIACOMIT ORAL CAPSULE 250 MG	T5	PA-NS; QL (341 EA per 31 days)
DIACOMIT ORAL CAPSULE 500 MG	T5	PA-NS; QL (186 EA per 31 days)
DIACOMIT ORAL POWDER IN PACKET 250 MG	T5	PA-NS; QL (341 EA per 31 days)
DIACOMIT ORAL POWDER IN PACKET 500 MG	T5	PA-NS; QL (186 EA per 31 days)
DIASTAT	T4	
DIASTAT ACUDIAL	T4	
DIAZEPAM INTENSOL	T2	QL (248 ML per 31 days)
diazepam oral solution 5 mg/5 ml (1 mg/ml)	T2	QL (1500 ML per 31 days)
diazepam oral tablet	T2	QL (124 EA per 31 days)
diazepam rectal	T4	
diclofenac epolamine	T4	PA; QL (62 EA per 31 days)
diclofenac potassium oral capsule	T5	
diclofenac potassium oral powder in packet	T4	
diclofenac potassium oral tablet 25 mg	T5	
diclofenac potassium oral tablet 50 mg	T2	
diclofenac sodium oral	T2	
diclofenac sodium topical drops	T4	QL (450 ML per 28 days)
diclofenac sodium topical gel 1 %	T3	QL (900 GM per 28 days)
diclofenac sodium topical solution in metered-dose pump	T5	QL (224 GM per 28 days)
diclofenac-misoprostol	T4	
diflunisal	T2	
dihydroergotamine nasal	T5	PA; QL (8 ML per 31 days)
DILANTIN	T3	
DILANTIN EXTENDED	T4	
DILANTIN INFATABS	T4	
DILANTIN-125	T4	
DILAUDID ORAL LIQUID	T4	PA; QL (1550 ML per 31 days)
DILAUDID ORAL TABLET	T4	PA; QL (186 EA per 31 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg (14)- 240 mg (46)	T5	PA; QL (120 EA per 365 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 240 mg	T5	PA; QL (62 EA per 31 days)
divalproex	T2	
donepezil oral tablet 10 mg, 5 mg	T1	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
donepezil oral tablet 23 mg	T4	QL (31 EA per 31 days)
donepezil oral tablet,disintegrating	T1	
doxepin oral capsule	T2	PA-NS
doxepin oral concentrate	T2	PA-NS
doxepin oral tablet	T3	PA
DUEXIS	T4	PA; QL (93 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 20 mg, 60 mg	T2	QL (62 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 30 mg	T2	QL (31 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 40 mg	T4	QL (31 EA per 31 days)
DUOPA	T5	PA-BvD
DYANAVEL XR ORAL SUSPEN, IR - ER, BIPHASIC 24HR	T4	ST; QL (248 ML per 31 days)
DYANAVEL XR ORAL TABLET, IR - ER, BIPHASIC 24HR	T4	ST; QL (31 EA per 31 days)
EDLUAR	T4	PA; QL (31 EA per 31 days)
EFFEXOR XR ORAL CAPSULE,EXTENDED RELEASE 24HR 150 MG, 37.5 MG	T4	QL (31 EA per 31 days)
EFFEXOR XR ORAL CAPSULE,EXTENDED RELEASE 24HR 75 MG	T4	QL (93 EA per 31 days)
eletriptan oral tablet 20 mg	T4	QL (12 EA per 28 days)
eletriptan oral tablet 40 mg	T4	QL (6 EA per 28 days)
EMGALITY PEN	T3	PA; QL (1 ML per 28 days)
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML	T3	PA; QL (1 ML per 28 days)
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3)	T5	PA; QL (3 ML per 28 days)
EMSAM	T5	QL (30 EA per 30 days)
ENDOCET	T3	PA; QL (372 EA per 31 days)
entacapone	T3	
EPIDIOLEX	T5	PA-NS
EPITOL	T2	
EPRONTIA	T4	PA-NS; QL (496 ML per 31 days)
EQUETRO	T4	
ergoloid	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ergotamine-caffeine	T3	PA
escitalopram oxalate oral solution	T2	QL (620 ML per 31 days)
escitalopram oxalate oral tablet 10 mg	T1	QL (45 EA per 30 days)
escitalopram oxalate oral tablet 20 mg, 5 mg	T1	QL (30 EA per 30 days)
ESGIC ORAL TABLET	T4	QL (372 EA per 31 days)
estazolam	T4	
eszopiclone	T4	PA; QL (31 EA per 31 days)
ethosuximide	T2	
etodolac	T2	
EVEKEO	T4	PA
EVEKEO ODT	T4	ST
EVRYSDI	T5	PA; QL (240 ML per 31 days)
EXELON PATCH	T4	QL (30 EA per 30 days)
FANAPT ORAL TABLET 1 MG	T4	QL (62 EA per 31 days)
FANAPT ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG	T5	QL (62 EA per 31 days)
FANAPT ORAL TABLETS,DOSE PACK	T4	QL (16 EA per 365 days)
felbamate oral suspension	T5	
felbamate oral tablet	T4	
FELBATOL ORAL TABLET	T5	
FELDENE	T4	
fenoprofen oral capsule 400 mg	T4	
fenoprofen oral tablet	T4	
fentanyl citrate buccal lozenge on a handle 1,200 mcg	T5	PA; QL (40 EA per 31 days)
fentanyl citrate buccal lozenge on a handle 1,600 mcg	T5	PA; QL (30 EA per 31 days)
fentanyl citrate buccal lozenge on a handle 200 mcg	T4	PA; QL (124 EA per 31 days)
fentanyl citrate buccal lozenge on a handle 400 mcg	T5	PA; QL (119 EA per 31 days)
fentanyl citrate buccal lozenge on a handle 600 mcg	T5	PA; QL (79 EA per 31 days)
fentanyl citrate buccal lozenge on a handle 800 mcg	T5	PA; QL (59 EA per 31 days)
fentanyl citrate buccal tablet, effervescent 100 mcg, 200 mcg	T5	PA; QL (124 EA per 31 days)
fentanyl citrate buccal tablet, effervescent 400 mcg	T5	PA; QL (119 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
fentanyl citrate buccal tablet, effervescent 600 mcg	T5	PA; QL (79 EA per 31 days)
fentanyl citrate buccal tablet, effervescent 800 mcg	T5	PA; QL (59 EA per 31 days)
fentanyl transdermal patch 72 hour 100 mcg/hr	T4	PA; QL (10 EA per 30 days)
fentanyl transdermal patch 72 hour 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour	T4	PA; QL (20 EA per 30 days)
fentanyl transdermal patch 72 hour 50 mcg/hr	T4	PA; QL (17 EA per 30 days)
fentanyl transdermal patch 72 hour 62.5 mcg/hour	T4	PA; QL (15 EA per 30 days)
fentanyl transdermal patch 72 hour 75 mcg/hr	T4	PA; QL (12 EA per 30 days)
fentanyl transdermal patch 72 hour 87.5 mcg/hour	T5	PA; QL (11 EA per 30 days)
FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG	T5	PA; QL (124 EA per 31 days)
FENTORA BUCCAL TABLET, EFFERVESCENT 400 MCG	T5	PA; QL (119 EA per 31 days)
FENTORA BUCCAL TABLET, EFFERVESCENT 600 MCG	T5	PA; QL (79 EA per 31 days)
FENTORA BUCCAL TABLET, EFFERVESCENT 800 MCG	T5	PA; QL (59 EA per 31 days)
FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK	T3	PA-NS; QL (56 EA per 365 days)
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 40 MG, 80 MG	T3	PA-NS; QL (31 EA per 31 days)
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 20 MG	T3	PA-NS; QL (93 EA per 31 days)
FEXMID	T4	QL (124 EA per 31 days)
fingolimod	T5	PA; QL (31 EA per 31 days)
FINTEPLA	T5	PA-NS; QL (360 ML per 30 days)
FIORICET	T4	QL (403 EA per 31 days)
FIORICET WITH CODEINE	T4	PA; QL (403 EA per 31 days)
FIRDAPSE	T5	PA; QL (248 EA per 31 days)
FLECTOR	T4	PA; QL (62 EA per 31 days)
FLEQSUVY	T4	PA; QL (496 ML per 31 days)
fluoxetine (pmdd)	T2	
fluoxetine oral capsule	T1	
fluoxetine oral capsule,delayed release(dr/ec)	T2	
fluoxetine oral solution	T2	
fluoxetine oral tablet 10 mg, 20 mg	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
fluoxetine oral tablet 60 mg	T4	
fluphenazine decanoate	T4	
fluphenazine hcl	T4	
flurbiprofen oral tablet 100 mg	T2	
fluvoxamine oral capsule,extended release 24hr	T4	
fluvoxamine oral tablet	T2	
FOCALIN ORAL TABLET 10 MG	T4	ST; QL (62 EA per 31 days)
FOCALIN ORAL TABLET 2.5 MG, 5 MG	T4	ST; QL (93 EA per 31 days)
FOCALIN XR	T4	ST; QL (31 EA per 31 days)
FORFIVO XL	T4	QL (31 EA per 31 days)
FROVA	T4	QL (12 EA per 28 days)
frovatriptan	T4	QL (12 EA per 28 days)
FYCOMPA ORAL SUSPENSION	T5	QL (744 ML per 31 days)
FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG	T5	QL (31 EA per 31 days)
FYCOMPA ORAL TABLET 2 MG	T4	QL (31 EA per 31 days)
gabapentin oral capsule 100 mg, 400 mg	T1	PA-NS; QL (270 EA per 30 days)
gabapentin oral capsule 300 mg	T1	PA-NS; QL (360 EA per 30 days)
gabapentin oral solution 250 mg/5 ml	T2	PA-NS; QL (2160 ML per 30 days)
gabapentin oral tablet 600 mg	T1	PA-NS; QL (180 EA per 30 days)
gabapentin oral tablet 800 mg	T1	PA-NS; QL (120 EA per 30 days)
galantamine	T3	
GEODON INTRAMUSCULAR	T4	
GEODON ORAL CAPSULE 20 MG	T4	QL (62 EA per 31 days)
GEODON ORAL CAPSULE 40 MG, 60 MG, 80 MG	T5	QL (62 EA per 31 days)
GILENYA	T5	PA; QL (31 EA per 31 days)
glatiramer subcutaneous syringe 20 mg/ml	T5	QL (31 ML per 31 days)
glatiramer subcutaneous syringe 40 mg/ml	T5	QL (12 ML per 28 days)
GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML	T5	QL (31 ML per 31 days)
GLATOPA SUBCUTANEOUS SYRINGE 40 MG/ML	T5	QL (12 ML per 28 days)
GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG	T5	PA; QL (62 EA per 31 days)
GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 68.5 MG	T5	PA; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG	T3	PA; QL (155 EA per 31 days)
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 450 MG	T4	PA; QL (31 EA per 31 days)
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 600 MG	T5	PA; QL (93 EA per 31 days)
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 750 MG, 900 MG	T4	PA; QL (62 EA per 31 days)
guanfacine oral tablet extended release 24 hr	T4	PA
HALCION ORAL TABLET 0.25 MG	T4	PA
HALDOL DECANOATE	T4	
haloperidol	T1	
haloperidol decanoate	T2	
haloperidol lactate injection	T2	
haloperidol lactate oral	T2	
HETLIOZ	T5	PA; QL (31 EA per 31 days)
HETLIOZ LQ	T5	PA; QL (158 ML per 31 days)
HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG	T4	PA; QL (90 EA per 30 days)
HORIZANT ORAL TABLET EXTENDED RELEASE 600 MG	T4	PA; QL (60 EA per 30 days)
hydrocodone bitartrate oral capsule, oral only, er 12hr	T4	PA; QL (100 EA per 31 days)
hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr 100 mg, 120 mg	T5	PA; QL (31 EA per 31 days)
hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr 20 mg, 30 mg, 40 mg, 60 mg, 80 mg	T4	PA; QL (31 EA per 31 days)
hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml	T3	PA; QL (5723 ML per 31 days)
hydrocodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg	T3	PA; QL (403 EA per 31 days)
hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg	T3	PA; QL (372 EA per 31 days)
hydrocodone-ibuprofen	T3	PA; QL (155 EA per 31 days)
hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml	T4	PA; QL (124 ML per 31 days)
hydromorphone oral liquid	T4	PA; QL (1550 ML per 31 days)
hydromorphone oral tablet	T3	PA; QL (186 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 8 mg	T4	PA; QL (62 EA per 31 days)
hydromorphone oral tablet extended release 24 hr 32 mg	T4	PA; QL (48 EA per 31 days)
HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 100 MG, 120 MG, 60 MG, 80 MG	T5	PA; QL (31 EA per 31 days)
HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 20 MG, 30 MG, 40 MG	T4	PA; QL (31 EA per 31 days)
IBU ORAL TABLET 600 MG, 800 MG	T1	
ibuprofen oral suspension	T2	
ibuprofen oral tablet 400 mg, 600 mg, 800 mg	T1	
ibuprofen-famotidine	T4	PA; QL (93 EA per 31 days)
imipramine hcl	T4	PA-NS
imipramine pamoate	T4	PA-NS
IMITREX NASAL SPRAY,NON-AEROSOL 20 MG/ACTUATION	T4	QL (8 EA per 28 days)
IMITREX NASAL SPRAY,NON-AEROSOL 5 MG/ACTUATION	T4	QL (32 EA per 28 days)
IMITREX ORAL TABLET 100 MG	T4	QL (9 EA per 28 days)
IMITREX ORAL TABLET 25 MG	T4	QL (36 EA per 28 days)
IMITREX ORAL TABLET 50 MG	T4	QL (18 EA per 28 days)
IMITREX STATDOSE PEN SUBCUTANEOUS PEN INJECTOR 4 MG/0.5 ML	T4	QL (6 ML per 28 days)
IMITREX STATDOSE REFILL SUBCUTANEOUS CARTRIDGE 6 MG/0.5 ML	T5	QL (4 ML per 28 days)
INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE	T5	PA; QL (300 EA per 30 days)
INDOCIN ORAL	T4	
INDOCIN RECTAL	T5	
indomethacin oral	T4	
indomethacin rectal suppository 50 mg	T5	
INGREZZA INITIATION PACK	T5	PA; QL (56 EA per 365 days)
INGREZZA ORAL CAPSULE 40 MG	T5	PA; QL (62 EA per 31 days)
INGREZZA ORAL CAPSULE 60 MG, 80 MG	T5	PA; QL (31 EA per 31 days)
INTUNIV ER	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML	T5	QL (3.5 ML per 180 days)
INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML	T5	QL (5 ML per 180 days)
INVEGA ORAL TABLET EXTENDED RELEASE 24HR 3 MG, 9 MG	T5	QL (31 EA per 31 days)
INVEGA ORAL TABLET EXTENDED RELEASE 24HR 6 MG	T5	QL (62 EA per 31 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML	T5	QL (0.75 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML	T5	QL (1 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML	T5	QL (1.5 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML	T3	QL (0.25 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML	T5	QL (0.5 ML per 28 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML	T5	QL (0.88 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML	T5	QL (1.32 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML	T5	QL (1.75 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML	T5	QL (2.63 ML per 84 days)
JORNAY PM	T4	ST; QL (31 EA per 31 days)
KAPVAY	T4	PA
KEPPRA ORAL	T4	
KEPPRA XR	T4	
KESIMPTA PEN	T5	PA; QL (0.4 ML per 28 days)
ketoprofen oral capsule 25 mg, 50 mg	T4	
ketoprofen oral capsule,ext rel. pellets 24 hr 200 mg	T4	
ketorolac nasal	T5	QL (5 EA per 31 days)
ketorolac oral	T4	
KEVEYIS	T5	PA; QL (124 EA per 31 days)
KLONOPIN ORAL TABLET 0.5 MG	T4	QL (93 EA per 31 days)
KLONOPIN ORAL TABLET 1 MG	T4	QL (124 EA per 31 days)
KLONOPIN ORAL TABLET 2 MG	T4	QL (310 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
KLOXXADO	T3	
lacosamide oral	T4	
LAMICTAL ODT	T4	
LAMICTAL ORAL TABLET	T4	
LAMICTAL ORAL TABLET, CHEWABLE DISPERSIBLE 25 MG, 5 MG	T4	
LAMICTAL STARTER (BLUE) KIT	T4	
LAMICTAL STARTER (GREEN) KIT	T4	
LAMICTAL STARTER (ORANGE) KIT	T4	
LAMICTAL XR	T4	
LAMICTAL XR STARTER (BLUE)	T4	
LAMICTAL XR STARTER (GREEN)	T4	
LAMICTAL XR STARTER (ORANGE)	T4	
lamotrigine oral tablet	T1	
lamotrigine oral tablet disintegrating, dose pk	T4	
lamotrigine oral tablet extended release 24hr	T4	
lamotrigine oral tablet, chewable dispersible	T2	
lamotrigine oral tablet,disintegrating	T4	
lamotrigine oral tablets,dose pack	T4	
LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG	T5	PA-NS; QL (31 EA per 31 days)
LATUDA ORAL TABLET 80 MG	T5	PA-NS; QL (62 EA per 31 days)
levetiracetam oral solution 100 mg/ml	T2	
levetiracetam oral tablet	T2	
levetiracetam oral tablet extended release 24 hr	T2	
levorphanol tartrate	T5	PA; QL (186 EA per 31 days)
LEXAPRO ORAL TABLET 10 MG	T4	QL (45 EA per 30 days)
LEXAPRO ORAL TABLET 20 MG, 5 MG	T4	QL (30 EA per 30 days)
LICART	T4	PA; QL (31 EA per 31 days)
lisdexamfetamine oral capsule	T4	ST; QL (31 EA per 31 days)
lithium carbonate	T1	
lithium citrate oral solution 8 meq/5 ml	T1	
LITHOBID	T4	
LODINE ORAL TABLET	T4	
LODOSYN	T4	
LOFENA	T5	
LORAZEPAM INTENSOL	T2	QL (155 ML per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
lorazepam oral tablet 0.5 mg	T2	QL (124 EA per 31 days)
lorazepam oral tablet 1 mg	T2	QL (186 EA per 31 days)
lorazepam oral tablet 2 mg	T2	QL (155 EA per 31 days)
LOREEV XR ORAL CAPSULE,EXTENDED RELEASE 24HR 1 MG, 3 MG	T4	QL (93 EA per 31 days)
LOREEV XR ORAL CAPSULE,EXTENDED RELEASE 24HR 1.5 MG, 2 MG	T4	QL (155 EA per 31 days)
LORZONE	T4	PA
loxapine succinate	T2	
LUCEMYRA	T5	
LUMRYZ	T5	PA; QL (31 EA per 31 days)
LUNESTA	T4	PA; QL (31 EA per 31 days)
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg	T5	PA-NS; QL (31 EA per 31 days)
lurasidone oral tablet 80 mg	T5	PA-NS; QL (62 EA per 31 days)
LYBALVI	T5	PA-NS; QL (31 EA per 31 days)
LYRICA CR	T4	PA; QL (31 EA per 31 days)
LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG	T4	PA-NS; QL (93 EA per 31 days)
LYRICA ORAL CAPSULE 225 MG, 300 MG	T4	PA-NS; QL (62 EA per 31 days)
LYRICA ORAL SOLUTION	T4	PA-NS; QL (930 ML per 31 days)
LYVISPAH	T4	PA; QL (124 EA per 31 days)
MARPLAN	T4	
MAVENCLAD (10 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (4 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (5 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (6 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (7 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (8 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (9 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAXALT ORAL TABLET 10 MG	T4	QL (12 EA per 28 days)
MAXALT-MLT ORAL TABLET,DISINTEGRATING 10 MG	T4	QL (12 EA per 28 days)
MAYZENT ORAL TABLET 0.25 MG	T5	PA; QL (155 EA per 31 days)
MAYZENT ORAL TABLET 1 MG, 2 MG	T5	PA; QL (31 EA per 31 days)
MAYZENT STARTER(FOR 1MG MAINT)	T4	PA; QL (14 EA per 365 days)
MAYZENT STARTER(FOR 2MG MAINT)	T5	PA; QL (24 EA per 365 days)
meclofenamate	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
mefenamic acid	T4	
meloxicam oral tablet	T1	
meloxicam submicronized	T4	PA; QL (31 EA per 31 days)
memantine oral capsule,sprinkle,er 24hr	T4	
memantine oral solution	T3	
memantine oral tablet	T2	
memantine oral tablets,dose pack	T4	
meperidine (pf) injection solution 100 mg/ml	T4	PA; QL (200 ML per 31 days)
meperidine (pf) injection solution 25 mg/ml	T4	PA; QL (800 ML per 31 days)
meperidine (pf) injection solution 50 mg/ml	T4	PA; QL (400 ML per 31 days)
meperidine oral solution	T4	PA; QL (6200 ML per 31 days)
meperidine oral tablet 50 mg	T4	PA; QL (1240 EA per 31 days)
meprobamate oral tablet 200 mg	T4	QL (341 EA per 31 days)
meprobamate oral tablet 400 mg	T4	QL (186 EA per 31 days)
MESTINON ORAL	T5	
MESTINON TIMESPAN	T5	
metaxalone	T4	PA
methadone oral solution 10 mg/5 ml	T3	PA; QL (1033 ML per 31 days)
methadone oral solution 5 mg/5 ml	T3	PA; QL (2066 ML per 31 days)
methadone oral tablet 10 mg	T3	PA; QL (206 EA per 31 days)
methadone oral tablet 5 mg	T3	PA; QL (248 EA per 31 days)
methamphetamine	T4	PA
methocarbamol oral tablet 1,000 mg	T5	
methocarbamol oral tablet 500 mg, 750 mg	T4	
methsuximide	T4	
METHYLIN ORAL SOLUTION	T4	ST
methylphenidate hcl oral cap,er sprinkle,biphasic 40-60	T4	QL (31 EA per 31 days)
methylphenidate hcl oral capsule, er biphasic 30-70	T4	QL (31 EA per 31 days)
methylphenidate hcl oral capsule,er biphasic 50-50 10 mg	T4	QL (186 EA per 31 days)
methylphenidate hcl oral capsule,er biphasic 50-50 20 mg	T4	QL (93 EA per 31 days)
methylphenidate hcl oral capsule,er biphasic 50-50 30 mg, 40 mg	T4	QL (62 EA per 31 days)
methylphenidate hcl oral capsule,er biphasic 50-50 60 mg	T4	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
methylphenidate hcl oral solution	T4	
methylphenidate hcl oral tablet	T3	QL (93 EA per 31 days)
methylphenidate hcl oral tablet extended release 10 mg	T4	QL (186 EA per 31 days)
methylphenidate hcl oral tablet extended release 20 mg	T4	QL (93 EA per 31 days)
methylphenidate hcl oral tablet extended release 24hr 18 mg, 18 mg (bx rating), 27 mg, 27 mg (bx rating), 36 mg, 36 mg (bx rating), 54 mg, 54 mg (bx rating)	T4	QL (31 EA per 31 days)
methylphenidate hcl oral tablet extended release 24hr 45 mg, 63 mg, 72 mg	T4	ST; QL (31 EA per 31 days)
methylphenidate hcl oral tablet,chewable 10 mg	T4	QL (186 EA per 31 days)
methylphenidate hcl oral tablet,chewable 2.5 mg, 5 mg	T4	QL (93 EA per 31 days)
MIGERGOT	T4	
MIGRANAL	T5	PA; QL (8 ML per 31 days)
MIRAPEX ER	T4	
mirtazapine oral tablet	T1	
mirtazapine oral tablet,disintegrating	T2	
modafinil	T2	PA; QL (31 EA per 31 days)
molindone	T2	
morphine concentrate oral solution	T3	PA; QL (310 ML per 31 days)
morphine oral capsule, er multiphase 24 hr 120 mg	T4	PA; QL (51 EA per 31 days)
morphine oral capsule, er multiphase 24 hr 30 mg, 45 mg, 60 mg, 75 mg, 90 mg	T4	PA; QL (62 EA per 31 days)
morphine oral capsule,extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg	T4	PA; QL (62 EA per 31 days)
morphine oral solution 10 mg/5 ml	T3	PA; QL (2800 ML per 31 days)
morphine oral solution 20 mg/5 ml (4 mg/ml)	T3	PA; QL (1400 ML per 31 days)
morphine oral tablet	T3	PA; QL (186 EA per 31 days)
morphine oral tablet extended release 100 mg	T3	PA; QL (62 EA per 31 days)
morphine oral tablet extended release 15 mg, 30 mg, 60 mg	T3	PA; QL (100 EA per 31 days)
morphine oral tablet extended release 200 mg	T3	PA; QL (31 EA per 31 days)
MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG	T5	PA; QL (62 EA per 31 days)
MS CONTIN ORAL TABLET EXTENDED RELEASE 15 MG, 30 MG	T4	PA; QL (100 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
MS CONTIN ORAL TABLET EXTENDED RELEASE 200 MG	T5	PA; QL (31 EA per 31 days)
MS CONTIN ORAL TABLET EXTENDED RELEASE 60 MG	T5	PA; QL (100 EA per 31 days)
MYDAYIS	T4	ST; QL (31 EA per 31 days)
MYSOLINE	T5	
nabumetone	T2	
NALFON ORAL CAPSULE 400 MG	T4	
NALFON ORAL TABLET	T4	
NALOCET	T4	PA; QL (403 EA per 31 days)
naloxone injection solution	T2	
naloxone injection syringe	T2	
naloxone nasal	T4	
naltrexone	T2	
NAMENDA ORAL TABLET	T4	PA
NAMENDA TITRATION PAK	T4	PA
NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR 14 MG, 21 MG, 28 MG	T4	PA
NAMZARIC	T3	PA
NAPRELAN CR	T4	
naproxen oral suspension	T2	
naproxen oral tablet	T1	
naproxen oral tablet,delayed release (dr/ec)	T2	
naproxen sodium oral tablet 275 mg, 550 mg	T2	
naproxen sodium oral tablet, er multiphase 24 hr 375 mg, 750 mg	T4	
naproxen sodium oral tablet, er multiphase 24 hr 500 mg	T5	
naproxen-esomeprazole	T5	PA; QL (62 EA per 31 days)
naratriptan oral tablet 1 mg	T3	QL (20 EA per 28 days)
naratriptan oral tablet 2.5 mg	T3	QL (9 EA per 28 days)
NARCAN	T3	
NARDIL	T4	
NAYZILAM	T5	PA-NS; QL (10 EA per 30 days)
nefazodone	T2	
NEUPRO	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
NEURONTIN ORAL CAPSULE 100 MG, 400 MG	T4	PA-NS; QL (270 EA per 30 days)
NEURONTIN ORAL CAPSULE 300 MG	T4	PA-NS; QL (360 EA per 30 days)
NEURONTIN ORAL SOLUTION	T4	PA-NS; QL (2160 ML per 30 days)
NEURONTIN ORAL TABLET 600 MG	T5	PA-NS; QL (180 EA per 30 days)
NEURONTIN ORAL TABLET 800 MG	T4	PA-NS; QL (120 EA per 30 days)
NORGESIC	T4	PA; QL (124 EA per 31 days)
NORGESIC FORTE	T4	PA; QL (124 EA per 31 days)
NORPRAMIN ORAL TABLET 10 MG, 25 MG	T4	
nortriptyline	T2	
NOURIANZ	T5	PA; QL (31 EA per 31 days)
NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HR 100 MG, 200 MG, 250 MG	T5	PA; QL (62 EA per 31 days)
NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HR 150 MG, 50 MG	T4	PA; QL (62 EA per 31 days)
NUCYNTA ORAL TABLET 100 MG	T5	PA; QL (186 EA per 31 days)
NUCYNTA ORAL TABLET 50 MG, 75 MG	T4	PA; QL (186 EA per 31 days)
NUEDEXTA	T5	PA; QL (62 EA per 31 days)
NUPLAZID	T5	PA-NS; QL (31 EA per 31 days)
NURTEC ODT	T5	PA; QL (18 EA per 28 days)
NUVIGIL ORAL TABLET 150 MG, 200 MG, 250 MG	T5	PA; QL (31 EA per 31 days)
NUVIGIL ORAL TABLET 50 MG	T4	PA; QL (31 EA per 31 days)
olanzapine intramuscular	T4	
olanzapine oral	T2	QL (31 EA per 31 days)
olanzapine-fluoxetine	T4	
ONFI ORAL SUSPENSION	T5	PA-NS; QL (496 ML per 31 days)
ONFI ORAL TABLET	T5	PA-NS; QL (62 EA per 31 days)
ONGENTYS	T4	PA; QL (31 EA per 31 days)
ONZETRA XSAIL	T4	QL (16 EA per 28 days)
orphenadrine citrate oral	T4	PA
orphenadrine-asa-caffeine oral tablet 25-385-30 mg	T4	PA; QL (124 EA per 31 days)
OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 193 MG	T4	PA; QL (31 EA per 31 days)
oxaprozin	T4	
oxazepam	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
oxcarbazepine oral suspension	T4	
oxcarbazepine oral tablet	T3	
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 300 MG	T4	
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 600 MG	T5	
oxycodone oral capsule	T3	PA; QL (186 EA per 31 days)
oxycodone oral concentrate	T4	PA; QL (180 ML per 31 days)
oxycodone oral solution	T3	PA; QL (4133 ML per 31 days)
oxycodone oral tablet 10 mg, 15 mg, 20 mg, 5 mg	T3	PA; QL (186 EA per 31 days)
oxycodone oral tablet 30 mg	T3	PA; QL (138 EA per 31 days)
oxycodone oral tablet,oral only,ext.rel.12 hr 10 mg, 20 mg	T4	PA; QL (100 EA per 31 days)
oxycodone-acetaminophen oral solution 5-325 mg/5 ml	T4	PA; QL (1907 ML per 31 days)
oxycodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg	T5	PA; QL (403 EA per 31 days)
oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg	T3	PA; QL (372 EA per 31 days)
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG	T3	PA; QL (100 EA per 31 days)
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 40 MG	T5	PA; QL (100 EA per 31 days)
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 60 MG	T5	PA; QL (69 EA per 31 days)
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 80 MG	T5	PA; QL (62 EA per 31 days)
oxymorphone oral tablet	T4	PA; QL (186 EA per 31 days)
oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 5 mg, 7.5 mg	T4	PA; QL (100 EA per 31 days)
oxymorphone oral tablet extended release 12 hr 30 mg	T4	PA; QL (69 EA per 31 days)
oxymorphone oral tablet extended release 12 hr 40 mg	T5	PA; QL (51 EA per 31 days)
paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg	T4	QL (31 EA per 31 days)
paliperidone oral tablet extended release 24hr 6 mg	T4	QL (62 EA per 31 days)
PAMELOR	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PARLODEL	T4	
PARNATE	T4	
paroxetine hcl oral suspension	T4	
paroxetine hcl oral tablet	T1	
paroxetine hcl oral tablet extended release 24 hr	T4	
paroxetine mesylate(menop.sym)	T4	
PAXIL	T4	
PAXIL CR	T4	
PENNSAID TOPICAL SOLUTION IN METERED-DOSE PUMP	T5	QL (224 GM per 28 days)
pentazocine-naloxone	T4	QL (335 EA per 31 days)
PERCOCET ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG	T5	PA; QL (372 EA per 31 days)
PERCOCET ORAL TABLET 2.5-325 MG	T4	PA; QL (372 EA per 31 days)
perphenazine	T2	
perphenazine-amitriptyline	T4	PA-NS
PERSERIS	T5	QL (1 EA per 28 days)
phenelzine	T3	
phenobarbital	T2	PA-NS
PHENYTEK	T4	
phenytoin oral suspension 125 mg/5 ml	T2	
phenytoin oral tablet,chewable	T2	
phenytoin sodium extended	T2	
pimozide	T4	
piroxicam	T2	
PONVORY	T5	PA; QL (31 EA per 31 days)
PONVORY 14-DAY STARTER PACK	T5	PA; QL (28 EA per 365 days)
pramipexole oral tablet	T2	
pramipexole oral tablet extended release 24 hr	T4	
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg	T3	PA-NS; QL (93 EA per 31 days)
pregabalin oral capsule 225 mg, 300 mg	T3	PA-NS; QL (62 EA per 31 days)
pregabalin oral solution	T3	PA-NS; QL (930 ML per 31 days)
pregabalin oral tablet extended release 24 hr	T4	PA; QL (31 EA per 31 days)
primidone oral tablet 125 mg	T4	
primidone oral tablet 250 mg, 50 mg	T2	
PRISTIQ	T4	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PROCENTRA	T4	
PROLATE ORAL SOLUTION	T4	PA; QL (5167 ML per 31 days)
PROLATE ORAL TABLET	T4	PA; QL (403 EA per 31 days)
protriptyline	T4	
PROVIGIL	T5	PA; QL (31 EA per 31 days)
PROZAC ORAL CAPSULE	T4	
pyridostigmine bromide oral syrup	T5	
pyridostigmine bromide oral tablet 30 mg	T4	
pyridostigmine bromide oral tablet 60 mg	T3	
pyridostigmine bromide oral tablet extended release	T3	
QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 200 MG	T4	PA; QL (93 EA per 31 days)
QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 150 MG	T4	PA; QL (62 EA per 31 days)
QUDEXY XR ORAL CAPSULE,SPRINKLE,ER 24HR 100 MG, 150 MG, 25 MG, 50 MG	T4	
QUDEXY XR ORAL CAPSULE,SPRINKLE,ER 24HR 200 MG	T5	
quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg	T2	QL (62 EA per 31 days)
quetiapine oral tablet 150 mg	T3	QL (62 EA per 31 days)
quetiapine oral tablet extended release 24 hr	T2	QL (62 EA per 31 days)
QUILLICHEW ER ORAL TABLET,CHEW,IR-ER.BIPHASIC24HR 20 MG, 40 MG	T4	ST; QL (31 EA per 31 days)
QUILLICHEW ER ORAL TABLET,CHEW,IR-ER.BIPHASIC24HR 30 MG	T4	ST; QL (62 EA per 31 days)
QUILLIVANT XR	T4	ST; QL (360 ML per 30 days)
QULIPTA	T5	PA; QL (31 EA per 31 days)
QUVIVIQ	T4	ST; QL (31 EA per 31 days)
RADICAVA ORS STARTER KIT SUSP	T5	PA; QL (70 ML per 28 days)
ramelteon	T3	QL (31 EA per 31 days)
rasagiline	T4	
RELAFEN DS	T5	
RELEXXII ORAL TABLET EXTENDED RELEASE 24HR 45 MG, 63 MG, 72 MG	T4	ST; QL (31 EA per 31 days)
RELPAX ORAL TABLET 20 MG	T4	QL (12 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
RELPAX ORAL TABLET 40 MG	T4	QL (6 EA per 28 days)
RELYVRIO	T5	PA; QL (62 EA per 31 days)
REMERON ORAL TABLET 15 MG, 30 MG	T4	
REMERON SOLTAB	T4	
RESTORIL ORAL CAPSULE 15 MG, 22.5 MG, 7.5 MG	T4	QL (31 EA per 31 days)
RESTORIL ORAL CAPSULE 30 MG	T5	QL (31 EA per 31 days)
REXULTI ORAL TABLET	T5	PA-NS; QL (31 EA per 31 days)
REYVOW ORAL TABLET 100 MG	T4	QL (8 EA per 28 days)
REYVOW ORAL TABLET 50 MG	T4	QL (4 EA per 28 days)
RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 12.5 MG/2 ML, 25 MG/2 ML	T3	QL (2 EA per 28 days)
RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 37.5 MG/2 ML, 50 MG/2 ML	T5	QL (2 EA per 28 days)
RISPERDAL ORAL SOLUTION	T4	QL (496 ML per 31 days)
RISPERDAL ORAL TABLET 0.5 MG, 1 MG, 2 MG	T4	QL (31 EA per 31 days)
RISPERDAL ORAL TABLET 3 MG	T4	QL (93 EA per 31 days)
RISPERDAL ORAL TABLET 4 MG	T4	QL (124 EA per 31 days)
risperidone oral solution	T2	QL (496 ML per 31 days)
risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg	T1	QL (31 EA per 31 days)
risperidone oral tablet 3 mg	T1	QL (93 EA per 31 days)
risperidone oral tablet 4 mg	T1	QL (124 EA per 31 days)
risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg	T4	QL (31 EA per 31 days)
risperidone oral tablet,disintegrating 3 mg	T4	QL (93 EA per 31 days)
risperidone oral tablet,disintegrating 4 mg	T4	QL (124 EA per 31 days)
RITALIN	T4	ST; QL (93 EA per 31 days)
RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 10 MG	T4	ST; QL (186 EA per 31 days)
RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 20 MG, 40 MG	T4	ST; QL (31 EA per 31 days)
RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 30 MG	T4	ST; QL (62 EA per 31 days)
rivastigmine	T4	QL (30 EA per 30 days)
rivastigmine tartrate	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
rizatriptan oral tablet 10 mg	T2	QL (12 EA per 28 days)
rizatriptan oral tablet 5 mg	T2	QL (24 EA per 28 days)
rizatriptan oral tablet,disintegrating 10 mg	T3	QL (12 EA per 28 days)
rizatriptan oral tablet,disintegrating 5 mg	T3	QL (24 EA per 28 days)
ropinirole oral tablet	T2	
ropinirole oral tablet extended release 24 hr	T4	
ROWEEPRA ORAL TABLET 500 MG	T2	
ROXICODONE ORAL TABLET 15 MG	T4	PA; QL (186 EA per 31 days)
ROXICODONE ORAL TABLET 30 MG	T4	PA; QL (138 EA per 31 days)
ROXYBOND	T5	PA; QL (186 EA per 31 days)
ROZEREM	T4	QL (31 EA per 31 days)
rufinamide oral suspension	T5	PA-NS
rufinamide oral tablet 200 mg	T4	PA-NS
rufinamide oral tablet 400 mg	T5	PA-NS
RYTARY	T4	ST
SABRIL	T5	PA-NS
SAPHRIS	T4	QL (62 EA per 31 days)
SECUADO	T5	QL (31 EA per 31 days)
SEGLENTIS	T4	PA; QL (124 EA per 31 days)
selegiline hcl	T2	
SEROQUEL	T4	QL (62 EA per 31 days)
SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HR	T4	QL (62 EA per 31 days)
sertraline oral capsule	T4	PA-NS; QL (31 EA per 31 days)
sertraline oral concentrate	T2	
sertraline oral tablet	T1	
SILENOR	T4	PA
SINEMET ORAL TABLET 10-100 MG, 25-100 MG	T4	
SKYCLARYS	T5	PA; QL (93 EA per 31 days)
sodium oxybate	T5	PA; QL (540 ML per 30 days)
SOMA	T4	PA
SPRITAM	T4	
SPRIX	T5	QL (5 EA per 31 days)
STALEVO 100	T4	
STALEVO 125	T4	
STALEVO 150	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
STALEVO 200	T4	
STALEVO 50	T4	
STALEVO 75	T4	
STRATTERA ORAL CAPSULE 10 MG, 25 MG, 40 MG	T4	ST; QL (62 EA per 31 days)
STRATTERA ORAL CAPSULE 100 MG, 60 MG, 80 MG	T4	ST; QL (31 EA per 31 days)
STRATTERA ORAL CAPSULE 18 MG	T4	ST; QL (124 EA per 31 days)
SUBOXONE SUBLINGUAL FILM 12-3 MG, 4-1 MG, 8-2 MG	T4	ST; QL (62 EA per 31 days)
SUBOXONE SUBLINGUAL FILM 2-0.5 MG	T4	ST; QL (93 EA per 31 days)
SUBVENITE	T2	
SUBVENITE STARTER (BLUE) KIT	T4	
SUBVENITE STARTER (GREEN) KIT	T4	
SUBVENITE STARTER (ORANGE) KIT	T4	
sulindac	T2	
sumatriptan nasal spray,non-aerosol 20 mg/actuation	T4	QL (8 EA per 28 days)
sumatriptan nasal spray,non-aerosol 5 mg/actuation	T4	QL (32 EA per 28 days)
sumatriptan succinate oral tablet 100 mg	T2	QL (9 EA per 28 days)
sumatriptan succinate oral tablet 25 mg	T2	QL (36 EA per 28 days)
sumatriptan succinate oral tablet 50 mg	T2	QL (18 EA per 28 days)
sumatriptan succinate subcutaneous cartridge 4 mg/0.5 ml	T4	QL (6 ML per 28 days)
sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml	T4	QL (4 ML per 28 days)
sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml	T4	QL (6 ML per 28 days)
sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml	T4	QL (4 ML per 28 days)
sumatriptan succinate subcutaneous solution	T4	QL (4 ML per 28 days)
sumatriptan-naproxen	T4	QL (9 EA per 28 days)
SUNOSI	T4	PA; QL (31 EA per 31 days)
SYMBYAX ORAL CAPSULE 3-25 MG, 6-25 MG	T4	
SYMPAZAN ORAL FILM 10 MG, 20 MG	T5	PA-NS; QL (62 EA per 31 days)
SYMPAZAN ORAL FILM 5 MG	T4	PA-NS; QL (62 EA per 31 days)
TASCENSO ODT	T5	PA; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
tasimelteon	T5	PA; QL (31 EA per 31 days)
TASMAR ORAL TABLET 100 MG	T5	
TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG (14)- 240 MG (46)	T5	PA; QL (120 EA per 365 days)
TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG, 240 MG	T5	PA; QL (62 EA per 31 days)
TEGRETOL ORAL SUSPENSION	T4	
TEGRETOL ORAL TABLET	T4	
TEGRETOL XR	T4	
TEGSEDI	T5	PA; QL (6 ML per 28 days)
temazepam	T2	QL (31 EA per 31 days)
TENCON	T4	QL (372 EA per 31 days)
teriflunomide	T5	PA; QL (31 EA per 31 days)
tetrabenazine oral tablet 12.5 mg	T5	PA; QL (93 EA per 31 days)
tetrabenazine oral tablet 25 mg	T5	PA; QL (124 EA per 31 days)
thioridazine	T3	
thiothixene	T2	
tiagabine	T4	
tizanidine oral capsule	T4	
tizanidine oral tablet	T2	
tolcapone	T5	
TOPAMAX	T4	
topiramate oral capsule, sprinkle	T2	
topiramate oral capsule,extended release 24hr	T4	
topiramate oral capsule,sprinkle,er 24hr	T4	
topiramate oral tablet	T1	
TOSYMRA	T4	QL (12 EA per 28 days)
tramadol oral capsule,er biphase 24 hr 17-83	T4	PA; QL (30 EA per 30 days)
tramadol oral capsule,er biphase 24 hr 25-75 100 mg, 200 mg	T4	PA; QL (30 EA per 30 days)
tramadol oral solution	T4	PA; QL (2480 ML per 31 days)
tramadol oral tablet 100 mg	T4	PA; QL (124 EA per 31 days)
tramadol oral tablet 50 mg	T2	PA; QL (240 EA per 30 days)
tramadol oral tablet extended release 24 hr	T4	PA; QL (30 EA per 30 days)
tramadol oral tablet, er multiphase 24 hr	T4	PA; QL (30 EA per 30 days)
tramadol-acetaminophen	T2	PA; QL (372 EA per 31 days)
tranylcypromine	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
trazodone	T1	
TREXIMET	T4	QL (9 EA per 28 days)
TREZIX	T4	PA; QL (372 EA per 31 days)
triazolam	T4	PA
trifluoperazine	T2	
trihexyphenidyl	T4	
TRILEPTAL	T4	
trimipramine	T4	PA-NS
TRINTELLIX	T3	
TROKENDI XR ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 25 MG, 50 MG	T4	
TROKENDI XR ORAL CAPSULE,EXTENDED RELEASE 24HR 200 MG	T5	
TRUDHESA	T5	PA; QL (12 ML per 28 days)
UBRELVY ORAL TABLET 100 MG	T5	PA; QL (17 EA per 28 days)
UBRELVY ORAL TABLET 50 MG	T5	PA; QL (34 EA per 28 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 100 MG/0.28 ML	T5	QL (0.28 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 125 MG/0.35 ML	T5	QL (0.35 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 150 MG/0.42 ML	T5	QL (0.42 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 200 MG/0.56 ML	T5	QL (0.56 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 250 MG/0.7 ML	T5	QL (0.7 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 50 MG/0.14 ML	T5	QL (0.14 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 75 MG/0.21 ML	T5	QL (0.21 ML per 30 days)
VALIUM	T4	QL (124 EA per 31 days)
valproic acid	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
valproic acid (as sodium salt) oral solution 250 mg/5 ml	T2	
VALTOCO	T5	PA-NS; QL (10 EA per 30 days)
venlafaxine besylate	T4	PA-NS; QL (62 EA per 31 days)
venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg	T2	QL (31 EA per 31 days)
venlafaxine oral capsule,extended release 24hr 75 mg	T2	QL (93 EA per 31 days)
venlafaxine oral tablet	T2	
venlafaxine oral tablet extended release 24hr	T2	QL (31 EA per 31 days)
VERSACLOZ	T5	QL (558 ML per 31 days)
vigabatrin	T5	PA-NS
VIGADRONE	T5	PA-NS
VIIBRYD ORAL TABLET	T4	QL (31 EA per 31 days)
VIIBRYD ORAL TABLETS,DOSE PACK 10 MG (7)- 20 MG (23)	T3	QL (60 EA per 365 days)
vilazodone	T3	QL (31 EA per 31 days)
VIMOVO	T5	PA; QL (62 EA per 31 days)
VIMPAT ORAL SOLUTION	T5	
VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG	T5	
VIMPAT ORAL TABLET 50 MG	T3	
VIVITROL	T5	
VRAYLAR ORAL CAPSULE	T5	PA-NS; QL (31 EA per 31 days)
VRAYLAR ORAL CAPSULE,DOSE PACK	T4	PA-NS; QL (14 EA per 365 days)
VUMERITY	T5	PA; QL (124 EA per 31 days)
VYVANSE	T4	ST; QL (31 EA per 31 days)
WAKIX	T5	PA; QL (62 EA per 31 days)
WELLBUTRIN SR	T4	QL (62 EA per 31 days)
WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HR 150 MG	T4	QL (93 EA per 31 days)
WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HR 300 MG	T4	QL (31 EA per 31 days)
XANAX ORAL TABLET 0.25 MG, 0.5 MG	T4	PA; QL (93 EA per 31 days)
XANAX ORAL TABLET 1 MG, 2 MG	T4	PA; QL (155 EA per 31 days)
XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG	T4	PA; QL (31 EA per 31 days)
XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 2 MG	T4	PA; QL (155 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 3 MG	T4	PA; QL (93 EA per 31 days)
XCOPRI	T5	PA-NS
XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1)	T5	PA-NS
XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14)	T4	PA-NS
XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14)	T5	PA-NS
XELSTRYM	T4	ST; QL (30 EA per 30 days)
XENAZINE ORAL TABLET 12.5 MG	T5	PA; QL (93 EA per 31 days)
XENAZINE ORAL TABLET 25 MG	T5	PA; QL (124 EA per 31 days)
XTAMPZA ER	T4	PA; QL (62 EA per 31 days)
XYREM	T5	PA; QL (540 ML per 30 days)
XYWAV	T5	PA; QL (540 ML per 30 days)
zaleplon oral capsule 10 mg	T4	PA; QL (62 EA per 31 days)
zaleplon oral capsule 5 mg	T4	PA; QL (93 EA per 31 days)
ZANAFLEX	T4	
ZARONTIN	T4	
ZAVZPRET	T5	PA; QL (8 EA per 30 days)
ZELAPAR	T5	
ZEMBRACE SYMTOUCH	T5	QL (8 ML per 28 days)
ZENZEDI	T4	QL (62 EA per 31 days)
ZEPOSIA	T5	PA; QL (31 EA per 31 days)
ZEPOSIA STARTER KIT (28-DAY)	T5	PA; QL (56 EA per 365 days)
ZEPOSIA STARTER PACK (7-DAY)	T5	PA; QL (14 EA per 365 days)
ZIMHI	T4	
ziprasidone hcl	T2	QL (62 EA per 31 days)
ziprasidone mesylate	T4	
ZIPSOR	T5	
zolmitriptan nasal spray,non-aerosol 5 mg	T4	QL (8 EA per 28 days)
zolmitriptan oral tablet 2.5 mg	T4	QL (16 EA per 28 days)
zolmitriptan oral tablet 5 mg	T4	QL (8 EA per 28 days)
zolmitriptan oral tablet,disintegrating 2.5 mg	T4	QL (16 EA per 28 days)
zolmitriptan oral tablet,disintegrating 5 mg	T4	QL (8 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ZOLOFT	T4	
zolpidem oral capsule	T4	PA; QL (31 EA per 31 days)
zolpidem oral tablet	T2	PA; QL (31 EA per 31 days)
zolpidem oral tablet,ext release multiphase	T4	PA; QL (31 EA per 31 days)
zolpidem sublingual	T4	PA; QL (31 EA per 31 days)
ZOMIG NASAL SPRAY,NON-AEROSOL 2.5 MG	T4	QL (16 EA per 28 days)
ZOMIG NASAL SPRAY,NON-AEROSOL 5 MG	T4	QL (8 EA per 28 days)
ZOMIG ORAL TABLET 2.5 MG	T4	QL (16 EA per 28 days)
ZOMIG ORAL TABLET 5 MG	T4	QL (8 EA per 28 days)
ZONEGRAN ORAL CAPSULE 100 MG, 25 MG	T4	
ZONISADE	T5	PA-NS; QL (930 ML per 31 days)
zonisamide	T2	
ZTALMY	T5	PA-NS; QL (1100 ML per 30 days)
ZUBSOLV SUBLINGUAL TABLET 0.7-0.18 MG, 2.9-0.71 MG, 8.6-2.1 MG	T3	QL (62 EA per 31 days)
ZUBSOLV SUBLINGUAL TABLET 1.4-0.36 MG	T3	QL (93 EA per 31 days)
ZUBSOLV SUBLINGUAL TABLET 11.4-2.9 MG, 5.7-1.4 MG	T3	QL (31 EA per 31 days)
ZYPREXA INTRAMUSCULAR	T4	
ZYPREXA ORAL TABLET 10 MG, 2.5 MG, 5 MG, 7.5 MG	T4	QL (31 EA per 31 days)
ZYPREXA ORAL TABLET 15 MG, 20 MG	T5	QL (31 EA per 31 days)
ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG	T5	QL (2 EA per 28 days)
ZYPREXA ZYDIS ORAL TABLET,DISINTEGRATING 10 MG, 5 MG	T4	QL (31 EA per 31 days)
ZYPREXA ZYDIS ORAL TABLET,DISINTEGRATING 15 MG, 20 MG	T5	QL (31 EA per 31 days)
Cardiovascular, Hypertension / Lipids		
acebutolol	T2	
ALDACTONE	T4	
aliskiren	T4	
ALTACE ORAL CAPSULE 1.25 MG	T4	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ALTACE ORAL CAPSULE 10 MG	T4	QL (93 EA per 31 days)
ALTACE ORAL CAPSULE 2.5 MG, 5 MG	T4	
ALTOPREV	T5	
amiloride	T2	
amiloride-hydrochlorothiazide	T2	
amiodarone oral	T2	
amlodipine	T1	
amlodipine-atorvastatin	T2	
amlodipine-benazepril	T1	
amlodipine-olmesartan	T2	QL (31 EA per 31 days)
amlodipine-valsartan	T1	
amlodipine-valsartan-hcthiazid	T4	
ANTARA ORAL CAPSULE 90 MG	T4	
ARIXTRA SUBCUTANEOUS SYRINGE 10 MG/0.8 ML, 5 MG/0.4 ML, 7.5 MG/0.6 ML	T5	
ARIXTRA SUBCUTANEOUS SYRINGE 2.5 MG/0.5 ML	T4	
aspirin-dipyridamole	T4	
ASPRUZYO SPRINKLE	T4	PA; QL (60 EA per 30 days)
ATACAND	T4	
ATACAND HCT	T4	
atenolol	T1	
atenolol-chlorthalidone	T2	
ATORVALIQ	T4	PA; QL (600 ML per 30 days)
atorvastatin	T1	
AVALIDE	T4	QL (31 EA per 31 days)
AVAPRO	T4	QL (31 EA per 31 days)
AZOR	T4	QL (31 EA per 31 days)
benazepril	T1	
benazepril-hydrochlorothiazide	T1	
BENICAR HCT	T4	QL (31 EA per 31 days)
BENICAR ORAL TABLET 20 MG, 40 MG	T4	QL (31 EA per 31 days)
BENICAR ORAL TABLET 5 MG	T4	QL (93 EA per 31 days)
BETAPACE AF	T4	
betaxolol oral	T3	
BIDIL	T4	
bisoprolol fumarate	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
bisoprolol-hydrochlorothiazide	T1	
BRILINTA	T3	
bumetanide	T2	
BYSTOLIC ORAL TABLET 10 MG, 2.5 MG	T3	QL (93 EA per 31 days)
BYSTOLIC ORAL TABLET 20 MG	T3	QL (62 EA per 31 days)
BYSTOLIC ORAL TABLET 5 MG	T3	QL (217 EA per 31 days)
CABLIVI INJECTION KIT	T5	PA; QL (31 EA per 31 days)
CADUET	T4	
CAMZYOS	T5	PA; QL (31 EA per 31 days)
candesartan	T2	
candesartan-hydrochlorothiazid	T2	
captopril	T2	
CARDIZEM CD ORAL CAPSULE,EXTENDED RELEASE 24HR 120 MG, 180 MG, 240 MG, 300 MG	T4	
CARDIZEM CD ORAL CAPSULE,EXTENDED RELEASE 24HR 360 MG	T5	
CARDIZEM LA	T4	
CARDIZEM ORAL TABLET 120 MG, 30 MG	T4	
CARDIZEM ORAL TABLET 60 MG	T5	
CARDURA	T4	
CARDURA XL	T4	
CAROSPIR	T4	
CARTIA XT	T2	
carvedilol	T1	
carvedilol phosphate	T4	
CATAPRES-TTS-1	T4	
CATAPRES-TTS-2	T4	
CATAPRES-TTS-3	T4	
chlorthalidone oral tablet 25 mg, 50 mg	T2	
cholestyramine (with sugar) oral powder in packet	T2	
CHOLESTYRAMINE LIGHT ORAL POWDER IN PACKET	T2	
cilostazol	T2	
clonidine	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
clonidine hcl oral tablet	T1	
clopidogrel oral tablet 75 mg	T1	
colesevelam	T4	
COLESTID ORAL TABLET	T4	
colestipol oral packet	T4	
colestipol oral tablet	T4	
CONJUPRI	T4	ST; QL (31 EA per 31 days)
COREG CR	T4	
COREG ORAL TABLET 25 MG	T4	
CORGARD ORAL TABLET 20 MG, 40 MG	T4	
CORLANOR ORAL SOLUTION	T3	PA; QL (420 ML per 28 days)
CORLANOR ORAL TABLET 5 MG	T3	PA; QL (93 EA per 31 days)
CORLANOR ORAL TABLET 7.5 MG	T3	PA; QL (62 EA per 31 days)
COZAAR ORAL TABLET 100 MG	T4	QL (31 EA per 31 days)
COZAAR ORAL TABLET 25 MG	T4	QL (93 EA per 31 days)
COZAAR ORAL TABLET 50 MG	T4	QL (62 EA per 31 days)
CRESTOR	T4	
dabigatran etexilate	T4	QL (62 EA per 31 days)
DEMSER	T5	
DIBENZYLINE	T5	PA
digoxin oral solution	T3	QL (155 ML per 31 days)
digoxin oral tablet 125 mcg (0.125 mg)	T2	QL (62 EA per 31 days)
digoxin oral tablet 250 mcg (0.25 mg)	T2	QL (31 EA per 31 days)
digoxin oral tablet 62.5 mcg (0.0625 mg)	T3	QL (124 EA per 31 days)
diltiazem hcl oral capsule,extended release 12 hr	T2	
diltiazem hcl oral capsule,extended release 24 hr 360 mg, 420 mg	T2	
diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg	T2	
diltiazem hcl oral tablet	T2	
diltiazem hcl oral tablet extended release 24 hr 120 mg	T4	
diltiazem hcl oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg	T2	
DILT-XR	T2	
DIOVAN HCT	T4	QL (31 EA per 31 days)
DIOVAN ORAL TABLET 160 MG, 40 MG, 80 MG	T4	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
DIOVAN ORAL TABLET 320 MG	T4	QL (31 EA per 31 days)
dipyridamole oral	T4	
disopyramide phosphate oral capsule	T4	
DIURIL	T4	
dofetilide	T4	
DOPTELET (10 TAB PACK)	T5	PA
DOPTELET (15 TAB PACK)	T5	PA
DOPTELET (30 TAB PACK)	T5	PA
doxazosin	T1	
DYRENIUM	T4	
EDARBI	T3	
EDARBYCLOR	T3	
EDECRIN	T5	
EFFIENT	T4	
ELIQUIS DVT-PE TREAT 30D START	T3	QL (74 EA per 30 days)
ELIQUIS ORAL TABLET 2.5 MG	T3	QL (60 EA per 30 days)
ELIQUIS ORAL TABLET 5 MG	T3	QL (74 EA per 30 days)
enalapril maleate oral solution	T4	
enalapril maleate oral tablet	T1	
enalapril-hydrochlorothiazide	T1	
enoxaparin subcutaneous syringe	T4	
ENTRESTO ORAL TABLET 24-26 MG	T3	QL (186 EA per 31 days)
ENTRESTO ORAL TABLET 49-51 MG	T3	QL (93 EA per 31 days)
ENTRESTO ORAL TABLET 97-103 MG	T3	QL (62 EA per 31 days)
eplerenone	T2	
ethacrynic acid	T4	
EXFORGE	T4	
EXFORGE HCT	T4	
EZALLOR SPRINKLE	T4	
ezetimibe	T2	
ezetimibe-simvastatin	T2	
felodipine	T2	
fenofibrate micronized oral capsule 130 mg, 90 mg	T4	
fenofibrate micronized oral capsule 134 mg, 200 mg, 43 mg, 67 mg	T2	
fenofibrate nanocrystallized	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
fenofibrate oral capsule	T4	
fenofibrate oral tablet 120 mg, 40 mg	T4	
fenofibrate oral tablet 160 mg, 54 mg	T2	
fenofibric acid (choline)	T4	
FENOGLIDE	T4	
FILSPARI	T5	PA; QL (31 EA per 31 days)
flecainide	T2	
FLOLIPID	T4	
fluvastatin oral capsule	T2	
fluvastatin oral tablet extended release 24 hr	T4	
fondaparinux subcutaneous syringe 10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml	T5	
fondaparinux subcutaneous syringe 2.5 mg/0.5 ml	T4	
fosinopril	T1	
fosinopril-hydrochlorothiazide	T2	
FRAGMIN SUBCUTANEOUS SOLUTION 25,000 ANTI-XA UNIT/ML	T5	
FRAGMIN SUBCUTANEOUS SYRINGE 10,000 ANTI-XA UNIT/ML, 12,500 ANTI-XA UNIT/0.5 ML, 15,000 ANTI-XA UNIT/0.6 ML, 18,000 ANTI-XA UNIT/0.72 ML, 7,500 ANTI-XA UNIT/0.3 ML	T5	
FRAGMIN SUBCUTANEOUS SYRINGE 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML	T4	
FUROSCIX	T5	PA; QL (8 EA per 30 days)
furosemide injection solution	T2	
furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)	T2	
furosemide oral tablet	T1	
gemfibrozil	T1	
guanfacine oral tablet	T4	
heparin (porcine) injection solution	T3	
hydralazine oral	T2	
hydrochlorothiazide	T1	
HYZAAR	T4	
icosapent ethyl oral capsule 0.5 gram	T2	QL (248 EA per 31 days)
icosapent ethyl oral capsule 1 gram	T2	QL (124 EA per 31 days)
indapamide	T1	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
INDERAL LA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 160 MG, 60 MG	T4	
INDERAL LA ORAL CAPSULE,EXTENDED RELEASE 24 HR 80 MG	T5	
INNOPRAN XL	T4	
INSPRA	T4	
irbesartan	T1	QL (31 EA per 31 days)
irbesartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
ISORDIL	T5	
ISORDIL TITRADOSE ORAL TABLET 5 MG	T4	
isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg	T2	
isosorbide dinitrate oral tablet 40 mg	T4	
isosorbide mononitrate	T1	
isosorbide-hydralazine	T3	
isradipine	T2	
JANTOVEN	T1	
JUXTAPID	T5	PA
KATERZIA	T4	PA
KERENDIA	T4	PA; QL (31 EA per 31 days)
labetalol oral	T2	
LANOXIN ORAL TABLET 125 MCG (0.125 MG)	T4	QL (62 EA per 31 days)
LANOXIN ORAL TABLET 250 MCG (0.25 MG)	T4	QL (31 EA per 31 days)
LANOXIN ORAL TABLET 62.5 MCG (0.0625 MG)	T4	QL (124 EA per 31 days)
LASIX	T4	
LESCOL XL	T4	
levamlodipine	T4	ST; QL (31 EA per 31 days)
LIPITOR	T4	
LIPOFEN	T4	
lisinopril	T1	
lisinopril-hydrochlorothiazide	T1	
LIVALO	T3	
LODOCO	T4	PA; QL (31 EA per 31 days)
LOPID	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LOPRESSOR ORAL	T4	
losartan oral tablet 100 mg	T1	QL (31 EA per 31 days)
losartan oral tablet 25 mg	T1	QL (93 EA per 31 days)
losartan oral tablet 50 mg	T1	QL (62 EA per 31 days)
losartan-hydrochlorothiazide	T1	
LOTENSIN ORAL TABLET 10 MG, 20 MG, 40 MG	T4	
LOTREL ORAL CAPSULE 10-20 MG, 10-40 MG, 5-10 MG, 5-20 MG	T4	
lovastatin	T1	
LOVAZA	T4	PA; QL (124 EA per 31 days)
LOVENOX SUBCUTANEOUS SYRINGE	T4	
MATZIM LA	T2	
MAXZIDE	T4	
MAXZIDE-25MG	T4	
metolazone	T2	
metoprolol succinate	T1	
metoprolol ta-hydrochlorothiaz	T2	
metoprolol tartrate oral	T1	
metyrosine	T5	
mexiletine	T2	
MICARDIS	T4	
MICARDIS HCT	T4	
MINIPRESS	T4	
minoxidil oral	T2	
moexipril	T1	
MULPLETA	T5	PA
MULTAQ	T3	
nadolol	T2	
nebivolol oral tablet 10 mg, 2.5 mg	T2	QL (93 EA per 31 days)
nebivolol oral tablet 20 mg	T2	QL (62 EA per 31 days)
nebivolol oral tablet 5 mg	T2	QL (217 EA per 31 days)
NEXLETOL	T3	PA; QL (31 EA per 31 days)
NEXLIZET	T3	PA; QL (31 EA per 31 days)
niacin oral tablet 500 mg	T5	
niacin oral tablet extended release 24 hr 1,000 mg, 750 mg	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
niacin oral tablet extended release 24 hr 500 mg	T4	QL (31 EA per 31 days)
NIACOR	T4	
nicardipine oral	T4	
nifedipine oral capsule	T4	
nifedipine oral tablet extended release	T2	
nifedipine oral tablet extended release 24hr	T2	
nimodipine	T4	
nisoldipine	T4	
NITRO-BID	T2	
NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.1 MG/HR, 0.2 MG/HR, 0.3 MG/HR, 0.4 MG/HR, 0.6 MG/HR	T4	
NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.8 MG/HR	T5	
nitroglycerin sublingual	T2	
nitroglycerin transdermal patch 24 hour	T2	
nitroglycerin translingual	T4	
NITROLINGUAL	T4	
NITROSTAT	T4	
NORLIQVA	T4	PA; QL (300 ML per 30 days)
NORPACE	T4	
NORPACE CR	T4	
NORVASC	T4	
NYMALIZE ORAL SYRINGE 60 MG/10 ML	T5	
olmesartan oral tablet 20 mg, 40 mg	T1	QL (31 EA per 31 days)
olmesartan oral tablet 5 mg	T1	QL (93 EA per 31 days)
olmesartan-amlodipin-hcthiazid	T3	
olmesartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
omega-3 acid ethyl esters	T2	QL (124 EA per 31 days)
ORENITRAM MONTH 1 TITRATION KT	T5	PA; QL (336 EA per 365 days)
ORENITRAM MONTH 2 TITRATION KT	T5	PA; QL (672 EA per 365 days)
ORENITRAM MONTH 3 TITRATION KT	T5	PA; QL (504 EA per 365 days)
ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG	T4	PA; QL (93 EA per 31 days)
ORENITRAM ORAL TABLET EXTENDED RELEASE 0.25 MG, 1 MG	T5	PA; QL (186 EA per 31 days)
ORENITRAM ORAL TABLET EXTENDED RELEASE 2.5 MG	T5	PA; QL (521 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ORENITRAM ORAL TABLET EXTENDED RELEASE 5 MG	T5	PA; QL (261 EA per 31 days)
PACERONE ORAL TABLET 100 MG, 200 MG, 400 MG	T2	
pentoxifylline	T2	
perindopril erbumine	T1	
phenoxybenzamine	T5	PA
pindolol	T3	
PLAVIX ORAL TABLET 75 MG	T4	
PRADAXA ORAL CAPSULE 110 MG	T4	QL (124 EA per 31 days)
PRADAXA ORAL CAPSULE 150 MG, 75 MG	T4	QL (62 EA per 31 days)
PRADAXA ORAL PELLETS IN PACKET 110 MG, 30 MG, 40 MG, 50 MG	T5	QL (124 EA per 31 days)
PRADAXA ORAL PELLETS IN PACKET 150 MG, 20 MG	T5	QL (62 EA per 31 days)
PRALUENT PEN	T4	PA; QL (2 ML per 28 days)
prasugrel	T2	
pravastatin	T1	
prazosin	T2	
PREVALITE ORAL POWDER IN PACKET	T2	
PROCARDIA XL	T4	
PROMACTA ORAL POWDER IN PACKET 12.5 MG	T5	PA; QL (372 EA per 31 days)
PROMACTA ORAL POWDER IN PACKET 25 MG	T5	PA; QL (31 EA per 31 days)
PROMACTA ORAL TABLET 12.5 MG, 25 MG	T5	PA; QL (31 EA per 31 days)
PROMACTA ORAL TABLET 50 MG, 75 MG	T5	PA; QL (62 EA per 31 days)
propafenone oral capsule,extended release 12 hr	T4	
propafenone oral tablet	T2	
propranolol oral capsule,extended release 24 hr	T2	
propranolol oral solution	T2	
propranolol oral tablet	T1	
QBRELIS	T5	
QUESTRAN LIGHT	T4	
QUESTRAN ORAL POWDER	T4	
quinapril	T1	
quinidine gluconate oral	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
quinidine sulfate oral tablet	T2	
ramipril	T1	
ranolazine	T2	QL (62 EA per 31 days)
REPATHA PUSHTRONEX	T3	PA; QL (7 ML per 28 days)
REPATHA SURECLICK	T3	PA; QL (3 ML per 28 days)
REPATHA SYRINGE	T3	PA; QL (3 ML per 28 days)
rosuvastatin	T1	
RYTHMOL SR ORAL CAPSULE,EXTENDED RELEASE 12 HR 225 MG, 425 MG	T4	
RYTHMOL SR ORAL CAPSULE,EXTENDED RELEASE 12 HR 325 MG	T5	
SAVAYSA	T4	QL (31 EA per 31 days)
simvastatin	T1	
SOAANZ	T4	ST
SORINE	T2	
SOTALOL AF	T2	
sotalol oral	T2	
SOTYLIZE	T4	
spironolactone oral tablet	T1	
spironolacton-hydrochlorothiaz	T2	
SULAR ORAL TABLET EXTENDED RELEASE 24 HR 17 MG, 34 MG, 8.5 MG	T4	
TAVALISSE	T5	PA; QL (62 EA per 31 days)
TAZTIA XT	T2	
TEKTURNA	T4	
telmisartan	T2	
telmisartan-amlodipine	T2	
telmisartan-hydrochlorothiazid	T2	
TENORETIC 100	T4	
TENORETIC 50	T4	
TENORMIN	T4	
terazosin	T1	
THALITONE	T4	
TIADYLT ER	T2	
TIAZAC	T4	
TIKOSYN	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
timolol maleate oral	T2	
TOPROL XL	T4	
torsemide oral	T2	
trandolapril	T1	
trandolapril-verapamil	T2	
triamterene	T4	
triamterene-hydrochlorothiazid	T1	
TRIBENZOR	T4	
TRICOR	T4	
TRILIPIX	T4	
UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG	T5	PA; QL (62 EA per 31 days)
UPTRAVI ORAL TABLET 200 MCG	T5	PA; QL (224 EA per 28 days)
UPTRAVI ORAL TABLETS,DOSE PACK	T5	PA; QL (400 EA per 365 days)
valsartan oral solution	T5	QL (2480 ML per 31 days)
valsartan oral tablet 160 mg, 40 mg, 80 mg	T1	QL (62 EA per 31 days)
valsartan oral tablet 320 mg	T1	QL (31 EA per 31 days)
valsartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
VASCEPA ORAL CAPSULE 0.5 GRAM	T3	QL (248 EA per 31 days)
VASCEPA ORAL CAPSULE 1 GRAM	T3	QL (124 EA per 31 days)
VASERETIC	T4	
VASOTEC	T4	
VECAMYL	T5	
verapamil oral capsule, 24 hr er pellet ct	T2	
verapamil oral capsule,ext rel. pellets 24 hr	T2	
verapamil oral tablet	T1	
verapamil oral tablet extended release	T2	
VERELAN	T4	
VERELAN PM	T4	
VERQUVO	T3	PA; QL (31 EA per 31 days)
VYNDAMAX	T5	PA; QL (31 EA per 31 days)
VYNDAQEL	T5	PA; QL (124 EA per 31 days)
VYTORIN 10-10	T4	
VYTORIN 10-20	T4	
VYTORIN 10-40	T4	
VYTORIN 10-80	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
warfarin	T1	
WELCHOL	T4	
XARELTO DVT-PE TREAT 30D START	T3	QL (51 EA per 30 days)
XARELTO ORAL SUSPENSION FOR RECONSTITUTION	T3	QL (930 ML per 31 days)
XARELTO ORAL TABLET 10 MG, 20 MG	T3	QL (31 EA per 31 days)
XARELTO ORAL TABLET 15 MG	T3	QL (52 EA per 31 days)
XARELTO ORAL TABLET 2.5 MG	T3	QL (62 EA per 31 days)
ZESTORETIC	T4	
ZESTRIL	T4	
ZETIA	T4	
ZIAC	T4	
ZOCOR ORAL TABLET 10 MG, 20 MG, 40 MG	T4	
ZONTIVITY	T4	
ZYPITAMAG	T4	
Dermatologicals/Topical Therapy		
ABSORICA	T5	
ABSORICA LD	T5	
ACANYA TOPICAL GEL WITH PUMP	T4	
ACCUTANE	T4	
acitretin	T4	PA
acyclovir topical cream	T4	QL (5 GM per 28 days)
acyclovir topical ointment	T4	QL (30 GM per 30 days)
ACZONE	T4	QL (90 GM per 28 days)
adapalene topical cream	T4	PA
adapalene topical gel 0.3 %	T4	PA
adapalene topical swab	T4	PA
adapalene-benzoyl peroxide	T4	PA
ADBRY	T5	PA; QL (4 ML per 28 days)
AKLIEF	T4	PA
ALA-CORT TOPICAL CREAM 1 %	T2	
ALA-CORT TOPICAL CREAM 2.5 %	T2	QL (30 GM per 28 days)
ALA-SCALP	T4	
alclometasone	T2	
ALTABAX	T4	QL (30 GM per 28 days)
ALTRENO	T4	PA; QL (45 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
amcinonide topical lotion	T4	
amcinonide topical ointment	T2	
ammonium lactate	T2	
AMNESTEEM	T4	
AMZEEQ	T4	
APEXICON E	T4	QL (60 GM per 28 days)
ARAZLO	T4	PA; QL (45 GM per 28 days)
ATRALIN	T4	PA; QL (45 GM per 28 days)
azelaic acid	T4	QL (50 GM per 28 days)
AZELEX	T4	QL (50 GM per 28 days)
BENZAMYCIN	T4	
betamethasone dipropionate	T2	
betamethasone valerate topical cream	T2	
betamethasone valerate topical foam	T4	
betamethasone valerate topical lotion	T2	
betamethasone valerate topical ointment	T2	
betamethasone, augmented	T2	
brimonidine topical	T4	
BRYHALI	T4	QL (100 GM per 28 days)
calcipotriene scalp	T3	QL (60 ML per 28 days)
calcipotriene topical cream	T4	QL (60 GM per 28 days)
calcipotriene topical foam	T4	ST; QL (120 GM per 28 days)
calcipotriene topical ointment	T4	QL (60 GM per 28 days)
calcipotriene-betamethasone	T4	ST; QL (400 GM per 28 days)
calcitriol topical	T4	ST
CAPEX	T4	QL (840 ML per 28 days)
CARAC	T5	PA
CIBINQO	T5	PA; QL (31 EA per 31 days)
ciclopirox topical cream	T2	QL (90 GM per 28 days)
ciclopirox topical gel	T2	QL (45 GM per 28 days)
ciclopirox topical shampoo	T2	QL (120 ML per 28 days)
ciclopirox topical solution	T2	
ciclopirox topical suspension	T2	QL (60 ML per 28 days)
CLARAVIS	T4	
CLEOCIN T TOPICAL LOTION	T4	QL (60 ML per 28 days)
CLINDACIN	T2	QL (100 GM per 28 days)
CLINDACIN ETZ TOPICAL SWAB	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
CLINDAGEL	T5	QL (75 ML per 28 days)
clindamycin phosphate topical foam	T4	QL (100 GM per 28 days)
clindamycin phosphate topical gel	T2	QL (75 GM per 28 days)
clindamycin phosphate topical lotion	T3	QL (60 ML per 28 days)
clindamycin phosphate topical solution	T3	QL (60 ML per 28 days)
clindamycin phosphate topical swab	T4	
clindamycin-benzoyl peroxide topical gel	T4	
clindamycin-benzoyl peroxide topical gel with pump 1.2-2.5 %	T4	
clindamycin-tretinoin	T4	PA; QL (60 GM per 28 days)
clobetasol scalp	T4	QL (50 ML per 28 days)
clobetasol topical cream	T4	QL (60 GM per 28 days)
clobetasol topical foam	T4	QL (100 GM per 28 days)
clobetasol topical gel	T4	QL (60 GM per 28 days)
clobetasol topical lotion	T4	QL (118 ML per 28 days)
clobetasol topical ointment	T4	QL (60 GM per 28 days)
clobetasol topical shampoo	T4	QL (118 ML per 28 days)
clobetasol topical spray,non-aerosol	T4	QL (125 ML per 28 days)
clobetasol-emollient topical cream	T4	QL (60 GM per 28 days)
clobetasol-emollient topical foam	T4	QL (100 GM per 28 days)
CLOBEX TOPICAL LOTION	T4	QL (118 ML per 28 days)
CLOBEX TOPICAL SHAMPOO	T4	QL (118 ML per 28 days)
CLOBEX TOPICAL SPRAY,NON-AEROSOL	T4	QL (125 ML per 28 days)
clocortolone pivalate	T4	
CLODAN	T4	QL (118 ML per 28 days)
CLODERM	T4	
clotrimazole topical cream	T2	QL (45 GM per 28 days)
clotrimazole topical solution	T2	QL (30 ML per 28 days)
clotrimazole-betamethasone topical cream	T2	QL (45 GM per 28 days)
clotrimazole-betamethasone topical lotion	T2	QL (60 ML per 28 days)
CONDYLOX TOPICAL GEL	T4	
CORDRAN TAPE LARGE ROLL	T4	
CORDRAN TOPICAL CREAM 0.05 %	T4	QL (120 GM per 28 days)
CORDRAN TOPICAL LOTION	T4	QL (120 ML per 28 days)
COSENTYX (2 SYRINGES)	T5	PA; QL (2 ML per 28 days)
COSENTYX PEN (2 PENS)	T5	PA; QL (2 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)
COSENTYX UNOREADY PEN	T5	PA; QL (2 ML per 28 days)
CROTAN	T4	
dapsone topical	T4	QL (90 GM per 28 days)
DENAVIR	T5	QL (5 GM per 28 days)
DERMA-SMOOTHE/FS SCALP OIL	T4	QL (118.28 ML per 28 days)
desonide topical cream	T4	QL (60 GM per 28 days)
desonide topical gel	T4	QL (60 GM per 28 days)
desonide topical lotion	T4	QL (118 ML per 28 days)
desonide topical ointment	T4	QL (60 GM per 28 days)
DESOWEN TOPICAL CREAM	T4	QL (60 GM per 28 days)
desoximetasone topical cream	T4	QL (100 GM per 28 days)
desoximetasone topical gel	T4	QL (60 GM per 28 days)
desoximetasone topical ointment	T4	QL (100 GM per 28 days)
desoximetasone topical spray,non-aerosol	T4	QL (100 ML per 28 days)
diclofenac sodium topical gel 3 %	T4	PA; QL (100 GM per 28 days)
DIFFERIN TOPICAL CREAM	T4	PA
DIFFERIN TOPICAL GEL WITH PUMP	T4	PA
DIFFERIN TOPICAL LOTION	T4	PA
diflorasone	T4	QL (60 GM per 28 days)
DIPROLENE (AUGMENTED) TOPICAL OINTMENT	T4	
doxepin topical	T4	PA; QL (45 GM per 28 days)
DUOBRII	T5	PA; QL (200 GM per 28 days)
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML	T5	PA; QL (2.28 ML per 28 days)
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML	T5	PA; QL (8 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML	T5	PA; QL (1.34 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML	T5	PA; QL (2.28 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML	T5	PA; QL (8 ML per 28 days)
econazole	T4	QL (85 GM per 28 days)
EFUDEX TOPICAL CREAM	T4	
ELIDEL	T4	QL (100 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ENSTILAR	T5	ST; QL (60 GM per 28 days)
EPIDUO FORTE	T4	PA
EPIDUO TOPICAL GEL WITH PUMP	T4	PA
EPSOLAY	T4	QL (30 GM per 28 days)
ERTACZO	T4	ST; QL (60 GM per 28 days)
ERY PADS	T2	
ERYGEL	T4	QL (60 GM per 28 days)
erythromycin with ethanol topical gel	T4	QL (60 GM per 28 days)
erythromycin with ethanol topical solution	T2	QL (60 ML per 28 days)
erythromycin-benzoyl peroxide	T4	
EUCRISA	T4	PA; QL (60 GM per 30 days)
EXELDERM TOPICAL CREAM	T4	ST; QL (60 GM per 28 days)
EXELDERM TOPICAL SOLUTION	T4	ST; QL (30 ML per 28 days)
FABIOR	T4	PA; QL (100 GM per 28 days)
FINACEA	T4	QL (50 GM per 28 days)
fluocinolone and shower cap	T4	QL (118.28 ML per 28 days)
fluocinolone topical cream 0.01 %	T4	QL (60 GM per 28 days)
fluocinolone topical cream 0.025 %	T4	QL (120 GM per 28 days)
fluocinolone topical ointment	T4	QL (120 GM per 28 days)
fluocinolone topical solution	T4	QL (90 ML per 28 days)
fluocinonide topical cream 0.05 %	T4	QL (60 GM per 28 days)
fluocinonide topical cream 0.1 %	T4	QL (120 GM per 28 days)
fluocinonide topical gel	T4	QL (60 GM per 28 days)
fluocinonide topical ointment	T4	QL (60 GM per 28 days)
fluocinonide topical solution	T4	QL (60 ML per 28 days)
fluocinonide-emollient	T4	QL (60 GM per 28 days)
fluorouracil topical cream 0.5 %	T5	
fluorouracil topical cream 5 %	T3	
fluorouracil topical solution	T3	
flurandrenolide topical cream	T4	QL (120 GM per 28 days)
flurandrenolide topical lotion	T4	QL (120 ML per 28 days)
fluticasone propionate topical cream	T4	
fluticasone propionate topical lotion	T4	QL (120 ML per 28 days)
fluticasone propionate topical ointment	T4	
gentamicin topical	T2	QL (60 GM per 28 days)
halcinonide	T4	
halobetasol propionate topical cream	T4	QL (50 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
halobetasol propionate topical foam	T4	QL (120 GM per 28 days)
halobetasol propionate topical ointment	T4	QL (50 GM per 28 days)
HALOG	T4	
hydrocortisone butyrate topical cream	T4	QL (45 GM per 28 days)
hydrocortisone butyrate topical lotion	T4	QL (118 ML per 28 days)
hydrocortisone butyrate topical ointment	T4	QL (45 GM per 28 days)
hydrocortisone butyrate topical solution	T4	QL (60 ML per 28 days)
hydrocortisone topical cream 1 %	T2	
hydrocortisone topical lotion 2.5 %	T2	QL (118 ML per 28 days)
hydrocortisone topical ointment 1 %, 2.5 %	T2	
hydrocortisone valerate	T4	QL (60 GM per 28 days)
HYFTOR	T5	PA; QL (30 GM per 30 days)
ILUMYA	T5	PA; QL (1 ML per 84 days)
imiquimod topical cream in metered-dose pump	T5	
imiquimod topical cream in packet 5 %	T2	
isotretinoin	T4	
ivermectin topical cream	T2	
JUBLIA	T4	
KENALOG TOPICAL	T4	QL (100 GM per 28 days)
KERYDIN	T4	
ketoconazole topical cream	T2	QL (60 GM per 28 days)
ketoconazole topical foam	T4	QL (100 GM per 28 days)
ketoconazole topical shampoo	T2	QL (120 ML per 28 days)
KETODAN	T4	ST; QL (100 GM per 28 days)
KLARON	T4	
LEXETTE	T5	QL (200 GM per 28 days)
lidocaine hcl mucous membrane solution 4 % (40 mg/ml)	T2	PA; QL (50 ML per 28 days)
lidocaine topical adhesive patch,medicated 5 %	T2	PA; QL (93 EA per 31 days)
lidocaine topical ointment	T4	PA; QL (50 GM per 28 days)
LIDOCAINE VISCOUS	T2	
lidocaine-prilocaine topical cream	T2	PA; QL (30 GM per 28 days)
LIDODERM	T4	PA; QL (93 EA per 31 days)
LOCOID LIPOCREAM	T4	QL (60 GM per 28 days)
LOCOID TOPICAL LOTION	T4	QL (118 ML per 28 days)
LOPROX TOPICAL SHAMPOO	T4	QL (120 ML per 28 days)
luliconazole	T4	QL (60 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LUZU	T4	QL (60 GM per 28 days)
mafenide acetate	T2	
malathion	T2	
methoxsalen	T5	
METROCREAM	T4	
METROGEL TOPICAL GEL 1 %	T4	
METROLOTION	T4	
metronidazole topical cream	T4	
metronidazole topical gel	T4	
metronidazole topical lotion	T4	
MIRVASO	T4	
mometasone topical	T2	
mupirocin	T2	
mupirocin calcium	T4	ST
naftifine topical cream 1 %	T4	ST; QL (90 GM per 28 days)
naftifine topical cream 2 %	T4	ST; QL (60 GM per 28 days)
naftifine topical gel 2 %	T4	ST; QL (60 GM per 28 days)
NAFTIN TOPICAL GEL 1 %	T4	ST; QL (90 GM per 28 days)
NAFTIN TOPICAL GEL 2 %	T4	ST; QL (60 GM per 28 days)
NATROBA	T4	
NEO-SYNALAR	T4	
NEUAC	T4	
NORITATE	T5	
NYAMYC	T2	QL (60 GM per 28 days)
nystatin topical cream	T2	QL (30 GM per 28 days)
nystatin topical ointment	T2	QL (30 GM per 28 days)
nystatin topical powder	T2	QL (60 GM per 28 days)
nystatin-triamcinolone	T3	QL (60 GM per 28 days)
NYSTOP	T2	QL (60 GM per 28 days)
ONEXTON TOPICAL GEL WITH PUMP	T4	
OPZELURA	T5	PA; QL (60 GM per 7 days)
OVIDE	T4	
oxiconazole	T4	ST; QL (90 GM per 28 days)
OXISTAT TOPICAL CREAM	T4	ST; QL (90 GM per 28 days)
OXISTAT TOPICAL LOTION	T4	ST; QL (60 ML per 28 days)
PANDEL	T5	QL (80 GM per 28 days)
PANRETIN	T5	PA-NS

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
penciclovir	T3	QL (5 GM per 28 days)
permethrin	T2	
pimecrolimus	T4	QL (100 GM per 28 days)
PLIAGLIS	T4	PA; QL (100 GM per 28 days)
podofilox	T2	
PRUDOXIN	T4	PA; QL (45 GM per 28 days)
REGRANEX	T5	PA
RETIN-A	T4	PA; QL (45 GM per 28 days)
RETIN-A MICRO	T4	PA; QL (45 GM per 28 days)
RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 %	T4	PA; QL (50 GM per 28 days)
RHOFADE	T4	
SANTYL	T3	QL (180 GM per 30 days)
selenium sulfide topical lotion	T2	
SILIQ	T5	PA; QL (6 ML per 28 days)
SILVADENE	T4	
silver sulfadiazine	T2	
SKYRIZI SUBCUTANEOUS PEN INJECTOR	T5	PA; QL (1 ML per 84 days)
SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML	T5	PA; QL (1 ML per 84 days)
SOOLANTRA	T4	
SORILUX	T4	ST; QL (120 GM per 28 days)
SOTYKTU	T5	PA; QL (31 EA per 31 days)
spinosad	T4	
SSD	T4	
STELARA SUBCUTANEOUS SOLUTION	T5	PA; QL (0.5 ML per 84 days)
STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T5	PA; QL (0.5 ML per 84 days)
STELARA SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
sulfacetamide sodium (acne)	T2	
SULFAMYLON TOPICAL CREAM	T3	
SYNALAR TOPICAL CREAM	T4	QL (120 GM per 28 days)
SYNALAR TOPICAL SOLUTION	T4	QL (90 ML per 28 days)
TACLONEX	T5	ST; QL (400 GM per 28 days)
tacrolimus topical	T4	QL (100 GM per 28 days)
TALTZ AUTOINJECTOR	T5	PA; QL (1 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
TALTZ SYRINGE	T5	PA; QL (1 ML per 28 days)
tavaborole	T4	
tazarotene topical cream	T4	PA; QL (60 GM per 28 days)
tazarotene topical foam	T4	PA; QL (100 GM per 28 days)
tazarotene topical gel	T4	PA; QL (100 GM per 28 days)
TAZORAC TOPICAL CREAM	T4	PA; QL (60 GM per 28 days)
TAZORAC TOPICAL GEL	T4	PA; QL (100 GM per 28 days)
TEXACORT	T4	
TOPICORT TOPICAL CREAM	T4	QL (100 GM per 28 days)
TOPICORT TOPICAL GEL	T4	QL (60 GM per 28 days)
TOPICORT TOPICAL OINTMENT 0.05 %	T4	QL (100 GM per 28 days)
TOPICORT TOPICAL SPRAY,NON-AEROSOL	T4	QL (100 ML per 28 days)
TOVET EMOLLIENT	T4	QL (100 GM per 28 days)
TREMFYA	T5	PA; QL (1 ML per 56 days)
tretinoin microspheres topical gel	T4	PA; QL (50 GM per 28 days)
tretinoin microspheres topical gel with pump 0.08 %	T4	PA; QL (50 GM per 28 days)
tretinoin topical cream	T4	PA; QL (45 GM per 28 days)
tretinoin topical gel	T3	PA; QL (45 GM per 28 days)
triamcinolone acetonide topical aerosol	T4	QL (100 GM per 28 days)
triamcinolone acetonide topical cream	T2	
triamcinolone acetonide topical lotion	T2	
triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %	T2	
triamcinolone acetonide topical ointment 0.05 %	T4	
TRIANEX	T4	
TRIDERM TOPICAL CREAM	T2	
TWYNEO	T4	PA; QL (30 GM per 28 days)
ULTRAVATE TOPICAL LOTION	T5	QL (120 ML per 28 days)
VALCHLOR	T5	PA-NS
VANOS	T5	QL (120 GM per 28 days)
VECTICAL	T4	ST
VELTIN	T4	PA; QL (60 GM per 28 days)
VERDESO	T4	QL (100 GM per 28 days)
VTAMA	T5	PA; QL (60 GM per 28 days)
WINLEVI	T4	PA; QL (60 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
XERESE	T5	
ZENATANE	T4	
ZIANA	T4	PA; QL (60 GM per 28 days)
ZILXI	T4	
ZONALON	T4	PA; QL (30 GM per 28 days)
ZORYVE	T4	PA; QL (60 GM per 28 days)
ZOVIRAX TOPICAL CREAM	T4	QL (5 GM per 28 days)
ZOVIRAX TOPICAL OINTMENT	T4	QL (30 GM per 30 days)
ZTLIDO	T4	PA; QL (93 EA per 31 days)
ZYCLARA TOPICAL CREAM IN METERED-DOSE PUMP	T5	
Diagnostics / Miscellaneous Agents		
acamprosate	T4	
AGRYLIN	T4	
anagrelide	T2	
ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG	T5	PA
AURYXIA	T5	PA; QL (372 EA per 31 days)
BUPHENYL	T5	PA
bupropion hcl (smoking deter)	T2	QL (62 EA per 31 days)
CARBAGLU	T5	PA
carglumic acid	T5	PA
CARNITOR ORAL	T4	PA-BvD
cevimeline	T4	
CHEMET	T4	
CLINIMIX 4.25%/D5W SULFIT FREE	T4	PA-BvD
CLINIMIX E 2.75%/D5W SULF FREE	T4	PA-BvD
CUVRIOR	T5	PA; QL (310 EA per 31 days)
d10 %-0.45 % sodium chloride	T2	
d2.5 %-0.45 % sodium chloride	T2	
d5 % and 0.9 % sodium chloride	T2	
d5 %-0.45 % sodium chloride	T2	
deferasirox oral granules in packet	T5	PA
deferasirox oral tablet 180 mg, 360 mg	T5	PA
deferasirox oral tablet 90 mg	T4	PA
deferasirox oral tablet, dispersible	T5	PA
deferiprone	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
dextrose 10 % and 0.2 % nacl	T2	
dextrose 10 % in water (d10w)	T2	
dextrose 5 % in water (d5w) intravenous piggyback	T2	
dextrose 5%-0.2 % sod chloride	T2	
disulfiram	T2	
droxidopa oral capsule 100 mg	T5	PA; QL (465 EA per 31 days)
droxidopa oral capsule 200 mg, 300 mg	T5	PA; QL (186 EA per 31 days)
ENDARI	T5	PA; QL (180 EA per 30 days)
EVOXAC	T4	
EXJADE	T5	PA
EXSERVAN	T5	PA; QL (62 EA per 31 days)
FERRIPROX (2 TIMES A DAY)	T5	PA
FERRIPROX ORAL SOLUTION	T5	PA
FERRIPROX ORAL TABLET 500 MG	T5	PA
FOSRENOL	T4	
GLASSIA	T5	PA
INCRELEX	T5	PA
JADENU	T5	PA
JADENU SPRINKLE	T5	PA
lanthanum oral tablet,chewable 1,000 mg	T5	
lanthanum oral tablet,chewable 500 mg, 750 mg	T4	
levocarnitine (with sugar)	T2	PA-BvD
levocarnitine oral tablet	T2	PA-BvD
LITFULO	T5	PA; QL (28 EA per 28 days)
LITHOSTAT	T5	
LOKELMA	T3	PA; QL (93 EA per 31 days)
midodrine	T2	
NICOTROL	T4	
NICOTROL NS	T4	
nitisinone	T5	
NITYR	T5	
NORTHERA ORAL CAPSULE 100 MG	T5	PA; QL (465 EA per 31 days)
NORTHERA ORAL CAPSULE 200 MG, 300 MG	T5	PA; QL (186 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 2 GRAM, 3 GRAM	T5	PA; QL (186 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
OLPRUVA ORAL PELLETS IN PACKET 4 GRAM	T5	PA; QL (155 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 5 GRAM	T5	PA; QL (124 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 6 GRAM	T5	PA; QL (93 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 6.67 GRAM	T5	PA; QL (62 EA per 31 days)
ORFADIN	T5	
OXBRYTA ORAL TABLET 300 MG	T5	PA; QL (248 EA per 31 days)
OXBRYTA ORAL TABLET 500 MG	T5	PA; QL (155 EA per 31 days)
OXBRYTA ORAL TABLET FOR SUSPENSION	T5	PA; QL (248 EA per 31 days)
PHEBURANE	T5	PA; QL (620 GM per 31 days)
pilocarpine hcl oral	T2	
PROLASTIN-C INTRAVENOUS RECON SOLN	T5	PA
PYRUKYND ORAL TABLET 20 MG, 5 MG (4-WEEK PACK), 50 MG	T5	PA; QL (56 EA per 28 days)
PYRUKYND ORAL TABLET 5 MG	T5	PA; QL (14 EA per 365 days)
PYRUKYND ORAL TABLETS,DOSE PACK	T5	PA; QL (28 EA per 365 days)
RAVICTI	T5	PA
RENAGEL ORAL TABLET 800 MG	T4	
RENVELA ORAL POWDER IN PACKET	T4	
REVCOVI	T5	
RILUTEK	T5	
riluzole	T3	
risedronate oral tablet 30 mg	T2	
SALAGEN (PILOCARPINE)	T4	
sevelamer carbonate oral powder in packet	T4	
sevelamer carbonate oral tablet	T3	
sevelamer hcl	T4	
sodium chloride 0.9 % intravenous piggyback	T2	
sodium chloride irrigation	T2	
sodium phenylbutyrate	T5	PA
sodium polystyrene sulfonate oral powder	T2	
SPS (WITH SORBITOL) ORAL	T2	
SYPRINE	T5	QL (248 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
TAVNEOS	T5	PA; QL (186 EA per 31 days)
THIOLA	T5	PA
THIOLA EC	T5	PA
TIGLUTIK	T5	PA
tiopronin	T5	PA
trientine oral capsule 250 mg	T5	QL (248 EA per 31 days)
varenicline oral tablet	T4	QL (60 EA per 30 days)
varenicline oral tablets,dose pack	T4	QL (106 EA per 365 days)
VELPHORO	T5	
VELTASSA	T3	PA; QL (30 EA per 30 days)
XURIDEN	T5	PA; QL (124 EA per 31 days)
ZEMAIRA	T5	PA
ZOKINVY	T5	PA
Ear, Nose / Throat Medications		
acetic acid otic (ear)	T2	
azelastine nasal aerosol,spray	T3	QL (30 ML per 25 days)
CETRAXAL	T4	
chlorhexidine gluconate mucous membrane	T1	
CIPRO HC	T4	
ciprofloxacin hcl otic (ear)	T4	
ciprofloxacin-dexamethasone	T3	
ciprofloxacin-fluocinolone	T4	
DERMOTIC OIL	T4	
FLAC OTIC OIL	T4	
fluocinolone acetonide oil	T4	
hydrocortisone-acetic acid	T2	
ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)	T2	QL (30 ML per 28 days)
ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)	T2	QL (15 ML per 28 days)
neomycin-polymyxin-hc otic (ear)	T2	
ofloxacin otic (ear)	T2	
olopatadine nasal	T4	QL (30.5 GM per 30 days)
OTOVEL	T4	
PERIOGARD	T1	
triamcinolone acetonide dental	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
Endocrine/Diabetes		
acarbose	T2	QL (93 EA per 31 days)
ACTHAR	T5	PA
ACTOPLUS MET ORAL TABLET 15-850 MG	T4	QL (93 EA per 31 days)
ACTOS	T4	QL (31 EA per 31 days)
ADMELOG SOLOSTAR U-100 INSULIN	T4	
ADMELOG U-100 INSULIN LISPRO	T4	
AFREZZA INHALATION CARTRIDGE WITH INHALER 12 UNIT, 4 UNIT, 4 UNIT/8 UNIT/ 12 UNIT (60), 8 UNIT	T4	
AFREZZA INHALATION CARTRIDGE WITH INHALER 4 UNIT (90)/ 8 UNIT (90), 8 UNIT (90)/ 12 UNIT (90)	T5	
ALCOHOL PADS	T3	
ALKINDI SPRINKLE ORAL CAPSULE, SPRINKLE 0.5 MG	T4	PA
ALKINDI SPRINKLE ORAL CAPSULE, SPRINKLE 1 MG, 2 MG, 5 MG	T5	PA
alogliptin	T4	QL (31 EA per 31 days)
alogliptin-metformin	T4	QL (62 EA per 31 days)
alogliptin-pioglitazone oral tablet 12.5-30 mg, 25-15 mg, 25-30 mg, 25-45 mg	T4	QL (31 EA per 31 days)
ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP	T4	PA
APIDRA SOLOSTAR U-100 INSULIN	T4	
APIDRA U-100 INSULIN	T4	
AVEED	T4	PA
BAQSIMI	T3	
BASAGLAR KWIKPEN U-100 INSULIN	T4	
BASAGLAR TEMPO PEN(U-100)INSLN	T4	
BYDUREON BCISE	T3	PA
BYETTA	T3	PA
cabergoline	T3	
calcitonin (salmon) nasal	T2	PA-BvD
calcitriol oral	T2	PA-BvD
CERDELGA	T5	PA; QL (62 EA per 31 days)
cinacalcet oral tablet 30 mg, 60 mg	T4	PA-BvD; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
cinacalcet oral tablet 90 mg	T4	PA-BvD; QL (124 EA per 31 days)
CORTEF	T4	
CORTROPHIN GEL	T5	PA
CYCLOSET	T4	
CYTOMEL	T4	
danazol	T4	
DDAVP ORAL	T4	
DEPO-TESTOSTERONE	T4	PA
desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)	T3	
desmopressin oral	T3	
DEXABLISS	T4	
dexamethasone oral solution	T2	
dexamethasone oral tablet	T1	
dexamethasone oral tablets,dose pack	T4	
diazoxide	T4	
doxercalciferol oral	T4	PA-BvD
DUETACT	T4	QL (31 EA per 31 days)
EMFLAZA	T5	PA
ERMEZA	T4	
EUTHYROX	T3	
FARXIGA	T3	QL (31 EA per 31 days)
FIASP FLEXTOUCH U-100 INSULIN	T4	
FIASP PENFILL U-100 INSULIN	T4	
FIASP U-100 INSULIN	T4	
fludrocortisone	T1	
FORTESTA	T4	PA
GALAFOLD	T5	PA; QL (14 EA per 28 days)
glimepiride	T1	
glipizide oral tablet 10 mg, 5 mg	T1	
glipizide oral tablet extended release 24hr	T1	
glipizide-metformin	T1	
GLUCAGEN HYPOKIT	T4	
GLUCAGON EMERGENCY KIT (HUMAN)	T4	
GLUCOTROL XL	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
GLUMETZA ORAL TABLET,ER GAST.RETENTION 24 HR 1,000 MG	T5	ST; QL (62 EA per 31 days)
GLUMETZA ORAL TABLET,ER GAST.RETENTION 24 HR 500 MG	T5	ST; QL (31 EA per 31 days)
glyburide	T4	
glyburide micronized	T4	
glyburide-metformin	T4	
GLYNASE	T4	
GLYXAMBI	T3	QL (31 EA per 31 days)
GVOKE	T3	
GVOKE HYPOPEN 2-PACK	T3	
GVOKE PFS 1-PACK SYRINGE	T3	
HEMADY	T4	PA-NS
HUMALOG JUNIOR KWIKPEN U-100	T3	
HUMALOG KWIKPEN INSULIN	T3	
HUMALOG MIX 50-50 INSULN U-100	T3	
HUMALOG MIX 50-50 KWIKPEN	T3	
HUMALOG MIX 75-25 KWIKPEN	T3	
HUMALOG MIX 75-25(U-100)INSULN	T3	
HUMALOG TEMPO PEN(U-100)INSULN	T3	
HUMALOG U-100 INSULIN	T3	
HUMULIN 70/30 U-100 INSULIN	T3	
HUMULIN 70/30 U-100 KWIKPEN	T3	
HUMULIN N NPH INSULIN KWIKPEN	T3	
HUMULIN N NPH U-100 INSULIN	T3	
HUMULIN R REGULAR U-100 INSULN	T3	
HUMULIN R U-500 (CONC) INSULIN	T3	
HUMULIN R U-500 (CONC) KWIKPEN	T3	
hydrocortisone oral	T2	
INPEFA ORAL TABLET 200 MG	T4	QL (62 EA per 31 days)
insulin asp prt-insulin aspart	T4	
insulin aspart u-100	T4	
insulin degludec	T4	
insulin glargine	T4	
insulin glargine-yfgn	T4	
insulin lispro	T4	
insulin lispro protamin-lispro	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
INVOKAMET	T4	QL (62 EA per 31 days)
INVOKAMET XR	T4	QL (62 EA per 31 days)
INVOKANA ORAL TABLET 100 MG	T4	QL (62 EA per 31 days)
INVOKANA ORAL TABLET 300 MG	T4	QL (31 EA per 31 days)
ISTURISA ORAL TABLET 1 MG	T5	PA; QL (248 EA per 31 days)
ISTURISA ORAL TABLET 10 MG	T5	PA; QL (186 EA per 31 days)
ISTURISA ORAL TABLET 5 MG	T5	PA; QL (62 EA per 31 days)
JANUMET	T3	QL (62 EA per 31 days)
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-500 MG	T3	QL (31 EA per 31 days)
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG	T3	QL (62 EA per 31 days)
JANUVIA ORAL TABLET 100 MG, 50 MG	T3	QL (31 EA per 31 days)
JANUVIA ORAL TABLET 25 MG	T3	QL (93 EA per 31 days)
JARDIANCE ORAL TABLET 10 MG	T3	QL (62 EA per 31 days)
JARDIANCE ORAL TABLET 25 MG	T3	QL (31 EA per 31 days)
JATENZO ORAL CAPSULE 158 MG, 198 MG	T4	PA; QL (124 EA per 31 days)
JATENZO ORAL CAPSULE 237 MG	T5	PA; QL (62 EA per 31 days)
JAVYGTOR	T5	PA
JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG	T4	QL (62 EA per 31 days)
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG	T4	QL (62 EA per 31 days)
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG	T4	QL (31 EA per 31 days)
JYNARQUE ORAL TABLET	T5	PA; QL (112 EA per 28 days)
JYNARQUE ORAL TABLETS, SEQUENTIAL	T5	PA; QL (56 EA per 28 days)
KAZANO	T4	QL (62 EA per 31 days)
KOMBIGLYZE XR ORAL TABLET, ER MULTIPHASE 24 HR 2.5-1,000 MG	T4	QL (62 EA per 31 days)
KOMBIGLYZE XR ORAL TABLET, ER MULTIPHASE 24 HR 5-1,000 MG, 5-500 MG	T4	QL (31 EA per 31 days)
KORLYM	T5	PA; QL (124 EA per 31 days)
KUVAN	T5	PA
LANTUS SOLOSTAR U-100 INSULIN	T3	
LANTUS U-100 INSULIN	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LEVEMIR FLEXPEN	T4	
LEVEMIR U-100 INSULIN	T4	
levothyroxine oral capsule	T4	
levothyroxine oral tablet	T1	
LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG	T3	
liothyronine oral	T2	
LYUMJEV KWIKPEN U-100 INSULIN	T3	
LYUMJEV KWIKPEN U-200 INSULIN	T3	
LYUMJEV TEMPO PEN(U-100)INSULN	T3	
LYUMJEV U-100 INSULIN	T3	
MEDROL (PAK)	T4	
MEDROL ORAL TABLET 16 MG, 2 MG, 4 MG, 8 MG	T4	
metformin oral solution	T4	ST; QL (791 ML per 31 days)
metformin oral tablet 1,000 mg, 500 mg, 850 mg	T1	
metformin oral tablet 625 mg	T4	QL (124 EA per 31 days)
metformin oral tablet extended release 24 hr	T1	
metformin oral tablet extended release 24hr 1,000 mg	T4	ST; QL (62 EA per 31 days)
metformin oral tablet extended release 24hr 500 mg	T4	ST; QL (31 EA per 31 days)
metformin oral tablet,er gast.retention 24 hr 1,000 mg	T4	ST; QL (62 EA per 31 days)
metformin oral tablet,er gast.retention 24 hr 500 mg	T4	ST; QL (31 EA per 31 days)
methimazole oral tablet 10 mg, 5 mg	T1	
METHITEST	T4	PA
methylprednisolone	T2	
methyltestosterone oral capsule	T5	PA
miglitol	T4	
miglustat	T5	PA; QL (93 EA per 31 days)
MILLIPRED ORAL TABLET	T4	
MOUNJARO	T3	PA
MYALEPT	T5	PA
nateglinide	T2	QL (93 EA per 31 days)
NATESTO	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
NATPARA	T5	PA; QL (31 EA per 31 days)
NESINA	T4	QL (31 EA per 31 days)
NOCDURNA (MEN)	T4	QL (31 EA per 31 days)
NOCDURNA (WOMEN)	T4	QL (31 EA per 31 days)
NOVOLIN 70/30 U-100 INSULIN	T4	
NOVOLIN 70-30 FLEXPEN U-100	T4	
NOVOLIN N FLEXPEN	T4	
NOVOLIN N NPH U-100 INSULIN	T4	
NOVOLIN R FLEXPEN	T4	
NOVOLIN R REGULAR U100 INSULIN	T4	
NOVOLOG FLEXPEN U-100 INSULIN	T4	
NOVOLOG MIX 70-30 U-100 INSULN	T4	
NOVOLOG MIX 70-30FLEXPEN U-100	T4	
NOVOLOG PENFILL U-100 INSULIN	T4	
NOVOLOG U-100 INSULIN ASPART	T4	
ONGLYZA	T3	QL (31 EA per 31 days)
ORAPRED ODT	T4	
ORILISSA ORAL TABLET 150 MG	T5	PA; QL (31 EA per 31 days)
ORILISSA ORAL TABLET 200 MG	T5	PA; QL (62 EA per 31 days)
OSENI ORAL TABLET 12.5-30 MG, 25-15 MG, 25-30 MG, 25-45 MG	T4	QL (31 EA per 31 days)
OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)	T3	PA
PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML	T5	PA; QL (15 ML per 30 days)
PALYNZIQ SUBCUTANEOUS SYRINGE 2.5 MG/0.5 ML	T5	PA; QL (4 ML per 30 days)
PALYNZIQ SUBCUTANEOUS SYRINGE 20 MG/ML	T5	PA; QL (90 ML per 30 days)
paricalcitol oral	T4	PA-BvD
pioglitazone	T1	QL (31 EA per 31 days)
pioglitazone-glimepiride	T4	QL (31 EA per 31 days)
pioglitazone-metformin	T4	QL (93 EA per 31 days)
prednisolone oral solution	T2	
prednisolone oral tablet	T4	
prednisolone sodium phosphate oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)	T2	
prednisolone sodium phosphate oral tablet,disintegrating	T4	
PREDNISONE INTENSOL	T2	
prednisone oral solution	T2	
prednisone oral tablet	T1	
prednisone oral tablets,dose pack	T1	
PROGLYCEM	T4	
propylthiouracil	T2	
QTERN	T3	QL (31 EA per 31 days)
RAYALDEE	T5	QL (62 EA per 31 days)
RAYOS	T5	
RECORLEV	T5	PA; QL (248 EA per 31 days)
repaglinide oral tablet 0.5 mg, 1 mg	T2	QL (124 EA per 31 days)
repaglinide oral tablet 2 mg	T2	QL (248 EA per 31 days)
REZVOGLAR KWIKPEN	T4	
ROCALTROL	T4	PA-BvD
RYBELSUS	T3	PA
SAMSCA	T5	PA
sapropterin	T5	PA
saxagliptin	T4	QL (31 EA per 31 days)
saxagliptin-metformin oral tablet, er multiphase 24 hr 2.5-1,000 mg	T4	QL (62 EA per 31 days)
saxagliptin-metformin oral tablet, er multiphase 24 hr 5-1,000 mg, 5-500 mg	T4	QL (31 EA per 31 days)
SEGLUROMET	T4	QL (62 EA per 31 days)
SEMGLEE(INSULIN GLARGINE-YFGN)	T4	
SEMGLEE(INSULIN GLARG-YFGN)PEN	T4	
SENSIPAR ORAL TABLET 30 MG, 60 MG	T4	PA-BvD; QL (62 EA per 31 days)
SENSIPAR ORAL TABLET 90 MG	T4	PA-BvD; QL (124 EA per 31 days)
SOLIQUA 100/33	T3	QL (18 ML per 30 days)
SOMAVERT	T5	PA
STEGLATRO	T3	QL (31 EA per 31 days)
STEGLUJAN	T4	ST; QL (31 EA per 31 days)
SYMLINPEN 120	T5	QL (10.8 ML per 28 days)
SYMLINPEN 60	T5	QL (6 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
SYNAREL	T5	PA
SYNJARDY	T3	QL (62 EA per 31 days)
SYNTHROID	T4	
TAPERDEX	T4	
TARPEYO	T5	PA; QL (124 EA per 31 days)
TESTIM	T4	PA
testosterone cypionate	T3	PA
testosterone enanthate	T3	PA
testosterone transdermal gel in metered-dose pump 10 mg/0.5 gram /actuation, 20.25 mg/1.25 gram (1.62 %)	T3	PA
testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)	T4	PA
testosterone transdermal gel in packet	T3	PA
testosterone transdermal solution in metered pump w/app	T3	PA
THYQUIDITY	T4	
TIROSINT	T4	
TIROSINT-SOL	T4	
TLANDO	T4	PA; QL (124 EA per 31 days)
tolvaptan	T5	PA
TOUJEO MAX U-300 SOLOSTAR	T3	
TOUJEO SOLOSTAR U-300 INSULIN	T3	
TRADJENTA	T4	QL (31 EA per 31 days)
TRESIBA FLEXTOUCH U-100	T4	
TRESIBA FLEXTOUCH U-200	T4	
TRESIBA U-100 INSULIN	T4	
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG	T3	QL (31 EA per 31 days)
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG	T3	QL (62 EA per 31 days)
TRULICITY	T3	PA
UNITHROID	T3	
VICTOZA 3-PAK	T3	PA
VOGELXO TRANSDERMAL GEL	T4	PA
VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
VOXZOGO	T5	PA; QL (31 EA per 31 days)
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-500 MG	T3	QL (31 EA per 31 days)
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG	T3	QL (62 EA per 31 days)
XULTOPHY 100/3.6	T3	QL (15 ML per 30 days)
XYOSTED	T4	PA
ZAVESCA	T5	PA; QL (93 EA per 31 days)
ZEGALOGUE AUTOINJECTOR	T4	
ZEGALOGUE SYRINGE	T4	
ZEMPLAR ORAL CAPSULE 1 MCG, 2 MCG	T4	PA-BvD
Gastroenterology		
ACIPHEX	T4	QL (62 EA per 31 days)
alosetron oral tablet 0.5 mg	T5	PA; QL (93 EA per 31 days)
alosetron oral tablet 1 mg	T5	PA; QL (62 EA per 31 days)
AMITIZA	T4	QL (62 EA per 31 days)
amoxicil-clarithromy-lansopraz	T4	
ANTIVERT ORAL TABLET 50 MG	T4	
ANTIVERT ORAL TABLET,CHEWABLE	T4	
ANUSOL-HC TOPICAL	T4	
ANZEMET ORAL TABLET 50 MG	T4	PA-BvD
aprepitant	T4	PA-BvD
APRISO	T4	
AZULFIDINE	T4	
AZULFIDINE EN-TABS	T4	
balsalazide	T2	
betaine	T5	
bismuth subcit k-metronidz-tcn	T4	
BONJESTA	T4	PA; QL (62 EA per 31 days)
budesonide oral capsule,delayed,extend.release	T4	
budesonide oral tablet,delayed and ext.release	T5	
budesonide rectal	T4	
BYLVAY ORAL CAPSULE 1,200 MCG	T5	PA; QL (186 EA per 31 days)
BYLVAY ORAL CAPSULE 400 MCG	T5	PA; QL (558 EA per 31 days)
BYLVAY ORAL PELLET 200 MCG	T5	PA; QL (1116 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
BYLVAY ORAL PELLET 600 MCG	T5	PA; QL (372 EA per 31 days)
CANASA	T5	
CARAFATE	T4	
CHENODAL	T5	PA
chlordiazepoxide-clidinium	T4	
CHOLBAM	T5	PA
cimetidine	T2	
CIMZIA	T5	PA; QL (2 EA per 28 days)
CIMZIA POWDER FOR RECONST	T5	PA; QL (2 EA per 28 days)
CLENPIQ	T4	
COLAZAL	T5	
COMPRO	T2	
CONSTULOSE	T2	
CREON	T3	
cromolyn oral	T4	
CUVPOSA	T4	
CYSTADANE	T5	
CYTOTEC	T4	
DARTISLA	T4	PA; QL (124 EA per 31 days)
DELZICOL	T4	
DEXILANT	T4	QL (31 EA per 31 days)
dexlansoprazole	T4	QL (31 EA per 31 days)
DICLEGIS	T4	PA; QL (124 EA per 31 days)
dicyclomine oral capsule	T2	
dicyclomine oral solution	T2	
dicyclomine oral tablet	T2	
DIPENTUM	T5	
diphenoxylate-atropine	T2	
doxylamine-pyridoxine (vit b6)	T4	PA; QL (124 EA per 31 days)
dronabinol	T4	PA-BvD
EMEND ORAL CAPSULE 80 MG	T4	PA-BvD
EMEND ORAL CAPSULE,DOSE PACK	T4	PA-BvD
EMEND ORAL SUSPENSION FOR RECONSTITUTION	T4	PA-BvD
ENULOSE	T2	
esomeprazole magnesium oral capsule,delayed release(dr/ec)	T2	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
esomeprazole magnesium oral granules dr for susp in packet	T4	QL (31 EA per 31 days)
famotidine oral suspension	T2	
famotidine oral tablet 20 mg, 40 mg	T1	
GASTROCROM	T4	
GATTEX 30-VIAL	T5	PA
GAVILYTE-C	T2	
GAVILYTE-G	T2	
GENERLAC	T2	
GIMOTI	T5	PA; QL (9.8 ML per 28 days)
GLYCATE	T4	PA
glycopyrrolate oral solution	T4	
glycopyrrolate oral tablet 1 mg, 2 mg	T3	
glycopyrrolate oral tablet 1.5 mg	T4	PA
GOLYTELY	T4	
granisetron hcl oral	T2	PA-BvD
HELIDAC	T4	
hydrocortisone rectal	T4	
hydrocortisone topical cream with perineal applicator 2.5 %	T2	
hydrocortisone-pramoxine rectal cream 1-1 %	T4	
IBSRELA	T5	PA; QL (62 EA per 31 days)
KONVOMEP	T4	
KRISTALOSE	T4	ST
lactulose oral packet	T5	ST
lactulose oral solution 10 gram/15 ml	T2	
lansoprazole oral capsule,delayed release(dr/ec) 15 mg	T2	QL (31 EA per 31 days)
lansoprazole oral capsule,delayed release(dr/ec) 30 mg	T2	QL (62 EA per 31 days)
lansoprazole oral tablet,disintegrat, delay rel 15 mg	T4	QL (31 EA per 31 days)
lansoprazole oral tablet,disintegrat, delay rel 30 mg	T4	QL (62 EA per 31 days)
LIALDA	T5	
LIBRAX (WITH CLIDINIUM)	T5	
LINZESS	T3	QL (31 EA per 31 days)
LIVMARLI	T5	PA; QL (93 ML per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LOMOTIL	T4	
loperamide oral capsule	T2	
LOTRONEX ORAL TABLET 0.5 MG	T5	PA; QL (93 EA per 31 days)
LOTRONEX ORAL TABLET 1 MG	T5	PA; QL (62 EA per 31 days)
lubiprostone	T4	QL (62 EA per 31 days)
MARINOL ORAL CAPSULE 10 MG, 5 MG	T5	PA-BvD
MARINOL ORAL CAPSULE 2.5 MG	T4	PA-BvD
meclizine oral tablet 12.5 mg, 25 mg	T2	
mesalamine oral capsule (with del rel tablets)	T4	
mesalamine oral capsule, extended release	T5	
mesalamine oral capsule,extended release 24hr	T4	
mesalamine oral tablet,delayed release (dr/ec)	T4	
mesalamine rectal	T4	
methscopolamine	T4	
metoclopramide hcl oral solution	T2	
metoclopramide hcl oral tablet	T1	
metoclopramide hcl oral tablet,disintegrating 5 mg	T4	
misoprostol	T3	
MOTEGRITY	T4	PA; QL (31 EA per 31 days)
MOVANTIK	T3	QL (31 EA per 31 days)
MOVIPREP	T4	
MYTESI	T5	QL (62 EA per 31 days)
NEXIUM	T4	QL (31 EA per 31 days)
NEXIUM PACKET	T4	QL (31 EA per 31 days)
nizatidine oral capsule	T2	
OCALIVA	T5	PA; QL (31 EA per 31 days)
omeprazole oral capsule,delayed release(dr/ec)	T1	
omeprazole-sodium bicarbonate oral capsule	T4	
omeprazole-sodium bicarbonate oral packet	T5	
ondansetron	T2	PA-BvD
ondansetron hcl oral solution	T2	PA-BvD
ondansetron hcl oral tablet 4 mg, 8 mg	T2	PA-BvD
OSMOPREP	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PANCREAZE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,500-35,500- 61,500 UNIT, 16,800-56,800- 98,400 UNIT, 2,600-8,800- 15,200 UNIT, 21,000-54,700- 83,900 UNIT, 4,200-14,200- 24,600 UNIT	T4	
PANCREAZE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 37,000-97,300- 149,900 UNIT	T5	
pantoprazole oral granules dr for susp in packet	T4	
pantoprazole oral tablet,delayed release (dr/ec)	T1	
peg 3350-electrolytes	T2	
peg3350-sod sul-nacl-kcl-asb-c	T4	
peg-electrolyte soln	T2	
PENTASA ORAL CAPSULE, EXTENDED RELEASE 250 MG	T3	
PENTASA ORAL CAPSULE, EXTENDED RELEASE 500 MG	T5	
PEPCID ORAL TABLET	T4	
PERTZYE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 16,000-57,500- 60,500 UNIT, 24,000-86,250- 90,750 UNIT	T5	
PERTZYE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 4,000-14,375- 15,125 UNIT, 8,000-28,750- 30,250 UNIT	T4	
PLENVU	T4	
PREVACID ORAL CAPSULE,DELAYED RELEASE(DR/EC) 30 MG	T4	QL (62 EA per 31 days)
PREVACID SOLUTAB ORAL TABLET,DISINTEGRAT, DELAY REL 15 MG	T4	QL (31 EA per 31 days)
PREVACID SOLUTAB ORAL TABLET,DISINTEGRAT, DELAY REL 30 MG	T4	QL (62 EA per 31 days)
PRILOSEC ORAL SUSP,DELAYED RELEASE FOR RECON	T4	
prochlorperazine	T2	
prochlorperazine maleate	T2	
PROCTO-MED HC	T2	
PROCTOSOL HC TOPICAL	T2	
PROCTOZONE-HC	T2	
PROTONIX ORAL	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PYLERA	T4	
rabeprazole oral tablet,delayed release (dr/ec)	T4	QL (62 EA per 31 days)
RECTIV	T3	
REGLAN ORAL	T4	
RELISTOR ORAL	T5	PA; QL (93 EA per 31 days)
RELISTOR SUBCUTANEOUS SOLUTION	T5	PA; QL (18.6 ML per 31 days)
RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML	T5	PA; QL (18.6 ML per 31 days)
RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML	T5	PA; QL (12.4 ML per 31 days)
RELTONE	T5	ST
ROBINUL FORTE	T4	
ROBINUL ORAL	T4	
ROWASA RECTAL ENEMA KIT	T4	
SANCUSO	T5	
scopolamine base	T3	QL (10 EA per 30 days)
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML)	T5	PA; QL (1.2 ML per 56 days)
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML)	T5	PA; QL (2.4 ML per 56 days)
sodium,potassium,mag sulfates	T4	
SUCRAID	T5	
sucralfate oral suspension	T4	
sucralfate oral tablet	T2	
SUFLAVE	T4	
sulfasalazine	T2	
SUPREP BOWEL PREP KIT	T4	
SUTAB	T4	
SYMPROIC	T4	PA; QL (31 EA per 31 days)
SYNDROS	T5	PA
TALICIA	T4	
TRANSDERM-SCOP	T4	QL (10 EA per 30 days)
trimethobenzamide oral	T4	PA
TRULANCE	T3	QL (31 EA per 31 days)
UCERIS ORAL	T5	
UCERIS RECTAL	T4	
URSO 250	T4	ST
URSO FORTE	T4	ST

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ursodiol oral capsule 200 mg, 400 mg	T4	ST
ursodiol oral capsule 300 mg	T3	
ursodiol oral tablet	T3	
VARUBI	T4	PA-BvD
VIBERZI	T5	PA; QL (62 EA per 31 days)
VIOKACE ORAL TABLET 10,440-39,150-39,150 UNIT	T4	
VIOKACE ORAL TABLET 20,880-78,300-78,300 UNIT	T5	
VOWST	T5	PA; QL (12 EA per 14 days)
ZEGERID	T5	
ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT	T3	
Immunology, Vaccines / Biotechnology		
ABRYSVO	T3	QL (2 EA per 365 days)
ACTHIB (PF)	T3	
ACTIMMUNE	T5	PA
ADACEL(TDAP ADOLESN/ADULT)(PF)	T3	
ARANESP (IN POLYSORBATE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML	T5	PA-BvD
ARANESP (IN POLYSORBATE) INJECTION SOLUTION 25 MCG/ML, 40 MCG/ML, 60 MCG/ML	T4	PA-BvD
ARANESP (IN POLYSORBATE) INJECTION SYRINGE 10 MCG/0.4 ML, 25 MCG/0.42 ML, 40 MCG/0.4 ML	T4	PA-BvD
ARANESP (IN POLYSORBATE) INJECTION SYRINGE 100 MCG/0.5 ML, 150 MCG/0.3 ML, 200 MCG/0.4 ML, 300 MCG/0.6 ML, 500 MCG/ML, 60 MCG/0.3 ML	T5	PA-BvD
ARCALYST	T5	PA
AREXVY (PF)	T3	QL (2 EA per 365 days)
AVONEX INTRAMUSCULAR PEN INJECTOR KIT	T5	QL (4 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
AVONEX INTRAMUSCULAR SYRINGE KIT	T5	QL (4 EA per 28 days)
bcg vaccine, live (pf)	T3	
BESREMI	T5	PA-NS; QL (2 ML per 28 days)
BETASERON SUBCUTANEOUS KIT	T5	QL (14 EA per 28 days)
BEXSERO	T3	
BIVIGAM	T5	PA
BOOSTRIX TDAP	T3	
DAPTACEL (DTAP PEDIATRIC) (PF)	T3	
EGRIFTA SV	T5	PA
ENGERIX-B (PF)	T3	PA-BvD
ENGERIX-B PEDIATRIC (PF)	T3	PA-BvD
EPOGEN INJECTION SOLUTION 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML	T4	PA-BvD
EXTAVIA SUBCUTANEOUS KIT	T5	QL (15 EA per 30 days)
FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %	T5	PA
FULPHILA	T5	
FYLNETRA	T5	
GAMMAGARD LIQUID	T5	PA
GAMMAGARD S-D (IGA < 1 MCG/ML)	T5	PA
GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %)	T5	PA
GAMMAPLEX	T5	PA
GAMMAPLEX (WITH SORBITOL)	T5	PA
GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)	T5	PA
GARDASIL 9 (PF)	T3	
GENOTROPIN	T5	PA
GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.2 MG/0.25 ML	T4	PA
GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML	T5	PA
GRANIX	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
GRASTEK	T4	PA
HAVRIX (PF)	T3	
HEPLISAV-B (PF)	T3	PA-BvD
HIBERIX (PF)	T3	
HUMATROPE INJECTION CARTRIDGE	T5	PA
IMOVAX RABIES VACCINE (PF)	T3	PA-BvD
INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE	T3	
IPOL	T3	
IXIARO (PF)	T3	
JYNNEOS (PF)(STOCKPILE)	T3	PA-BvD
KINRIX (PF) INTRAMUSCULAR SYRINGE	T3	
LEUKINE INJECTION RECON SOLN	T5	PA
MENACTRA (PF) INTRAMUSCULAR SOLUTION	T3	
MENQUADFI (PF)	T3	
MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT	T3	
M-M-R II (PF)	T3	
NEULASTA	T5	
NEUPOGEN	T5	
NGENLA	T5	PA
NIVESTYM	T5	
NORDITROPIN FLEXPRO	T5	PA
NUTROPIN AQ NUSPIN	T5	PA
NYVEPRIA	T5	
OCTAGAM	T5	PA
ODACTRA	T4	PA
OMNITROPE SUBCUTANEOUS CARTRIDGE 10 MG/1.5 ML (6.7 MG/ML)	T5	PA
OMNITROPE SUBCUTANEOUS CARTRIDGE 5 MG/1.5 ML (3.3 MG/ML)	T4	PA
OMNITROPE SUBCUTANEOUS RECON SOLN	T5	PA
ORALAIR SUBLINGUAL TABLET 300 INDX REACTIVITY	T4	PA
PANZYGA	T5	PA
PEDIARIX (PF)	T3	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PEDVAX HIB (PF)	T3	
PEGASYS	T5	PA
PENTACEL (PF) INTRAMUSCULAR KIT 15LF-48MCG-62DU -10 MCG/0.5ML	T3	
PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML	T5	QL (1 ML per 28 days)
PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML	T5	QL (1 ML per 28 days)
PREHEVBRIO (PF)	T3	PA-BvD
PRIORIX (PF)	T3	
PRIVIGEN	T5	PA
PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML	T3	PA-BvD
PROCRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML	T5	PA-BvD
PROQUAD (PF)	T3	
QUADRACEL (PF)	T3	
RABAVERT (PF)	T3	PA-BvD
REBIF (WITH ALBUMIN)	T5	QL (6 ML per 28 days)
REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML	T5	QL (6 ML per 28 days)
REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 8.8MCG/0.2ML-22 MCG/0.5ML (6)	T5	QL (4.2 ML per 365 days)
REBIF TITRATION PACK	T5	QL (8.4 ML per 365 days)
RECOMBIVAX HB (PF)	T3	PA-BvD
RELEUKO SUBCUTANEOUS	T5	
RETACRIT	T3	PA-BvD
ROTARIX	T3	
ROTATEQ VACCINE	T3	
SAIZEN	T5	PA
SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG	T5	PA
SHINGRIX (PF)	T3	QL (2 EA per 999 days)
SKYTROFA	T5	PA
SOGROYA	T5	PA
TDVAX	T3	
TENIVAC (PF)	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
tetanus,diphtheria tox ped(pf)	T3	
TICOVAC	T3	
TRUMENBA	T3	
TWINRIX (PF)	T3	
TYPHIM VI	T3	
UDENYCA	T5	
UDENYCA AUTOINJECTOR	T5	
VAQTA (PF)	T3	
VARIVAX (PF)	T3	
YF-VAX (PF)	T3	
ZARXIO	T5	
ZIEXTENZO	T5	
ZOMACTON	T4	PA
ZORBTIVE	T5	PA
Miscellaneous Supplies		
ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"	T3	
GAUZE PAD TOPICAL BANDAGE 2 X 2 "	T3	
insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge	T3	
pen needle, diabetic needle 29 gauge x 1/2"	T3	
Musculoskeletal / Rheumatology		
ACTEMRA ACTPEN	T5	PA; QL (3.6 ML per 28 days)
ACTEMRA SUBCUTANEOUS	T5	PA; QL (3.6 ML per 28 days)
ACTONEL ORAL TABLET 150 MG, 35 MG	T4	
adalimumab-fkjp	T5	PA; QL (2 EA per 28 days)
alendronate oral solution	T2	
alendronate oral tablet 10 mg, 35 mg, 70 mg	T1	
allopurinol oral tablet 100 mg, 300 mg	T1	
allopurinol oral tablet 200 mg	T4	
AMJEVITA(CF) AUTOINJECTOR	T5	PA; QL (1.6 EA per 28 days)
AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML	T5	PA; QL (0.4 ML per 28 days)
AMJEVITA(CF) SUBCUTANEOUS SYRINGE 20 MG/0.4 ML	T5	PA; QL (0.8 EA per 28 days)
AMJEVITA(CF) SUBCUTANEOUS SYRINGE 40 MG/0.8 ML	T5	PA; QL (1.6 EA per 28 days)
ARAVA	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ATELVIA	T4	
BENLYSTA SUBCUTANEOUS	T5	PA; QL (4 ML per 28 days)
BINOSTO	T4	
colchicine oral capsule	T4	QL (62 EA per 31 days)
colchicine oral tablet	T2	QL (62 EA per 31 days)
COLCRYS	T4	QL (124 EA per 31 days)
CUPRIMINE	T5	
CYLTEZO(CF)	T5	PA; QL (2 EA per 28 days)
CYLTEZO(CF) PEN	T5	PA; QL (2 EA per 28 days)
CYLTEZO(CF) PEN CROHN'S-UC-HS	T5	PA; QL (12 EA per 365 days)
CYLTEZO(CF) PEN PSORIASIS-UV	T5	PA; QL (8 EA per 365 days)
DEPEN TITRATABS	T5	
ENBREL MINI	T5	PA; QL (7.84 ML per 28 days)
ENBREL SUBCUTANEOUS SOLUTION	T5	PA; QL (4 ML per 28 days)
ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5)	T5	PA; QL (4 ML per 28 days)
ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML)	T5	PA; QL (7.84 ML per 28 days)
ENBREL SURECLICK	T5	PA; QL (7.84 ML per 28 days)
EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2)	T5	PA; QL (2.34 ML per 28 days)
EVISTA	T4	
febuxostat	T3	PA
FORTEO	T5	PA; QL (2.4 ML per 28 days)
FOSAMAX ORAL TABLET 70 MG	T4	
FOSAMAX PLUS D	T4	
HADLIMA	T5	PA; QL (1.6 ML per 28 days)
HADLIMA PUSHTOUCH	T5	PA; QL (1.6 ML per 28 days)
HADLIMA(CF)	T5	PA; QL (0.8 ML per 28 days)
HADLIMA(CF) PUSHTOUCH	T5	PA; QL (0.8 ML per 28 days)
HULIO(CF)	T5	PA; QL (2 EA per 28 days)
HULIO(CF) PEN	T5	PA; QL (2 EA per 28 days)
HUMIRA PEN	T5	PA; QL (2 EA per 28 days)
HUMIRA PEN CROHNS-UC-HS START	T5	PA; QL (6 EA per 28 days)
HUMIRA PEN PSOR-UVEITS-ADOL HS	T5	PA; QL (4 EA per 28 days)
HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML	T5	PA; QL (2 EA per 28 days)
HUMIRA(CF)	T5	PA; QL (2 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML	T5	PA; QL (3 EA per 28 days)
HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML-40 MG/0.4 ML	T5	PA; QL (2 EA per 28 days)
HUMIRA(CF) PEN	T5	PA; QL (2 EA per 28 days)
HUMIRA(CF) PEN CROHNS-UC-HS	T5	PA; QL (3 EA per 28 days)
HUMIRA(CF) PEN PEDIATRIC UC	T5	PA; QL (4 EA per 28 days)
HUMIRA(CF) PEN PSOR-UV-ADOL HS	T5	PA; QL (3 EA per 28 days)
HYRIMOZ PEN CROHN'S-UC STARTER	T5	PA; QL (4.8 ML per 365 days)
HYRIMOZ PEN PSORIASIS STARTER	T5	PA; QL (3.2 ML per 365 days)
HYRIMOZ(CF) PEDI CROHN STARTER	T5	PA; QL (2.4 ML per 365 days)
HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML	T5	PA; QL (0.8 ML per 28 days)
HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 80 MG/0.8 ML	T5	PA; QL (1.6 ML per 28 days)
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML	T5	PA; QL (0.2 ML per 28 days)
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 20 MG/0.2 ML	T5	PA; QL (0.4 ML per 28 days)
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 40 MG/0.4 ML	T5	PA; QL (0.8 ML per 28 days)
ibandronate oral	T2	
KEVZARA	T5	PA; QL (2.28 ML per 28 days)
KINERET	T5	PA; QL (18.76 ML per 28 days)
leflunomide	T2	
MITIGARE	T4	QL (62 EA per 31 days)
OLUMIANT	T5	PA; QL (31 EA per 31 days)
ORENCIA CLICKJECT	T5	PA; QL (4 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML	T5	PA; QL (4 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML	T5	PA; QL (1.6 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 87.5 MG/0.7 ML	T5	PA; QL (2.8 ML per 28 days)
OTEZLA	T5	PA; QL (62 EA per 31 days)
OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)	T5	PA; QL (55 EA per 28 days)
OTREXUP (PF)	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
penicillamine	T5	
probenecid	T2	
probenecid-colchicine	T2	
PROLIA	T3	PA; QL (1 ML per 180 days)
raloxifene	T2	
RASUVO (PF)	T4	PA
RIDAURA	T5	
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG	T5	PA; QL (31 EA per 31 days)
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG	T5	PA; QL (168 EA per 365 days)
risedronate oral tablet 150 mg, 35 mg, 35 mg (12 pack), 35 mg (4 pack), 5 mg	T2	
risedronate oral tablet,delayed release (dr/ec)	T4	
SAVELLA	T3	PA
SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML	T5	PA; QL (1 ML per 28 days)
SIMPONI SUBCUTANEOUS PEN INJECTOR 50 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)
SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML	T5	PA; QL (1 ML per 28 days)
SIMPONI SUBCUTANEOUS SYRINGE 50 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)
teriparatide	T5	PA; QL (2.48 ML per 28 days)
TYMLOS	T5	PA; QL (1.56 ML per 30 days)
ULORIC	T4	PA
XELJANZ ORAL SOLUTION	T5	PA; QL (310 ML per 31 days)
XELJANZ ORAL TABLET	T5	PA; QL (62 EA per 31 days)
XELJANZ XR	T5	PA; QL (31 EA per 31 days)
YUFLYMA(CF)	T5	PA; QL (2 EA per 28 days)
YUFLYMA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML	T5	PA; QL (2 EA per 28 days)
YUSIMRY(CF) PEN	T5	PA; QL (1.6 ML per 28 days)
Obstetrics / Gynecology		
ACTIVELLA	T4	
ALTAVERA (28)	T2	
ALYACEN 1/35 (28)	T2	
AMABELZ	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
AMETHIA	T4	
ANGELIQ	T4	
ANNOVERA	T4	
APRI	T2	
ARANELLE (28)	T2	
ASHLYNA	T4	
AUBRA EQ	T2	
AVIANE	T2	
AYGESTIN	T4	
BALCOLTRA	T4	
BALZIVA (28)	T4	
BEYAZ	T4	
BIJUVA	T4	
BLISOVI 24 FE	T4	
BLISOVI FE 1.5/30 (28)	T4	
BRIELLYN	T4	
CAMILA	T2	
CAMRESE LO	T4	
CLEOCIN VAGINAL	T4	
CLIMARA	T4	
CLIMARA PRO	T4	
clindamycin phosphate vaginal	T2	
CLINDESSE	T4	
COMBIPATCH	T4	
CRINONE	T4	PA
CRYSELLE (28)	T2	
CYRED EQ	T2	
DEBLITANE	T2	
DELESTROGEN	T4	
DEPO-ESTRADIOL	T4	
DEPO-PROVERA INTRAMUSCULAR SUSPENSION 150 MG/ML	T4	
DEPO-PROVERA INTRAMUSCULAR SYRINGE	T4	
DEPO-SUBQ PROVERA 104	T4	
desog-e.estradiol/e.estradiol	T2	
desogestrel-ethinyl estradiol	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
DIVIGEL	T4	
DOLISHALE	T4	
DOTTI	T3	
drospirenone-e.estradiol-lm.fa oral tablet 3-0.02-0.451 mg (24) (4)	T4	
drospirenone-ethinyl estradiol	T2	
DUAVEE	T3	
ELESTRIN	T4	
ELURYNG	T4	
ENPRESSE	T2	
ENSKYCE	T2	
ERRIN	T2	
ESTARYLLA	T2	
ESTRACE	T4	
estradiol oral	T4	
estradiol transdermal gel in packet	T4	
estradiol transdermal patch semiweekly	T3	
estradiol transdermal patch weekly	T3	
estradiol vaginal	T4	
estradiol valerate	T4	
estradiol-norethindrone acet	T3	
ESTRING	T4	
ESTROGEL	T4	
ethynodiol diac-eth estradiol	T2	
etonogestrel-ethinyl estradiol	T4	
EVAMIST	T4	
FALMINA (28)	T2	
FEMRING	T4	
FINZALA	T4	
FYAVOLV	T4	
GEMMILY	T4	
GYNAZOLE-1	T4	
HAILEY 24 FE	T4	
HALOETTE	T4	
ICLEVIA	T4	
IMVEXXY MAINTENANCE PACK	T4	
IMVEXXY STARTER PACK	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
INCASSIA	T2	
INTRAROSA	T4	PA; QL (28 EA per 28 days)
INTROVALE	T2	
ISIBLOOM	T2	
JASMIEL (28)	T2	
JINTELI	T4	
JULEBER	T2	
JUNEL 1.5/30 (21)	T4	
JUNEL 1/20 (21)	T4	
JUNEL FE 1.5/30 (28)	T4	
JUNEL FE 1/20 (28)	T4	
JUNEL FE 24	T4	
KAITLIB FE	T4	
KARIVA (28)	T2	
KELNOR 1/35 (28)	T2	
KELNOR 1-50 (28)	T2	
KURVELO (28)	T2	
KYLEENA	T4	
l norgest/e.estradiol-e.estrad	T2	
LARIN 1.5/30 (21)	T2	
LARIN 1/20 (21)	T2	
LARIN FE 1.5/30 (28)	T2	
LARIN FE 1/20 (28)	T2	
LAYOLIS FE	T4	
LEENA 28	T4	
LESSINA	T2	
LEVONEST (28)	T2	
levonorgestrel-ethinyl estrad	T2	
levonorg-eth estrad triphasic	T2	
LEVORA-28	T2	
LILETTA	T4	
LO LOESTRIN FE	T4	
LOESTRIN 1.5/30 (21)	T4	
LOESTRIN 1/20 (21)	T4	
LOESTRIN FE 1.5/30 (28-DAY)	T4	
LOESTRIN FE 1/20 (28-DAY)	T4	
LORYNA (28)	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LOSEASONIQUE	T4	
LOW-OGESTREL (28)	T2	
LUTERA (28)	T2	
LYLEQ	T2	
LYLLANA	T3	
LYZA	T2	
MARLISSA (28)	T2	
medroxyprogesterone	T2	
MENEST	T3	
MENOSTAR	T4	
MERZEE	T4	
metronidazole vaginal	T3	
MIBELAS 24 FE	T2	
MICONAZOLE-3 VAGINAL SUPPOSITORY	T4	
MICROGESTIN 1.5/30 (21)	T2	
MICROGESTIN 1/20 (21)	T2	
MICROGESTIN 24 FE	T4	
MICROGESTIN FE 1.5/30 (28)	T2	
MICROGESTIN FE 1/20 (28)	T2	
MILI	T2	
MIMVEY	T3	
MINIVELLE	T4	
MIRENA	T4	
MYFEMBREE	T5	PA; QL (31 EA per 31 days)
NATAZIA	T4	
NECON 0.5/35 (28)	T4	
NEXPLANON	T4	
NEXTSTELLIS	T4	
NIKKI (28)	T2	
NORA-BE	T2	
noreth-ethinyl estradiol-iron	T4	
norethindrone (contraceptive)	T2	
norethindrone acetate	T2	
norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg	T2	
norethindrone-e.estradiol-iron oral capsule	T4	
norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7), 1-20(5)/1-30(7) /1mg-35mcg (9)	T2	
norethindrone-e.estradiol-iron oral tablet,chewable	T4	
norgestimate-ethinyl estradiol	T2	
NORTREL 0.5/35 (28)	T2	
NORTREL 1/35 (21)	T2	
NORTREL 1/35 (28)	T2	
NORTREL 7/7/7 (28)	T2	
NUVARING	T4	
NYLIA 1/35 (28)	T4	
NYLIA 7/7/7 (28)	T4	
NYMYO	T4	
OCELLA	T4	
ORIAHNN	T5	PA; QL (56 EA per 28 days)
OSPHENA	T4	PA; QL (31 EA per 31 days)
PHEXXI	T4	
PIMTREA (28)	T2	
PORTIA 28	T2	
PREFEST	T4	
PREMARIN ORAL	T3	
PREMARIN VAGINAL	T3	
PREMPHASE	T3	
PREMPRO	T3	
progesterone micronized	T2	
PROMETRIUM	T4	
PROVERA	T4	
QUARTETTE	T4	
RECLIPSEN (28)	T2	
RIVELSA	T4	
SAFYRAL	T4	
SEASONIQUE	T4	
SETLAKIN	T2	
SHAROBEL	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
SKYLA	T4	
SLYND	T4	
SPRINTEC (28)	T2	
SRONYX	T2	
SYEDA	T2	
TARINA 24 FE	T2	
TARINA FE 1-20 EQ (28)	T2	
terconazole	T3	
TILIA FE	T2	
tranexamic acid oral	T3	
TRI-ESTARYLLA	T2	
TRI-LEGEST FE	T2	
TRI-LO-ESTARYLLA	T2	
TRI-LO-SPRINTEC	T2	
TRI-MILI	T4	
TRI-NYMYO	T4	
TRI-SPRINTEC (28)	T2	
TRIVORA (28)	T2	
TRI-VYLIBRA	T4	
TRI-VYLIBRA LO	T4	
TYBLUME	T4	
TYDEMY	T4	
VAGIFEM	T4	
VANDAZOLE	T3	
VELIVET TRIPHASIC REGIMEN (28)	T2	
VEOZAH	T4	PA; QL (31 EA per 31 days)
VESTURA (28)	T2	
VIENVA	T2	
VIVELLE-DOT	T4	
VYFEMLA (28)	T4	
VYLIBRA	T4	
WYMZYA FE	T4	
XULANE	T4	
YASMIN (28)	T4	
YAZ (28)	T4	
YUVAFEM	T4	
ZAFEMY	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ZOVIA 1-35 (28)	T2	
Ophthalmology		
acetazolamide	T3	
ACULAR	T4	
ACULAR LS	T4	
ACUVAIL (PF)	T4	
ALOMIDE	T4	
ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1 %	T3	
ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.15 %	T4	
ALREX	T3	
apraclonidine	T3	
atropine ophthalmic (eye) drops	T2	
AZASITE	T3	
azelastine ophthalmic (eye)	T2	
AZOPT	T4	
bacitracin ophthalmic (eye)	T2	
bacitracin-polymyxin b	T2	
bepotastine besilate	T3	
BEPREVE	T4	
BESIVANCE	T3	
betaxolol ophthalmic (eye)	T3	
BETIMOL	T4	
BETOPTIC S	T4	
bimatoprost ophthalmic (eye)	T4	
brimonidine ophthalmic (eye) drops 0.15 %, 0.2 %	T2	
brimonidine-timolol	T3	
brinzolamide	T4	
bromfenac	T3	
BROMSITE	T3	
carteolol	T2	
CEQUA	T4	ST; QL (60 EA per 30 days)
CILOXAN OPHTHALMIC (EYE) OINTMENT	T4	
ciprofloxacin hcl ophthalmic (eye)	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
COMBIGAN	T3	
COSOPT	T4	
COSOPT (PF)	T4	
cromolyn ophthalmic (eye)	T2	
cyclosporine ophthalmic (eye)	T3	QL (60 EA per 30 days)
CYSTADROPS	T5	PA; QL (20 ML per 28 days)
CYSTARAN	T5	PA; QL (60 ML per 28 days)
dexamethasone sodium phosphate ophthalmic (eye)	T2	
diclofenac sodium ophthalmic (eye)	T2	
difluprednate	T3	
dorzolamide	T2	
dorzolamide-timolol	T2	
dorzolamide-timolol (pf) ophthalmic (eye) dropperette	T4	
DUREZOL	T4	
epinastine	T3	
erythromycin ophthalmic (eye)	T2	
EYSUVIS	T3	QL (8.3 ML per 30 days)
FLAREX	T4	
fluorometholone	T3	
flurbiprofen sodium	T2	
FML FORTE	T4	
FML LIQUIFILM	T4	
gatifloxacin	T2	
gentamicin ophthalmic (eye) drops	T2	
ILEVRO	T4	
INVELTYS	T3	
IOPIDINE OPHTHALMIC (EYE) DROPPERETTE	T4	
ISTALOL	T4	
IYUZEH	T4	ST; QL (30 EA per 30 days)
ketorolac ophthalmic (eye)	T2	
LACRISERT	T4	
latanoprost	T1	
levobunolol ophthalmic (eye) drops 0.5 %	T2	
levofloxacin ophthalmic (eye) drops 0.5 %	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LOTEMAX	T4	
LOTEMAX SM	T4	
loteprednol etabonate	T3	
LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 %	T3	QL (5 ML per 31 days)
MAXIDEX	T4	
MAXITROL	T4	
methazolamide	T4	
MIEBO	T5	ST; QL (12 ML per 30 days)
moxifloxacin ophthalmic (eye) drops	T3	
NATACYN	T4	
neomycin-bacitracin-poly-hc	T2	
neomycin-bacitracin-polymyxin	T2	
neomycin-polymyxin b-dexameth	T2	
neomycin-polymyxin-gramicidin	T2	
neomycin-polymyxin-hc ophthalmic (eye)	T3	
NEO-POLYCIN	T2	
NEO-POLYCIN HC	T2	
NEVANAC	T4	
OCUFLOX	T4	
ofloxacin ophthalmic (eye)	T2	
olopatadine ophthalmic (eye) drops 0.1 %	T2	
OXERVATE	T5	PA; QL (112 ML per 56 days)
PHOSPHOLINE IODIDE	T5	PA; QL (5 ML per 25 days)
pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %	T2	
POLYCIN	T2	
polymyxin b sulf-trimethoprim	T2	
PRED FORTE	T4	
PRED MILD	T4	
prednisolone acetate	T2	
prednisolone sodium phosphate ophthalmic (eye)	T2	
PROLENSA	T3	
RESTASIS	T3	QL (60 EA per 30 days)
RESTASIS MULTIDOSE	T3	QL (5.5 ML per 27 days)
RHOPRESSA	T3	ST
ROCKLATAN	T3	ST

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
SIMBRINZA	T4	
sulfacetamide sodium ophthalmic (eye)	T2	
sulfacetamide-prednisolone	T2	
tafluprost (pf)	T4	
timolol maleate (pf)	T4	
timolol maleate ophthalmic (eye) drops	T1	
timolol maleate ophthalmic (eye) drops, once daily	T3	
timolol maleate ophthalmic (eye) gel forming solution	T3	
TIMOPTIC OCUDOSE (PF)	T4	
TOBRADEX OPHTHALMIC (EYE) OINTMENT	T3	
TOBRADEX ST	T4	
tobramycin ophthalmic (eye)	T2	
tobramycin-dexamethasone	T3	
TOBREX OPHTHALMIC (EYE) OINTMENT	T4	
TRAVATAN Z	T4	
travoprost	T3	
trifluridine	T3	
TYRVAYA	T4	ST; QL (8.4 ML per 30 days)
VERKAZIA	T5	PA; QL (120 EA per 30 days)
VIGAMOX	T4	
VUITY	T4	PA; QL (2.5 ML per 25 days)
VYZULTA	T4	ST; QL (5 ML per 31 days)
XALATAN	T4	
XDEMVY	T5	PA; QL (10 ML per 42 days)
XELPROS	T4	
XIIDRA	T3	QL (60 EA per 30 days)
ZERVIATE	T4	
ZIOPTAN (PF)	T4	
ZIRGAN	T4	ST
ZYLET	T4	
ZYMAXID	T4	
Respiratory And Allergy		
ACCOLATE ORAL TABLET 10 MG	T4	QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
acetylcysteine	T3	PA-BvD
ADCIRCA	T5	PA; QL (62 EA per 31 days)
ADEMPAS	T5	PA; QL (93 EA per 31 days)
ADVAIR DISKUS	T3	QL (60 EA per 30 days)
ADVAIR HFA	T3	QL (12 GM per 30 days)
AIRDUO DIGIHALER	T4	PA; QL (2 EA per 365 days)
AIRDUO RESPICLICK	T4	QL (1 EA per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation	T2	QL (17 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)	T2	QL (13.4 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)	T4	ST; QL (36 GM per 30 days)
albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml	T2	PA-BvD
albuterol sulfate oral syrup	T2	
albuterol sulfate oral tablet	T4	
ALVESCO	T3	QL (12.2 GM per 30 days)
ALYQ	T5	PA; QL (62 EA per 31 days)
ambrisentan	T5	PA; QL (31 EA per 31 days)
ANORO ELLIPTA	T4	QL (60 EA per 30 days)
arformoterol	T3	PA-BvD
ARMONAIR DIGIHALER	T4	PA; QL (2 EA per 365 days)
ARNUITY ELLIPTA	T3	QL (30 EA per 30 days)
ASMANEX HFA	T3	QL (13 GM per 30 days)
ASMANEX TWISTHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60)	T3	QL (1 EA per 30 days)
ATROVENT HFA	T3	QL (25.8 GM per 30 days)
AUVI-Q	T5	ST
azelastine-fluticasone	T4	QL (23 GM per 30 days)
BECONASE AQ	T4	QL (25 GM per 21 days)
BERINERT INTRAVENOUS KIT	T5	PA
BEVESPI AEROSPHERE	T4	QL (10.7 GM per 30 days)
bosentan	T5	PA; QL (62 EA per 31 days)
BREO ELLIPTA	T3	QL (60 EA per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
BREZTRI AEROSPHERE	T3	QL (10.7 GM per 30 days)
BRONCHITOL	T5	PA; QL (560 EA per 28 days)
BROVANA	T4	PA-BvD
budesonide inhalation	T4	PA-BvD
budesonide-formoterol	T4	QL (10.2 GM per 30 days)
carbinoxamine maleate oral liquid	T4	PA
carbinoxamine maleate oral tablet 4 mg	T4	PA
cetirizine oral solution 1 mg/ml	T2	QL (310 ML per 31 days)
CINRYZE	T5	PA; QL (20 EA per 28 days)
CLARINEX ORAL TABLET	T4	QL (31 EA per 31 days)
CLARINEX-D 12 HOUR	T4	
clemastine oral syrup	T4	PA
clemastine oral tablet 2.68 mg	T4	
COMBIVENT RESPIMAT	T3	QL (4 GM per 30 days)
cromolyn inhalation	T5	PA-BvD
cyproheptadine	T4	PA
DALIRESP	T4	QL (31 EA per 31 days)
desloratadine	T4	QL (31 EA per 31 days)
DUAKLIR PRESSAIR	T5	QL (1 EA per 30 days)
DULERA	T4	QL (13 GM per 30 days)
DYMISTA	T4	ST; QL (23 GM per 30 days)
epinephrine injection auto-injector 0.15 mg/0.15 ml, 0.3 mg/0.3 ml	T4	
epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml	T3	
EPIPEN 2-PAK	T4	
EPIPEN JR 2-PAK	T4	
ESBRIET ORAL CAPSULE	T5	PA; QL (279 EA per 31 days)
ESBRIET ORAL TABLET 267 MG	T5	PA; QL (279 EA per 31 days)
ESBRIET ORAL TABLET 801 MG	T5	PA; QL (93 EA per 31 days)
FASENRA	T5	PA; QL (1 ML per 56 days)
FASENRA PEN	T5	PA; QL (1 ML per 56 days)
FIRAZYR	T5	PA; QL (18 ML per 30 days)
FLOVENT DISKUS	T3	QL (60 EA per 30 days)
FLOVENT HFA INHALATION HFA AEROSOL INHALER 110 MCG/ACTUATION	T3	QL (12 GM per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
FLOVENT HFA INHALATION HFA AEROSOL INHALER 220 MCG/ACTUATION	T3	QL (24 GM per 30 days)
FLOVENT HFA INHALATION HFA AEROSOL INHALER 44 MCG/ACTUATION	T3	QL (10.6 GM per 30 days)
flunisolide	T2	QL (50 ML per 25 days)
fluticasone furoate-vilanterol	T4	ST; QL (60 EA per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation	T4	ST; QL (12 GM per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 220 mcg/actuation	T4	ST; QL (24 GM per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation	T4	ST; QL (10.6 GM per 30 days)
fluticasone propionate nasal	T2	QL (16 GM per 30 days)
fluticasone propion-salmeterol inhalation aerosol powdr breath activated	T3	QL (1 EA per 30 days)
fluticasone propion-salmeterol inhalation blister with device	T4	QL (60 EA per 30 days)
fluticasone propion-salmeterol inhalation hfa aerosol inhaler	T4	ST; QL (12 GM per 30 days)
formoterol fumarate	T3	PA-BvD
HAEGARDA	T5	PA
hydroxyzine hcl oral solution 10 mg/5 ml	T4	PA
hydroxyzine hcl oral tablet	T2	PA
hydroxyzine pamoate	T4	PA
icatibant	T5	PA; QL (18 ML per 30 days)
INCRUSE ELLIPTA	T3	QL (30 EA per 30 days)
ipratropium bromide inhalation	T2	PA-BvD
ipratropium-albuterol	T2	PA-BvD
KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 50 MG, 75 MG	T5	PA; QL (56 EA per 28 days)
KALYDECO ORAL GRANULES IN PACKET 25 MG	T5	PA; QL (62 EA per 31 days)
KALYDECO ORAL TABLET	T5	PA; QL (62 EA per 31 days)
LETAIRIS	T5	PA; QL (31 EA per 31 days)
levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml	T2	PA-BvD
levalbuterol hcl inhalation solution for nebulization 1.25 mg/0.5 ml	T4	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
levalbuterol hcl inhalation solution for nebulization 1.25 mg/3 ml	T3	PA-BvD
levalbuterol tartrate	T4	QL (30 GM per 30 days)
levocetirizine oral solution	T2	QL (310 ML per 31 days)
levocetirizine oral tablet	T2	QL (31 EA per 31 days)
LIQREV	T5	PA; QL (744 ML per 31 days)
mometasone nasal	T2	QL (34 GM per 30 days)
montelukast	T2	QL (31 EA per 31 days)
NUCALA SUBCUTANEOUS AUTO-INJECTOR	T5	PA; QL (3 ML per 28 days)
NUCALA SUBCUTANEOUS RECON SOLN	T5	PA; QL (3 EA per 28 days)
NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML	T5	PA; QL (3 ML per 28 days)
NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML	T5	PA; QL (0.4 ML per 28 days)
OFEV	T5	PA; QL (62 EA per 31 days)
OMNARIS	T4	QL (12.5 GM per 30 days)
OPSUMIT	T5	PA; QL (31 EA per 31 days)
ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG	T5	PA; QL (62 EA per 31 days)
ORKAMBI ORAL GRANULES IN PACKET 75-94 MG	T5	QL (62 EA per 31 days)
ORKAMBI ORAL TABLET	T5	PA; QL (124 EA per 31 days)
ORLADEYO	T5	PA; QL (31 EA per 31 days)
PERFOROMIST	T4	PA-BvD
pirfenidone oral capsule	T5	PA; QL (279 EA per 31 days)
pirfenidone oral tablet 267 mg	T5	PA; QL (279 EA per 31 days)
pirfenidone oral tablet 534 mg, 801 mg	T5	PA; QL (93 EA per 31 days)
PROAIR DIGIHALER	T4	PA; QL (2 EA per 365 days)
PROAIR RESPICLICK	T4	ST; QL (2 EA per 30 days)
promethazine oral	T4	PA
promethazine rectal suppository 12.5 mg, 25 mg	T4	
PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG	T4	
PROVENTIL HFA	T4	ST; QL (13.4 GM per 30 days)
PULMICORT	T4	PA-BvD
PULMICORT FLEXHALER	T3	QL (1 EA per 30 days)
PULMOZYME	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
QNASL NASAL HFA AEROSOL INHALER 40 MCG/ACTUATION	T4	QL (6.8 GM per 30 days)
QNASL NASAL HFA AEROSOL INHALER 80 MCG/ACTUATION	T4	QL (10.6 GM per 30 days)
QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION	T3	QL (10.6 GM per 30 days)
QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 80 MCG/ACTUATION	T3	QL (21.2 GM per 30 days)
REVATIO ORAL SUSPENSION FOR RECONSTITUTION	T5	PA; QL (784 ML per 31 days)
REVATIO ORAL TABLET	T5	PA; QL (372 EA per 31 days)
roflumilast	T4	QL (31 EA per 31 days)
RUCONEST	T5	PA
RYALTRIS	T4	ST; QL (29 GM per 30 days)
RYCLORA	T4	
RYVENT	T4	PA
SAJAZIR	T5	PA; QL (18 ML per 30 days)
SEREVENT DISKUS	T4	QL (60 EA per 30 days)
sildenafil (pulm.hypertension) oral suspension for reconstitution	T5	PA; QL (784 ML per 31 days)
sildenafil (pulm.hypertension) oral tablet	T3	PA; QL (372 EA per 31 days)
SINGULAIR	T4	QL (31 EA per 31 days)
SPIRIVA RESPIMAT	T3	QL (4 GM per 30 days)
SPIRIVA WITH HANDIHALER	T3	QL (30 EA per 30 days)
STIOLTO RESPIMAT	T3	QL (4 GM per 30 days)
STRIVERDI RESPIMAT	T3	QL (4 GM per 30 days)
SYMBICORT	T3	QL (10.2 GM per 30 days)
SYMDEKO	T5	PA; QL (56 EA per 28 days)
SYMJEPI	T4	
tadalafil (pulm. hypertension)	T5	PA; QL (62 EA per 31 days)
TADLIQ	T5	PA; QL (310 ML per 31 days)
TAKHZYRO SUBCUTANEOUS SOLUTION	T5	PA; QL (4 ML per 28 days)
TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML	T5	PA; QL (2 ML per 28 days)
TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML)	T5	PA; QL (4 ML per 28 days)
terbutaline oral	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
THEO-24	T3	
theophylline oral solution	T2	
theophylline oral tablet extended release 12 hr 300 mg, 450 mg	T2	
theophylline oral tablet extended release 24 hr	T2	
tiotropium bromide	T3	QL (30 EA per 30 days)
TRACLEER ORAL TABLET	T5	PA; QL (62 EA per 31 days)
TRACLEER ORAL TABLET FOR SUSPENSION	T5	PA; QL (124 EA per 31 days)
TRELEGY ELLIPTA	T3	QL (60 EA per 30 days)
TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL	T5	PA; QL (56 EA per 28 days)
TRIKAFTA ORAL TABLETS, SEQUENTIAL	T5	PA; QL (84 EA per 28 days)
TUDORZA PRESSAIR	T4	QL (1 EA per 30 days)
TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG (112)- 32 MCG (84)	T5	PA; QL (392 EA per 365 days)
TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 32 MCG, 32-48 MCG, 48 MCG, 64 MCG	T5	PA
TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16(112)-32(112) -48(28) MCG	T5	PA; QL (504 EA per 365 days)
VENTAVIS	T5	PA
VENTOLIN HFA	T4	QL (36 GM per 30 days)
VISTARIL	T4	PA
WIXELA INHUB	T4	QL (60 EA per 30 days)
XHANCE	T4	QL (32 ML per 30 days)
XOLAIR	T5	PA
XOPENEX HFA	T4	ST; QL (30 GM per 30 days)
YUPELRI	T5	PA-BvD
zafirlukast oral tablet 10 mg	T2	QL (93 EA per 31 days)
zafirlukast oral tablet 20 mg	T2	QL (62 EA per 31 days)
ZETONNA	T4	QL (6.1 GM per 30 days)
zileuton	T5	PA; QL (124 EA per 31 days)
ZYFLO	T5	PA; QL (124 EA per 31 days)
Urologicals		
alfuzosin	T2	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
bethanechol chloride	T2	
CIALIS ORAL TABLET 2.5 MG	T4	PA; QL (62 EA per 31 days)
CIALIS ORAL TABLET 5 MG	T4	PA; QL (31 EA per 31 days)
CYSTAGON	T4	
darifenacin	T4	QL (31 EA per 31 days)
DETROL	T4	QL (62 EA per 31 days)
DETROL LA	T4	QL (31 EA per 31 days)
dutasteride	T2	QL (31 EA per 31 days)
dutasteride-tamsulosin	T4	QL (31 EA per 31 days)
ELMIRON	T5	
ENTADFI	T4	PA; QL (31 EA per 31 days)
fesoterodine	T3	QL (31 EA per 31 days)
finasteride oral tablet 5 mg	T2	
flavoxate	T2	
FLOMAX	T4	
GELNIQUE TRANSDERMAL GEL IN PACKET	T4	QL (30 GM per 30 days)
GEMTESA	T4	QL (31 EA per 31 days)
JALYN	T4	QL (31 EA per 31 days)
MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON	T3	QL (300 ML per 30 days)
MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR	T3	QL (31 EA per 31 days)
oxybutynin chloride oral syrup	T3	
oxybutynin chloride oral tablet 5 mg	T3	
oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg	T3	QL (31 EA per 31 days)
oxybutynin chloride oral tablet extended release 24hr 15 mg	T3	QL (62 EA per 31 days)
OXYTROL	T4	QL (8 EA per 28 days)
potassium citrate oral tablet extended release	T2	
PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET	T5	PA
PROSCAR	T4	
RAPAFLO	T4	
silodosin	T2	
solifenacin	T4	QL (31 EA per 31 days)
tadalafil oral tablet 2.5 mg	T4	PA; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
tadalafil oral tablet 5 mg	T4	PA; QL (31 EA per 31 days)
tamsulosin	T1	
tolterodine oral capsule,extended release 24hr	T3	QL (31 EA per 31 days)
tolterodine oral tablet	T3	QL (62 EA per 31 days)
TOVIAZ	T4	QL (31 EA per 31 days)
trospium oral capsule,extended release 24hr	T4	QL (31 EA per 31 days)
trospium oral tablet	T2	QL (93 EA per 31 days)
UROCIT-K 10	T4	
UROCIT-K 15	T4	
UROCIT-K 5	T4	
UROXATRAL	T4	QL (31 EA per 31 days)
VESICARE	T4	QL (31 EA per 31 days)
VESICARE LS	T4	QL (310 ML per 31 days)
Vitamins, Hematinics / Electrolytes		
calcium acetate(phosphat bind)	T2	
CLINIMIX 5%/D15W SULFITE FREE	T4	PA-BvD
CLINIMIX 4.25%/D10W SULF FREE	T4	PA-BvD
CLINIMIX 5%-D20W(SULFITE-FREE)	T4	PA-BvD
CLINIMIX E 4.25%/D10W SUL FREE	T4	PA-BvD
CLINIMIX E 4.25%/D5W SULF FREE	T4	PA-BvD
CLINIMIX E 5%/D15W SULFIT FREE	T4	PA-BvD
CLINIMIX E 5%/D20W SULFIT FREE	T4	PA-BvD
CLINISOL SF 15 %	T4	PA-BvD
DOJOLVI	T5	PA
electrolyte-148	T3	PA-BvD
fluoride (sodium) oral tablet	T2	
INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %	T4	PA-BvD
ISOLYTE S PH 7.4	T4	PA-BvD
ISOLYTE-P IN 5 % DEXTROSE	T4	PA-BvD
KLOR-CON	T4	
KLOR-CON 10	T3	
KLOR-CON 8	T3	
KLOR-CON M10	T2	
KLOR-CON M15	T2	
KLOR-CON M20	T2	
magnesium sulfate injection	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
NUTRILIPID	T4	PA-BvD
PLASMA-LYTE 148	T3	PA-BvD
PLASMA-LYTE A	T3	PA-BvD
PLENAMINE	T4	PA-BvD
potassium chlorid-d5-0.45%nacl	T2	
potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l	T2	
potassium chloride in 5 % dex intravenous parenteral solution 20 meq/l	T2	
potassium chloride in lr-d5 intravenous parenteral solution 20 meq/l	T2	
potassium chloride in water intravenous piggyback 10 meq/100 ml, 20 meq/100 ml, 40 meq/100 ml	T2	
potassium chloride intravenous	T2	
potassium chloride oral capsule, extended release	T2	
potassium chloride oral liquid	T4	
potassium chloride oral packet	T4	
potassium chloride oral tablet extended release	T2	
potassium chloride oral tablet,er particles/crystals	T2	
potassium chloride-0.45 % nacl	T2	
potassium chloride-d5-0.2%nacl intravenous parenteral solution 20 meq/l	T2	
potassium chloride-d5-0.9%nacl	T2	
PREMASOL 10 %	T4	PA-BvD
PRENATAL VITAMIN PLUS LOW IRON	T2	PA
PROSOL 20 %	T4	PA-BvD
sodium chloride 0.45 % intravenous	T2	
sodium chloride 3 % hypertonic	T2	
sodium chloride 5 % hypertonic	T2	
TPN ELECTROLYTES	T4	
TRAVASOL 10 %	T4	PA-BvD
TROPHAMINE 10 %	T4	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

Index of Drugs

abacavir 5
abacavir-lamivudine 5
ABELCET 5
ABILIFY 26
ABILIFY ASIMTUFII 26
ABILIFY MAINTENA 26
ABILIFY MYCITE MAINTENANCE KIT 26
ABILIFY MYCITE STARTER KIT 26
abiraterone 17
ABRYSVO 96
ABSORICA 69
ABSORICA LD 69
acamprosate 78
ACANYA 69
acarbose 82
ACCOLATE 113
ACCUTANE 69
acebutolol 57
acetaminophen-caff-dihydrocod . 26
acetaminophen-codeine 26
acetazolamide 110
acetic acid 81
acetylcysteine 114
ACIPHEX 90
acitretin 69
ACTEMRA 100
ACTEMRA ACTPEN 100
ACTHAR 82
ACTHIB (PF) 96
ACTIMMUNE 96
ACTIVELLA 103
ACTONEL 100
ACTOPLUS MET 82
ACTOS 82
ACULAR 110
ACULAR LS 110
ACUVAIL (PF) 110
acyclovir 5, 69
acyclovir sodium 5
ACZONE 69
ADACEL(TDAP ADOLESN/ADULT)(PF) 96
adalimumab-fkjp 100
adapalene 69
adapalene-benzoyl peroxide 69
ADBRY 69
ADCIRCA 114
ADDERALL 26
ADDERALL XR 26
adefovir 5
ADEMPAS 114
ADLARITY 26
ADMELOG SOLOSTAR U-100 INSULIN 82
ADMELOG U-100 INSULIN LISPRO 82
ADVAIR DISKUS 114
ADVAIR HFA 114
ADZENYS XR-ODT 26
AEMCOLO 5
AFINITOR 17
AFINITOR DISPERZ 17
AFREZZA 82
AGRYLIN 78
AIMOVIG AUTOINJECTOR 26
AIRDUO DIGIHALER 114
AIRDUO RESPICLICK 114
AJOVY AUTOINJECTOR 26
AJOVY SYRINGE 26
AKLIEF 69
ALA-CORT 69
ALA-SCALP 69
albendazole 5
albuterol sulfate 114
alclometasone 69
ALCOHOL PADS 82
ALDACTONE 57
ALECENSA 18
alendronate 100
alfuzosin 119
aliskiren 57
ALKINDI SPRINKLE 82
allopurinol 100
ALLZITAL 26
almotriptan malate 26
alogliptin 82
alogliptin-metformin 82
alogliptin-pioglitazone 82
ALOMIDE 110
alosetron 90
ALPHAGAN P 110
alprazolam 26, 27
ALPRAZOLAM INTENSOL .. 26
ALREX 110
ALTABAX 69
ALTACE 57, 58
ALTAVERA (28) 103
ALTOPREV 58
ALTRENO 69
ALUNBRIG 18
ALVESCO 114
ALYACEN 1/35 (28) 103
ALYQ 114
AMABELZ 103
amantadine hcl 5
AMBIEN 27
AMBIEN CR 27
AMBISOME 5
ambrisentan 114
amcinonide 70
AMETHIA 104
amikacin 5
amiloride 58
amiloride-hydrochlorothiazide ... 58
amiodarone 58
AMITIZA 90
amitriptyline 27
amitriptyline-chlordiazepoxide ... 27
AMJEVITA(CF) 100
AMJEVITA(CF) AUTOINJECTOR 100
amlodipine 58
amlodipine-atorvastatin 58
amlodipine-benazepril 58
amlodipine-olmesartan 58
amlodipine-valsartan 58
amlodipine-valsartan-hcthiazid .. 58
ammonium lactate 70
AMNESTEEM 70
amoxapine 27
amoxicil-clarithromy-lansopraz . 90
amoxicillin 5
amoxicillin-pot clavulanate 5
amphetamine sulfate 27
amphotericin b 5
amphotericin b liposome 5
ampicillin 5
ampicillin sodium 5
ampicillin-sulbactam 5
AMPYRA 27
AMRIX 27
AMZEEQ 70
ANAFRANIL 27
anagrelide 78
anastrozole 18
ANCOBON 5
ANDROGEL 82
ANGELIQ 104
ANNOVERA 104
ANORO ELLIPTA 114
ANTARA 58

ANTIVERT 90
ANUSOL-HC 90
ANZEMET 90
APEXICON E 70
APIDRA SOLOSTAR U-100 INSULIN 82
APIDRA U-100 INSULIN 82
APLENZIN 27
APOKYN 27
apomorphine 27
apraclonidine 110
aprepitant 90
APRI 104
APRISO 90
APTENSIO XR 27
APTIOM 27
APTIVUS 5
ARALAST NP 78
ARANELLE (28) 104
ARANESP (IN POLYSORBATE) 96
ARAVA 100
ARAZLO 70
ARCALYST 96
AREXVY (PF) 96
arformoterol 114
ARICEPT 27
ARIKAYCE 5
ARIMIDEX 18
aripiprazole 27
ARISTADA 27, 28
ARISTADA INITIO 27
ARIXTRA 58
armodafinil 28
ARMONAIR DIGIHALER 114
ARNUITY ELLIPTA 114
AROMASIN 18
ARTHROTEC 50 28
ARTHROTEC 75 28
ASCOMP WITH CODEINE 28
asenapine maleate 28
ASHLYNA 104
ASMANEX HFA 114
ASMANEX TWISTHALER 114
aspirin-dipyridamole 58
ASPRUZYO SPRINKLE 58
ASSURE ID INSULIN SAFETY 100
ASTAGRAF XL 18
ATACAND 58
ATACAND HCT 58
atazanavir 5
ATELVIA 101
atenolol 58
atenolol-chlorthalidone 58
ATIVAN 28
atomoxetine 28
ATORVALIQ 58
atorvastatin 58
atovaquone 5
atovaquone-proguanil 6
ATRALIN 70
atropine 110
ATROVENT HFA 114
AUBAGIO 28
AUBRA EQ 104
AUGMENTIN 6
AUGMENTIN ES-600 6
AURYXIA 78
AUSTEDO 28
AUSTEDO XR 28
AUSTEDO XR TITRATION KT(WK1-4) 28
AUVELITY 28
AUVI-Q 114
AVALIDE 58
AVAPRO 58
AVEED 82
AVIANE 104
AVONEX 96, 97
AVYCAZ 6
AYGESTIN 104
AYVAKIT 18
AZACTAM 6
AZASAN 18
AZASITE 110
azathioprine 18
azelaic acid 70
azelastine 81, 110
azelastine-fluticasone 114
AZELEX 70
AZILECT 28
azithromycin 6
AZOPT 110
AZOR 58
AZSTARYS 28
aztreonam 6
AZULFIDINE 90
AZULFIDINE EN-TABS 90
bacitracin 110
bacitracin-polymyxin b 110
baclofen 28
BACTRIM 6
BACTRIM DS 6
BAFIERTAM 28
BALCOLTRA 104
balsalazide 90
BALVERSA 18
BALZIVA (28) 104
BANZEL 28
BAQSIMI 82
BARACLUDE 6
BASAGLAR KWIKPEN U-100 INSULIN 82
BASAGLAR TEMPO PEN(U-100)INSLN 82
BAXDELA 6
bcg vaccine, live (pf) 97
BECONASE AQ 114
BELBUCA 28
BELSOMRA 28
benazepril 58
benazepril-hydrochlorothiazide 58
BENICAR 58
BENICAR HCT 58
BENLYSTA 101
BENZAMYCIN 70
benznidazole 6
benztropine 28
bepotastine besilate 110
BEPREVE 110
BERINERT 114
BESIVANCE 110
BESREMI 97
betaine 90
betamethasone dipropionate 70
betamethasone valerate 70
betamethasone, augmented 70
BETAPACE AF 58
BETASERON 97
betaxolol 58, 110
bethanechol chloride 120
BETHKIS 6
BETIMOL 110
BETOPTIC S 110
BEVESPI AEROSPHERE 114
bexarotene 18
BEXSERO 97
BEYAZ 104
bicalutamide 18
BICILLIN C-R 6
BICILLIN L-A 6
BIDIL 58
BIJUVA 104
BIKTARVY 6
BILTRICIDE 6

bimatoprost 110
BINOSTO 101
bismuth subcit k-metronidz-tcn ... 90
bisoprolol fumarate 58
bisoprolol-hydrochlorothiazide .. 59
BIVIGAM 97
BLISOVI 24 FE 104
BLISOVI FE 1.5/30 (28) 104
BONJESTA 90
BOOSTRIX TDAP 97
bosentan 114
BOSULIF 18
BRAFTOVI 18
BREO ELLIPTA 114
BREZTRI AEROSPHERE 115
BRIELLYN 104
BRILINTA 59
brimonidine 70, 110
brimonidine-timolol 110
brinzolamide 110
BRIVIACT 29
bromfenac 110
bromocriptine 29
BROMSITE 110
BRONCHITOL 115
BROVANA 115
BRUKINSA 18
BRYHALI 70
budesonide 90, 115
budesonide-formoterol 115
bumetanide 59
BUPAP 29
BUPHENYL 78
buprenorphine 29
buprenorphine hcl 29
buprenorphine-naloxone 29
bupropion hcl 29
bupropion hcl (smoking deter) 78
buspirone 29
butalbital-acetaminop-caf-cod 29
butalbital-acetaminophen 29
butalbital-acetaminophen-caff 29
butalbital-aspirin-caffeine 29
butorphanol 29
BUTRANS 29, 30
BYDUREON BCISE 82
BYETTA 82
BYLVAY 90, 91
BYSTOLIC 59
cabergoline 82
CABLIVI 59
CABOMETYX 18
CADUET 59
calcipotriene 70
calcipotriene-betamethasone 70
calcitonin (salmon) 82
calcitriol 70, 82
calcium acetate(phosphat bind) 121
CALQUENCE 18
CALQUENCE (ACALABRUTINIB MAL) 18
CAMBIA 30
CAMILA 104
CAMRESE LO 104
CAMZYOS 59
CANASA 91
CANCIDAS 6
candesartan 59
candesartan-hydrochlorothiazid . 59
CAPEX 70
CAPLYTA 30
CAPRELSA 18
captopril 59
CARAC 70
CARAFATE 91
CARBAGLU 78
carbamazepine 30
CARBATROL 30
carbidopa 30
carbidopa-levodopa 30
carbidopa-levodopa-entacapone 30
carbinoxamine maleate 115
CARDIZEM 59
CARDIZEM CD 59
CARDIZEM LA 59
CARDURA 59
CARDURA XL 59
carglumic acid 78
carisoprodol 30
CARNITOR 78
CAROSPIR 59
carteolol 110
CARTIA XT 59
carvedilol 59
carvedilol phosphate 59
CASODEX 18
caspofungin 6
CATAPRES-TTS-1 59
CATAPRES-TTS-2 59
CATAPRES-TTS-3 59
CAYSTON 6
cefaclor 6
cefadroxil 6
cefazolin 6
cefdinir 6
cefepime 6
cefixime 6
cefotetan 6
cefoxitin 6
cefpodoxime 7
cefprozil 7
ceftazidime 7
ceftriaxone 7
cefuroxime axetil 7
cefuroxime sodium 7
CELEBREX 30
celecoxib 30
CELEXA 30
CELLCEPT 18
CELONTIN 30
cephalexin 7
CEQUA 110
CERDELGA 82
cetirizine 115
CETRAXAL 81
cevimeline 78
CHEMET 78
CHENODAL 91
chlordiazepoxide hcl 30
chlordiazepoxide-clidinium 91
chlorhexidine gluconate 81
chloroquine phosphate 7
chlorpromazine 30
chlorthalidone 59
chlorzoxazone 30
CHOLBAM 91
cholestyramine (with sugar) 59
CHOLESTYRAMINE LIGHT 59
CIALIS 120
CIBINQO 70
ciclopirox 70
cilostazol 59
CILOXAN 110
CIMDUO 7
cimetidine 91
CIMZIA 91
CIMZIA POWDER FOR RECONST 91
cinacalcet 82, 83
CINRYZE 115
CIPRO 7
CIPRO HC 81
ciprofloxacin hcl 7, 81, 110
ciprofloxacin in 5 % dextrose 7
ciprofloxacin-dexamethasone 81

ciprofloxacin-fluocinolone 81
citalopram 30
CLARAVIS 70
CLARINEX 115
CLARINEX-D 12 HOUR 115
clarithromycin 7
clemastine 115
CLENPIQ 91
CLEOCIN 7, 104
CLEOCIN HCL 7
CLEOCIN PEDIATRIC 7
CLEOCIN T 70
CLIMARA 104
CLIMARA PRO 104
CLINDACIN 70
CLINDACIN ETZ 70
CLINDAGEL 71
clindamycin hcl 7
clindamycin in 5 % dextrose 7
CLINDAMYCIN PEDIATRIC 7
clindamycin phosphate ... 7, 71, 104
clindamycin-benzoyl peroxide 71
clindamycin-tretinoin 71
CLINDESSE 104
CLINIMIX 5%/D15W SULFITE FREE 121
CLINIMIX 4.25%/D10W SULF FREE 121
CLINIMIX 4.25%/D5W SULFIT FREE 78
CLINIMIX 5%-D20W(SULFITE-FREE) 121
CLINIMIX E 2.75%/D5W SULF FREE 78
CLINIMIX E 4.25%/D10W SUL FREE 121
CLINIMIX E 4.25%/D5W SULF FREE 121
CLINIMIX E 5%/D15W SULFIT FREE 121
CLINIMIX E 5%/D20W SULFIT FREE 121
CLINISOL SF 15 % 121
clobazam 30
clobetasol 71
clobetasol-emollient 71
CLOBEX 71
clocortolone pivalate 71
CLODAN 71
CLODERM 71
clomipramine 30
clonazepam 30
clonidine 59
clonidine hcl 30, 60
clopidogrel 60
clorazepate dipotassium 31
clotrimazole 7, 71
clotrimazole-betamethasone 71
clozapine 31
CLOZARIL 31
COARTEM 7
codeine sulfate 31
codeine-butalbital-asa-caff 31
COLAZAL 91
colchicine 101
COLCRYS 101
colesevelam 60
COLESTID 60
colestipol 60
colistin (colistimethate na) 7
COMBIGAN 111
COMBIPATCH 104
COMBIVENT RESPIMAT ... 115
COMBIVIR 7
COMETRIQ 18
COMPLERA 7
COMPRO 91
COMTAN 31
CONCERTA 31
CONDYLOX 71
CONJUPRI 60
CONSTULOSE 91
CONZIP 31
COPAXONE 31
COPIKTRA 18
CORDRAN 71
CORDRAN TAPE LARGE ROLL 71
COREG 60
COREG CR 60
CORGARD 60
CORLANOR 60
CORTEF 83
CORTROPHIN GEL 83
COSENTYX 72
COSENTYX (2 SYRINGES) ... 71
COSENTYX PEN (2 PENS) 71
COSENTYX UNOREADY PEN 72
COSOPT 111
COSOPT (PF) 111
COTELLIC 19
COTEMPLA XR-ODT 31
COZAAR 60
CREON 91
CRESEMBA 7
CRESTOR 60
CRINONE 104
cromolyn 91, 111, 115
CROTAN 72
CRYSELLE (28) 104
CUBICIN RF 8
CUPRIMINE 101
CUVPOSA 91
CUVRIOR 78
cyclobenzaprine 31
cyclophosphamide 19
CYCLOSET 83
cyclosporine 19, 111
cyclosporine modified 19
CYLTEZO(CF) 101
CYLTEZO(CF) PEN 101
CYLTEZO(CF) PEN CROHN'S-UC-HS 101
CYLTEZO(CF) PEN PSORIASIS-UV 101
CYMBALTA 31
cyproheptadine 115
CYRED EQ 104
CYSTADANE 91
CYSTADROPS 111
CYSTAGON 120
CYSTARAN 111
CYTOMEL 83
CYTOTEC 91
d10 %-0.45 % sodium chloride ... 78
d2.5 %-0.45 % sodium chloride .. 78
d5 % and 0.9 % sodium chloride 78
d5 %-0.45 % sodium chloride 78
dabigatran etexilate 60
dalfampridine 31
DALIRESP 115
DALVANCE 8
danazol 83
DANTRIUM 31
dantrolene 31
dapsone 8, 72
DAPTACEL (DTAP PEDIATRIC) (PF) 97
daptomycin 8
darifenacin 120
DARTISLA 91
darunavir ethanolate 8
DAURISMO 19

DAYBUE 31
DAYPRO 31
DAYTRANA 32
DAYVIGO 32
DDAVP 83
DEBLITANE 104
deferasirox 78
deferiprone 78
DELESTROGEN 104
DELSTRIGO 8
DELZICOL 91
demeclocycline 8
DEMEROL 32
DEMEROL (PF) 32
DEMSER 60
DENAVIR 72
DEPAKOTE 32
DEPAKOTE ER 32
DEPAKOTE SPRINKLES 32
DEPEN TITRATABS 101
DEPO-ESTRADIOL 104
DEPO-PROVERA 104
DEPO-SUBQ PROVERA 104 104
DEPO-TESTOSTERONE 83
DERMA-SMOOTHE/FS SCALP OIL 72
DERMOTIC OIL 81
DESCOVY 8
desipramine 32
desloratadine 115
desmopressin 83
desog-e.estradiol/e.estradiol 104
desogestrel-ethinyl estradiol 104
desonide 72
DESOWEN 72
desoximetasone 72
desvenlafaxine 32
desvenlafaxine succinate 32
DETROL 120
DETROL LA 120
DEXABLISS 83
dexamethasone 83
dexamethasone sodium phosphate 111
DEXEDRINE SPANSULE 32
DEXILANT 91
dexlansoprazole 91
dexmethylphenidate 32
dextroamphetamine sulfate 32
dextroamphetamine-amphetamine 32
dextrose 10 % and 0.2 % nacl 79
dextrose 10 % in water (d10w) 79
dextrose 5 % in water (d5w) 79
dextrose 5%-0.2 % sod chloride 79
DHIVY 33
DIACOMIT 33
DIASTAT 33
DIASTAT ACUDIAL 33
diazepam 33
DIAZEPAM INTENSOL 33
diazoxide 83
DIBENZYLINE 60
DICLEGIS 91
diclofenac epolamine 33
diclofenac potassium 33
diclofenac sodium 33, 72, 111
diclofenac-misoprostol 33
dicloxacillin 8
dicyclomine 91
DIFFERIN 72
DIFICID 8
diflorasone 72
DIFLUCAN 8
diflunisal 33
difluprednate 111
digoxin 60
dihydroergotamine 33
DILANTIN 33
DILANTIN EXTENDED 33
DILANTIN INFATABS 33
DILANTIN-125 33
DILAUDID 33
diltiazem hcl 60
DILT-XR 60
dimethyl fumarate 33
DIOVAN 60, 61
DIOVAN HCT 60
DIPENTUM 91
diphenoxylate-atropine 91
DIPROLENE (AUGMENTED) 72
dipyridamole 61
disopyramide phosphate 61
disulfiram 79
DIURIL 61
divalproex 33
DIVIGEL 105
dofetilide 61
DOJOLVI 121
DOLISHALE 105
donepezil 33, 34
DOPTELET (10 TAB PACK) . 61
DOPTELET (15 TAB PACK) . 61
DOPTELET (30 TAB PACK) . 61
DORYX 8
DORYX MPC 8
dorzolamide 111
dorzolamide-timolol 111
dorzolamide-timolol (pf) 111
DOTTI 105
DOVATO 8
doxazosin 61
doxepin 34, 72
doxercalciferol 83
DOXY-100 8
doxycycline hyclate 8
doxycycline monohydrate 8, 9
doxylamine-pyridoxine (vit b6) 91
dronabinol 91
drospirenone-e.estradiol-lm.fa . 105
drospirenone-ethinyl estradiol .. 105
DROXIA 19
droxidopa 79
DUAKLIR PRESSAIR 115
DUAVEE 105
DUETACT 83
DUEXIS 34
DULERA 115
duloxetine 34
DUOBRII 72
DUOPA 34
DUPIXENT PEN 72
DUPIXENT SYRINGE 72
DUREZOL 111
dutasteride 120
dutasteride-tamsulosin 120
DYANAVEL XR 34
DYMISTA 115
DYRENIUM 61
E.E.S. 400 9
E.E.S. GRANULES 9
econazole 72
EDARBI 61
EDARBYCLOR 61
EDECRIN 61
EDLUAR 34
EDURANT 9
efavirenz 9
efavirenz-emtricitabin-tenofov 9
efavirenz-lamivu-tenofov disop 9
EFFEXOR XR 34
EFFIENT 61
EFUDEX 72
EGRIFTA SV 97
electrolyte-148 121

ELESTRIN 105
eletriptan 34
ELIDEL 72
ELIGARD 19
ELIGARD (3 MONTH) 19
ELIGARD (4 MONTH) 19
ELIGARD (6 MONTH) 19
ELIQUIS 61
ELIQUIS DVT-PE TREAT 30D START 61
ELMIRON 120
ELURYNG 105
EMCYT 19
EMEND 91
EMFLAZA 83
EMGALITY PEN 34
EMGALITY SYRINGE 34
EMSAM 34
emtricitabine 9
emtricitabine-tenofovir (tdf) 9
EMTRIVA 9
EMVERM 9
enalapril maleate 61
enalapril-hydrochlorothiazide 61
ENBREL 101
ENBREL MINI 101
ENBREL SURECLICK 101
ENDARI 79
ENDOCET 34
ENGERIX-B (PF) 97
ENGERIX-B PEDIATRIC (PF) 97
enoxaparin 61
ENPRESSE 105
ENSKYCE 105
ENSPRYNG 19
ENSTILAR 73
entacapone 34
ENTADFI 120
entecavir 9
ENTRESTO 61
ENULOSE 91
ENVARSUS XR 19
EPCLUSA 9
EPIDIOLEX 34
EPIDUO 73
EPIDUO FORTE 73
epinastine 111
epinephrine 115
EPIPEN 2-PAK 115
EPIPEN JR 2-PAK 115
EPITOL 34
EPIVIR 9
eplerenone 61
EPOGEN 97
EPRONTIA 34
EPSOLAY 73
EPZICOM 9
EQUETRO 34
ERAXIS(WATER DILUENT) 9
ergoloid 34
ergotamine-caffeine 35
ERIVEDGE 19
ERLEADA 19
erlotinib 19
ERMEZA 83
ERRIN 105
ERTACZO 73
ertapenem 9
ERY PADS 73
ERYGEL 73
ERYPED 200 9
ERYPED 400 9
ERY-TAB 9
ERYTHROCIN 9
ERYTHROCIN (AS STEARATE) 9
erythromycin 10, 111
erythromycin ethylsuccinate 10
erythromycin with ethanol 73
erythromycin-benzoyl peroxide 73
ESBRIET 115
escitalopram oxalate 35
ESGIC 35
esomeprazole magnesium 91, 92
ESTARYLLA 105
estazolam 35
ESTRACE 105
estradiol 105
estradiol valerate 105
estradiol-norethindrone acet 105
ESTRING 105
ESTROGEL 105
eszopiclone 35
ethacrynic acid 61
ethambutol 10
ethosuximide 35
ethynodiol diac-eth estradiol 105
etodolac 35
etonogestrel-ethinyl estradiol 105
etravirine 10
EUCRISA 73
EUTHYROX 83
EVAMIST 105
EVEKEO 35
EVEKEO ODT 35
EVENITY 101
everolimus (antineoplastic) 19
everolimus (immunosuppressive) 19
EVISTA 101
EVOTAZ 10
EVOXAC 79
EVRYSDI 35
EXELDERM 73
EXELON PATCH 35
exemestane 19
EXFORGE 61
EXFORGE HCT 61
EXJADE 79
EXKIVITY 19
EXSERVAN 79
EXTAVIA 97
EYSUVIS 111
EZALLOR SPRINKLE 61
ezetimibe 61
ezetimibe-simvastatin 61
FABIOR 73
FALMINA (28) 105
famciclovir 10
famotidine 92
FANAPT 35
FARESTON 19
FARXIGA 83
FASENRA 115
FASENRA PEN 115
febuxostat 101
felbamate 35
FELBATOL 35
FELDENE 35
felodipine 61
FEMARA 19
FEMRING 105
fenofibrate 62
fenofibrate micronized 61
fenofibrate nanocrystallized 61
fenofibric acid (choline) 62
FENOGLIDE 62
fenoprofen 35
fentanyl 36
fentanyl citrate 35, 36
FENTORA 36
FERRIPROX 79
FERRIPROX (2 TIMES A DAY) 79
fesoterodine 120

FETZIMA 36
FEXMID 36
FIASP FLEXTOUCH U-100 INSULIN 83
FIASP PENFILL U-100 INSULIN 83
FIASP U-100 INSULIN 83
FILSPARI 62
FINACEA 73
finasteride 120
fingolimod 36
FINTEPLA 36
FINZALA 105
FIORICET 36
FIORICET WITH CODEINE 36
FIRAZYR 115
FIRDAPSE 36
FIRMAGON KIT W DILUENT SYRINGE 19
FIRVANQ 10
FLAC OTIC OIL 81
FLAGYL 10
FLAREX 111
flavoxate 120
FLEBOGAMMA DIF 97
flecainide 62
FLECTOR 36
FLEQSUVY 36
FLOLIPID 62
FLOMAX 120
FLOVENT DISKUS 115
FLOVENT HFA 115, 116
fluconazole 10
fluconazole in nacl (iso-osm) 10
flucytosine 10
fludrocortisone 83
flunisolide 116
fluocinolone 73
fluocinolone acetonide oil 81
fluocinolone and shower cap 73
fluocinonide 73
fluocinonide-emollient 73
fluoride (sodium) 121
fluorometholone 111
fluorouracil 73
fluoxetine 36, 37
fluoxetine (pmdd) 36
fluphenazine decanoate 37
fluphenazine hcl 37
flurandrenolide 73
flurbiprofen 37
flurbiprofen sodium 111
fluticasone furoate-vilanterol 116
fluticasone propionate 73, 116
fluticasone propion-salmeterol 116
fluvastatin 62
fluvoxamine 37
FML FORTE 111
FML LIQUIFILM 111
FOCALIN 37
FOCALIN XR 37
fondaparinux 62
FORFIVO XL 37
formoterol fumarate 116
FORTEO 101
FORTESTA 83
FOSAMAX 101
FOSAMAX PLUS D 101
fosamprenavir 10
fosfomycin tromethamine 10
fosinopril 62
fosinopril-hydrochlorothiazide 62
FOSRENOL 79
FOTIVDA 19
FRAGMIN 62
FROVA 37
frovatriptan 37
FULPHILA 97
FUROSCIX 62
furosemide 62
FUZEON 10
FYAVOLV 105
FYCOMPA 37
FYLNETRA 97
gabapentin 37
GALAFOLD 83
galantamine 37
GAMMAGARD LIQUID 97
GAMMAGARD S-D (IGA < 1 MCG/ML) 97
GAMMAKED 97
GAMMAPLEX 97
GAMMAPLEX (WITH SORBITOL) 97
GAMUNEX-C 97
GARDASIL 9 (PF) 97
GASTROCROM 92
gatifloxacin 111
GATTEX 30-VIAL 92
GAUZE PAD 100
GAVILYTE-C 92
GAVILYTE-G 92
GAVRETO 19
gefitinib 19
GELNIQUE 120
gemfibrozil 62
GEMMILY 105
GEMTESA 120
GENERLAC 92
GENGRAF 20
GENOTROPIN 97
GENOTROPIN MINIQUICK 97
gentamicin 10, 73, 111
gentamicin in nacl (iso-osm) 10
GENVOYA 10
GEODON 37
GILENYA 37
GILOTRIF 20
GIMOTI 92
GLASSIA 79
glatiramer 37
GLATOPA 37
GLEEVEC 20
GLEOSTINE 20
glimepiride 83
glipizide 83
glipizide-metformin 83
GLUCAGEN HYPOKIT 83
GLUCAGON EMERGENCY KIT (HUMAN) 83
GLUCOTROL XL 83
GLUMETZA 84
glyburide 84
glyburide micronized 84
glyburide-metformin 84
GLYCATE 92
glycopyrrolate 92
GLYNASE 84
GLYXAMBI 84
GOCOVRI 37
GOLYTELY 92
GRALISE 38
granisetron hcl 92
GRANIX 97
GRASTEK 98
griseofulvin microsize 10
griseofulvin ultramicrosize 10
guanfacine 38, 62
GVOKE 84
GVOKE HYPOPEN 2-PACK 84
GVOKE PFS 1-PACK SYRINGE 84
GYNAZOLE-1 105
HADLIMA 101
HADLIMA PUSHTOUCH 101
HADLIMA(CF) 101

HADLIMA(CF) PUSHTOUCH 101
HAEGARDA 116
HAILEY 24 FE 105
halcinonide 73
HALCION 38
HALDOL DECANOATE 38
halobetasol propionate 73, 74
HALOETTE 105
HALOG 74
haloperidol 38
haloperidol decanoate 38
haloperidol lactate 38
HARVONI 10
HAVRIX (PF) 98
HELIDAC 92
HEMADY 84
heparin (porcine) 62
HEPLISAV-B (PF) 98
HETLIOZ 38
HETLIOZ LQ 38
HIBERIX (PF) 98
HIPREX 10
HORIZANT 38
HULIO(CF) 101
HULIO(CF) PEN 101
HUMALOG JUNIOR KWIKPEN U-100 84
HUMALOG KWIKPEN INSULIN 84
HUMALOG MIX 50-50 INSULN U-100 84
HUMALOG MIX 50-50 KWIKPEN 84
HUMALOG MIX 75-25 KWIKPEN 84
HUMALOG MIX 75-25(U-100)INSULN 84
HUMALOG TEMPO PEN(U-100)INSULN 84
HUMALOG U-100 INSULIN .. 84
HUMATIN 10
HUMATROPE 98
HUMIRA 101
HUMIRA PEN 101
HUMIRA PEN CROHNS-UC-HS START 101
HUMIRA PEN PSOR-UVEITS-ADOL HS 101
HUMIRA(CF) 101
HUMIRA(CF) PEDI CROHNS STARTER 102
HUMIRA(CF) PEN 102
HUMIRA(CF) PEN CROHNS-UC-HS 102
HUMIRA(CF) PEN PEDIATRIC UC 102
HUMIRA(CF) PEN PSOR-UV-ADOL HS 102
HUMULIN 70/30 U-100 INSULIN 84
HUMULIN 70/30 U-100 KWIKPEN 84
HUMULIN N NPH INSULIN KWIKPEN 84
HUMULIN N NPH U-100 INSULIN 84
HUMULIN R REGULAR U-100 INSULN 84
HUMULIN R U-500 (CONC) INSULIN 84
HUMULIN R U-500 (CONC) KWIKPEN 84
hydralazine 62
HYDREA 20
hydrochlorothiazide 62
hydrocodone bitartrate 38
hydrocodone-acetaminophen 38
hydrocodone-ibuprofen 38
hydrocortisone 74, 84, 92
hydrocortisone butyrate 74
hydrocortisone valerate 74
hydrocortisone-acetic acid 81
hydrocortisone-pramoxine 92
hydromorphone 38, 39
hydromorphone (pf) 38
hydroxychloroquine 10
hydroxyurea 20
hydroxyzine hcl 116
hydroxyzine pamoate 116
HYFTOR 74
HYRIMOZ PEN CROHN'S-UC STARTER 102
HYRIMOZ PEN PSORIASIS STARTER 102
HYRIMOZ(CF) 102
HYRIMOZ(CF) PEDI CROHN STARTER 102
HYRIMOZ(CF) PEN 102
HYSINGLA ER 39
HYZAAR 62
ibandronate 102
IBRANCE 20
IBSRELA 92
IBU 39
ibuprofen 39
ibuprofen-famotidine 39
icatibant 116
ICLEVIA 105
ICLUSIG 20
icosapent ethyl 62
IDHIFA 20
ILEVRO 111
ILUMYA 74
imatinib 20
IMBRUVICA 20
imipenem-cilastatin 10
imipramine hcl 39
imipramine pamoate 39
imiquimod 74
IMITREX 39
IMITREX STATDOSE PEN ... 39
IMITREX STATDOSE REFILL 39
IMOVAX RABIES VACCINE (PF) 98
IMPAVIDO 10
IMURAN 20
IMVEXXY MAINTENANCE PACK 105
IMVEXXY STARTER PACK 105
INBRIJA 39
INCASSIA 106
INCRELEX 79
INCRUSE ELLIPTA 116
indapamide 62
INDERAL LA 63
INDOCIN 39
indomethacin 39
INFANRIX (DTAP) (PF) 98
INGREZZA 39
INGREZZA INITIATION PACK 39
INLYTA 20
INNOPRAN XL 63
INPEFA 84
INQOVI 20
INREBIC 20
INSPRA 63
insulin asp prt-insulin aspart 84
insulin aspart u-100 84
insulin degludec 84
insulin glargine 84
insulin glargine-yfgn 84
insulin lispro 84

insulin lispro protamin-lispro.....84
insulin syringe-needle u-100.....100
INTELENCE.....10
INTRALIPID..... 121
INTRAROSA..... 106
INTROVALE..... 106
INTUNIV ER..... 39
INVANZ.....11
INVEGA..... 40
INVEGA HAFYERA.....40
INVEGA SUSTENNA.....40
INVEGA TRINZA.....40
INVELTYS.....111
INVOKAMET.....85
INVOKAMET XR.....85
INVOKANA.....85
IOPIDINE.....111
IPOL.....98
ipratropium bromide.....81, 116
ipratropium-albuterol.....116
irbesartan.....63
irbesartan-hydrochlorothiazide..63
IRESSA.....20
ISENTRESS..... 11
ISENTRESS HD..... 11
ISIBLOOM.....106
ISOLYTE S PH 7.4.....121
ISOLYTE-P IN 5 % DEXTROSE..... 121
isoniazid.....11
ISORDIL..... 63
ISORDIL TITRADOSE.....63
isosorbide dinitrate.....63
isosorbide mononitrate..... 63
isosorbide-hydralazine..... 63
isotretinoin.....74
isradipine..... 63
ISTALOL.....111
ISTURISA..... 85
itraconazole..... 11
ivermectin.....11, 74
IXIARO (PF).....98
IYUZEH.....111
JADENU..... 79
JADENU SPRINKLE.....79
JAKAFI..... 20
JALYN..... 120
JANTOVEN..... 63
JANUMET.....85
JANUMET XR.....85
JANUVIA..... 85
JARDIANCE.....85
JASMIEL (28)..... 106
JATENZO..... 85
JAVYGTOR.....85
JAYPIRCA.....20
JENTADUETO.....85
JENTADUETO XR..... 85
JINTELI..... 106
JORNAY PM.....40
JUBLIA.....74
JULEBER.....106
JULUCA..... 11
JUNEL 1.5/30 (21)..... 106
JUNEL 1/20 (21)..... 106
JUNEL FE 1.5/30 (28)..... 106
JUNEL FE 1/20 (28)..... 106
JUNEL FE 24..... 106
JUXTAPID..... 63
JYNARQUE..... 85
JYNNEOS (PF)(STOCKPILE).....98
KAITLIB FE..... 106
KALETRA.....11
KALYDECO..... 116
KAPVAY..... 40
KARIVA (28).....106
KATERZIA.....63
KAZANO.....85
KELNOR 1/35 (28)..... 106
KELNOR 1-50 (28).....106
KENALOG.....74
KEPPRA.....40
KEPPRA XR..... 40
KERENDIA.....63
KERYDIN..... 74
KESIMPTA PEN.....40
ketoconazole.....11, 74
KETODAN..... 74
ketoprofen..... 40
ketorolac..... 40, 111
KEVEYIS..... 40
KEVZARA..... 102
KINERET.....102
KINRIX (PF).....98
KISQALI..... 20, 21
KISQALI FEMARA CO-PACK.....20
KITABIS PAK..... 11
KLARON.....74
KLISYRI..... 21
KLONOPIN.....40
KLOR-CON..... 121
KLOR-CON 10..... 121
KLOR-CON 8..... 121
KLOR-CON M10.....121
KLOR-CON M15.....121
KLOR-CON M20.....121
KLOXXADO.....41
KOMBIGLYZE XR..... 85
KONVOMEP..... 92
KORLYM.....85
KOSELUGO..... 21
KRAZATI.....21
KRINTAFEL.....11
KRISTALOSE..... 92
KURVELO (28)..... 106
KUVAN.....85
KYLEENA.....106
l norgest/e.estradiol-e.estrad.... 106
labetalol..... 63
lacosamide..... 41
LACRISERT..... 111
lactulose.....92
LAMICTAL..... 41
LAMICTAL ODT.....41
LAMICTAL STARTER (BLUE) KIT..... 41
LAMICTAL STARTER (GREEN) KIT..... 41
LAMICTAL STARTER (ORANGE) KIT.....41
LAMICTAL XR.....41
LAMICTAL XR STARTER (BLUE).....41
LAMICTAL XR STARTER (GREEN)..... 41
LAMICTAL XR STARTER (ORANGE)..... 41
lamivudine.....11
lamivudine-zidovudine..... 11
lamotrigine.....41
LAMPIT..... 11
LANOXIN..... 63
lansoprazole.....92
lanthanum..... 79
LANTUS SOLOSTAR U-100 INSULIN.....85
LANTUS U-100 INSULIN..... 85
lapatinib.....21
LARIN 1.5/30 (21).....106
LARIN 1/20 (21).....106
LARIN FE 1.5/30 (28).....106
LARIN FE 1/20 (28).....106
LASIX..... 63
latanoprost.....111

LATUDA 41
LAYOLIS FE 106
ledipasvir-sofosbuvir 11
LEENA 28 106
leflunomide 102
lenalidomide 21
LENVIMA 21
LESCOL XL 63
LESSINA 106
LETAIRIS 116
letrozole 21
leucovorin calcium 21
LEUKERAN 21
LEUKINE 98
leuprolide 21
leuprolide (3 month) 21
levalbuterol hcl 116, 117
levalbuterol tartrate 117
levamlodipine 63
LEVEMIR FLEXPEN 86
LEVEMIR U-100 INSULIN 86
levetiracetam 41
levobunolol 111
levocarnitine 79
levocarnitine (with sugar) 79
levocetirizine 117
levofloxacin 11, 111
levofloxacin in d5w 11
LEVONEST (28) 106
levonorgestrel-ethinyl estrad 106
levonorg-eth estrad triphasic 106
LEVORA-28 106
levorphanol tartrate 41
levothyroxine 86
LEVOXYL 86
LEXAPRO 41
LEXETTE 74
LEXIVA 11
LIALDA 92
LIBRAX (WITH CLIDINIUM) 92
LICART 41
lidocaine 74
lidocaine hcl 74
LIDOCAINE VISCOUS 74
lidocaine-prilocaine 74
LIDODERM 74
LILETTA 106
linezolid 11
linezolid in dextrose 5% 11
LINZESS 92
liothyronine 86
LIPITOR 63
LIPOFEN 63
LIQREV 117
lisdexamfetamine 41
lisinopril 63
lisinopril-hydrochlorothiazide 63
LITFULO 79
lithium carbonate 41
lithium citrate 41
LITHOBID 41
LITHOSTAT 79
LIVALO 63
LIVMARLI 92
LIVTENCITY 11
LO LOESTRIN FE 106
LOCOID 74
LOCOID LIPOCREAM 74
LODINE 41
LODOCO 63
LODOSYN 41
LOESTRIN 1.5/30 (21) 106
LOESTRIN 1/20 (21) 106
LOESTRIN FE 1.5/30 (28-DAY) 106
LOESTRIN FE 1/20 (28-DAY) 106
LOFENA 41
LOKELMA 79
LOMOTIL 93
LONSURF 21
loperamide 93
LOPID 63
lopinavir-ritonavir 11
LOPRESSOR 64
LOPROX 74
lorazepam 42
LORAZEPAM INTENSOL 41
LORBRENA 21
LOREEV XR 42
LORYNA (28) 106
LORZONE 42
losartan 64
losartan-hydrochlorothiazide 64
LOSEASONIQUE 107
LOTEMAX 112
LOTEMAX SM 112
LOTENSIN 64
loteprednol etabonate 112
LOTREL 64
LOTRONEX 93
lovastatin 64
LOVAZA 64
LOVENOX 64
LOW-OGESTREL (28) 107
loxapine succinate 42
lubiprostone 93
LUCEMYRA 42
luliconazole 74
LUMAKRAS 21
LUMIGAN 112
LUMRYZ 42
LUNESTA 42
LUPKYNIS 21
LUPRON DEPOT 21
LUPRON DEPOT (3 MONTH) 21
LUPRON DEPOT (4 MONTH) 21
LUPRON DEPOT (6 MONTH) 21
LUPRON DEPOT-PED 21
LUPRON DEPOT-PED (3 MONTH) 21
lurasidone 42
LUTERA (28) 107
LUZU 75
LYBALVI 42
LYLEQ 107
LYLLANA 107
LYNPARZA 21
LYRICA 42
LYRICA CR 42
LYSODREN 21
LYTGOBI 21
LYUMJEV KWIKPEN U-100 INSULIN 86
LYUMJEV KWIKPEN U-200 INSULIN 86
LYUMJEV TEMPO PEN(U-100)INSULN 86
LYUMJEV U-100 INSULIN 86
LYVISPAH 42
LYZA 107
MACROBID 11
MACRODANTIN 11, 12
mafenide acetate 75
magnesium sulfate 121
MALARONE 12
MALARONE PEDIATRIC 12
malathion 75
maraviroc 12
MARINOL 93
MARLISSA (28) 107
MARPLAN 42

MATULANE 22
MATZIM LA 64
MAVENCLAD (10 TABLET PACK) 42
MAVENCLAD (4 TABLET PACK) 42
MAVENCLAD (5 TABLET PACK) 42
MAVENCLAD (6 TABLET PACK) 42
MAVENCLAD (7 TABLET PACK) 42
MAVENCLAD (8 TABLET PACK) 42
MAVENCLAD (9 TABLET PACK) 42
MAVYRET 12
MAXALT 42
MAXALT-MLT 42
MAXIDEX 112
MAXITROL 112
MAXZIDE 64
MAXZIDE-25MG 64
MAYZENT 42
MAYZENT STARTER(FOR 1MG MAINT) 42
MAYZENT STARTER(FOR 2MG MAINT) 42
meclizine 93
meclofenamate 42
MEDROL 86
MEDROL (PAK) 86
medroxyprogesterone 107
mefenamic acid 43
mefloquine 12
megestrol 22
MEKINIST 22
MEKTOVI 22
meloxicam 43
meloxicam submicronized 43
memantine 43
MENACTRA (PF) 98
MENEST 107
MENOSTAR 107
MENQUADFI (PF) 98
MENVEO A-C-Y-W-135-DIP (PF) 98
meperidine 43
meperidine (pf) 43
meprobamate 43
MEPRON 12
mercaptopurine 22
meropenem 12
MERZEE 107
mesalamine 93
MESNEX 22
MESTINON 43
MESTINON TIMESPAN 43
metaxalone 43
metformin 86
methadone 43
methamphetamine 43
methazolamide 112
methenamine hippurate 12
methimazole 86
METHITEST 86
methocarbamol 43
methotrexate sodium 22
methotrexate sodium (pf) 22
methoxsalen 75
methscopolamine 93
methsuximide 43
METHYLIN 43
methylphenidate hcl 43, 44
methylprednisolone 86
methyltestosterone 86
metoclopramide hcl 93
metolazone 64
metoprolol succinate 64
metoprolol ta-hydrochlorothiaz 64
metoprolol tartrate 64
METROCREAM 75
METROGEL 75
METROLOTION 75
metronidazole 12, 75, 107
metronidazole in nacl (iso-os) 12
metyrosine 64
mexiletine 64
MIBELAS 24 FE 107
micafungin 12
MICARDIS 64
MICARDIS HCT 64
MICONAZOLE-3 107
MICROGESTIN 1.5/30 (21) 107
MICROGESTIN 1/20 (21) 107
MICROGESTIN 24 FE 107
MICROGESTIN FE 1.5/30 (28) 107
MICROGESTIN FE 1/20 (28) 107
midodrine 79
MIEBO 112
MIGERGOT 44
miglitol 86
miglustat 86
MIGRANAL 44
MILI 107
MILLIPRED 86
MIMVEY 107
MINIPRESS 64
MINIVELLE 107
minocycline 12
MINOLIRA ER 12
minoxidil 64
MIRAPEX ER 44
MIRENA 107
mirtazapine 44
MIRVASO 75
misoprostol 93
MITIGARE 102
M-M-R II (PF) 98
modafinil 44
moexipril 64
molindone 44
mometasone 75, 117
montelukast 117
morphine 44
morphine concentrate 44
MOTEGRITY 93
MOUNJARO 86
MOVANTIK 93
MOVIPREP 93
moxifloxacin 12, 112
moxifloxacin-sod.chloride(iso) 12
MS CONTIN 44, 45
MULPLETA 64
MULTAQ 64
mupirocin 75
mupirocin calcium 75
MYALEPT 86
MYAMBUTOL 12
MYCAMINE 12
MYCAPSSA 22
MYCOBUTIN 12
mycophenolate mofetil 22
mycophenolate sodium 22
MYDAYIS 45
MYFEMBREE 107
MYFORTIC 22
MYRBETRIQ 120
MYSOLINE 45
MYTESI 93
nabumetone 45
nadolol 64
nafcillin 12
naftifine 75

NAFTIN 75
NALFON 45
NALOCET 45
naloxone 45
naltrexone 45
NAMENDA 45
NAMENDA TITRATION PAK 45
NAMENDA XR 45
NAMZARIC 45
NAPRELAN CR 45
naproxen 45
naproxen sodium 45
naproxen-esomeprazole 45
naratriptan 45
NARCAN 45
NARDIL 45
NATACYN 112
NATAZIA 107
nateglinide 86
NATESTO 86
NATPARA 87
NATROBA 75
NAYZILAM 45
nebivolol 64
NEBUPENT 12
NECON 0.5/35 (28) 107
nefazodone 45
neomycin 12
neomycin-bacitracin-poly-hc 112
neomycin-bacitracin-polymyxin 112
neomycin-polymyxin b-dexameth 112
neomycin-polymyxin-gramicidin 112
neomycin-polymyxin-hc 81, 112
NEO-POLYCIN 112
NEO-POLYCIN HC 112
NEORAL 22
NEO-SYNALAR 75
NERLYNX 22
NESINA 87
NEUAC 75
NEULASTA 98
NEUPOGEN 98
NEUPRO 45
NEURONTIN 46
NEVANAC 112
nevirapine 12
NEXAVAR 22
NEXIUM 93
NEXIUM PACKET 93
NEXLETOL 64
NEXLIZET 64
NEXPLANON 107
NEXTSTELLIS 107
NGENLA 98
niacin 64, 65
NIACOR 65
nicardipine 65
NICOTROL 79
NICOTROL NS 79
nifedipine 65
NIKKI (28) 107
NILANDRON 22
nilutamide 22
nimodipine 65
NINLARO 22
nisoldipine 65
nitazoxanide 12
nitisinone 79
NITRO-BID 65
NITRO-DUR 65
nitrofurantoin 13
nitrofurantoin macrocrystal 12
nitrofurantoin monohyd/m-cryst 13
nitroglycerin 65
NITROLINGUAL 65
NITROSTAT 65
NITYR 79
NIVESTYM 98
nizatidine 93
NOCDURNA (MEN) 87
NOCDURNA (WOMEN) 87
NORA-BE 107
NORDITROPIN FLEXPRO 98
noreth-ethinyl estradiol-iron 107
norethindrone (contraceptive) 107
norethindrone acetate 107
norethindrone ac-eth estradiol 107, 108
norethindrone-e.estradiol-iron 108
NORGESIC 46
NORGESIC FORTE 46
norgestimate-ethinyl estradiol 108
NORITATE 75
NORLIQVA 65
NORPACE 65
NORPACE CR 65
NORPRAMIN 46
NORTHERA 79
NORTREL 0.5/35 (28) 108
NORTREL 1/35 (21) 108
NORTREL 1/35 (28) 108
NORTREL 7/7/7 (28) 108
nortriptyline 46
NORVASC 65
NORVIR 13
NOURIANZ 46
NOVOLIN 70/30 U-100 INSULIN 87
NOVOLIN 70-30 FLEXPEN U-100 87
NOVOLIN N FLEXPEN 87
NOVOLIN N NPH U-100 INSULIN 87
NOVOLIN R FLEXPEN 87
NOVOLIN R REGULAR U100 INSULIN 87
NOVOLOG FLEXPEN U-100 INSULIN 87
NOVOLOG MIX 70-30 U-100 INSULN 87
NOVOLOG MIX 70-30FLEXPEN U-100 87
NOVOLOG PENFILL U-100 INSULIN 87
NOVOLOG U-100 INSULIN ASPART 87
NOXAFIL 13
NUBEQA 22
NUCALA 117
NUCYNTA 46
NUCYNTA ER 46
NUEDEXTA 46
NUPLAZID 46
NURTEC ODT 46
NUTRILIPID 122
NUTROPIN AQ NUSPIN 98
NUVARING 108
NUVIGIL 46
NUZYRA 13
NYAMYC 75
NYLIA 1/35 (28) 108
NYLIA 7/7/7 (28) 108
NYMALIZE 65
NYMYO 108
nystatin 13, 75
nystatin-triamcinolone 75
NYSTOP 75
NYVEPRIA 98
OCALIVA 93
OCELLA 108
OCTAGAM 98
octreotide acetate 22
OCUFLOX 112

ODACTRA 98
ODEFSEY 13
ODOMZO 22
OFEV 117
ofloxacin 13, 81, 112
olanzapine 46
olanzapine-fluoxetine 46
olmesartan 65
olmesartan-amlodipin-hcthiazid . 65
olmesartan-hydrochlorothiazide . 65
olopatadine 81, 112
OLPRUVA 79, 80
OLUMIANT 102
omega-3 acid ethyl esters 65
omeprazole 93
omeprazole-sodium bicarbonate . 93
OMNARIS 117
OMNITROPE 98
ondansetron 93
ondansetron hcl 93
ONEXTON 75
ONFI 46
ONGENTYS 46
ONGLYZA 87
ONUREG 22
ONZETRA XSAIL 46
OPSUMIT 117
OPZELURA 75
ORACEA 13
ORALAIR 98
ORAPRED ODT 87
ORENCIA 102
ORENCIA CLICKJECT 102
ORENITRAM 65, 66
ORENITRAM MONTH 1 TITRATION KT 65
ORENITRAM MONTH 2 TITRATION KT 65
ORENITRAM MONTH 3 TITRATION KT 65
ORFADIN 80
ORGOVYX 22
ORIAHNN 108
ORILISSA 87
ORKAMBI 117
ORLADEYO 117
orphenadrine citrate 46
orphenadrine-asa-caffeine 46
ORSERDU 22, 23
oseltamivir 13
OSENI 87
OSMOLEX ER 46
OSMOPREP 93
OSPHENA 108
OTEZLA 102
OTEZLA STARTER 102
OTOVEL 81
OTREXUP (PF) 102
OVIDE 75
oxacillin 13
oxacillin in dextrose(iso-osm) 13
oxaprozin 46
oxazepam 46
OXBRYTA 80
oxcarbazepine 47
OXERVATE 112
oxiconazole 75
OXISTAT 75
OXTELLAR XR 47
oxybutynin chloride 120
oxycodone 47
oxycodone-acetaminophen 47
OXYCONTIN 47
oxymorphone 47
OXYTROL 120
OZEMPIC 87
PACERONE 66
paliperidone 47
PALYNZIQ 87
PAMELOR 47
PANCREAZE 94
PANDEL 75
PANRETIN 75
pantoprazole 94
PANZYGA 98
paricalcitol 87
PARLODEL 48
PARNATE 48
paromomycin 13
paroxetine hcl 48
paroxetine mesylate(menop.sym) 48
PAXIL 48
PAXIL CR 48
PEDIARIX (PF) 98
PEDVAX HIB (PF) 99
peg 3350-electrolytes 94
peg3350-sod sul-nacl-kcl-asb-c .. 94
PEGASYS 99
peg-electrolyte soln 94
PEMAZYRE 23
pen needle, diabetic 100
penciclovir 76
penicillamine 103
penicillin g pot in dextrose 13
penicillin g potassium 13
penicillin g sodium 13
penicillin v potassium 13
PENNSAID 48
PENTACEL (PF) 99
PENTAM 13
pentamidine 13
PENTASA 94
pentazocine-naloxone 48
pentoxifylline 66
PEPCID 94
PERCOCET 48
PERFOROMIST 117
perindopril erbumine 66
PERIOGARD 81
permethrin 76
perphenazine 48
perphenazine-amitriptyline 48
PERSERIS 48
PERTZYE 94
PHEBURANE 80
phenelzine 48
phenobarbital 48
phenoxybenzamine 66
PHENYTEK 48
phenytoin 48
phenytoin sodium extended 48
PHEXXI 108
PHOSPHOLINE IODIDE 112
PIFELTRO 13
pilocarpine hcl 80, 112
pimecrolimus 76
pimozide 48
PIMTREA (28) 108
pindolol 66
pioglitazone 87
pioglitazone-glimepiride 87
pioglitazone-metformin 87
piperacillin-tazobactam 13
PIQRAY 23
pirfenidone 117
piroxicam 48
PLAQUENIL 13
PLASMA-LYTE 148 122
PLASMA-LYTE A 122
PLAVIX 66
PLEGRIDY 99
PLENAMINE 122
PLENVU 94
PLIAGLIS 76
podofilox 76

POLYCIN 112
polymyxin b sulfate 13
polymyxin b sulf-trimethoprim .. 112
POMALYST 23
PONVORY 48
PONVORY 14-DAY STARTER PACK 48
PORTIA 28 108
posaconazole 13
potassium chlorid-d5-0.45%nacl 122
potassium chloride 122
potassium chloride in 0.9%nacl 122
potassium chloride in 5 % dex .. 122
potassium chloride in lr-d5 122
potassium chloride in water 122
potassium chloride-0.45 % nacl 122
potassium chloride-d5-0.2%nacl 122
potassium chloride-d5-0.9%nacl 122
potassium citrate 120
PRADAXA 66
PRALUENT PEN 66
pramipexole 48
prasugrel 66
pravastatin 66
praziquantel 13
prazosin 66
PRED FORTE 112
PRED MILD 112
prednisolone 87
prednisolone acetate 112
prednisolone sodium phosphate 87, 88, 112
prednisone 88
PREDNISONE INTENSOL 88
PREFEST 108
pregabalin 48
PREHEVBRIO (PF) 99
PREMARIN 108
PREMASOL 10 % 122
PREMPHASE 108
PREMPRO 108
PRENATAL VITAMIN PLUS LOW IRON 122
pretomanid 13
PREVACID 94
PREVACID SOLUTAB 94
PREVALITE 66
PREVYMIS 13
PREZCOBIX 14
PREZISTA 14
PRIFTIN 14
PRILOSEC 94
primaquine 14
PRIMAXIN IV 14
primidone 48
PRIORIX (PF) 99
PRISTIQ 48
PRIVIGEN 99
PROAIR DIGIHALER 117
PROAIR RESPICLICK 117
probenecid 103
probenecid-colchicine 103
PROCARDIA XL 66
PROCENTRA 49
prochlorperazine 94
prochlorperazine maleate 94
PROCRIT 99
PROCTO-MED HC 94
PROCTOSOL HC 94
PROCTOZONE-HC 94
PROCYSBI 120
progesterone micronized 108
PROGLYCEM 88
PROGRAF 23
PROLASTIN-C 80
PROLATE 49
PROLENSA 112
PROLIA 103
PROMACTA 66
promethazine 117
PROMETHEGAN 117
PROMETRIUM 108
propafenone 66
propranolol 66
propylthiouracil 88
PROQUAD (PF) 99
PROSCAR 120
PROSOL 20 % 122
PROTONIX 94
protriptyline 49
PROVENTIL HFA 117
PROVERA 108
PROVIGIL 49
PROZAC 49
PRUDOXIN 76
PULMICORT 117
PULMICORT FLEXHALER 117
PULMOZYME 117
PURIXAN 23
PYLERA 95
pyrazinamide 14
pyridostigmine bromide 49
pyrimethamine 14
PYRUKYND 80
QBRELIS 66
QELBREE 49
QINLOCK 23
QNASL 118
QTERN 88
QUADRACEL (PF) 99
QUALAQUIN 14
QUARTETTE 108
QUDEXY XR 49
QUESTRAN 66
QUESTRAN LIGHT 66
quetiapine 49
QUILLICHEW ER 49
QUILLIVANT XR 49
quinapril 66
quinidine gluconate 66
quinidine sulfate 67
quinine sulfate 14
QULIPTA 49
QUVIVIQ 49
QVAR REDIHALER 118
RABAVERT (PF) 99
rabeprazole 95
RADICAVA ORS STARTER KIT SUSP 49
raloxifene 103
ramelteon 49
ramipril 67
ranolazine 67
RAPAFLO 120
RAPAMUNE 23
rasagiline 49
RASUVO (PF) 103
RAVICTI 80
RAYALDEE 88
RAYOS 88
REBIF (WITH ALBUMIN) 99
REBIF REBIDOSE 99
REBIF TITRATION PACK 99
RECLIPSEN (28) 108
RECOMBIVAX HB (PF) 99
RECORLEV 88
RECTIV 95
REGLAN 95
REGRANEX 76
RELAFEN DS 49
RELENZA DISKHALER 14
RELEUKO 99
RELEXXII 49

RELISTOR 95
RELPAX 49, 50
RELTONE 95
RELYVRIO 50
REMERON 50
REMERON SOLTAB 50
RENAGEL 80
RENVELA 80
repaglinide 88
REPATHA PUSHTRONEX 67
REPATHA SURECLICK 67
REPATHA SYRINGE 67
RESTASIS 112
RESTASIS MULTIDOSE 112
RESTORIL 50
RETACRIT 99
RETEVMO 23
RETIN-A 76
RETIN-A MICRO 76
RETIN-A MICRO PUMP 76
RETROVIR 14
REVATIO 118
REVCOVI 80
REVLIMID 23
REXULTI 50
REYATAZ 14
REYVOW 50
REZLIDHIA 23
REZUROCK 23
REZVOGLAR KWIKPEN 88
RHOFADE 76
RHOPRESSA 112
ribavirin 14
RIDAURA 103
rifabutin 14
rifampin 14
RILUTEK 80
riluzole 80
rimantadine 14
RINVOQ 103
risedronate 80, 103
RISPERDAL 50
RISPERDAL CONSTA 50
risperidone 50
RITALIN 50
RITALIN LA 50
ritonavir 14
rivastigmine 50
rivastigmine tartrate 50
RIVELSA 108
rizatriptan 51
ROBINUL 95
ROBINUL FORTE 95
ROCALTROL 88
ROCKLATAN 112
roflumilast 118
ropinirole 51
rosuvastatin 67
ROTARIX 99
ROTATEQ VACCINE 99
ROWASA 95
ROWEEPRA 51
ROXICODONE 51
ROXYBOND 51
ROZEREM 51
ROZLYTREK 23
RUBRACA 23
RUCONEST 118
rufinamide 51
RUKOBIA 14
RYALTRIS 118
RYBELSUS 88
RYCLORA 118
RYDAPT 23
RYTARY 51
RYTHMOL SR 67
RYVENT 118
SABRIL 51
SAFYRAL 108
SAIZEN 99
SAJAZIR 118
SALAGEN (PILOCARPINE) 80
SAMSCA 88
SANCUSO 95
SANDIMMUNE 23
SANDOSTATIN 23
SANTYL 76
SAPHRIS 51
sapropterin 88
SAVAYSA 67
SAVELLA 103
saxagliptin 88
saxagliptin-metformin 88
SCEMBLIX 23
scopolamine base 95
SEASONIQUE 108
SECUADO 51
SEGLENTIS 51
SEGLUROMET 88
selegiline hcl 51
selenium sulfide 76
SELZENTRY 14
SEMGLEE(INSULIN GLARGINE-YFGN) 88
SEMGLEE(INSULIN GLARG-YFGN)PEN 88
SENSIPAR 88
SEREVENT DISKUS 118
SEROQUEL 51
SEROQUEL XR 51
SEROSTIM 99
sertraline 51
SETLAKIN 108
sevelamer carbonate 80
sevelamer hcl 80
SEYSARA 14
SHAROBEL 108
SHINGRIX (PF) 99
SIGNIFOR 23
SIKLOS 23
sildenafil (pulm.hypertension) 118
SILENOR 51
SILIQ 76
silodosin 120
SILVADENE 76
silver sulfadiazine 76
SIMBRINZA 113
SIMPONI 103
simvastatin 67
SINEMET 51
SINGULAIR 118
sirolimus 23
SIRTURO 14
SITAVIG 14
SIVEXTRO 14
SKYCLARYS 51
SKYLA 109
SKYRIZI 76, 95
SKYTROFA 99
SLYND 109
SOAANZ 67
sodium chloride 80
sodium chloride 0.45 % 122
sodium chloride 0.9 % 80
sodium chloride 3 % hypertonic 122
sodium chloride 5 % hypertonic 122
sodium oxybate 51
sodium phenylbutyrate 80
sodium polystyrene sulfonate 80
sodium,potassium,mag sulfates 95
sofosbuvir-velpatasvir 14
SOGROYA 99
solifenacin 120
SOLIQUA 100/33 88

SOLODYN 15
SOLOSEC 15
SOLTAMOX 23
SOMA 51
SOMAVERT 88
SOOLANTRA 76
sorafenib 24
SORILUX 76
SORINE 67
sotalol 67
SOTALOL AF 67
SOTYKTU 76
SOTYLIZE 67
SOVALDI 15
spinosad 76
SPIRIVA RESPIMAT 118
SPIRIVA WITH HANDIHALER 118
spironolactone 67
spironolacton-hydrochlorothiaz . 67
SPORANOX 15
SPRINTEC (28) 109
SPRITAM 51
SPRIX 51
SPRYCEL 24
SPS (WITH SORBITOL) 80
SRONYX 109
SSD 76
STALEVO 100 51
STALEVO 125 51
STALEVO 150 51
STALEVO 200 52
STALEVO 50 52
STALEVO 75 52
STEGLATRO 88
STEGLUJAN 88
STELARA 76
STIOLTO RESPIMAT 118
STIVARGA 24
STRATTERA 52
streptomycin 15
STRIBILD 15
STRIVERDI RESPIMAT 118
STROMECTOL 15
SUBOXONE 52
SUBVENITE 52
SUBVENITE STARTER (BLUE) KIT 52
SUBVENITE STARTER (GREEN) KIT 52
SUBVENITE STARTER (ORANGE) KIT 52
SUCRAID 95
sucralfate 95
SUFLAVE 95
SULAR 67
sulfacetamide sodium 113
sulfacetamide sodium (acne) 76
sulfacetamide-prednisolone 113
sulfadiazine 15
sulfamethoxazole-trimethoprim .. 15
SULFAMYLON 76
sulfasalazine 95
sulindac 52
sumatriptan 52
sumatriptan succinate 52
sumatriptan-naproxen 52
sunitinib malate 24
SUNLENCA 15
SUNOSI 52
SUPRAX 15
SUPREP BOWEL PREP KIT . 95
SUTAB 95
SUTENT 24
SYEDA 109
SYMBICORT 118
SYMBYAX 52
SYMDEKO 118
SYMFI 15
SYMFI LO 15
SYMJEPI 118
SYMLINPEN 120 88
SYMLINPEN 60 88
SYMPAZAN 52
SYMPROIC 95
SYMTUZA 15
SYNALAR 76
SYNAREL 89
SYNDROS 95
SYNJARDY 89
SYNRIBO 24
SYNTHROID 89
SYPRINE 80
TABLOID 24
TABRECTA 24
TACLONEX 76
tacrolimus 24, 76
tadalafil 120, 121
tadalafil (pulm. hypertension) .. 118
TADLIQ 118
TAFINLAR 24
tafluprost (pf) 113
TAGRISSO 24
TAKHZYRO 118
TALICIA 95
TALTZ AUTOINJECTOR 76
TALTZ SYRINGE 77
TALZENNA 24
TAMIFLU 15
tamoxifen 24
tamsulosin 121
TAPERDEX 89
TARGADOX 15
TARGRETIN 24
TARINA 24 FE 109
TARINA FE 1-20 EQ (28) 109
TARPEYO 89
TASCENSO ODT 52
TASIGNA 24
tasimelteon 53
TASMAR 53
tavaborole 77
TAVALISSE 67
TAVNEOS 81
tazarotene 77
TAZICEF 15
TAZORAC 77
TAZTIA XT 67
TAZVERIK 24
TDVAX 99
TECFIDERA 53
TEFLARO 15
TEGRETOL 53
TEGRETOL XR 53
TEGSEDI 53
TEKTURNA 67
telmisartan 67
telmisartan-amlodipine 67
telmisartan-hydrochlorothiazid .. 67
temazepam 53
TENCON 53
TENIVAC (PF) 99
tenofovir disoproxil fumarate 15
TENORETIC 100 67
TENORETIC 50 67
TENORMIN 67
TEPMETKO 24
terazosin 67
terbinafine hcl 15
terbutaline 118
terconazole 109
teriflunomide 53
teriparatide 103
TESTIM 89
testosterone 89
testosterone cypionate 89

testosterone enanthate 89
tetanus,diphtheria tox ped(pf) ...100
tetrabenazine 53
tetracycline 15
TEXACORT 77
THALITONE 67
THALOMID 24
THEO-24 119
theophylline 119
THIOLA 81
THIOLA EC 81
thioridazine 53
thiothixene 53
THYQUIDITY 89
TIADYLT ER 67
tiagabine 53
TIAZAC 67
TIBSOVO 24
TICOVAC 100
tigecycline 15
TIGLUTIK 81
TIKOSYN 67
TILIA FE 109
timolol maleate 68, 113
timolol maleate (pf) 113
TIMOPTIC OCUDOSE (PF) 113
tinidazole 15
tiopronin 81
tiotropium bromide 119
TIROSINT 89
TIROSINT-SOL 89
TIVICAY 15
TIVICAY PD 15
tizanidine 53
TLANDO 89
TOBI 15
TOBI PODHALER 15
TOBRADEX 113
TOBRADEX ST 113
tobramycin 16, 113
tobramycin in 0.225 % nacl 16
tobramycin sulfate 16
tobramycin-dexamethasone 113
TOBREX 113
tolcapone 53
TOLSURA 16
tolterodine 121
tolvaptan 89
TOPAMAX 53
TOPICORT 77
topiramate 53
TOPROL XL 68
toremifene 24
torsemide 68
TOSYMRA 53
TOUJEO MAX U-300 SOLOSTAR 89
TOUJEO SOLOSTAR U-300 INSULIN 89
TOVET EMOLLIENT 77
TOVIAZ 121
TPN ELECTROLYTES 122
TRACLEER 119
TRADJENTA 89
tramadol 53
tramadol-acetaminophen 53
trandolapril 68
trandolapril-verapamil 68
tranexamic acid 109
TRANSDERM-SCOP 95
tranylcypromine 53
TRAVASOL 10 % 122
TRAVATAN Z 113
travoprost 113
trazodone 54
TRECATOR 16
TRELEGY ELLIPTA 119
TRELSTAR 24
TREMFYA 77
TRESIBA FLEXTOUCH U-100 89
TRESIBA FLEXTOUCH U-200 89
TRESIBA U-100 INSULIN 89
tretinoin 77
tretinoin (antineoplastic) 24
tretinoin microspheres 77
TREXALL 24
TREXIMET 54
TREZIX 54
triamcinolone acetonide 77, 81
triamterene 68
triamterene-hydrochlorothiazid ..68
TRIANEX 77
triazolam 54
TRIBENZOR 68
TRICOR 68
TRIDERM 77
trientine 81
TRI-ESTARYLLA 109
trifluoperazine 54
trifluridine 113
trihexyphenidyl 54
TRIJARDY XR 89
TRIKAFTA 119
TRI-LEGEST FE 109
TRILEPTAL 54
TRILIPIX 68
TRI-LO-ESTARYLLA 109
TRI-LO-SPRINTEC 109
trimethobenzamide 95
trimethoprim 16
TRI-MILI 109
trimipramine 54
TRINTELLIX 54
TRI-NYMYO 109
TRI-SPRINTEC (28) 109
TRIUMEQ 16
TRIUMEQ PD 16
TRIVORA (28) 109
TRI-VYLIBRA 109
TRI-VYLIBRA LO 109
TRIZIVIR 16
TROKENDI XR 54
TROPHAMINE 10 % 122
trospium 121
TRUDHESA 54
TRULANCE 95
TRULICITY 89
TRUMENBA 100
TRUVADA 16
TUDORZA PRESSAIR 119
TUKYSA 24
TURALIO 24
TWINRIX (PF) 100
TWYNEO 77
TYBLUME 109
TYBOST 16
TYDEMY 109
TYGACIL 16
TYKERB 24
TYMLOS 103
TYPHIM VI 100
TYRVAYA 113
TYVASO DPI 119
UBRELVY 54
UCERIS 95
UDENYCA 100
UDENYCA AUTOINJECTOR 100
ULORIC 103
ULTRAVATE 77
UNASYN 16
UNITHROID 89
UPTRAVI 68
UROCIT-K 10 121

UROCIT-K 15 121
UROCIT-K 5 121
UROXATRAL 121
URSO 250 95
URSO FORTE 95
ursodiol 96
UZEDY 54
VABOMERE 16
VAGIFEM 109
valacyclovir 16
VALCHLOR 77
VALCYTE 16
valganciclovir 16
VALIUM 54
valproic acid 54
valproic acid (as sodium salt) 55
valsartan 68
valsartan-hydrochlorothiazide 68
VALTOCO 55
VALTREX 16
VANCOCIN 16
vancomycin 16
VANDAZOLE 109
VANFLYTA 24
VANOS 77
VAQTA (PF) 100
varenicline 81
VARIVAX (PF) 100
VARUBI 96
VASCEPA 68
VASERETIC 68
VASOTEC 68
VECAMYL 68
VECTICAL 77
VELIVET TRIPHASIC REGIMEN (28) 109
VELPHORO 81
VELTASSA 81
VELTIN 77
VEMLIDY 16
VENCLEXTA 24
VENCLEXTA STARTING PACK 25
venlafaxine 55
venlafaxine besylate 55
VENTAVIS 119
VENTOLIN HFA 119
VEOZAH 109
verapamil 68
VERDESO 77
VERELAN 68
VERELAN PM 68
VERKAZIA 113
VERQUVO 68
VERSACLOZ 55
VERZENIO 25
VESICARE 121
VESICARE LS 121
VESTURA (28) 109
VFEND 16
VFEND IV 16
VIBERZI 96
VIBRAMYCIN 16
VIBRAMYCIN (CALCIUM) 16
VIBRAMYCIN (MONO) 16
VICTOZA 3-PAK 89
VIENVA 109
vigabatrin 55
VIGADRONE 55
VIGAMOX 113
VIIBRYD 55
VIJOICE 25
vilazodone 55
VIMOVO 55
VIMPAT 55
VIOKACE 96
VIRACEPT 16
VIREAD 16
VISTARIL 119
VITRAKVI 25
VIVELLE-DOT 109
VIVITROL 55
VIVJOA 17
VIZIMPRO 25
VOGELXO 89
VONJO 25
voriconazole 17
VOSEVI 17
VOTRIENT 25
VOWST 96
VOXZOGO 90
VRAYLAR 55
VTAMA 77
VUITY 113
VUMERITY 55
VYFEMLA (28) 109
VYLIBRA 109
VYNDAMAX 68
VYNDAQEL 68
VYTORIN 10-10 68
VYTORIN 10-20 68
VYTORIN 10-40 68
VYTORIN 10-80 68
VYVANSE 55
VYZULTA 113
WAKIX 55
warfarin 69
WELCHOL 69
WELIREG 25
WELLBUTRIN SR 55
WELLBUTRIN XL 55
WINLEVI 77
WIXELA INHUB 119
WYMZYA FE 109
XALATAN 113
XALKORI 25
XANAX 55
XANAX XR 55, 56
XARELTO 69
XARELTO DVT-PE TREAT 30D START 69
XATMEP 25
XCOPRI 56
XCOPRI MAINTENANCE PACK 56
XCOPRI TITRATION PACK 56
XDEMVY 113
XELJANZ 103
XELJANZ XR 103
XELPROS 113
XELSTRYM 56
XENAZINE 56
XENLETA 17
XERESE 78
XERMELO 25
XGEVA 25
XHANCE 119
XIFAXAN 17
XIGDUO XR 90
XIIDRA 113
XIMINO 17
XOFLUZA 17
XOLAIR 119
XOPENEX HFA 119
XOSPATA 25
XPOVIO 25
XTAMPZA ER 56
XTANDI 25
XULANE 109
XULTOPHY 100/3.6 90
XURIDEN 81
XYOSTED 90
XYREM 56
XYWAV 56
YASMIN (28) 109
YAZ (28) 109

YF-VAX (PF).....100
YONSA..... 25
YUFLYMA(CF).....103
YUFLYMA(CF) AUTOINJECTOR.....103
YUPELRI..... 119
YUSIMRY(CF) PEN..... 103
YUVAFEM.....109
ZAFEMY.....109
zafirlukast..... 119
zaleplon.....56
ZANAFLEX..... 56
ZARONTIN.....56
ZARXIO..... 100
ZAVESCA..... 90
ZAVZPRET.....56
ZEGALOGUE AUTOINJECTOR..... 90
ZEGALOGUE SYRINGE..... 90
ZEGERID.....96
ZEJULA.....25
ZELAPAR..... 56
ZELBORAF..... 25
ZEMAIRA.....81
ZEMBRACE SYMTOUCH.....56
ZEMDRI.....17
ZEMPLAR..... 90
ZENATANE..... 78
ZENPEP.....96
ZENZEDI..... 56
ZEPATIER.....17
ZEPOSIA.....56
ZEPOSIA STARTER KIT (28-DAY).....56
ZEPOSIA STARTER PACK (7-DAY).....56
ZERBAXA.....17
ZERVIATE..... 113
ZESTORETIC..... 69
ZESTRIL.....69
ZETIA.....69
ZETONNA.....119
ZIAC..... 69
ZIAGEN.....17
ZIANA..... 78
zidovudine.....17
ZIEXTENZO.....100
zileuton.....119
ZILXI..... 78
ZIMHI.....56
ZIOPTAN (PF).....113
ziprasidone hcl.....56
ziprasidone mesylate.....56
ZIPSOR..... 56
ZIRGAN..... 113
ZITHROMAX.....17
ZITHROMAX TRI-PAK.....17
ZITHROMAX Z-PAK..... 17
ZOCOR.....69
ZOKINVY..... 81
ZOLINZA.....25
zolmitriptan.....56
ZOLOFT.....57
zolpidem.....57
ZOMACTON..... 100
ZOMIG..... 57
ZONALON..... 78
ZONEGRAN..... 57
ZONISADE..... 57
zonisamide..... 57
ZONTIVITY..... 69
ZORBTIVE..... 100
ZORTRESS.....25
ZORYVE..... 78
ZOSYN IN DEXTROSE (ISO-OSM)..... 17
ZOVIA 1-35 (28)..... 110
ZOVIRAX..... 78
ZTALMY.....57
ZTLIDO.....78
ZUBSOLV..... 57
ZYCLARA.....78
ZYDELIG.....25
ZYFLO.....119
ZYKADIA..... 25
ZYLET.....113
ZYMAXID.....113
ZYPITAMAG..... 69
ZYPREXA.....57
ZYPREXA RELPREVV.....57
ZYPREXA ZYDIS.....57
ZYTIGA.....25, 26
ZYVOX.....17

Acitretin

Products Affected

- *acitretin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Actemra

Products Affected

- **ACTEMRA ACTPEN**
- **ACTEMRA SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	Part A covered for Covid-19 in hospitalized patients
Required Medical Information	Documentation of diagnosis. For rheumatoid arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide). For giant cell arteritis, patients must have therapeutic failure or intolerance to one systemic corticosteroid (e.g., prednisone). For polyarticular juvenile idiopathic arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For systemic sclerosis-associated interstitial lung disease (SSc-ILD), patients must have therapeutic failure or intolerance to one immunosuppressant (e.g., mycophenolate mofetil, corticosteroids, cyclophosphamide). Documentation of systemic juvenile idiopathic arthritis.
Age Restrictions	Deny if less than 18 years of age for systemic sclerosis-associated interstitial lung disease (SSc-ILD), Rheumatoid Arthritis, and Giant Cell Arteritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Acthar H.P.

Products Affected

- **ACTHAR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Covered for the following indications: 1. Infantile spasms (West syndrome) in children less than 2 years of age. 2. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy (e.g., interferon beta, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide) 3. Rheumatic disorders for patients receiving maintenance therapy with at least one NSAID, DMARD (e.g. leflunomide) or biologic (e.g. adalimumab) 4. Collagen diseases for members receiving maintenance therapy with at least one antimalarial (e.g. hydroxychloroquine) or immunosuppressant (e.g. azathioprine) 5. Dermatologic diseases 6. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction 7. Ophthalmic diseases 8. Respiratory diseases 9. Gout and unable to take first-line therapies. 10. Pediatric acquired epileptic aphasia. 11. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). For covered indications 2 through 10, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month

PA Criteria	Criteria Details
Other Criteria	For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that H.P. Acthar is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Gout, Epileptic Aphasia
Part B Prerequisite	No

Actimmune

Products Affected

- **ACTIMMUNE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Adalimumab

Products Affected

- *adalimumab-fkjp*
- **HADLIMA**
- **HADLIMA PUSHTOUCH**
- **HADLIMA(CF)**
- **HADLIMA(CF) PUSHTOUCH**
- **HULIO(CF)**
- **HULIO(CF) PEN**
- **YUFLYMA(CF)**
- **YUFLYMA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML**
- **YUSIMRY(CF) PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 2 immunosuppressants.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Juvenile Idiopathic Arthritis and Uveitis
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	Therapeutic failure or intolerance to 2 of the following preferred products is required: Humira, Cyltezo, and Hyrimoz. For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Adbry

Products Affected

- **ADBRY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement or severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

ADHD Drugs

Products Affected

- *clonidine hcl oral tablet extended release 12 hr*
- *guanfacine oral tablet extended release 24 hr*
- **INTUNIV ER**
- **KAPVAY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Adlarity

Products Affected

- **ADLARITY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- one of the following (1 or 2): 1) therapeutic failure or intolerance to donepezil tablets, 2) Unable to take daily oral donepezil due to impaired memory.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Afinitor

Products Affected

- **AFINITOR**
- **AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG**
- *everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy 4) Candidacy for surgical resection
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Afinitor, documentation of failure on generic everolimus tablets is required. For brand Afinitor Disperz, documentation of failure on generic everolimus tablets for suspension is required
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Aimovig

Products Affected

- **AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Airduo Digihaler

Products Affected

- **AIRDUO DIGIHALER**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of asthma -AND- Inadequate response to non-digitized LABA/ICS inhaler-AND- Attestation that a digital inhaler is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ajovy

Products Affected

- **AJOVY AUTOINJECTOR**
- **AJOVY SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Alecensa

Products Affected

- **ALECENSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Alkindi

Products Affected

- **ALKINDI SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of adrenocortical insufficiency -AND- Therapeutic failure or intolerance to oral generic hydrocortisone tablets.
Age Restrictions	Deny if greater than 17 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Alpha1-Proteinase Inhibitors

Products Affected

- **ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG**
- **GLASSIA**
- **PROLASTIN-C INTRAVENOUS RECON SOLN**
- **ZEMAIRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of panacinar emphysema AND documentation of a decline in forced expiratory volume in 1 second (fev1) despite medical therapy (bronchodilators, corticosteroids) AND documentation of phenotype (pi*zz, pi*znull or pi*nullnull) associated with causing serum alpha 1-antitrypsin of less than 80 mg/dl AND documentation of an alpha 1-antitrypsin serum level below the value of 35% of normal (less than 80 mg/dl).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered under Part B when furnished incident to a physician service and is not self-administered.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Alunbrig

Products Affected

- **ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG**
- **ALUNBRIG ORAL TABLETS,DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Amlodipine Liquid

Products Affected

- **KATERZIA**
- **NORLIQVA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Inability to swallow amlodipine tablets
Age Restrictions	Deny if less than 6 years of age for Hypertension
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ampyra

Products Affected

- **AMPYRA**
- *dalfampridine*

PA Criteria	Criteria Details
Exclusion Criteria	History of seizure disorder, Cr Cl less than 50ml/min
Required Medical Information	Documentation of diagnosis -AND- documentation that the patient is ambulatory and has walking impairment as evidenced by one of the following. 1. Functional status score (EDSS score). 2. Timed 25-foot Walk Test (T25W).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For brand Ampyra, documentation of failure on generic dalfampridine. For reauthorization, documentation supporting improvement in walking impairment from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Anabolic Steroids

Products Affected

- **METHITEST**
- *methyltestosterone oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Apokyn

Products Affected

- **APOKYN**
- *apomorphine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Parkinson's disease -AND- for use in acute, intermittent treatment of hypomobility off episodes -AND- experiencing off episodes despite the use of oral carbidopa/levodopa -AND- Therapeutic failure, intolerance, or contraindication to one of the following generic products: pramipexole, ropinirole, entacapone, selegiline or rasagiline
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Arikayce

Products Affected

- **ARIKAYCE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Mycobacterium avium complex lung disease -AND- Attestation of not achieving negative sputum cultures despite at least 6 months with a multidrug background regimen containing 2 of the following: 1) macrolide 2) rifamycin or 3) ethambutal -AND- Arikayce will be used in conjunction with a background multidrug regimen.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive sputum cultures -OR- negative sputum cultures for insufficient period of time (e.g. less than 12 months).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Armonair Digihaler

Products Affected

- **ARMONAIR DIGIHALER**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of asthma -AND- Inadequate response to non-digitized ICS inhaler-AND- Attestation that a digital inhaler is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Aspruzyo Sprinkle

Products Affected

- **ASPRUZYO SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of chronic angina -AND- Therapeutic failure, contraindication, or intolerance to one beta-blocker (e.g., propranolol oral solution, metoprolol tartrate, propranolol immediate-release) -AND- Inability to swallow generic ranolazine tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

ATTR-CM drugs

Products Affected

- **VYNDAMAX**
- **VYNDAQEL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) with amyloid deposits on cardiac biopsy or scintigraphy with heart contralateral greater than 1.5 (Grade III) -AND- Cardiac involvement supported by cardiac magnetic resonance, echocardiography or serum cardiac biomarker (e.g. B-type natriuretic peptide, cardiac troponin) - AND- Primary (light chain) amyloidosis has been ruled out by immunohistochemistry, mass spectrometry or scintigraphy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement or delayed disease progression from baseline demonstrated by 6-minute walk test, cardiac function (e.g. LVEF, NYHA class), Kansas City Cardiomyopathy Questionnaire-Overall Summary, number of cardiovascular-related hospitalizations or serum cardiac biomarkers (e.g. B-type natriuretic peptide, cardiac troponin)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Atypical Antipsychotics

Products Affected

- **ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET WITH SENSOR AND STRIP 15 MG, 2 MG, 20 MG, 30 MG, 5 MG**
- **ABILIFY MYCITE STARTER KIT ORAL TABLET WITH SENSOR, STRIP, POD 10 MG**
- **ABILIFY ORAL TABLET**
- *aripiprazole*
- **REXULTI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If medication is being used for major depressive disorder, documentation of adjunctive therapy and therapeutic failure on 1 alternative antidepressant is required (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). For Rexulti, trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Aubagio

Products Affected

- **AUBAGIO**
- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as fingolimod, interferons, Copaxone, Tysabri
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Auryxia

Products Affected

- **AURYXIA**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of iron deficiency anemia
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Austedo

Products Affected

- **AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG**
- **AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 24 MG, 6 MG**
- **AUSTEDO XR TITRATION KT(WK1-4)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3) 1) Chorea associated with Huntington's disease 2) In patients with comorbid depression, attestation of adequate treatment for depression is required. 3) Attestation that patient is not actively suicidal. -OR- 4) Tardive Dyskinesia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Auvelity

Products Affected

- **AUVELITY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder (MDD) -AND- Therapeutic failure or intolerance to generic bupropion hydrochloride tablets -AND- Therapeutic failure, intolerance or contraindication to one other generic antidepressant (e.g. SNRI, SSRI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ayvakit

Products Affected

- **AYVAKIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For unresectable or metastatic Gastrointestinal Stromal Tumor (GIST), PDGFRA exon 18 mutation status. For Advanced Systemic Mastocytosis (AdvSM), platelet count greater than or equal to 50 x 10*9/L AND aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or Mast cell leukemia (MCL). For Indolent System Mastocytosis, platelet count greater than or equal to 50 x 10*9/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Bafiertam

Products Affected

- **BAFIERTAM**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Balversa

Products Affected

- **BALVERSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR3 or FGFR2 mutation status as detected by an FDA approved test 2) alternatives tried/failed within labelled time frame
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Banzel

Products Affected

- **BANZEL**
- *rufinamide*

PA Criteria	Criteria Details
Exclusion Criteria	Patients with familial short QT syndrome
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Belbuca

Products Affected

- **BELBUCA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of moderate to severe chronic pain -AND- trial and failure of at least two previous federal legend medications for pain, including NSAIDs, tramadol, or opioid analgesics. For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxant (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1)Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2)Patient is not long acting opioid naive. 3)Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4)Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5)Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Benlysta

Products Affected

- **BENLYSTA SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of active systemic lupus erythematosus (SLE) -AND- documentation of positive anti-nuclear antibody (ANA) titer (greater than or equal to 1:80) or anti-double-stranded DNA antibody (anti-dsDNA) greater than or equal to 30IU/mL -AND- trial, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- member will continue to receive concomitant standard of care treatment with use of at least one of the following (alone or in combination): 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -OR- Documentation of active lupus nephritis -AND- documentation of positive ANA titer (greater than or equal to 1:80) or anti-dsDNA greater than or equal to 30 IU/mL -AND- trial, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- member will continue to receive concomitant standard of care treatment which includes corticosteroids (e.g. prednisone) with at least one of the following: 1.) mycophenolate for induction followed by mycophenolate for maintenance 2.) cyclophosphamide for induction followed by azathioprine for maintenance
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For SLE reauthorization, attestation of disease stability or improvement - AND- attestation the member will continue to receive standard of care therapy with corticosteroids, antimalarials, or immunosuppressives. For active LN reauthorization, attestation of disease stability or improvement - AND- attestation the member will continue to receive standard of care therapy with mycophenolate or azathioprine. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Benznidazole

Products Affected

- *benznidazole*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	Deny if less than 2 years of age.
Prescriber Restrictions	
Coverage Duration	2 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Berinert

Products Affected

- **BERINERT INTRAVENOUS KIT**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
Required Medical Information	For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.
Age Restrictions	Deny if less than 5 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Besremi

Products Affected

- **BESREMI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of polycythemia vera
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Bonjesta

Products Affected

- **BONJESTA**
- **DICLEGIS**
- *doxylamine-pyridoxine (vit b6)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	9 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Bosulif

Products Affected

- **BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis AND all of the following, if applicable to diagnosis: 1) phase of CML 2) Philadelphia chromosome status 3) alternatives tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Braftovi

Products Affected

- **BRAFTOVI ORAL CAPSULE 75 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Use in wild-type BRAF melanoma or wild-type BRAF CRC
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF V600E or V600K mutation status 2) alternatives tried/failed 3) concomitant therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Bronchitol

Products Affected

- **BRONCHITOL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis -AND- Passed a Bronchitol Tolerance Test -AND- Used in conjunction with standard therapies for the management of cystic fibrosis to improve pulmonary function (e.g. bronchodilators, antibiotics, anti-inflammatory therapy).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of increase in FEV1
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Brukinsa

Products Affected

- **BRUKINSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Buphenyl

Products Affected

- **BUPHENYL**
- *sodium phenylbutyrate*

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of acute hyperammonemia in urea cycle disorders
Required Medical Information	Documentation of chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, argininosuccinic acid synthetase, or ornithine transcarbamylase.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Buphenyl, trial and failure of generic sodium phenylbutyrate is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Butrans

Products Affected

- *buprenorphine*
- **BUTRANS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of moderate to severe chronic pain -AND- trial and failure of at least two previous federal legend medications for pain, including NSAIDs, tramadol, or opioid analgesics. For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxant (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1)Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2)Patient is not long acting opioid naive. 3)Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4)Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5)Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Bylvay

Products Affected

- **BYLVAY ORAL CAPSULE 1,200 MCG, 400 MCG**
- **BYLVAY ORAL PELLET 200 MCG, 600 MCG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of one of the following diagnoses (1-2): 1) progressive familial intrahepatic cholestasis confirmed by genetic testing -AND- pruritis -OR- 2) Alagille syndrome -AND- cholestatic pruritis -AND- Documentation that the member does not have any of the following diagnoses (3-5): 3) decompensated cirrhosis, 4) portal hypertension, 5) history of a hepatic decompensation event.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial, 12 months reauthorization
Other Criteria	For reauthorization, attestation of improvement in pruritis -AND- attestation that the member has not progressed to any of the following (1-3): 1) portal hypertension, 2) cirrhosis, or 3) experienced a hepatic decompensation event.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cablivi

Products Affected

- **CABLIVI INJECTION KIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of acquired thrombocytopenic purpura (aTTP) -AND- Used in conjunction with plasma exchange and immunosuppressive therapy (i.e. systemic corticosteroids or rituximab)
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	75 days initial authorization, 28 days reauthorization
Other Criteria	For reauthorization, attestation of remaining signs and symptoms of persistent disease (e.g. suppressed ADAMTS 13 activity level remain present)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cabometyx

Products Affected

- **CABOMETYX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) alternatives tried/failed 2) attestation of first line use 3) concomitant therapy 4) radioactive iodine refractory status
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Calquence

Products Affected

- **CALQUENCE**
- **CALQUENCE (ACALABRUTINIB MAL)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Camzyos

Products Affected

- **CAMZYOS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy -AND- Left ventricular ejection fraction of greater than or equal to 55% -AND- Valsalva left ventricular outflow tract peak gradient of greater than or equal to 50 mmHg at rest or after provocation -AND- Therapeutic failure or intolerance to one of the following (1 or 2) or contraindication to all: 1) Non-vasodilating beta blocker (e.g. metoprolol) 2) non-dihydropyridine calcium channel blocker (e.g. diltiazem) -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement in pV02 by greater than or equal to 1.5 mL/kg/min plus at least 1 NYHA class reduction or improvement in pV02 by greater than or equal to 3.0 mL/kg/min without NYHA class worsening -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Caplyta

Products Affected

- **CAPLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Caprelsa

Products Affected

- **CAPRELSA ORAL TABLET 100 MG, 300 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Carac

Products Affected

- **CARAC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure of 1 generic fluorouracil topical product (with shared indication) is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Carbaglu

Products Affected

- **CARBAGLU**
- *carglumic acid*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use as an adjunct therapy for acute hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency, propionic acidemia (PA), or methylmalonic acidemia (MMA) -OR- maintenance therapy for chronic hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Carbinoxamine

Products Affected

- *carbinoxamine maleate oral liquid*
- *carbinoxamine maleate oral tablet 4 mg*
- **RYVENT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Failure, contraindication or intolerance to 2 antihistamines indicated for diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cayston

Products Affected

- **CAYSTON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cerdelga

Products Affected

- **CERDELGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of type 1 Gaucher disease confirmed by the following A. or B. A) With one of the following symptoms (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm*3. 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B) Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles -AND- Documentation of CYP2D6 metabolizer status (e.g. intermediate metabolizer).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

CF drugs

Products Affected

- **BETHKIS**
- **KITABIS PAK**
- **TOBI**
- **TOBI PODHALER**
- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis. For Bethkis: failure on, intolerance to, or contraindication to generic tobramycin inhalation solution
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization of tobramycin products, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Chenodal

Products Affected

- **CHENODAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of radiolucent gallstones AND an inadequate response or intolerance to ursodiol therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months for initial approval with an additional 12 months upon renewal
Other Criteria	Safety of use beyond 24 months is not established. For reauthorization, attestation of partial dissolution of gallstones
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cholbam

Products Affected

- **CHOLBAM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of bile acid synthesis disorders due to single enzyme defects (e.g. AKR1D1, CTX, CYP7A1) -OR- documentation of use as adjunctive therapy for peroxisomal disorders (PDs), including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cialis

Products Affected

- **CIALIS ORAL TABLET 2.5 MG, 5 MG**
- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of benign prostatic hyperplasia (BPH) and trial/failure of at least two alternative medications in the following classes (alpha-1 adrenergic blockers and/or 5-alpha reductase inhibitors)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Cialis, trial and failure of generic tadalafil is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cibinqo

Products Affected

- **CIBINQO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement or severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cimzia

Products Affected

- **CIMZIA**
- **CIMZIA POWDER FOR RECONST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs). For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred biologic products: Humira, Stelara, Rinvoq, and Skyrizi. For Rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq. For plaque psoriasis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Cosentyx, Otezla, Stelara, Skyrizi, and Enbrel. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For Psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Cosentyx, Enbrel, Humira, Xeljanz/Xeljanz XR, Otezla, Stelara, Rinvoq, and Skyrizi. For initial and induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended initial and induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cinryze

Products Affected

- **CINRYZE**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	Deny if less than 6 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Citalopram Capsule

Products Affected

- *citalopram oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder -AND- citalpram 20 mg has been received for greater than or equal to 7 days -AND- Therapeutic failure or intolerance to generic citalopram tablets -AND-Therapeutic failure, intolerance or contraindication to at least one other antidepressant (e.g. SNRI, SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Clemastine Syrup

Products Affected

- *clemastine oral syrup*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of allergic rhinitis or mild, uncomplicated allergic skin manifestations of urticaria and angioedema -AND- Therapeutic failure, contraindication or intolerance to one generic antihistamine product -AND- Therapeutic failure or intolerance to generic clemastine fumarate tablets or an inability to swallow tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cometriq

Products Affected

- **COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of progressive, metastatic medullary thyroid cancer
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Copiktra

Products Affected

- **COPIKTRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Corlanor

Products Affected

- **CORLANOR ORAL SOLUTION**
- **CORLANOR ORAL TABLET 5 MG, 7.5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis AND all of the following: 1) Normal sinus rhythm. 2) Resting heart rate greater than or equal to 70 beats per minute. 3) Left ventricular ejection fraction less than or equal to 35 percent, when applicable. 4) In adult patients (greater than or equal to 18 years), trial/failure of maximum tolerated dose of one beta-blocker used for treatment of heart failure (e.g., bisoprolol, carvedilol, metoprolol succinate) OR contraindication to beta-blocker use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For oral solution, attestation of inability to swallow tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cosentyx

Products Affected

- **COSENTYX (2 SYRINGES)**
- **COSENTYX PEN (2 PENS)**
- **COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML**
- **COSENTYX UNOREADY PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs. For enthesitis-related arthritis, inadequate response or intolerance to at least 1 non-biologic disease modifying anti-rheumatic drugs (DMARD), or all are contraindicated.
Age Restrictions	Deny if less than 6 years of age for moderate to severe plaque psoriasis -OR- less than 2 years of age for psoriatic arthritis -OR- less than 4 years of age for enthesitis-related arthritis -OR- less than 18 years of age for all other indications
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cotellic

Products Affected

- **COTELLIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF V600E or V600K mutation status 2) Concomitant therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Crinone

Products Affected

- **CRINONE**

PA Criteria	Criteria Details
Exclusion Criteria	Use to promote fertility
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cuvrior

Products Affected

- **CUVRIOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of stable Wilson's disease -AND- Previously tolerated one penicillamine product used for de-coppering (e.g., generic penicillamine tablet or capsule, Depen) -AND- Therapeutic failure or intolerance to generic trientine hydrochloride
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Cysteamine Ophthalmic Drops

Products Affected

- **CYSTADROPS**
- **CYSTARAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystinosis -AND- Attestation of accumulation of corneal cystine crystals
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Daraprim

Products Affected

- *pyrimethamine*

PA Criteria	Criteria Details
Exclusion Criteria	Under CMS Review
Required Medical Information	Under CMS Review
Age Restrictions	Under CMS Review
Prescriber Restrictions	Under CMS Review
Coverage Duration	Under CMS Review
Other Criteria	Under CMS Review
Indications	Under CMS Review
Off Label Uses	Under CMS Review
Part B Prerequisite	No

Dartisla ODT

Products Affected

- **DARTISLA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Documentation of adjunctive therapy -AND- Therapeutic failure or intolerance to generic glycopyrrolate 2 mg tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Daurismo

Products Affected

- **DAURISMO ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of newly diagnosed Acute Myeloid Leukemia -AND- Used in combination with cytarabine -AND- At least one comorbidity that preclude use of intensive induction chemotherapy defined as one of the following: 1) Age greater than or equal to 75 2) Severe cardiac or pulmonary comorbidity 3) Reduced renal function 4) Hepatic impairment 5.) Physician attests patient is not a candidate for intensive induction therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Daybue

Products Affected

- **DAYBUE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis confirmed by all of the following (1 thru 4): 1) Partial or complete loss of acquired purposeful hand skills, 2) Partial or complete loss of acquired spoken language, 3) Gait abnormalities: impaired or absence of ability, 4) Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing, and washing/rubbing automatisms
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Daytrana

Products Affected

- **DAYTRANA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	Deny if less than 6 years of age or greater than 17 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For ADHD, trial/failure or intolerance to 2 of the following generic medications: methylphenidate, atomoxetine, or dextroamphetamine/amphetamine is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Deferasirox

Products Affected

- *deferasirox*
- **EXJADE**
- **JADENU**
- **JADENU SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For chronic iron overload due to blood transfusions, transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -And- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw). For Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia (NTDT) Syndrome, LIC of at least 5 mg Fe/g dw -AND- serum ferritin greater than 300 mcg/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Jadenu and brand Exjade, trial and failure of deferasirox (generic Exjade) is required. For reauthorization of chronic iron overload due to blood transfusion, continued requirement for regular blood transfusions -AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw. For reauthorization of chronic iron overload in NTDT syndrome, LIC greater than or equal to 3 mg Fe/g dw.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Diacomit

Products Affected

- **DIACOMIT ORAL CAPSULE 250 MG, 500 MG**
- **DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Dravets syndrome - AND- Used in combination with clobazam
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation supporting reduction in seizure frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Dihydroergotamine

Products Affected

- *dihydroergotamine nasal*
- **MIGRANAL**
- **TRUDHESA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute migraine headaches with or without aura -AND- requires non-oral route of administration -AND- therapeutic failure or intolerance to generic sumatriptan nasal spray.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Dojolvi

Products Affected

- **DOJOLVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of molecularly confirmed long-chain fatty acid oxidation disorders
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Doptelet

Products Affected

- **DOPTELET (10 TAB PACK)**
- **DOPTELET (15 TAB PACK)**
- **DOPTELET (30 TAB PACK)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -OR- Documentation of chronic immune thrombocytopenia -AND- Trial, intolerance, or inadequate response to corticosteroid therapy, immunoglobulin therapy or splenectomy -AND- One of the following (1 or 2): 1) Platelet count less than or equal to 50 x 10*9/L and has significant mucous member bleeding or at least one risk factor for bleeding (e.g. hypertension, peptic ulcer disease). 2) Platelets count of less than or equal to 30 x 10*9/L
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	For thrombocytopenia with chronic liver disease- 1 mo. For chronic immune thrombocytopenia- 12 mo.
Other Criteria	Platelet count is provided for applicable dosing.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Doxepin Cream

Products Affected

- *doxepin topical*
- **PRUDOXIN**
- **ZONALON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- course of therapy will not exceed 8 days -AND- experienced therapeutic failure, intolerance, or contraindication to one of the following (1 or 2): 1) at least 2 generic formulary topical corticosteroids. 2) generic topical tacrolimus or pimecrolimus for topic dermatitis with the facial or anogenital involvement.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Duexis

Products Affected

- **DUEXIS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen/famotidine. -AND- 2) Trial/failure of naproxen/esomeprazole.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Duexis2

Products Affected

- *ibuprofen-famotidine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen used in combination with famotidine. -AND- 2) Trial/failure of one additional generic formulary NSAID (other than ibuprofen) used in combination with another generic formulary H2-receptor blocker (other than famotidine).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Duobrii

Products Affected

- **DUOBRII**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of plaque psoriasis -AND- therapeutic failure or intolerance to generic tazarotene cream -AND- therapeutic failure or intolerance to 1 high-potency topical corticosteroid (e.g. betamethasone dipropionate 0.05%, halobetasol propionate 0.05%)
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Dupixent

Products Affected

- **DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML**
- **DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-2): 1) moderate to severe atopic dermatitis 2) trial & failure, or intolerance to at least one topical corticosteroid -OR- If 2 years of age or older, topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- The member has severe atopic dermatitis and is incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin -OR- Documentation of the following (3-6): 3) moderate-to-severe asthma 4) documented pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration 5) Blood eosinophils greater than or equal to 150 cells/uL -OR- patient is currently taking daily or alternate-day oral corticosteroids 6) using a medium- or high-dose inhaled corticosteroid and a long acting beta agonist -OR- Documentation of the following (7-8): 7) chronic rhinosinusitis with nasal polyposis (CRSwNP) 8) trial & failure, intolerance or contraindication to intra-nasal corticosteroid and 14 day course of oral corticosteroids -OR- Documentation of the following (9-12): 9) eosinophilic esophagitis 10) weight at least 40 kg 11) esophageal eosinophil count greater than or equal to 15 eos/hpf on esophageal biopsy 12) clinical symptoms of esophageal dysfunction -OR- Documentation of the following (13): 13) prurigo nodularis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization

PA Criteria	Criteria Details
Other Criteria	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization, attestation of positive clinical response to therapy, for atopic dermatitis -OR- attestation of decreased rescue medication or oral corticosteroid use, decreased frequency of severe asthma exacerbation, increased pulmonary function from baseline (e.g. FEV1) or reduction in reported asthma related symptoms, for asthma -OR- attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score, for CRSwNP -OR- attestation of histological remission (less than 15 eos/hpf) on esophageal biopsy or reduced severity or frequency of clinical symptoms of esophageal dysfunction, for EoE -OR- attestation of reduction in itch from baseline, for prurigo nodularis
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

EGFR Tyrosine Kinase Inhibitors

Products Affected

- *erlotinib*
- **EXKIVITY**
- **GILOTRIF**

PA Criteria	Criteria Details
Exclusion Criteria	Afatinib products: tumors with resistant EGFR mutations. Erlotinib products: use in NSCLC tumors with mutations other than those in FDA-approved indications. Use in combination with platinum based chemotherapy.
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) Epidermal growth factor receptor (EGFR) mutations, including exon 19 deletions, exon 21 (L858R) substitution mutations or exon 20 insertion mutations 2) Alternatives tried/failed 3) Concomitant therapy 4) Line of therapy in which medication will be used
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Egrifta

Products Affected

- **EGRIFTA SV**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of HIV and lipodystrophy, member must actively be receiving antiretroviral therapy including protease inhibitors, nucleoside reverse transcriptase inhibitors, or non-nucleoside reverse transcriptase inhibitors
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Emflaza

Products Affected

- **EMFLAZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Duchenne muscular dystrophy (DMD) with mutation of dystrophin gene -AND- onset of weakness or history of DMD starting before age 5 -AND- One of the following (1, 2, or 3). 1) Documented trial/failure, intolerance or contraindication to prednisone. 2) Documented trial of prednisone has resulted in intolerable adverse events (e.g. diabetes, hypertension that is difficult to manage, Cushingoid features, truncal obesity, greater than or equal to 10 percent increase in body weight over a 6 month period). 3) Documented severe behavioral adverse event while on prednisone that warrants prednisone dose reduction impacting efficacy for management of DMD (i.e. abnormal behavior, aggression, irritability, disturbance in mood)
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Emgality

Products Affected

- **EMGALITY PEN**
- **EMGALITY SYRINGE**
  SUBCUTANEOUS SYRINGE 120
  MG/ML, 300 MG/3 ML (100 MG/ML X 3)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. For episodic cluster headaches, characterized by severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15 to 180 minutes when left untreated -AND- Attack frequency of at least one attack every other day during the cluster period.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization of episodic migraine prevention, attestation of reduction in migraine frequency is required. For reauthorization of cluster headache, attestation of reduction in the number of mean weekly cluster headaches from baseline is required.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Enbrel

Products Affected

- **ENBREL MINI**
- **ENBREL SUBCUTANEOUS SOLUTION**
- **ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)**
- **ENBREL SURECLICK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis or less than 2 years of age for Juvenile Idiopathic Arthritis or Less than 4 years of age for Plaque Psoriasis
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Endari

Products Affected

- **ENDARI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Sickle Cell Disease with 2 or more sickle cell acute complications (e.g. vaso-occlusive crisis, acute anemia, acute chest syndrome, etc.) -AND-documentation of previous trial of hydroxyurea or plans of continued therapy while taking Endari
Age Restrictions	Deny if less than 5 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of stability in sickle cell acute complications or decrease in number of sickle cell acute complications is required (e.g. vaso-occlusive crisis, acute anemia, acute chest syndrome, etc.)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Enspryng

Products Affected

- **ENSPRYNG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of neuromyelitis optica spectrum disorder (NMOSD) -AND- Attestation of anti-aquaporin-4 (AQP4) antibody positive -AND- Not used in combination with another monoclonal antibody used for the treatment of NMOSD.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decrease in number of NMOSD relapses. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Entadfi

Products Affected

- **ENTADFI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use for the initial treatment of benign prostatic hyperplasia (BPH) -AND- Trial/failure of finasteride used in combination with tadalafil.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For reauthorization, attestation that the member is reinitiating treatment for BPH.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Epclusa

Products Affected

- **EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG, 200-50 MG**
- **EPCLUSA ORAL TABLET**
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Epidiolex

Products Affected

- **EPIDIOLEX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Lennox-Gastaut, Dravet syndromes or Tuberous Sclerosis Complex. For Lennox-Gastaut, trial and failure or intolerance of at least two standard of care treatments (e.g. lamotrigine, clobazam). For Lennox-Gastaut and Dravet syndromes, treatment is in combination with other conventional agents.
Age Restrictions	Deny if less than 1 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation supporting reduction in seizure frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Eprontia

Products Affected

- **EPRONTIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- inability to swallow pills or food. For migraine, therapeutic failure, intolerance, or contraindication to two generic preventive migraine therapies. For partial onset seizures, primary generalized tonic-clonic seizures, or adjunctive treatment of Lennox-Gastaut Syndrome, therapeutic failure, contraindication, or intolerance to two generic anti-epileptic drugs.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Erivedge

Products Affected

- **ERIVEDGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if disease is locally advanced all of the following: 1) disease has recurred following surgery, or is not a candidate for surgery, 2) is not a candidate for radiation.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Erleada

Products Affected

- **ERLEADA ORAL TABLET 240 MG, 60 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- the member meets one of the following (1 or 2) 1. Documentation of use in combination with a GnRH analog -OR- 2. The member has had a bilateral orchiectomy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Eucrisa

Products Affected

- **EUCRISA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1 and 2): 1) mild to moderate atopic dermatitis 2) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- documentation of facial or anogenital involvement
Age Restrictions	Deny if less than 3 months of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	If 2 years of age or older, therapeutic failure of one of the following is required: topical tacrolimus -OR- topical pimecrolimus. Reauthorization or continuation of therapy will be approved when documentation of improvement or response to therapy is provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Evekeo

Products Affected

- *amphetamine sulfate*
- **EVEKEO**

PA Criteria	Criteria Details
Exclusion Criteria	Obesity
Required Medical Information	Documentation of diagnosis. For narcolepsy the following are required: Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B)Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP.
Age Restrictions	Deny if less than 6 years of age for narcolepsy or 3 years of age for ADHD
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For narcolepsy, trial and failure, intolerance to 2 of the following generic alternatives is required: immediate release amphetamine/dextroamphetamine, dextroamphetamine, and methylphenidate. For ADHD, trial/failure or intolerance to 2 unique generic stimulants (e.g. methylphenidate) is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Evenity

Products Affected

- **EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Postmenopausal woman at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug. A cumulative lifetime approval of romosozumab will be limited to a coverage duration of 12 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Evrysdi

Products Affected

- **EVRYSDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of spinal muscular atrophy -AND- Baseline motor function test results (e.g. MFM, CHOP, HINE, RULM, HFMSE, 6MWT) -AND- Not using concomitantly with Spinraza -AND- Molecular genetic testing of 5q SMA showing Homozygous gene deletion, Homozygous conversion mutation or Compound heterozygote
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For reauthorization, attestation of stable or clinically significant improvement in Spinal Muscular Atrophy associated symptoms (e.g. stabilization or decreased decline in motor function compared to the predicted natural history trajectory of disease) -OR- Stable or improved motor function results compared to baseline (e.g. MFM, CHOP, HINE, RULM, HFMSE, 6MWT).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Exservan

Products Affected

- **EXSERVAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of amyotrophic lateral sclerosis (ALS) -AND- Inability to swallow tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of stability or improvement in symptoms of ALS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fasenra

Products Affected

- **FASENRA**
- **FASENRA PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of severe asthma -AND- history of at least one asthma exacerbations requiring oral or systemic corticosteroid treatment in the past 12 months -AND- documented pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration despite regular treatment with (a. or b.): a) high dose inhaled corticosteroid and additional asthma controller medication or b.) a medium or high dose inhaled corticosteroid plus a long-acting beta agonist with or without oral corticosteroids and additional asthma controller medication
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 150 cells/microliter within 6 weeks of initiation of therapy or greater than or equal to 300 cells/uL within 12 months of screening. For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fecal Microbiota Products

Products Affected

- **VOWST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of a recent diagnosis of recurrent Clostridioides difficile infection (CDI) -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	For reauthorization, attestation of recurrent CDI episodes after administration of the initial fecal microbiota product -AND- Will be used for prophylaxis and not treatment of recurrent CDI.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ferriprox

Products Affected

- *deferiprone*
- **FERRIPROX (2 TIMES A DAY)**
- **FERRIPROX ORAL SOLUTION**
- **FERRIPROX ORAL TABLET 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of transfusional iron overload due to thalassemia syndromes, sickle cell disease and other anemias -AND- transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -AND- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure of deferasirox (generic Exjade) is required. For reauthorization, continued requirement for regular blood transfusions -AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Fetzima

Products Affected

- **FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK** **HR 120 MG, 20 MG, 40 MG, 80 MG**
- **FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder and trial and failure of two other antidepressants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Filspari

Products Affected

- **FILSPARI**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with renin-angiotensin system inhibitors (i.e., ACE inhibitors, ARBs, aliskiren) or endothelin receptor antagonists (e.g., Letairis, Opsumit, Tracleer)
Required Medical Information	Documentation of primary immunoglobulin A nephropathy confirmed by biopsy -AND- Risk for rapid disease progression, evidenced by urine protein-to-creatinine ratio greater than or equal to 1.5 g/g or proteinuria greater than or equal to 1 g/day -AND- Therapeutic failure, contraindication, or intolerance to an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, reduction in urine protein-to-creatinine ratio or proteinuria from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fintepla

Products Affected

- **FINTEPLA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Dravet syndrome or Lennox-Gastaut syndrome. For Lennox-Gastaut syndrome, therapeutic failure, contraindication, or intolerance to at least 2 standard of care treatments (e.g. lamotrigine, clobazam).
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Firazyr

Products Affected

- **FIRAZYR**
- *icatibant*
- **SAJAZIR**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
Required Medical Information	For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Firazyr, therapeutic failure, intolerance or contraindication to icatibant.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Firdapse

Products Affected

- **FIRDAPSE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Flector

Products Affected

- *diclofenac epolamine*
- **FLECTOR**
- **LICART**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis AND one of the following (1,2 or 3): 1) trial/failure, intolerance, or contraindication to 2 oral generic NSAIDs one of which must be diclofenac 2) hypersensitivity to oral NSAIDs 3) history or high risk for adverse gastrointestinal effects associated with oral NSAID use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fleqsuvy

Products Affected

- *baclofen oral suspension*
- **FLEQSUVY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- the member has an inability to swallow generic baclofen tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Forteo

Products Affected

- **FORTEO**
- *teriparatide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. For brand Forteo, trial and failure of teriparatide is required. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Forteo/teriparatide will be limited to a coverage duration of 24 months in the absence of provider attestation that the member remains at or has returned to having a high risk for fracture
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Fotivda

Products Affected

- **FOTIVDA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if applicable to diagnosis, previous therapies tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Furoscix

Products Affected

- **FUROSCIX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of heart failure classified as NYHA Class II/III -AND- chronic heart failure medication regimen includes an oral loop diuretic (e.g. furosemide, bumetanide, torsemide) -AND- treatment with oral diuretics will replace the use of Furoscix as soon as practical.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gabapentin

Products Affected

- *gabapentin oral capsule 100 mg, 300 mg, 400 mg*
- *gabapentin oral solution 250 mg/5 ml*
- *gabapentin oral tablet 600 mg, 800 mg*
- **NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG**
- **NEURONTIN ORAL SOLUTION**
- **NEURONTIN ORAL TABLET 600 MG, 800 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Galafold

Products Affected

- **GALAFOLD**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Fabry disease confirmed by biochemical or genetic test -AND- Presence of an amenable GLA variant causing Fabry disease in the clinical context of the patient -AND- Will not be used concomitantly with enzyme replacement therapy (ERT) e.g. Fabrazyme.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy -AND- Will not be used concomitantly with enzyme replacement therapy (ERT) e.g. Fabrazyme.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gattex

Products Affected

- **GATTEX 30-VIAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of short bowel syndrome (SBS) having less than 200 cm of functional small bowel AND if age 18 and older, dependence on parenteral nutrition or intravenous nutritional support for at least 12 months AND requiring parenteral nutrition at least 3 times per week -OR- Documentation of SBS having less than 200 cm of functional small bowel AND age 1 to 17 years of age AND Dependence on parenteral nutrition AND weight of at least 10 kg.
Age Restrictions	Deny if less than 1 year of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gavreto

Products Affected

- **GAVRETO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) RET mutant or fusion status 2) Radioactive iodine-refractory (if radioactive iodine is appropriate)
Age Restrictions	Deny if less than 18 years of age for NSCLC or less than 12 years of age for thyroid cancer
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gilenya

Products Affected

- *fingolimod*
- **GILENYA**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Gilenya and other disease modifying agents such as interferons, Copaxone, Tysabri
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	Brand Gilenya requires therapeutic failure or intolerance to generic fingolimod. For Brand Gilenya 0.25mg, failure of generic is not required if age is between 10-17 years old and weight is less than or equal to 40kg.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gimoti

Products Affected

- **GIMOTI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute or recurrent diabetic gastroparesis -AND- Attestation of no signs or symptoms of tardive dyskinesia -AND- Therapeutic failure or intolerance to generic metoclopramide tablets or generic metoclopramide solution -AND- If over 65 years of age, member was titrated to a stable does of metoclopramide tablets or solution at 10mg four times a day before switching to Gimoti therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	For reauthorization, treatment is for a new episode of diabetic gastroparesis -AND- There has been a 2 week drug holiday without Gimoti since its last administration -AND- Attestation of no signs or symptoms of tardive dyskinesia -AND- Attestation that extended therapy with Gimoti outweighs risk of developing tardive dyskinesia.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gleevec

Products Affected

- **GLEEVEC ORAL TABLET 100 MG, 400 MG**
- *imatinib oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and all of the following, if applicable to diagnosis 1) Alternatives tried 2) Concomitant therapy 3) mutation status, if applicable to diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gleostine

Products Affected

- **GLEOSTINE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of one of the following (1. or 2.): 1) Diagnosis of primary or metastatic brain tumor(s) -AND- member has previously received surgical and/or radiotherapeutic procedure(s), or 2) Diagnosis of Hodgkin's Lymphoma -AND- member is using Gleostine in combination with other chemotherapies -AND- member has experienced disease progression with initial chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

GLP1

Products Affected

- **BYDUREON BCISE**
- **BYETTA**
- **MOUNJARO**
- **OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)**
- **RYBELSUS**
- **TRULICITY**
- **VICTOZA 3-PAK**

PA Criteria	Criteria Details
Exclusion Criteria	Obesity or use for weight loss
Required Medical Information	Documentation of diabetes mellitus type 2
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Glycate

Products Affected

- **GLYCATE**
- *glycopyrrolate oral tablet 1.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of using as an adjunctive treatment for peptic ulcer disease -AND- Therapeutic failure or intolerance to generic glycopyrrolate 1mg tablet
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy -AND- Additional courses of therapy are required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gocovri

Products Affected

- **GOCOVRI ORAL**
  CAPSULE,EXTENDED RELEASE 24HR
  137 MG, 68.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For dyskinesia associated with Parkinson's disease, documentation of concurrent levodopa-based therapy -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine. For off-episodes of Parkinson's disease, documentation of concurrent carbidopa/levodopa therapy -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine -AND- trial and failure, contraindication, or intolerance to one (1) of the following agents: entacapone, pramipexole, rasagiline, ropinirole, or selegiline.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Gralise

Products Affected

- **GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG, 450 MG, 600 MG, 750 MG, 900 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of postherpetic neuralgia (PHN) -AND- Trial and failure or intolerance to generic gabapentin. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Grastek

Products Affected

- **GRASTEK**

PA Criteria	Criteria Details
Exclusion Criteria	Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy
Required Medical Information	Documentation of allergic rhinitis and use for Timothy grass pollen or cross reactive grass pollens (Sweet Vernal, Orchard, Perennial Rye, Timothy, Kentucky Blue Grass pollen, Redtop, or meadow fescue) -AND- allergic rhinitis with or without conjunctivitis has been confirmed by a pollen specific positive skin test or in vitro testing for pollen-specific IgE antibodies -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent
Age Restrictions	Deny if less than 5 years of age or greater than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Growth Hormone

Products Affected

- **GENOTROPIN**
- **GENOTROPIN MINIQUICK**
- **HUMATROPE INJECTION CARTRIDGE**
- **NGENLA**
- **NORDITROPIN FLEXPRO**
- **NUTROPIN AQ NUSPIN**
- **OMNITROPE**
- **SAIZEN**
- **SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG**
- **ZOMACTON**
- **ZORBTIVE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis, growth chart, bone age, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria. Additionally for growth failure due to chronic kidney disease, glomerular filtration rate is less than 89ml/min per 1.73m*2. For HIV wasting and cachexia, Concurrent use of antiretroviral therapy -AND- weight loss of at least 10 percent from baseline. For short bowel syndrome, receiving management for short bowel syndrome, including specialized nutritional support -AND- less than 200 cm of functional small bowel.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines. For reauthorization of HIV wasting and cachexia, attestation of increase in weight from start of therapy. For reauthorization of short bowel syndrome, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline.
Indications	All Medically-accepted Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Haegarda

Products Affected

- **HAEGARDA**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.
Age Restrictions	Deny if less than 6 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Harvoni

Products Affected

- **HARVONI ORAL PELLETS IN PACKET**
- **HARVONI ORAL TABLET 90-400 MG**
- *ledipasvir-sofosbuvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Hemady

Products Affected

- **HEMADY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma -AND- used in combination with other anti-myeloma agents -AND- therapeutic failure or intolerance to generic dexamethasone.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Hetlioz

Products Affected

- **HETLIOZ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Non-24 Sleep-Wake disorder in patient that is totally blind -AND- evidenced by all the following (1 through 4): 1) history of insomnia, excessive daytime sleepiness, or both alternating with asymptomatic episodes 2) symptoms persistent for at least 3 months 3) daily sleep logs for at least 1 month demonstrating a sleep/wake pattern that delays each day 4) sleep disturbances are not better explained by another current disorder or medication/substance use -OR- Documented diagnosis of Smith-Magenis Syndrome as confirmed by chromosome analysis -AND- patient is experiencing nighttime sleep disturbances (e.g. difficulty falling asleep, shortened sleep cycles, inability to enter REM sleep, or frequent awaking during the night and early in the morning)
Age Restrictions	Deny if less than 16 years of age for nighttime sleep disturbances in Smith-Magenis Syndrome or deny if less than 18 years of age for Non-24 Hour Sleep-Wake Disorder
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For brand Hetlioz, documentation of trial and failure of generic tasimelteon is required. For reauthorization, attestation of increased total nighttime sleep or decreased daytime nap duration for Non-24 Sleep-Wake disorder -OR- attestation of positive clinical response to therapy with minimal side effects for Smith-Magenis Syndrome
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Hetlioz LQ

Products Affected

- **HETLIOZ LQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Smith-Magenis Syndrome as confirmed by chromosome analysis -AND- patient is experiencing nighttime sleep disturbances (e.g. difficulty falling asleep, shortened sleep cycles, inability to enter REM sleep, or frequent awaking during the night and early in the morning)
Age Restrictions	Deny if less than 3 or greater than 15 years of age.
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of positive clinical response to therapy with minimal side effects for Smith-Magenis Syndrome -AND- member is between 3 and 15 years of age
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

High-risk meds

Products Affected

- *amitriptyline*
- *amitriptyline-chlordiazepoxide*
- **ANAFRANIL**
- *benztropine oral*
- *carisoprodol*
- *chlorzoxazone*
- *clomipramine*
- *cyproheptadine*
- *doxepin oral capsule*
- *doxepin oral concentrate*
- *doxepin oral tablet*
- *ergoloid*
- *ergotamine-caffeine*
- *hydroxyzine hcl oral solution 10 mg/5 ml*
- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate*
- *imipramine hcl*
- *imipramine pamoate*
- **LORZONE**
- *metaxalone*
- **NORGESIC**
- **NORGESIC FORTE**
- *orphenadrine citrate oral*
- *orphenadrine-asa-caffeine oral tablet 25-385-30 mg*
- *perphenazine-amitriptyline*
- *promethazine oral*
- **SILENOR**
- **SOMA**
- *trimipramine*
- **VISTARIL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For all medications subject to this PA group, the following information (1 through 3) is required: 1. Documentation of diagnosis 2. Explanation of risk-benefit profile favoring use of the high-risk medication 3. Attestation of an intent to monitor and address treatment-related adverse events. For target tricyclic antidepressants (TCAs), in addition to criteria 1 through 3 above, trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs for the same indication, if available, is required (e.g. SSRIs and SNRIs). If using a TCA for a medically-accepted indication not shared by the safer alternatives listed, then no trial of alternatives is required.
Age Restrictions	Automatic approval if less than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Doxepin doses less than or equal to 6 mg per day will receive automatic approval.

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

High-risk meds phenobarbital

Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for use in sedation/insomnia
Required Medical Information	For use in seizures the following are required: 1. Explanation of risk-benefit profile favoring use of the high-risk medication 2. Attestation of an intent to monitor and address treatment-related adverse events. 3. For new starts, the trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs used for seizures (e.g. carbamazepine, lamotrigine) is required.
Age Restrictions	Automatic approval if less than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Seizure disorders
Part B Prerequisite	No

Homozygous FH

Products Affected

- **JUXTAPID**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of homozygous familial hypercholesterolemia (HoFH) supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene -OR- untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents -AND- The member has a current LDL-C greater than 100mg/dL despite use of maximally tolerated statin OR statin intolerance -AND- The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Patients must have a trial/failure or contraindication to the preferred product Repatha. For reauthorization, documentation showing an LDL-C reduction on Juxtapid therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Horizant

Products Affected

- **HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG, 600 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of moderate to severe active primary restless leg syndrome -AND- trial and failure of pramipexole or ropinirole -AND- trial and failure of an additional dopaminergic agent, clonidine or pregabalin -OR- Documentation of post herpetic neuralgia and trial and failure of generic gabapentin. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Humira

Products Affected

- **AMJEVITA(CF) AUTOINJECTOR**
- **AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML**
- **CYLTEZO(CF)**
- **CYLTEZO(CF) PEN**
- **CYLTEZO(CF) PEN CROHN'S-UC-HS**
- **CYLTEZO(CF) PEN PSORIASIS-UV**
- **HUMIRA PEN**
- **HUMIRA PEN CROHNS-UC-HS START**
- **HUMIRA PEN PSOR-UVEITS-ADOL HS**
- **HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML**
- **HUMIRA(CF)**
- **HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML**
- **HUMIRA(CF) PEN**
- **HUMIRA(CF) PEN CROHNS-UC-HS**
- **HUMIRA(CF) PEN PEDIATRIC UC**
- **HUMIRA(CF) PEN PSOR-UV-ADOL HS**
- **HYRIMOZ PEN CROHN'S-UC STARTER**
- **HYRIMOZ PEN PSORIASIS STARTER**
- **HYRIMOZ(CF) PEDI CROHN STARTER**
- **HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML**
- **HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 2 immunosuppressants.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Juvenile Idiopathic Arthritis and Uveitis

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit. For Amjevita, therapeutic failure or intolerance to one of the following preferred products is required: Humira, Cyltezo, and Hyrimoz.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Hyftor

Products Affected

- **HYFTOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of tuberous sclerosis complex with facial angiofibromas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of positive clinical response to therapy (e.g. decrease in size of facial angiofibromas, decrease in redness of facial angiofibromas)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ibrance

Products Affected

- **IBRANCE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of HR-positive, HER2-negative advanced or metastatic breast cancer -AND- meets one of the following (1 or 2): 1) documentation of use with an aromatase inhibitor as initial endocrine-based therapy -OR- 2) documentation of use with fulvestrant in patients with disease progression following endocrine therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ibsrela

Products Affected

- **IBSRELA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of irritable bowel syndrome with constipation -AND- failure or intolerance to Linzess -AND- if member is female, failure or intolerance to lubiprostone.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Iclusig

Products Affected

- **ICLUSIG**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of newly-diagnosed chronic phase CML
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Philadelphia chromosome status 2) T315I status 3) Alternatives tried/failed 4) Candidacy for other tyrosine kinase inhibitor therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Idhifa

Products Affected

- **IDHIFA ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

IG

Products Affected

- **BIVIGAM**
- **FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %**
- **GAMMAGARD LIQUID**
- **GAMMAGARD S-D (IGA**
- **GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %)**
- **GAMMAPLEX**
- **GAMMAPLEX (WITH SORBITOL)**
- **GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)**
- **OCTAGAM**
- **PANZYGA**
- **PRIVIGEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For select diagnoses the following apply 1) For Myasthenia Gravis Syndrome, documentation that the patient is refractory to other standard therapies (e.g., cholinesterase inhibitors, corticosteroids, azathioprine) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 2) For Multiple Sclerosis, patient is refractory to other standard therapies (e.g., interferons) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 3) For Inflammatory Myopathies, the patient is refractory to corticosteroids given in therapeutic doses over at least 4 months OR is intolerant/contraindication to corticosteroids or immunosuppressants. 4) For B-cell CLL, associated with recurrent bacterial infections OR with Associated Hypogammaglobulinemia defined as IgG level less than 600mg/dL or evidence of a specific antibody deficiency. 5) For Bone Marrow Transplantation, the member is 20 years of age or older and within the first 100 days after transplantation. 6) For Dermatomyositis/Polymyositis, trial and failure, intolerance, or contraindication to standard fist line therapy (i.e. corticosteroids or immunosuppressants). 7) For Pediatric HIV, the patient is less than 13 y.o. who have entry CD4 lymphocyte count greater than or equal to 200/mcl and IgG less than 400mg/dL OR recurrent bacterial infections. 8) For Guillain-Barre syndrome, impaired function by objective assessment and/or objective findings on physical exam at the time of initial therapy and IVIG therapy must be initiated within 2 weeks of symptom onset. 9) For Autoimmune Mucocutaneous Blistering Diseases (e.g. Stevens-Johnson Syndrome), trial and failure, intolerance, or contraindication to conventional therapy (e.g. corticosteroids) or the patient has rapidly progressive disease in which a clinical response could not be affected quickly enough using conventional agents.

PA Criteria	Criteria Details
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered under Part B when administered in the home to a member with a diagnosis of primary immunodeficiency disease
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Myasthenia Gravis syndrome, Multiple Sclerosis, Inflammatory Myopathies, Polymyositis, Bone Marrow Transplant, Pediatric HIV, Guillain-Barre syndrome, Autoimmune Mucocutaneous Blistering Diseases
Part B Prerequisite	No

Ilumya

Products Affected

- **ILUMYA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For psoriasis, patients must have therapeutic failure or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Skyrizi. For psoriasis induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Imbruvica

Products Affected

- **IMBRUVICA ORAL CAPSULE 140 MG, 280 MG, 420 MG 70 MG**
- **IMBRUVICA ORAL SUSPENSION**
- **IMBRUVICA ORAL TABLET 140 MG,**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) 17p deletion status 2) Alternatives tried/failed 3) concomitant therapy. For suspension, members must also have an inability to swallow oral tablets or oral capsules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Inbrija

Products Affected

- **INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use for the treatment of intermittent off episodes of Parkinson's disease while on carbidopa/levodopa
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Increlex

Products Affected

- **INCRELEX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of severe primary IGF-1 deficiency and all of the following: 1) Normal or elevated response (greater than 10 ng/ml) to two (2) of the following standard growth hormone stimulation tests: arginine, clonidine, glucagon, insulin, levodopa, propranolol. 2) Serum IGF-1 concentration that is less than or equal to three (3) standard deviations below the normal value based on laboratory reference range. 3) Height less than or equal to three (3) standard deviations below normal (at or below the third percentile for gender and age). 4) If female, bone age less than or equal to 14 years. If male, bone age less than or equal to 16. - OR- Documentation of diagnosis of growth hormone deficiency caused by gene deletion and all of the following: 1) Growth velocity at least 2 standard deviations below the age-appropriate mean or height at least 2.25 standard deviations below the age-appropriate mean. 2) Subnormal response (less than 10 ng/mL) to two (2) of the following standard growth hormone stimulation tests: arginine, clonidine, glucagon, insulin, levodopa, propranolol. 3) Development of neutralizing antibodies to growth hormone product(s). 4) If female, bone age of less than or equal to 14 years. If male, bone age less than or equal to 16.
Age Restrictions	Deny if greater than 17 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Ingrezza

Products Affected

- **INGREZZA INITIATION PACK**
- **INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of tardive dyskinesia OR documentation of chorea associated with Huntington's disease.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Inlyta

Products Affected

- **INLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Alternatives tried/failed 2) Concomitant therapy 3) Line of therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Inqovi

Products Affected

- **INQOVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation chronic myelomonocytic leukemia. Documentation of de novo or secondary myelodysplastic syndrome -AND- One of the following (1 or 2): 1) French American-British MDS subtypes of refractory anemia, refractory anemia with ringed sideroblasts or refractory anemia with excess blasts. 2) International Prognostic Scoring System group of intermediate-1, intermediate-2 or high-risk.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Inrebic

Products Affected

- **INREBIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate-2 or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) -AND- If a new start, baseline platelet count of greater than 50x10*9/L
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Baseline platelet count to be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Interferon Alfa

Products Affected

- **PEGASYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Interleukin-1b Blockers

Products Affected

- **ARCALYST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), documentation of need for maintenance of remission. For Recurrent Pericarditis (RP), documentation of trial/failure or intolerance to one, or contraindication to all of the following: oral nonsteroidal anti-inflammatory drug (NSAID), systemic corticosteroid, or colchicine.
Age Restrictions	Deny if less than 12 years of age for Recurrent Pericarditis and Cryopyrin-Associated Periodic Syndromes
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For DIRA: patient must weigh 10kg or more
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Intrarosa

Products Affected

- **INTRAROSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

IPF Agents

Products Affected

- **ESBRIET ORAL CAPSULE**
- **ESBRIET ORAL TABLET 267 MG, 801 MG**
- **OFEV**
- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of idiopathic pulmonary fibrosis -AND- baseline forced vital capacity (FVC) of at least 50% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30%. For Ofev only, documentation of systemic sclerosis-associated interstitial lung disease -AND- baseline forced vital capacity (FVC) of at least 40% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- documentation of a high-resolution chest computed tomography (CT) scan demonstrating greater than or equal to 10% pulmonary fibrosis. For Ofev only, documentation of chronic fibrosing interstitial lung disease with progressive phenotype -AND- high resolution chest computing tomography (HRCT) scan demonstrating greater than 10% fibrosing disease -AND- baseline forced vital capacity (FVC) of at least 45% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- disease progression in previous 24 months shown by one of the following : 1. Relative decline in FVC greater than or equal to 10% predicted 2. Relative decline in FVC greater than or equal to 5% but less than 10% predicted and either worsening of respiratory symptoms or increased extent of fibrotic changes on HRCT 3. Worsening of respiratory symptoms and increasing extent of fibrotic changes on HRCT
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Iressa

Products Affected

- *gefitinib*
- **IRESSA**

PA Criteria	Criteria Details
Exclusion Criteria	Use in tumors with EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.
Required Medical Information	Documentation of diagnosis -AND- the following: 1) EGFR exon 19 deletion mutations or exon 21 (L858R) mutations as detected by an FDA-approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Iressa, documentation of trial and failure of generic gefitinib is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Isturisa

Products Affected

- **ISTURISA ORAL TABLET 1 MG, 10 MG, 5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Cushing's disease AND patient is not a candidate for pituitary surgery or surgery has not been curative
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of mean urine free cortisol (mUFC) less than starting baseline value.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Itraconazole

Products Affected

- *itraconazole*
- **SPORANOX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If using for diagnosis of onychomycosis, confirmation through positive laboratory testing (e.g. KOH preparation, fungal culture, or nail biopsy) is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Onychomycosis: 3 months. All other indications: 3 months initial, 12 months reauth
Other Criteria	Documentation of trial/failure or intolerance of amphotericin b must be provided for approval in patients with aspergillosis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ivermectin Oral

Products Affected

- *ivermectin oral*
- **STROMECTOL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of strongyloidiasis of the intestinal tract (non-disseminated disease) or onchocerciasis -AND- Member weighs greater than or equal to 15kg.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Jakafi

Products Affected

- **JAKAFI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) and if a new start, baseline platelet count of greater than 50x10*9/L -OR- documentation of polycythemia vera and inadequate response or intolerance to hydroxyurea -OR- Documentation of steroid refractory acute graft-versus-host disease and prior therapy with at least one systemic corticosteroid -OR- Documentation of chronic graft-versus-host disease with prior failure of at least one systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Baseline platelet count to be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Jaypirca

Products Affected

- **JAYPIRCA ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Jynarque

Products Affected

- **JYNARQUE ORAL TABLET**
- **JYNARQUE ORAL TABLETS, SEQUENTIAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of rapidly progressing autosomal dominant polycystic kidney disease defined by one of the following: 1.) Historical decline in eGFR greater than or equal to 5mL/min/1.73 m*2 within a 12 month period. 2.) Decline in eGFR of greater than or equal to 2.5mL/min/1.73m*2 over a period of 5 years. 3.) 5% increase in total kidney volume per year by 3 repeat CT or MRI. 4.) Average kidney length greater than 16.5cm. 5.) Family history of end-stage renal disease before age 58. 6.) Mayo imaging classification of 1C, 1D, or 1E. 7.) Kidney bleeds.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, prescriber attestation of slowed decline of kidney function
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kalydeco

Products Affected

- **KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 50 MG, 75 MG**
- **KALYDECO ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to ivacaftor based on clinical and or in vitro assay (e.g. G551D, G1244E, G1349D)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kerendia

Products Affected

- **KERENDIA**

PA Criteria	Criteria Details
Exclusion Criteria	eGFR less than or equal to 25 mL/min/1.73 m*2, serum potassium greater than 5.5 mEq/L
Required Medical Information	Documentation of type 2 diabetes mellitus with chronic kidney disease - AND- one of the following (1. 2. or 3.): 1) concomitant use of a sodium-glucose Cotransporter-2 (SGLT2) inhibitor 2) therapeutic failure to at least one SGLT2 inhibitor or 3) contraindication or intolerance to at least one SGLT2 inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation that signs or symptoms of hyperkalemia are not present.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kesimpta

Products Affected

- **KESIMPTA PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Keveyis

Products Affected

- **KEVEYIS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of one of the following: 1. Primary hyperkalemic periodic paralysis 2. Primary hypokalemic periodic paralysis 3. Related variants of primary periodic paralysis
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	2 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation the number of muscle weakness attacks per week has decreased from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kevzara

Products Affected

- **KEVZARA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide). For polymyalgia rheumatica (PMR), one of the following (1-3): 1) inadequate response to corticosteroids, 2) intolerance to corticosteroid taper, or 3) used in combination with corticosteroid tapering course.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to two of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kineret

Products Affected

- **KINERET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), therapeutic failure or intolerance to at least one (1) corticosteroid, or all corticosteroids are contraindicated.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kisqali

Products Affected

- **KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG**
- **KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following. 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy, if applicable to diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Klisyri

Products Affected

- **KLISYRI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of actinic keratosis of the face or scalp -AND- Therapeutic failure or intolerance to 1 of the following 1) generic topical imiquimod 5% cream 2) generic fluorouracil 5% topical cream 3) generic fluorouracil topical solution
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation that the member has previously experienced complete or partial clearance of actinic keratosis lesions with Klisyri -AND- additional course of therapy is required for recurrence of actinic keratosis -AND- member is restarting therapy at least 60 days after cessation of an initial Klisyri 5-day course.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Korlym

Products Affected

- **KORLYM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome -AND- Patient is not a candidate for surgery or where surgery has failed -AND- one of the following (1 or 2): 1) Diagnosis of diabetes with trial and failure, intolerance, or contraindication to one previous therapy for Type 2 Diabetes (e.g. metformin, sulfonylureas, insulin) or using in addition to a therapy for Type 2 diabetes. 2) Glucose intolerance
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Koselugo

Products Affected

- **KOSELUGO ORAL CAPSULE 10 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- for neurofibromatosis type 1 (NF1), documentation of symptomatic, inoperable plexiform neurofibromas (PN)
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Krazati

Products Affected

- **KRAZATI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and all of the following, if applicable to diagnosis 1) KRAS G12C mutation status, as detected by an FDA-approved test 2) Alternatives tried
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Kuvan

Products Affected

- **JAVYGTOR**
- **KUVAN**
- *sapropterin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of PKU -AND- documented baseline Phe level greater than 6 mg/dL -AND- clinical documentation of current weight -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, initial therapy has resulted in decrease in phenylalanine levels from baseline or current phenylalanine levels within the range of 120-360 micromol/L -AND- clinical documentation of current weight is required -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day. For brand Kuvan, a trial and failure of generic sapropterin dihydrochloride is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lampit

Products Affected

- **LAMPIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Weight of at least 2.5 kg
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	2 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Latuda

Products Affected

- **LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG**
- *lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If medication is being used for bipolar 1 disorder, documentation of trial and failure or intolerance to one other formulary medication indicated in bipolar 1 disorder (e.g. quetiapine)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Latuda, documentation of trial and failure of generic lurasidone is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lenvima

Products Affected

- **LENVIMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following if applicable to diagnosis: 1) Radioactive iodine refractory status 2) Microsatellite instability-high status or mismatch repair deficient status 3) Alternatives tried/failed or attestation of first line use 4) Concomitant therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Leukine

Products Affected

- **LEUKINE INJECTION RECON SOLN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis: following induction chemotherapy in patients who are 55 years or older with acute myelogenous leukemia (AML) -OR- mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation -OR- acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation -OR- acceleration of myeloid reconstitution following allogeneic BMT -OR- treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic BMT -OR- following acute exposure to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Leukotriene Modifiers

Products Affected

- *zileuton*
- **ZYFLO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of asthma -AND- trial/failure of generic montelukast and generic zafirlukast
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lidoderm

Products Affected

- *lidocaine topical adhesive patch,medicated 5 %*
- **LIDODERM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of postherpetic neuralgia (PHN) -AND- trial and failure of 1 other agent used to treat PHN (e.g. gabapentin), inability to swallow oral medication or unable to take an oral medication due to potential adverse events (e.g. sedation) -OR- documentation of diabetic peripheral neuropathy (DPN) -AND- trial and failure of one other agent used to treat DPN (e.g. duloxetine), inability to swallow oral medication or unable to take an oral medication due to potential adverse events (e.g. sedation)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	diabetic peripheral neuropathy
Part B Prerequisite	No

Litfulo

Products Affected

- **LITFULO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For severe alopecia areata, therapeutic failure/intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Livmarli

Products Affected

- **LIVMARLI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following diagnoses (1-2): 1) Alagille syndrome, 2) cholestatic pruritis -AND- Documentation that the member does not have any of the following diagnoses (3-5): 3) decompensated cirrhosis, 4) portal hypertension, 5) history of a hepatic decompensation event.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial, 12 months reauthorization
Other Criteria	For reauthorization, attestation of improvement in pruritis -AND- attestation that the member has not progressed to any of the following (1-3): 1) portal hypertension, 2) cirrhosis, or 3) experienced a hepatic decompensation event.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Livtencity

Products Affected

- **LIVTENCITY**

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of CMV prophylaxis.
Required Medical Information	Documentation of refractory cytomegalovirus infection or disease as evidenced by antigenemia or polymerase chain reaction (PCR) test -AND- all of the following (1-3): 1) member weighs at least 35 kg, 2) member is a recipient of hematopoietic stem cell transplant -OR- solid organ transplant. 3) member has experienced therapeutic failure to one of the following: ganciclovir, valganciclovir, cidofovir, or foscarnet.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of a previous reduction in CMV DNA level -AND- documentation of one of the following (1-2): 1) new onset symptomatic CMV infection -OR- 2) virologic relapse with treatment-emergent maribavir resistance.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lodoco

Products Affected

- **LODOCO**

PA Criteria	Criteria Details
Exclusion Criteria	Under CMS Review
Required Medical Information	Under CMS Review
Age Restrictions	Under CMS Review
Prescriber Restrictions	Under CMS Review
Coverage Duration	Under CMS Review
Other Criteria	Under CMS Review
Indications	Under CMS Review
Off Label Uses	Under CMS Review
Part B Prerequisite	No

Lokelma

Products Affected

- **LOKELMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 7.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in serum potassium levels following Lokelma administration and continued treatment for hyperkalemia is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lonsurf

Products Affected

- **LONSURF**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic colorectal cancer as a single agent or in combination with bevacizumab in patients who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy -OR- documentation of metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lorbrena

Products Affected

- **LORBRENA ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ALK-positive metastatic non-small cell lung cancer (NSCLC)
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lotronex

Products Affected

- *alosetron oral tablet 0.5 mg, 1 mg*
- **LOTRONEX ORAL TABLET 0.5 MG, 1 MG**

PA Criteria	Criteria Details
Exclusion Criteria	For irritable bowel syndrome (IBS): Exclude if male gender
Required Medical Information	Documentation of chronic severe diarrhea-predominant IBS -AND- trial and failure or intolerance to one anti-diarrheal (e.g. loperamide), anti-spasmodic, or tricyclic antidepressant, or contraindication to all
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 weeks initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation that symptoms of IBS continue to persist AND positive clinical response.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lovaza

Products Affected

- **LOVAZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For hypertriglyceridemia, triglycerides greater than or equal to 500mg/dL indicating sever hypertriglyceridemia -AND- Therapeutic failure or intolerance to a prescription, generic omega 3 acid ethyl ester capsules
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, reduction in triglyceride levels from baseline for hypertriglyceridemia
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lumakras

Products Affected

- **LUMAKRAS ORAL TABLET 120 MG, 320 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and all of the following, if applicable to diagnosis 1) KRAS G12C mutation status, as detected by an FDA-approved test 2) Alternatives tried
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lumryz

Products Affected

- **LUMRYZ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	If no diagnosis of cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy and cataplexy (if applicable) is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lupkynis

Products Affected

- **LUPKYNIS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of active lupus nephritis -AND- Documented positive ANA titer (greater than or equal to 1:80) or anti-dsDNA greater than or equal to 30 IU/mL -AND- Trial, contraindication, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- Member will continue to receive concomitant standard of care treatment with corticosteroids (e.g. prednisone) and mycophenolate mofetil.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	24 weeks initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of disease stability or disease improvement -AND- member will continue to receive concomitant standard of care treatment with corticosteroids (e.g. prednisone) and mycophenolate mofetil.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lupron Depot Ped

Products Affected

- **LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG**
- **LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED)**
- **LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of central precocious puberty -AND- advancement of bone age is beyond chronological age -AND- Basal luteinizing hormone (LH) level greater than 0.2-0.3 mIU/L or leuprolide-stimulating LH level greater than 3.3-5 mIU/L
Age Restrictions	Deny if greater than 8 years of age for females or greater than 9 years of age for males unless there is medical necessity for treatment of central precocious puberty
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy defined as pre-pubertal slowing/decline, normalization of FSH, normalization LH, normalization of bone age, normalization of bone age, normalization of estradiol level or normalization of testosterone level
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lybalvi

Products Affected

- **LYBALVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of schizophrenia or bipolar I disorder -AND- One of the following (1 or 2): 1) Therapeutic failure, intolerance or contraindication to generic risperidone and generic quetiapine 2) Currently stable and responding to olanzapine but experiencing weight gain from the medication
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lynparza

Products Affected

- **LYNPARZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) BRCA mutations 2) Genomic instability status 3) Homologous recombinant repair gene mutations 4) HER2 status 5) Alternatives tried/failed 6) Concomitant therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lyrica

Products Affected

- **LYRICA CR**
- **LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG**
- **LYRICA ORAL SOLUTION**
- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*
- *pregabalin oral tablet extended release 24 hr*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For immediate release and controlled release tablets, documentation of DPN and trial/failure or intolerance to duloxetine -OR- PHN and trial/failure or intolerance to gabapentin. For immediate release capsules, documentation of partial-onset seizures and trial/failure or intolerance to two AEDS -OR- neuropathic pain associated with spinal cord injury -OR- documentation to support a diagnosis of fibromyalgia and trial/failure or intolerance to duloxetine. When using pregabalin products concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lytgobi

Products Affected

- **LYTGOBI ORAL TABLET 4 MG, 4 MG (4X 4 MG TB), 4 MG (5X 4 MG TB)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR2 fusion or other rearrangement 2) Previous therapies tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Lyvispah

Products Affected

- **LYVISPAH**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- the member has an inability to swallow generic baclofen tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mavenclad

Products Affected

- **MAVENCLAD (10 TABLET PACK)**
- **MAVENCLAD (4 TABLET PACK)**
- **MAVENCLAD (5 TABLET PACK)**
- **MAVENCLAD (6 TABLET PACK)**
- **MAVENCLAD (7 TABLET PACK)**
- **MAVENCLAD (8 TABLET PACK)**
- **MAVENCLAD (9 TABLET PACK)**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Mavenclad and other disease modifying agents such as interferons, Copaxone, Tysabri. Treatment duration greater than 24 months.
Required Medical Information	Documentation of diagnosis of relapse-remitting multiples sclerosis or active secondary progressive disease -AND- therapeutic failure or intolerance to one other disease modifying therapy (e.g. Avonex, Gilenya, Copaxone)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	Coverage beyond 24 months will not be approved.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mavyret

Products Affected

- **MAVYRET ORAL PELLETS IN PACKET**
- **MAVYRET ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mayzent

Products Affected

- **MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG**
- **MAYZENT STARTER(FOR 1MG MAINT)**
- **MAYZENT STARTER(FOR 2MG MAINT)**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Mayzent and other disease modifying agents such as interferons, Copaxone, Tysabri.
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Testing for CYP2C9 variants has confirmed member does not have CYP2C9*3/*3 genotype
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Megace

Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mekinist

Products Affected

- **MEKINIST ORAL RECON SOLN**
- **MEKINIST ORAL TABLET 0.5 MG, 2 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following. 1) BRAF mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Mekinist powder for oral solution, attestation of inability to swallow Mekinist tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mektovi

Products Affected

- **MEKTOVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF mutation status 2) Concomitant therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Methamphetamine

Products Affected

- *methamphetamine*

PA Criteria	Criteria Details
Exclusion Criteria	Obesity
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For ADHD, trial/failure or intolerance to 2 of the following generic medications: methylphenidate, atomoxetine, or dextroamphetamine/amphetamine is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Motegrity

Products Affected

- **MOTEGRITY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of chronic idiopathic constipation -AND- Therapeutic failure, contraindication or intolerance to Linzess and lubiprostone.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mulpleta

Products Affected

- **MULPLETA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -AND- trial and failure or intolerance to Doptelet
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Myalept

Products Affected

- **MYALEPT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of congenital or acquired generalized lipodystrophy -AND- Leptin levels less than 8 ng/mL for males or less than 12 ng/mL for females -AND- the member has a diagnosis of diabetes or fasting insulin levels greater than 30uU/mL or fasting hypertriglyceridemia greater than 200mg/dL -AND- Therapeutic failure to one previous diabetes therapy (e.g. metformin, insulin) or hypertriglyceridemia therapy (e.g. statin, fibrate)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, decrease in HbA1c from baseline, decrease in fasting plasma glucose from baseline or decrease in fasting triglycerides from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Mycapssa

Products Affected

- **MYCAPSSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acromegaly -AND- High pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- Previous response to and tolerated treatment with octreotide or lanreotide.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decreased or normalized IGF-1 from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Myfembree

Products Affected

- **MYFEMBREE**

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of severe hepatic impairment or osteoporosis.
Required Medical Information	Documentation of Diagnosis. For premenopausal woman with uterine leiomyomas, experiencing heavy menstrual bleeding -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months. For moderate to severe pain associated with endometriosis in premenopausal woman, if the patient is a female of childbearing age, the patient is not pregnant - AND - Inadequate response, failure or contraindication to 2 standard of care treatments (i.e. NSAIDS, combined hormonal contraceptives, progestin, GnRH agonist) -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 18 months reauthorization
Other Criteria	For reauthorization of uterine leiomyomas, attestation of continued experience of heavy menstrual bleeding -AND- Attestation of decrease in menstrual blood loss -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months. For reauthorization of endometriosis, continued pain associated with endometriosis -AND- Attestation of reduction in pain -AND- For women of childbearing age, attestation of not pregnant -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Namenda

Products Affected

- **NAMENDA ORAL TABLET** **21 MG, 28 MG**
- **NAMENDA TITRATION PAK**
- **NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR 14 MG,**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and trial/failure of generic memantine
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Namzaric

Products Affected

- **NAMZARIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and trial/failure of generic memantine and generic donepezil
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Natpara

Products Affected

- **NATPARA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use as an adjunct to control hypocalcemia in patients with hypoparathyroidism -AND- Serum calcium concentration is greater than 7.5mg/dL -AND- Attestation of sufficient 25-hydroxyvitamin D stores
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement in total serum calcium from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nayzilam

Products Affected

- **NAYZILAM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizure clusters or acute repetitive seizures
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nerlynx

Products Affected

- **NERLYNX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following. 1) HER2 mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nexavar

Products Affected

- **NEXAVAR**
- *sorafenib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Nexavar, documentation of trial and failure of generic sorafenib is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nexletol

Products Affected

- **NEXLETOL**
- **NEXLIZET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	1.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite Simon Broome register criteria, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C greater than 100 mg/dL despite use of maximally tolerated statin or statin intolerance AND therapeutic failure, intolerance or contraindication to ezetimibe AND must be used with maximally tolerated statin dose or documentation of statin intolerance. 2.Hypercholesterolemia ASCVD AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance AND therapeutic failure, intolerance or contraindication to ezetimibe AND must be used with maximally tolerated statin dose or documentation of statin intolerance.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For reauthorization, documentation showing an LDL-C reduction from baseline AND attestation of continued use of Nexletol or Nexlizet with a maximally tolerated statin, unless statin intolerant. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statin which resolved upon discontinuation of statin or documentation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ninlaro

Products Affected

- **NINLARO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma -AND- previous treatment with at least 1 prior therapy -AND- used in combination with lenalidomide and dexamethasone
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Northera

Products Affected

- *droxidopa oral capsule 100 mg, 200 mg, 300 mg*
- **NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of neurogenic orthostatic hypotension caused by primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy -AND- documentation of inadequate response, intolerance or contraindication to preferred generic alternative midodrine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For brand Northera, documentation of trial and failure of generic droxidopa is required. For reauthorization, attestation of increase from baseline of systolic or diastolic blood pressure upon standing -OR- attestation of decrease from baseline of neurogenic orthostatic hypotension symptoms upon standing (e.g., dizziness, feeling faint, etc.).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nourianz

Products Affected

- **NOURIANZ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Parkinson's disease experiencing off episodes -AND- Used as adjunct to levodopa/carbidopa -AND- trial/failure, contraindication or intolerance to one of the following generic products: ropinirole, pramipexole, entacapone, selegiline, or rasagiline
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nubeqa

Products Affected

- **NUBEQA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following if applicable to diagnosis: 1. Concomitant therapy 2. History of a bilateral orchiectomy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nucala

Products Affected

- **NUCALA SUBCUTANEOUS AUTO-INJECTOR**
- **NUCALA SUBCUTANEOUS RECON SOLN**
- **NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of severe asthma evidenced by pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration -AND- 1.) A history of 2 or more exacerbations in the previous year or inadequate symptom control with inhaled corticosteroid in combination with 3 months of controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline), unless intolerant of or contraindication to all agents -AND- 2 or 3. 2) Greater than or equal to 150 cells/uL screening within 6 weeks of dosing. 3) Greater than or equal to 300 cells/uL within 12 months of screening. -OR- Documentation of eosinophilic granulomatosis with polyangiitis (EGPA) in patients who have a history of relapsing or refractory disease and will be receiving concomitant glucocorticoid treatment with or without immunosuppressive therapy -OR- Documentation of hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause for greater than or equal to 6 months -AND- At least 2 HES flares (HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy) within the past 12 months -AND- Stable on HES therapy for at least 4 weeks (chronic or episodic oral corticosteroids, immunosuppressive or cytotoxic therapy) -OR- Documentation of chronic rhinosinusitis with nasal polyps (CRSwNP) and trial/failure, contraindication, or intolerance to an intranasal corticosteroid.
Age Restrictions	Deny if less than 6 years old for asthma -OR- less than 12 years old for hypereosiniphilic syndrome -OR- less than 18 years old for CRSwNP
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nuedexta

Products Affected

- **NUEDEXTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation supporting improvement in symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nuplazid

Products Affected

- **NUPLAZID**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hallucinations and delusions associated with Parkinson's disease psychosis
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nurtec

Products Affected

- **NURTEC ODT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Episodic Migraine Prevention, defined as 4-14 migraine days per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. For acute treatment of migraine with or without aura, trial and failure of one generic triptan.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization of episodic migraine prevention, attestation of reduction in migraine frequency. For reauthorization of acute treatment of migraine, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Nuvigil

Products Affected

- *armodafinil*
- **NUVIGIL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For reauthorization, provider attestation of improvement in daytime sleepiness is required. For brand Nuvigil, documentation of failure on modafinil (generic Provigil).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ocaliva

Products Affected

- **OCALIVA**

PA Criteria	Criteria Details
Exclusion Criteria	Compensated cirrhosis with evidence of portal hypertension
Required Medical Information	Documentation of primary biliary cholangitis -AND- trial and failure, contraindication, or intolerance to ursodiol monotherapy -AND- will use concomitantly with ursodiol unless contraindicated or intolerant.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Octreotide

Products Affected

- *octreotide acetate injection solution*
- **SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- therapeutic failure or cannot be treated with surgical resection, pituitary irradiation or bromocriptine mesylate at maximally tolerated doses.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Odactra

Products Affected

- **ODACTRA**

PA Criteria	Criteria Details
Exclusion Criteria	Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy
Required Medical Information	Documentation of allergic rhinitis due to house dust mites -AND- allergic rhinitis with or without conjunctivitis has been confirmed by skin testing for licensed house dust mite allergen extracts or in vitro testing for IgE antibodies to D. pteronyssinus or D. Farina -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent
Age Restrictions	Deny if less than 12 years of age or greater than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Odomzo

Products Affected

- **ODOMZO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy or for use in patients who are not candidates for surgery or radiation therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Olpruva

Products Affected

- **OLPRUVA ORAL PELLETS IN PACKET 2 GRAM, 3 GRAM, 4 GRAM, 5 GRAM, 6 GRAM, 6.67 GRAM**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of acute hyperammonemia in urea cycle disorders
Required Medical Information	Documentation of chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, argininosuccinic acid synthetase, or ornithine transcarbamylase -AND- use as an adjunctive therapy to dietary management.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure of generic sodium phenylbutyrate is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Olumiant

Products Affected

- **OLUMIANT**

PA Criteria	Criteria Details
Exclusion Criteria	Part A covered for Covid-19 in hospitalized patients
Required Medical Information	Documentation of diagnosis. For moderate to severely active rheumatoid arthritis an inadequate response or intolerance to at least one non-biologic DMARD (e.g., methotrexate, leflunomide). For severe alopecia areata, inadequate response or intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis and Alopecia Areata
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR, with at least 1 being a tumor necrosis factor blocker.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Onfi

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- **ONFI ORAL SUSPENSION**
- **ONFI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ongentys

Products Affected

- **ONGENTYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Parkinson's disease experiencing off episodes -AND- Used as adjunct to levodopa/carbidopa -AND- trial/failure, contraindication or intolerance to the following (1. and 2.): 1) entacapone 2) one of the following generic products: rasagiline, pramipexole, ropinirole, selegiline
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Onureg

Products Affected

- **ONUREG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute myeloid leukemia that has achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy -AND- Inability to complete intensive curative therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Opzelura

Products Affected

- **OPZELURA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-4): 1) mild to moderate atopic dermatitis (AD), 2) attestation of up to 20 percent of body surface area (excluding scalp) with AD involvement, 3) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- documentation of facial or anogenital involvement, 4) trial & failure, intolerance, or contraindication to topical generic tacrolimus or topical generic pimecrolimus -OR- Documentation of all of the following (5-7): 5) Nonsegmental vitiligo, 6) body surface area with vitiligo involvement does not exceed 10%, 7) trial & failure or intolerance to at least 1 generic, formulary high or ultrahigh potency topical corticosteroid -OR- vitiligo with facial or anogenital involvement
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	Initial authorization: 8 weeks for AD, 24 weeks for vitiligo. Reauthorization: 12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy for atopic dermatitis -OR- meaningful repigmentation of affected areas for vitiligo
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Oralair

Products Affected

- **ORALAIR SUBLINGUAL TABLET 300 INDX REACTIVITY**

PA Criteria	Criteria Details
Exclusion Criteria	Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy, therapy initiation during active allergy season
Required Medical Information	Documentation of allergic rhinitis and use for Sweet Vernal, Orchard, Perennial Rye, Timothy or Kentucky Blue Grass pollens -AND- allergic rhinitis with or without conjunctivitis has been confirmed by a pollen specific positive skin test or in vitro testing for pollen-specific IgE antibodies -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent
Age Restrictions	Deny if less than 5 years of age or greater than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orencia

Products Affected

- **ORENCIA CLICKJECT**
- **ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, and Psoriatic Arthritis or less than 2 years of age for Juvenile Idiopathic Arthritis
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla and Stelara. For juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Xeljanx/Xeljanz solution and Actemra.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orgovyx

Products Affected

- **ORGOVYX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced prostate cancer
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Oriahnn

Products Affected

- **ORIAHNN**

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of severe hepatic impairment or osteoporosis.
Required Medical Information	Documentation of premenopausal woman with uterine leiomyomas -AND- Experiencing heavy menstrual bleeding -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 18 months reauthorization
Other Criteria	For reauthorization, attestation of continued experience of heavy menstrual bleeding -AND- Attestation of decrease in menstrual blood loss -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orilissa

Products Affected

- **ORILISSA ORAL TABLET 150 MG, 200 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of severe hepatic impairment or osteoporosis.
Required Medical Information	Documentation of female with diagnosis of endometriosis with moderate to severe pain -AND- For women of childbearing age, attestation of not pregnant -AND- Inadequate response, failure or contraindication to 2 standard of care treatments (e.g. NSAIDS, combined hormonal contraceptives, progestin, GnRH agonist, Danazol) -AND- Treatment with Orlissa does not exceed 24 months
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 18 months reauthorization
Other Criteria	For reauthorization, Orilissa is continued to be used for pain associated with endometriosis -AND- attestation of reduction in pain -AND- Total cumulative duration of therapy does not exceed 24 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orkambi

Products Affected

- **ORKAMBI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis and homozygous F508del mutation
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orkambi Granules

Products Affected

- **ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis and homozygous F508del mutation
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Orladeyo

Products Affected

- **ORLADEYO**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Orserdu

Products Affected

- **ORSERDU ORAL TABLET 345 MG, 86 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) ER mutation status, HER2 mutation status, and ESR1 mutation status 2) Alternatives tried/failed
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Osmolex

Products Affected

- **OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 193 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Parkinson's disease or drug-induced extrapyramidal symptoms -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine
Age Restrictions	Deny if less than 18 years of age.
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Osphena

Products Affected

- **OSPHENA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Otezla

Products Affected

- **OTEZLA**
- **OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For oral ulcers associated with Behcet's Disease, inadequate response or intolerance to topical triamcinolone for acute flare-up of oral ulcers -AND- inadequate response or intolerance to colchicine for prevention of recurrent oral ulcers
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Otrexup

Products Affected

- **OTREXUP (PF)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis AND trial/failure, intolerance, or contraindication to oral generic methotrexate tablets
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Oxbryta

Products Affected

- **OXBRYTA ORAL TABLET 300 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of sickle cell disease -AND- Failure, intolerance or contraindication to hydroxyurea
Age Restrictions	Deny if less than 4 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement of sickle cell disease signs, symptoms or complications
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Oxbryta for Suspension

Products Affected

- **OXBRYTA ORAL TABLET FOR SUSPENSION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of sickle cell disease -AND- Failure, intolerance or contraindication to hydroxyurea -AND- one of the following (1 or 2): 1) is eleven years of age or younger -OR- 2) has an inability to swallow tablets
Age Restrictions	Deny if less than 4 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement of sickle cell disease signs, symptoms or complications
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Oxervate

Products Affected

- **OXERVATE**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 8 weeks per eye
Required Medical Information	Documentation of diagnosis -AND- affected eye (e.g. right eye, both eyes).
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	8 weeks
Other Criteria	Coverage beyond 8 weeks per eye will not be approved
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Palynziq

Products Affected

- **PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of phenylketonuria. Member meets the following criteria 1.) Baseline Phe level greater than 600 micromoles/L -AND- 2.) Failure or intolerance to existing management (i.e. Kuvan therapy) -AND- 3.) Has a prescription for epinephrine agent unless contraindicated.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in baseline pretreatment Phe levels -OR- blood Phe levels are less than or equal to 600 micromoles/L -OR- attestation that additional therapy with Palynziq is needed to allow adequate trial of maximum dose of 60mg per day for 16 weeks or member is not currently on 60mg per day dose.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Panretin

Products Affected

- **PANRETIN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous lesions in patients with AIDS-related Kaposi Sarcoma (KS) who are not receiving systemic therapy for KS.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Pemazyre

Products Affected

- **PEMAZYRE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR2 fusion or other rearrangement as detected by an FDA-approved test 2) Previous therapies tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Pheburane

Products Affected

- **PHEBURANE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- therapeutic failure or intolerence to generic sodium phenylbutyrate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Phenoxybenzamine

Products Affected

- **DIBENZYLINE**
- *phenoxybenzamine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of excessive sweating and hypertension associated with pheochromocytoma supported by one of the following (1. or 2.): 1. Elevated metanephrines in plasma or urine. 2. Tumor evidence from CT scan or MRI
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Phospholine Iodide

Products Affected

- **PHOSPHOLINE IODIDE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For diagnosis of elevated intraocular pressure (IOP), the following criteria apply (1 and 2): therapeutic failure or intolerance to generic latanoprost, 2) therapeutic failure, contraindication, or intolerance to one generic ophthalmic alternative that lowers IOP (a. through f.): a) prostaglandin analog, b) ophthalmic beta-blocker, c) alpha-adrenergic agonist, d) carbonic anhydrase inhibitor, e) ophthalmic cholinergic agonist, f) combination products of these classes
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Piqray

Products Affected

- **PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of HR-positive, HER2-negative advanced or metastatic breast cancer in men and postmenopausal women with disease progression on or after endocrine-based therapy -AND- Used in combination with fulvestrant - AND- PI3K mutation positive as detected by an FDA approved test.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Pomalyst

Products Affected

- **POMALYST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma, and combination use with dexamethasone, and previous trial of at least 2 therapies including lenalidomide and a proteasome inhibitor, and disease progression on or within 60 days of completion of the last therapy -OR- Documentation of AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV negative
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ponvory

Products Affected

- **PONVORY**
- **PONVORY 14-DAY STARTER PACK**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Praluent

Products Affected

- **PRALUENT PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	1.HoFH supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene OR untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents AND The member has a current LDL-C of greater than 135 mg/dL (if 17 years of age or younger) or greater than 100mg/dL (18 years of age or older) despite use of maximally tolerated statin or statin intolerance AND The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH. 2.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C greater than 100 mg/dL despite use of maximally tolerated statin or statin intolerance. 3.Hypercholesterolemia ASCVD or Primary Hyperlipidemia AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization

PA Criteria	Criteria Details
Other Criteria	Patients must have a trial/failure or contraindication to the preferred product Repatha. Do not used with another PCSK9 inhibitor or siRNA directed to PCSK9. For reauthorization, documentation showing an LDL-C reduction on Praluent therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Prenatal Vitamins

Products Affected

- **PRENATAL VITAMIN PLUS LOW IRON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of nutritional supplementation required in a female of child-bearing potential during pre-conception, pregnancy, or lactation
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Prescription Drug Combo

Products Affected

- *acetaminophen-caff-dihydrocod oral capsule*
- *acetaminophen-codeine oral solution 120-12 mg/5 ml*
- *acetaminophen-codeine oral tablet*
- **ALPRAZOLAM INTENSOL**
- *alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg*
- *alprazolam oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- **AMBIEN**
- **AMBIEN CR**
- **ASCOMP WITH CODEINE**
- *butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg*
- *codeine sulfate*
- *codeine-butalbital-asa-caff*
- **CONZIP**
- **DEMEROL (PF) INJECTION SYRINGE 25 MG/ML**
- **DEMEROL INJECTION SOLUTION 50 MG/ML**
- **DILAUDID ORAL LIQUID**
- **DILAUDID ORAL TABLET**
- **EDLUAR**
- **ENDOCET**
- *eszopiclone*
- *fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour*
- **FIORICET WITH CODEINE**
- **HALCION ORAL TABLET 0.25 MG**
- *hydrocodone bitartrate oral capsule, oral only, er 12hr*
- *hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr*
- *hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml*
- *hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg*
- *hydrocodone-ibuprofen*
- *hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml*
- *hydromorphone oral liquid*
- *hydromorphone oral tablet*
- *hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 32 mg, 8 mg*
- **HYSINGLA ER**
- *levorphanol tartrate*
- **LUNESTA**
- *meperidine (pf) injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml*
- *meperidine oral solution*
- *meperidine oral tablet 50 mg*
- *methadone oral solution 10 mg/5 ml, 5 mg/5 ml*
- *methadone oral tablet 10 mg, 5 mg*
- *morphine concentrate oral solution*
- *morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg*
- *morphine oral capsule,extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg*
- *morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)*
- *morphine oral tablet*
- *morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg*
- **MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 15 MG, 200 MG, 30 MG, 60 MG**
- **NALOCET**
- **NUCYNTA**
- **NUCYNTA ER**
- *oxycodone oral capsule*
- *oxycodone oral concentrate*
- *oxycodone oral solution*
- *oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg*
- *oxycodone oral tablet,oral only,ext.rel.12 hr 10 mg, 20 mg*
- *oxycodone-acetaminophen oral solution 5-325 mg/5 ml*

- *oxycodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg*
- **OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG**
- *oxymorphone oral tablet*
- *oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg*
- **PERCOCET**
- **PROLATE ORAL SOLUTION**
- **PROLATE ORAL TABLET**
- **ROXICODONE ORAL TABLET 15 MG, 30 MG**
- **ROXYBOND**
- **SEGLENTIS**
- *tramadol oral capsule,er biphase 24 hr 17-83*
- *tramadol oral capsule,er biphase 24 hr 25-75 100 mg, 200 mg*
- *tramadol oral solution*
- *tramadol oral tablet 100 mg, 50 mg*
- *tramadol oral tablet extended release 24 hr*
- *tramadol oral tablet, er multiphase 24 hr*
- *tramadol-acetaminophen*
- **TREZIX**
- *triazolam*
- **XANAX ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG**
- **XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG, 2 MG, 3 MG**
- **XTAMPZA ER**
- *zaleplon oral capsule 10 mg, 5 mg*
- *zolpidem*

PA Criteria	Criteria Details
Exclusion Criteria	

PA Criteria	Criteria Details
Required Medical Information	For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine, and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxants (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines, sedative-hypnotics) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1)Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2)Patient is not opioid naive. 3)Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4)Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5)Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Opiate tx for pain+subs. abuse, app. opiate x 1mo. All other combos and dx approve x 12mo.
Other Criteria	Opiate agonists will receive automatic approval if no recent claims for a substance abuse therapy (e.g. buprenorphine-naloxone) OR a benzodiazepine (e.g. triazolam, alprazolam) OR a benzodiazepine with a centrally acting skeletal muscle relaxant (e.g., carisoprodol) OR a gabapentinoid OR a sedative-hypnotic. Benzodiazepines (e.g. triazolam, alprazolam) will receive automatic approval if no recent claims for an opiate agonist (e.g. oxycodone, hydrocodone, oxymorphone) or an opiate agonist with a centrally acting skeletal muscle relaxant (e.g. carisoprodol). Sedative-hypnotics (e.g. zolpidem) will receive automatic approval if no recent claims for an opiate agonist. Infusible opiate agonists will be covered under Part B when administered via infusion pump.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Pretomanid

Products Affected

- *pretomanid*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of extensively drug resistant, treatment intolerant or nonresponsive multidrug resistant tuberculosis -AND- Used as part of a combination regimen with bedaquiline and linezolid -AND- Therapeutic failure, contraindication or intolerance to both of the following (1 and 2): 1. A fluoroquinolone antibiotic 2. Isoniazid or Rifampin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	26 weeks
Other Criteria	For reauthorization, additional therapy required due to doses of the regimen being missed for safety reasons
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Proair Digihaler

Products Affected

- **PROAIR DIGIHALER**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of reversible obstructive airway disease (e.g. asthma) or exercise induced bronchospasm -AND- Inadequate response to non-digitized albuterol inhaler -AND- Attestation that a digital inhaler is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Procysbi

Products Affected

- **PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- previous trial and failure, intolerance, or contraindication to Cystagon (cysteamine bitartrate immediate-release)
Age Restrictions	Deny if less than 1 year of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Prolia

Products Affected

- **PROLIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -And- For osteoporosis at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 (i.e. osteopenia) -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For osteoporosis and osteopenia, documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Provigil

Products Affected

- *modafinil*
- **PROVIGIL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications. Diagnosis of fatigue associated with Multiple Sclerosis (MS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For reauthorization, provider attestation of improvement in daytime sleepiness is required. For brand Provigil, documentation of failure on generic modafinil.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Fatigue associated with Multiple Sclerosis (MS)
Part B Prerequisite	No

Pulmonary Arterial Hypertension

Products Affected

- **ADCIRCA**
- **ADEMPAS**
- **ALYQ**
- *ambrisentan*
- *bosentan*
- **LETAIRIS**
- **LIQREV**
- **OPSUMIT**
- **ORENITRAM MONTH 1 TITRATION KT**
- **ORENITRAM MONTH 2 TITRATION KT**
- **ORENITRAM MONTH 3 TITRATION KT**
- **ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG**
- **REVATIO ORAL SUSPENSION FOR RECONSTITUTION**
- **REVATIO ORAL TABLET**
- *sildenafil (pulm.hypertension) oral suspension for reconstitution*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- **TRACLEER ORAL TABLET**
- **TRACLEER ORAL TABLET FOR SUSPENSION**
- **UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG**
- **UPTRAVI ORAL TABLETS,DOSE PACK**
- **VENTAVIS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group. For bosentan and Revatio (sildenafil) in pediatric individuals, an exception to RHC will be allowed when the risk of RHC outweighs the benefit -AND- prescriber attests alternative studies have been completed (i.e. CT, MRI or specified test ruling out other causes of pulmonary hypertension). For Adempas, additional diagnosis of CTEPH as documented by right heart catheterization and V/Q scan substantiating mPAP greater than 20 mmHg at rest and PWP less than or equal to 15 mmHg and documented presence of occlusive thrombi within the pulmonary arteries will be approved.
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	Ventavis covered under Part B when using via nebulizer in the home setting. For brand Adcirca, trial and failure of generic tadalafil or Alyq is required. For brand Letairis, trial and failure of generic ambrisentan is required. For brand Revatio, trial and failure of generic sildenafil is required. For brand Tracleer 62.5mg and 125mg, trial and failure of generic bosentan is required. For Liqrev, trial and failure of generic sildenafil for oral suspension is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Pulmozyme

Products Affected

- **PULMOZYME**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis -AND- Used in conjunction with standard therapies for management of cystic fibrosis to improve pulmonary function.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization, attestation of increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Purified Cortrophin Gel

Products Affected

- **CORTROPHIN GEL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Covered for the following indications: 1. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy 2. Rheumatic disorders for patients receiving maintenance therapy 3. Collagen diseases for members receiving maintenance therapy 4. Dermatologic diseases, if using for severe psoriasis, then the member is concurrently receiving maintenance therapy 5. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction), if using for atopic dermatitis, then the member is concurrently receiving maintenance therapy 6. Ophthalmic diseases 7. Respiratory diseases 8. Gout and unable to take first-line therapies. 9. Pediatric acquired epileptic aphasia. 10. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). For covered indications 1 through 9, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month

PA Criteria	Criteria Details
Other Criteria	For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that Cortrophin is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Epileptic Aphasia
Part B Prerequisite	No

Pyrukynd

Products Affected

- **PYRUKYND ORAL TABLET 20 MG, 5 MG, 5 MG (4-WEEK PACK), 50 MG**
- **PYRUKYND ORAL TABLETS,DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hemolytic anemia with pyruvate kinase deficiency, as supported by one of the following (1-2): 1) mutations in the PKLR gene, 2) reduced activity of the pyruvate kinase enzyme.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	24 weeks initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of increase in hemoglobin level from baseline -OR- decrease in transfusion burden from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Qelbree

Products Affected

- **QELBREE ORAL**
  CAPSULE,EXTENDED RELEASE 24HR
  100 MG, 150 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant and generic atomoxetine
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Qinlock

Products Affected

- **QINLOCK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced gastrointestinal stromal tumor -AND- Prior treatment with imatinib and 2 other kinase inhibitors.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Quinine

Products Affected

- **QUALAQUIN**
- *quinine sulfate*

PA Criteria	Criteria Details
Exclusion Criteria	Treatment or prevention of leg cramps
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	10 days
Other Criteria	Doses for duration greater than 10 days will not be approved
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Qulipta

Products Affected

- **QULIPTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, of which 8 or more are migraine days. The following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Radicava ORS

Products Affected

- **RADICAVA ORS STARTER KIT SUSP**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of amyotrophic lateral sclerosis (ALS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rasuvo

Products Affected

- **RASUVO (PF)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis AND trial/failure, intolerance, or contraindication to oral generic methotrexate tablets
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ravicti

Products Affected

- **RAVICTI**

PA Criteria	Criteria Details
Exclusion Criteria	Urea cycle disorders due to N-acetylglutamate synthetase deficiency, Treatment of acute hyperammonemia in urea cycle disorders
Required Medical Information	Documentation of chronic management of a urea cycle disorders (UCDs)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Recorlev

Products Affected

- **RECORLEV**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of endogenous Cushing's syndrome AND patient is not a candidate for pituitary surgery or surgery has not been curative
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of mean urine free cortisol (mUFC) less than starting baseline value.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Regranex

Products Affected

- **REGRANEX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of lower-extremity diabetic neuropathic ulcer(s) that extends into the subcutaneous tissue or beyond and have an adequate blood supply -AND- being used as an adjunct to standard ulcer care practices (e.g. sharp debridement, non-weight bearing regimen, infection control) -AND- attestation of a wound care plan.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	20 weeks
Other Criteria	For reauthorization, one of the following (1-2): 1) documentation of decrease in ulcer(s) size without complete ulcer(s) closure -OR- 2) documentation of new lower extremity diabetic neuropathic ulcer(s) that extends into the subcutaneous tissue or beyond with an adequate blood supply, attestation of being used as an adjunct to standard ulcer care practices, and attestation of a wound care plan.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Relistor

Products Affected

- **RELISTOR ORAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of opioid induced constipation (OIC) due to any of the following (1-2): 1) chronic non-cancer pain, or 2) chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to 2 of the following (3-5): 3) Laxatives, 4) lubiprostone, 5) Movantik
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Relistor SC

Products Affected

- **RELISTOR SUBCUTANEOUS SOLUTION**
- **RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of opioid induced constipation (OIC) due to any of the following (1-3): 1) chronic non-cancer pain, 2) advanced illness or active cancer in palliative care or 3) chronic pain related to prior cancer or its treatments who do not require frequent (e.g., weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to 2 of the following (4 to 6): 4) Laxatives 5) lubiprostone 6) Movantik.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Relyvrio

Products Affected

- **RELYVRIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Repatha

Products Affected

- **REPATHA PUSHTRONEX**
- **REPATHA SURECLICK**
- **REPATHA SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	1.HoFH supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene OR untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents AND The member has a current LDL-C of greater than 135 mg/dL (if 17 years of age or younger) or greater than 100mg/dL (18 years of age or older) despite use of maximally tolerated statin or statin intolerance AND The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH. 2.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool, AND LDL-C greater than 100 mg/dL if 18 and older or LDL-C greater than 130 if 17 and younger despite use of maximally tolerated statin or statin intolerance. If 17 and younger will continue to receive concurrent lipid-lowering therapies. 3.Hypercholesterolemia ASCVD or Primary Hyperlipidemia AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance
Age Restrictions	Deny if less than 18 years of age for ASCVD and Primary Hyperlipidemia, or less than 10 years of age for HoFH and HeFH.
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization

PA Criteria	Criteria Details
Other Criteria	Do not used with another PCSK9 inhibitor or siRNA directed to PCSK9. For reauthorization, documentation showing an LDL-C reduction on Repatha therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Retevmo

Products Affected

- **RETEVMO ORAL CAPSULE 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) RET fusion status 2) Radioactive iodine-refractory (if radioactive iodine is appropriate)
Age Restrictions	Deny if less than 18 years of age for NSCLC or less than 12 years of age for thyroid cancer
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Revlimid

Products Affected

- *lenalidomide*
- **REVLIMID**

PA Criteria	Criteria Details
Exclusion Criteria	Documentation of chronic lymphocytic leukemia outside of a controlled clinical trial
Required Medical Information	Diagnosis of multiple myeloma in combination with dexamethasone -OR- diagnosis of multiple myeloma, as maintenance following autologous hematopoietic stem cell transplant (auto-HSCT) -OR- diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities -OR- diagnosis of mantle cell lymphoma (MCL) in which disease has relapsed or progressed after two prior therapies, one of which included bortezomib -OR- diagnosis of follicular lymphoma in combination with a rituximab product -OR- diagnosis of marginal zone lymphoma in combination with a rituximab product after previous treatment.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Rezlidhia

Products Affected

- **REZLIDHIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rezurock

Products Affected

- **REZUROCK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of chronic graft-versus-host disease (cGVHD) -AND- therapeutic failure or intolerance to 2 lines of systemic therapy
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rinvoq

Products Affected

- **RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe active rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate). For moderate to severe refractory atopic dermatitis whose disease is not adequately controlled with other systemic drug products, documentation of one of the following (1 or 2): 1) trial & failure, or intolerance to at least one topical corticosteroid -OR- topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) 2) The member has severe atopic dermatitis and is incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For Non-radiographic Axial Spondyloarthritis, trial & failure or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs) or contraindication to all.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For diagnoses in which tumor necrosis factor (TNF) blockers are also indicated (e.g., Rheumatoid Arthritis, Psoriatic Arthritis), the member has experienced therapeutic failure or intolerance to at least 1 TNF blocker.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Rozlytrek

Products Affected

- **ROZLYTREK ORAL CAPSULE 100 MG, 200 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer, the tumor status is ROS1-positive. For solid tumors with NTRK gene fusion without a known acquired resistance mutation, the tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or the tumors have progressed following treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Rubraca

Products Affected

- **RUBRACA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following. 1) BRCA mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ruconest

Products Affected

- **RUCONEST**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
Required Medical Information	For the treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.
Age Restrictions	Deny if less than 13 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Rydapt

Products Affected

- **RYDAPT**

PA Criteria	Criteria Details
Exclusion Criteria	Use as single agent induction therapy for AML
Required Medical Information	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) FLT3 mutations 2) Concomitant therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sabril

Products Affected

- **SABRIL**
- *vigabatrin*
- **VIGADRONE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of refractory complex partial seizures -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance to at least two alternative treatments (e.g. carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, tiagabine) -OR- documentation of use as monotherapy in treatment of infantile spasms
Age Restrictions	Deny if less than 2 years of age in treatment of refractory complex partial seizures -OR- if less than 1 month old and greater than 2 years of age in treatment of infantile spasms
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Samsca

Products Affected

- **SAMSCA**
- *tolvaptan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic hypervolemic or euvolemic hyponatremia evidenced by (1. or 2.): 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	Doses must be initiated in the hospital setting to closely monitor serum sodium. Treatment should be limited to 30 days to minimize risk of liver injury. For brand Samsca, a trial and failure of generic tolvaptan is required. For reauthorization, treatment is for a new episode of a clinically significant euvolemic or hypervolemic hyponatremia -AND- on of the following (1. or 2.) 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Savella

Products Affected

- **SAVELLA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation to support a diagnosis of fibromyalgia and trial/failure or intolerance to duloxetine
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Scemblix

Products Affected

- **SCEMBLIX ORAL TABLET 20 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) T3151 mutation status 2) Philadelphia chromosome status 3) Alternatives tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sertraline Capsule

Products Affected

- *sertraline oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder or obsessive-compulsive disorder -AND- Sertraline 100mg or sertraline 125mg has been received for greater than or equal to 7 days -AND- Therapeutic failure or intolerance to generic sertraline immediate release tablets -AND- Therapeutic failure, intolerance or contraindication to at least one other antidepressant (e.g. SNRI, SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Signifor

Products Affected

- **SIGNIFOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Cushing's disease AND patient is not a candidate for pituitary surgery or surgery has not been curative
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decrease in urinary free cortisol levels from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Siliq

Products Affected

- **SILIQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For psoriasis, patients must have therapeutic failure or intolerance to 2 preferred products Humira, Cosentyx, Otezla, Stelara, Enbrel, and Skyrizi. For psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Simponi

Products Affected

- **SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML**
- **SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Simponi 50mg: For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide) and Simponi will be used in combination with methotrexate. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). Diagnosis of psoriatic arthritis Simponi 100mg: Diagnosis of moderate to severe ulcerative colitis.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla, and Stelara. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel and Cosentyx. For ulcerative colitis, patients must have therapeutic failure or intolerance to the preferred products Humira, Stelara and Xeljanz/Xeljanz XR. For ulcerative colitis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Skyclarys

Products Affected

- **SKYCLARYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Friedreichs ataxia confirmed by genetic testing (i.e., FXN gene mutation).
Age Restrictions	Deny if less than 16 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Skyrizi

Products Affected

- **SKYRIZI SUBCUTANEOUS PEN INJECTOR**
- **SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML**
- **SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohns disease, attestation of clinical response or remission following IV administration of Skyrizi within 3 months of initiating therapy with Skyrizi SC.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Skytrofa

Products Affected

- **SKYTROFA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis, growth chart, bone age, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sogroya

Products Affected

- **SOGROYA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis, growth chart, bone age, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Solaraze

Products Affected

- *diclofenac sodium topical gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- trial and failure, intolerance, or contraindication to one of the following (1 or 2): 1) topical fluorouracil solution or fluorouracil 5% cream 2) topical imiquimod 5% cream
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of 30 day washout period since optimal therapeutic effect may not be evident until 30 days following cessation of therapy AND attestation of previous response to diclofenac sodium 3% topical gel therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Somavert

Products Affected

- **SOMAVERT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- inadequate or partial response to surgery or radiotherapy or not a candidate for surgery or radiotherapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sotyktu

Products Affected

- **SOTYKTU**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Cosentyx, Otezla, Stelara, Enbrel and Skyrizi.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sovaldi

Products Affected

- **SOVALDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance -AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir.
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sprycel

Products Affected

- **SPRYCEL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) Philadelphia Chromosome status (e.g. positive) 2) Alternatives tried/failed 3) Concomitant therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Statin Liquid

Products Affected

- **ATORVALIQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Inability to swallow tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Stelara

Products Affected

- **STELARA SUBCUTANEOUS SOLUTION**
- **STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- documentation of member weight and prescribed dose. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohn's Disease, attestation of clinical response or remission following single induction dose of IV Stelara within 2 months of initiating therapy with Stelara SC. For Ulcerative colitis, attestation of clinical response or remission following single induction dose of IV Stelara within 2 months of initiating therapy with Stelara SC
Age Restrictions	Deny if less than 18 years of age for Crohn's Disease and Ulcerative Colitis or less than 6 years of age for Plaque Psoriasis and Psoriatic Arthritis
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Must follow recommended dosing guidelines based upon weight. Psoriasis: For patients weighing less than 100 kilograms (220 pounds), 45 mg dosing will be approved. For patients weighing more than 100 kilograms (220 pounds), 90 mg dosing will be approved. Psoriatic Arthritis: 45 mg dosing will be approved. For patients with co-existent moderate to severe plaque psoriasis weighing greater than 100 kilograms (220 pounds), 90 mg dosing will be approved. Induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Stivarga

Products Affected

- **STIVARGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic colorectal cancer and trial of a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, AND an anti-VEGF therapy AND if RAS wild-type, an anti-EGFR therapy -OR- documentation of locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with both imatinib and sunitinib -OR- documentation of hepatocellular cancer AND previous treatment with sorafenib
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sunosi

Products Affected

- **SUNOSI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For narcolepsy and OSAHS, documentation of trial and failure, contraindication or intolerance to modafinil and armodafinil. For reauthorization, provider attestation of improvement in daytime sleepiness is required.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Sutent

Products Affected

- *sunitinib malate*
- **SUTENT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) disease progression on or intolerance to imatinib mesylate 2) high risk of recurrent RCC following nephrectomy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Symdeko

Products Affected

- **SYMDEKO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have either the homozygous F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to tezacaftor/ivacaftor based on clinical and/or in vitro assay (e.g. E56K, R117C, A455E)
Age Restrictions	Deny if less than 6 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Sympazan

Products Affected

- **SYMPAZAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy -AND- unable to tolerate generic clobazam
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Symproic

Products Affected

- **SYMPROIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of opioid induced constipation (OIC) due to any of the following (1-2): 1) chronic non-cancer pain, or 2) chronic pain related to prior cancer or its treatments who do not require frequent (e.g., weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to at least 2 of the following (3-5): 3) Laxatives, 4) lubiprostone, 5) Movantik
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Synarel

Products Affected

- **SYNAREL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For central precocious puberty (CPP), advancement of bone age is beyond chronological age -AND- Basal luteinizing hormone (LH) level greater than 0.2-0.3IU/L or leuprolide-stimulating LH level greater than 3.3-5 IU/L. For female with endometriosis, attestation of not pregnant if of childbearing age -AND- Therapeutic failure, contraindication or intolerance to 2 of the following standard of care treatments: NSAIDs, combination hormonal contraceptive, progestin (i.e. medroxyprogesterone injection), GnRH agonist (i.e. Leuprolide) or danazol
Age Restrictions	Deny if greater than 8 years of age for females or greater than 9 years of age for males unless there is medical necessity for treatment of central precocious puberty. Deny if less than 18 years of age for endometriosis.
Prescriber Restrictions	
Coverage Duration	Endometriosis: 6 months, CPP: 6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization for CPP, attestation of pubertal development slowing from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Syndros

Products Affected

- **SYNDROS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of one of the following (1 or 2): 1) anorexia associated with weight loss in patients with AIDS -and- trial and failure, contraindication, or intolerance to generic dronabinol capsules -OR- 2) nausea and vomiting associated with cancer chemotherapy in adults who have trial and failure, contraindication, or intolerance to a conventional antiemetic treatment (e.g., metoclopramide, promethazine, ondansetron, perphenazine, etc.) -and- trial and failure, contraindication, or intolerance to generic dronabinol capsules
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered under Part B when the following are met: 1) used for chemotherapy-induced nausea and vomiting. 2) used as full replacement for IV anti-emetic therapy. 3) using within 48 hours of receiving chemotherapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tabrecta

Products Affected

- **TABRECTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer with MET exon 14 skipping mutation as detected by an FDA approved test.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tadliq

Products Affected

- **TADLIQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure of generic tadalafil or Alyq -OR- Inability to swallow tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tagrisso

Products Affected

- **TAGRISSO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following. 1) EGFR mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Takhzyro

Products Affected

- **TAKHZYRO SUBCUTANEOUS SOLUTION (150 MG/ML)**
- **TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Taltz

Products Affected

- **TALTZ AUTOINJECTOR**
- **TALTZ SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs.
Age Restrictions	Deny if less than 18 years of age for Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis or less than 6 years of age for Plaque Psoriasis
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla, and Stelara. For plaque psoriasis patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Cosentyx, Otezla, Stelara, Enbrel and Skyrizi. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel and Cosentyx. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Talzenna

Products Affected

- **TALZENNA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of deleterious or suspected deleterious gBRCAm, HER2-negative locally advanced or metastatic breast cancer as a single agent -OR- Documentation of HRR gene-mutated metastatic castration-resistant prostate cancer in combination with enzalutamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Targretin

Products Affected

- *bexarotene oral*
- *bexarotene topical*
- **TARGRETIN ORAL**
- **TARGRETIN TOPICAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Targretin, documentation of trial and failure of generic bexarotene is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tarpeyo

Products Affected

- **TARPEYO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- one (1) of the following (A or B): A) Used in combination with one (1) of the following (1 or 2): 1) angiotensin-converting enzyme inhibitor (ACE-I), or 2) angiotensin II receptor blocker (ARB), -OR- B) Intolerance or contraindication to both of the following (3 and 4): 3) ACE-I, and 4) ARB.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tascenso ODT

Products Affected

- **TASCENSO ODT**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Gilenya and other disease modifying agents such as interferons, Copaxone, Tysabri
Required Medical Information	Documentation of a relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tasigna

Products Affected

- **TASIGNA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) Philadelphia Chromosome status (e.g. positive) 2) Alternatives tried/failed
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tasimelteon

Products Affected

- *tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Non-24 Sleep-Wake disorder in patient that is totally blind -AND- evidenced by all the following (1 through 4): 1) history of insomnia, excessive daytime sleepiness, or both alternating with asymptomatic episodes 2) symptoms persistent for at least 3 months 3) daily sleep logs for at least 1 month demonstrating a sleep/wake pattern that delays each day 4) sleep disturbances are not better explained by another current disorder or medication/substance use
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of increased total nighttime sleep or decreased daytime nap duration for Non-24 Sleep-Wake disorder
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tavalisse

Products Affected

- **TAVALISSE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For diagnosis of ITP, the following criteria apply (1 and 2): 1) trial, intolerance, or inadequate response to a corticosteroid, immunoglobulin, or splenectomy. 2) One of the following (A or B): A) Platelet count less than or equal to 50 x 10*9/L and has significant mucous member bleeding or at least one risk factor for bleeding (e.g. hypertension, peptic ulcer disease). B) Platelet count of less than or equal to 30 x 10*9/L.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tavneos

Products Affected

- **TAVNEOS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis -AND- Prescriber attests to positive test for anti-PR3 or positive test for anti-MPO -AND- Member will continue to receive concomitant standard of care treatment with systemic glucocorticoids (e.g. prednisone) and immunosuppressives (e.g. mycophenolate mofetil, azathioprine).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of therapeutic response defined by disease stability or disease improvement -AND- Member will continue to receive concomitant standard of care treatment with glucocorticoids (e.g. prednisone) and immunosuppressives (e.g. mycophenolate mofetil, azathioprine).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tazarotene

Products Affected

- **ARAZLO**
- **FABIOR**
- *tazarotene topical foam*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tazorac

Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*
- **TAZORAC TOPICAL CREAM**
- **TAZORAC TOPICAL GEL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of 1 of the following (A or B). A) Documentation of plaque psoriasis -AND- trial and failure or intolerance to at least one topical corticosteroid (e.g. fluocinonide, mometasone, triamcinolone, betamethasone). B) Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tazverik

Products Affected

- **TAZVERIK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic epithelioid sarcoma -AND- Disease is not eligible for complete resection. Documentation of relapsed or refractory follicular lymphoma -AND-Tumors are EZH2 mutation positive, as detected by FDA approved test, in a member that has received at least 2 prior systemic therapies -OR- Prescriber attests there are no satisfactory alternative treatment options.
Age Restrictions	Deny if less than 16 years of age for epithelioid sarcoma or deny if less than 18 years of age for follicular lymphoma
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tecfidera

Products Affected

- *dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg* **CAPSULE,DELAYED RELEASE(DR/EC) 120 MG, 120 MG (14)- 240 MG (46), 240 MG**
- **TECFIDERA ORAL**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	For brand Tecfidera, documentation of failure on generic dimethyl fumarate
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tegsedi

Products Affected

- **TEGSEDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of polyneuropathy associated with hereditary TTR (hATTR) amyloidosis with mutation in TTR gene confirmed by genetic testing -AND- Neurologic examination shows clinical signs and symptoms of the disease (e.g. peripheral/autonomic neuropathy, motor disability, carpel tunnel, etc.) -AND- Attestation of peripheral neuropathy impairment score (NIS) of 10 or greater -AND- Not simultaneously utilizing other gene targeted therapy for polyneuropathy of hATTR
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement of polyneuropathy from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tepmetko

Products Affected

- **TEPMETKO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer with a MET exon 14 skipping alteration
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Testosterone (androgens)

Products Affected

- **ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP**
- **AVEED**
- **DEPO-TESTOSTERONE**
- **FORTESTA**
- **JATENZO ORAL CAPSULE 158 MG, 198 MG, 237 MG**
- **NATESTO**
- **TESTIM**
- *testosterone cypionate*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*
- *testosterone transdermal solution in metered pump w/app*
- **TLANDO**
- **VOGELXO TRANSDERMAL GEL**
- **VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP**
- **XYOSTED**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of primary or secondary hypogonadism in males with testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, radiation or toxic damage -OR- documentation of primary or secondary hypogonadism in males with multiple symptoms of hypogonadism including at least one of the following specific symptoms: height loss due to vertebral fractures, low trauma fractures, low bone density, incomplete or delayed sexual development, breast discomfort, loss of axillar and/or pubic body hair, hot flushes -OR- documentation of HIV infection in men with weight loss -OR- documentation of chronic steroid treatment in men. In all previously noted indications, members must also have documented low total testosterone level below the normal range for the laboratory -OR- a total testosterone level near the lower limit of the normal range with a low free testosterone level which is less than normal based upon the laboratory reference range -OR- the member is not producing any testosterone. Additional approvable indications include female patients with metastatic breast cancer (testosterone enanthate only), primary or secondary hypogonadism in males with testicular failure due to double orchidectomy, and delayed puberty in males (testosterone enanthate only).
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	HIV Wasting
Part B Prerequisite	No

Thalomid

Products Affected

- **THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Use as monotherapy for ENL treatment in the presence of moderate to severe neuritis
Required Medical Information	Documentation of multiple myeloma in combination with dexamethasone -OR- documentation for use in the treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) -OR- documentation of therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Thiola

Products Affected

- **THIOLA**
- **THIOLA EC**
- *tiopronin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Confirmation of cystinuria by at least one 24-hour urine collection with measurement of urinary cysteine levels greater than 400 mg/day -AND- Attestation of failure of urine alkalization with potassium citrate (to achieve pH of 7.0).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of urine cystine concentration decreased from baseline -OR- decrease in production of cystine stones is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Thrombopoiesis Stimulating Agents

Products Affected

- **PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG**
- **PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of chronic immune idiopathic thrombocytopenia purpura and trial and failure of corticosteroid or immunoglobulin therapy or splenectomy -OR- documentation of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy (eltrombopag only)-OR- severe aplastic anemia who have had an insufficient response to immunosuppressive therapy -OR- documentation of first line treatment for severe aplastic anemia and used in combination with at least two immunosuppressive therapies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Platelet count to be provided
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tibsovo

Products Affected

- **TIBSOVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) IDH1 mutation status, 2) alternatives tried/failed, 3) comorbidity that precludes use of intensive induction chemotherapy (i.e. age greater than or equal to 75 years, severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tigan

Products Affected

- *trimethobenzamide oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tiglutik

Products Affected

- **TIGLUTIK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of amyotrophic lateral sclerosis (ALS) -AND- Inability to swallow tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of stability or improvement in symptoms of ALS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tolsura

Products Affected

- **TOLSURA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Unable to tolerate generic itraconazole capsules
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation the member is still unable to tolerate generic itraconazole capsules
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Topical Lidocaine

Products Affected

- *lidocaine hcl mucous membrane solution 4 % (40 mg/ml)*
- *lidocaine topical ointment*
- *lidocaine-prilocaine topical cream*
- **PLIAGLIS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Transmucosal Fentanyl Citrate

Products Affected

- *fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg*
- *fentanyl citrate buccal tablet, effervescent 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg*
- **FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of therapeutic use and the member is currently receiving and tolerant to long acting opioid therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tremfya

Products Affected

- **TREMFYA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For psoriasis, patients must have therapeutic failure or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Skyrizi. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Xeljanz/Xeljanz XR. For psoriasis and psoriatic arthritis induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tretinoin

Products Affected

- *adapalene topical cream*
- *adapalene topical gel 0.3 %*
- *adapalene topical swab*
- *adapalene-benzoyl peroxide*
- **AKLIEF**
- **ALTRENO**
- **ATRALIN**
- *clindamycin-tretinoin*
- **DIFFERIN TOPICAL CREAM**
- **DIFFERIN TOPICAL GEL WITH PUMP**
- **DIFFERIN TOPICAL LOTION**
- **EPIDUO FORTE**
- **EPIDUO TOPICAL GEL WITH PUMP**
- **RETIN-A**
- **RETIN-A MICRO**
- **RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 %**
- *tretinoin*
- *tretinoin microspheres topical gel*
- *tretinoin microspheres topical gel with pump 0.08 %*
- **TWYNEO**
- **VELTIN**
- **WINLEVI**
- **ZIANA**

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic use
Required Medical Information	Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two generic topical non-retinoid acne medications (e.g. clindamycin, sulfacetamide, erythromycin)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Trikafta

Products Affected

- **TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL**
- **TRIKAFTA ORAL TABLETS, SEQUENTIAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to elexacaftor/tezacaftor/ivacaftor based on in vitro assay (e.g. E56K, R117C, A455E)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tukysa

Products Affected

- **TUKYSA ORAL TABLET 150 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) HER2 mutations 2) RAS genetic status 3) Alternatives tried/failed 4) Concomitant therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Turalio

Products Affected

- **TURALIO ORAL CAPSULE 125 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic tenosynovial giant cell tumor associated with severe morbidity and functional limitations -AND- patient is not amenable to improvement with surgery or not a candidate for surgery
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tykerb

Products Affected

- *lapatinib*
- **TYKERB**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) HER2 mutations 2) Alternatives tried/failed 3) Concomitant therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Tykerb, trial and failure of generic lapatinib is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tymlos

Products Affected

- **TYMLOS**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 24 months.
Required Medical Information	Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Additional documentation of trial/failure, intolerance or contraindication to preferred parathyroid hormone analog teriparatide. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Tymlos will be limited to a coverage duration of 24 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Tyvaso DPI

Products Affected

- **TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 16 MCG (112)- 32 MCG (84), 16(112)-32(112) -48(28) MCG, 32 MCG, 32-48 MCG, 48 MCG, 64 MCG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- results of a right heart catheterization (RHC) meeting all of the following (1., 2., and 3.): 1) mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, 2) pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, 3) PVR greater than or equal to 3 Wood units
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ubrelvy

Products Affected

- **UBRELVY ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of acute treatment of migraine with or without aura -AND- trial and failure of one generic triptan.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	Patients must have therapeutic failure, intolerance, or contraindication to Nurtec ODT. For reauthorization, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Uloric

Products Affected

- *febuxostat*
- **ULORIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of chronic management of hyperuricemia due to gout -And- trial/failure, intolerance or contraindication to allopurinol.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Valchlor

Products Affected

- **VALCHLOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received at least one prior skin-directed therapy (e.g. topical corticosteroids, topical chemotherapy, local radiation and topical retinoids).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Valtoco

Products Affected

- **VALTOCO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizure clusters or acute repetitive seizures
Age Restrictions	Deny if less than 6 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vancomycin

Products Affected

- **VANCOCIN ORAL CAPSULE 125 MG, 250 MG**
- *vancomycin oral capsule 125 mg, 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For brand Vancocin, trial and failure of generic vancomycin capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vanflyta

Products Affected

- **VANFLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Induction, consolidation, or maintenance therapy 2) FLT3 ITD mutation status, as detected by an FDA-approved test 3) Concomitant therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Veltassa

Products Affected

- **VELTASSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 6.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in serum potassium levels following Veltassa administration and continued treatment for hyperkalemia is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Venbysi XR

Products Affected

- *venlafaxine besylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- venlafaxine extended-release product at a total daily dose greater than or equal to 75 mg has been received for greater than or equal to 4 days.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Venclexta

Products Affected

- **VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG**
- **VENCLEXTA STARTING PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and concomitant therapy, if applicable to diagnosis. For newly-diagnosed AML, age greater than or equal to 75 years or presence of at least one comorbidity that precludes use of intensive induction chemotherapy (i.e. severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation) is required.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Veozah

Products Affected

- **VEOZAH**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documenation of moderate to severe vasomotor symptoms due to menopause -AND- one of the following (1 or 2): 1) therapeutic failure, contraindication, or intolerance to a generic hormone therapy product, or 2) attestation that hormone therapy is not clinically appropriate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Verkazia

Products Affected

- **VERKAZIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- therapeutic failure or intolerance to 2 of the following medication classes or all are contraindicated: 1) generic ophthalmic antihistamines (e.g., olopatadine), 2) generic ophthalmic mast cell stabilizers (e.g., cromolyn sodium), 3) Generic ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Verquvo

Products Affected

- **VERQUVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of heart failure (NYHA Class II to IV) -AND- Left ventricular ejection fraction less than 45% -AND- Hospitalization for heart failure or received outpatient IV diuretics for heart failure -AND- Used in combination with a angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or Entresto -AND- Used in combination with bisoprolol, carvedilol IR/ER or metoprolol succinate ER.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Verzenio

Products Affected

- **VERZENIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy, if applicable to diagnosis.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Viberzi

Products Affected

- **VIBERZI**

PA Criteria	Criteria Details
Exclusion Criteria	Severe (Child-Pugh C) hepatic impairment
Required Medical Information	Documentation of diarrhea predominant, irritable bowel syndrome (IBS-D) -AND- trial/failure or intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vijoice

Products Affected

- **VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of severe manifestations of PIK3CA Related Overgrowth Spectrum (PROS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vimovo

Products Affected

- **VIMOVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen/famotidine. -AND- 2) Trial/failure of naproxen/esomeprazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vimovo2

Products Affected

- *naproxen-esomeprazole*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) Trial/failure of naproxen used in combination with omeprazole. -AND- 2) Trial/failure of one additional generic formulary NSAID (other than naproxen) used in combination with another generic formulary PPI (other than omeprazole).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vitrakvi

Products Affected

- **VITRAKVI ORAL CAPSULE 100 MG, 25 MG**
- **VITRAKVI ORAL SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation -AND- Tumors are metastatic or surgical resection is likely to result in severe morbidity -AND- There are no satisfactory alternative treatments or tumors have progressed following treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vivjoa

Products Affected

- **VIVJOA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of recurrent vulvovaginal candidiasis defined as at least 3 episodes of vulvovaginal candidiasis in less than one year -AND Documentation the member is NOT of reproductive potential defined as postmenopausal or another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vivlodex

Products Affected

- *meloxicam submicronized*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- trial and failure or intolerance to generic meloxicam tablets and one additional generic NSAID
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vizimpro

Products Affected

- **VIZIMPRO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer -AND- one of the following (1 or 2): 1. Epidermal growth factor (EGFR) exon 19 deletions - OR- 2. Epidermal growth factor receptor (EGFR) exon 21 L858R substitution mutations.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vonjo

Products Affected

- **VONJO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis -AND- attestation of a platelet count of less than 50 x 10*9/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Voriconazole

Products Affected

- **VFEND IV**
- *voriconazole intravenous*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation that the beneficiary cannot take oral voriconazole
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of continued indicators of active disease (e.g. histopathology, positive cultures) is required
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vosevi

Products Affected

- **VOSEVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Votrient

Products Affected

- **VOTRIENT**

PA Criteria	Criteria Details
Exclusion Criteria	Documentation of adipocytic soft tissue sarcoma or gastrointestinal stromal tumor
Required Medical Information	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Voxzogo

Products Affected

- **VOXZOGO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of achondroplasia as evidenced by an FGFR3 gene mutation detected by genetic testing -AND- all of the following (1-2): 1) baseline annualized growth velocity (AGV), 2) attestation that the member's epiphyses have not closed.
Age Restrictions	Deny if less than 5 years of age or greater than 17 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of increase in annualized growth velocity (AGV) from baseline and attestation that the member's epiphyses have not closed are required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vraylar

Products Affected

- **VRAYLAR ORAL CAPSULE**
- **VRAYLAR ORAL CAPSULE,DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For a diagnosis of schizophrenia and bipolar I disorder: Documentation of diagnosis -AND- trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine). For major depressive disorder (MDD): Documentation of diagnosis -AND- being used as an adjunct to an antidepressant for the treatment of MDD -AND- trial, intolerance or contraindication to one other antidepressant in addition to the antidepressant currently being used for the treatment of MDD.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vtama

Products Affected

- **VTAMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3). 1) Documentation of plaque psoriasis -AND- 2) trial and failure or intolerance to at least one generic, formulary medium, high, or ultrahigh potency topical corticosteroid (e.g. fluocinonide, triamcinolone, betamethasone) -OR- psoriasis on facial or intertriginous areas -AND- 3) trial and failure, contraindication, or intolerance to one generic, formulary vitamin D analog (e.g., calcipotriene, calcitriol)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vuity

Products Affected

- **VUITY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	Deny if less than 18 years of age.
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Vumerity

Products Affected

- **VUMERITY**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Wakix

Products Affected

- **WAKIX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	If no diagnosis of cataplexy, trial and failure, intolerance, or contraindication to generic modafinil and a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, provider attestation of improvement in symptoms of narcolepsy or improvement in symptoms of cataplexy (if applicable).
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No

Welireg

Products Affected

- **WELIREG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of von Hippel Lindau (VHL) syndrome -AND- one of the following diagnoses not requiring immediate surgery (1, 2, or 3): 1) Renal cell carcinoma. 2) CNS hemangioblastoma. 3) Pancreatic neuroendocrine tumor.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xalkori

Products Affected

- **XALKORI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) documentation of ALK or ROS1 mutation status
Age Restrictions	Deny if less than 18 years of age for NSCLC. Deny if less than 1 year of age or greater than 21 years of age for ALCL.
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xcopri

Products Affected

- **XCOPRI**
- **XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1)**
- **XCOPRI TITRATION PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of partial-onset seizures -AND- Therapeutic failure, intolerance or contraindication to 1 other anti-epileptic drug (e.g. carbamazepine, levetiracetam)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xdemvy

Products Affected

- **XDEMVY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis confirmed by identification of Demodex infection via microscopic examination of pulled eyelashes -OR- identification of collarettes via slit-lamp evaluation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xeljanz

Products Affected

- **XELJANZ ORAL TABLET**
- **XELJANZ XR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. Xeljanz immediate release for juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID).
Age Restrictions	Deny if less than 18 years of age for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis. For Xeljanz regular release tablet, deny if less than 2 years of age for juvenile idiopathic arthritis
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. Doses greater than 10 mg per day for Xeljanz and 11 mg per day for Xeljanz XR will not be approved for rheumatoid arthritis and psoriatic arthritis. Doses greater than 20mg per day for Xeljanz and 22 mg per day for Xeljanz XR will not be approved for ulcerative colitis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xeljanz Solution

Products Affected

- **XELJANZ ORAL SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of juvenile idiopathic arthritis -AND- Inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	The member has experienced therapeutic failure or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*
- **XENAZINE ORAL TABLET 12.5 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if requesting brand Xenazine, trial and failure or intolerance to generic tetrabenazine has been documented -AND- attestation that the beneficiary is not actively suicidal
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	In patients with comorbid depression, attestation of adequate treatment for depression is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xermelo

Products Affected

- **XERMELO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of carcinoid syndrome diarrhea AND used in combination with a somatostatin analog AND trial and failure of somatostatin analog monotherapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in average number of daily bowel movements -AND- the member will continue to use in combination with a somatostatin analog.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xgeva

Products Affected

- **XGEVA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For hypercalcemia of malignancy, refractory to bisphosphonates. For giant cell tumor of bone, unresectable or surgical resection is likely to result in severe morbidity -AND- one of the following (1. or 2.)- 1.) the member is 18 years old or older -OR- 2.) the member is a skeletally mature adolescent (e.g. has at least one mature long bone)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xifaxan

Products Affected

- **XIFAXAN ORAL TABLET 550 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of 1 or 2. 1) Diagnosis of hepatic encephalopathy AND trial/failure, intolerance, or contraindication to lactulose. 2) Diagnosis of Irritable Bowel Syndrome with Diarrhea (IBS-D) AND trial/failure, intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Hepatic encephalopathy: 1 year. IBS-D: 14 days.
Other Criteria	No more than three courses of rifaximin for the treatment of IBS-D will be approved per lifetime.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xolair

Products Affected

- **XOLAIR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of chronic idiopathic urticaria with trial/failure or intolerance of a second-generation non-sedating H1 antihistamine at the maximum recommended doses (e.g., cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine) -OR- Documentation of moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen -AND- Baseline IgE titer greater than or equal to 30 IU/mL -AND- symptoms that are inadequately controlled despite a 3 month trial of both 1. and 2. 1) medium-dose inhaled corticosteroid or systemic steroid 2) a long-acting beta-agonist or leukotriene antagonist -AND- patient is currently on a long-acting beta2-agonist, leukotriene modifier, or theophylline -OR- Documentation of add-on maintenance treatment for nasal polyps -AND- trial & failure, intolerance or contraindication to intra-nasal corticosteroids
Age Restrictions	Deny if less than 12 years of age in treatment for chronic idiopathic urticaria -OR- deny if less than 6 years of age for severe persistent asthma -OR- deny if less than 18 years of age for nasal polyps
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decreased rescue medication or oral corticosteroid use, decreased frequency of asthma exacerbations, increased pulmonary function from baseline (e.g. FEV1), or reduction in reported asthma related symptoms in treatment of asthma -OR- improved symptoms in treatment of CIU -OR- reduction in nasal polyp score or nasal congestion/obstruction severity score in treatment of nasal polyps.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Xospata

Products Affected

- **XOSPATA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- FLT3 mutations, if applicable to diagnosis
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xpovio

Products Affected

- **XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use in combination with dexamethasone for relapse or refractory multiple myeloma with failure, intolerance or contraindication to 5 therapies (e.g. bortezomib, carfilzomib, lenalidomide, pomalidomide and daratumumab) -OR- Documentation of use in combination with both bortezomib and dexamethasone for relapse or refractory multiple myeloma after receiving 1 prior multiple myeloma therapy -OR- Documentation of relapsing or refractory diffuse large B-cell lymphoma with failure, intolerance or contraindication to at least 2 lines of systemic therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xtandi

Products Affected

- **XTANDI ORAL CAPSULE**
- **XTANDI ORAL TABLET 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- one of the following (1. or 2.): 1. Concomitant GnRH analog 2. The member has had a bilateral orchiectomy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xuriden

Products Affected

- **XURIDEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hereditary orotic aciduria
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xyrem

Products Affected

- *sodium oxybate*
- **XYREM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.
Age Restrictions	Deny if less than 7 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	If no diagnosis of cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy and cataplexy (if applicable) is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Xywav

Products Affected

- **XYWAV**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP -AND- Sensitivity to sodium intake due to heart failure, hypertension or impaired renal function. If the member has a diagnosis of cataplexy, provision of baseline number of cataplexy episodes is required. -OR- (II) Diagnosis of idiopathic hypersomnia - AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- documentation the member does not have cataplexy -AND- documentation of less than 2 SOREMPs -AND- documentation of the following (1, 2, or 3): 1) MSLT documenting MSL less than or equal to 8 minutes -OR- 2) polysomnography demonstrating total sleep time greater than or equal to 660 minutes per 24 hours -OR- 3) wrist actigraphy demonstrating total sleep time greater than or equal to 660 minutes per 24 hours.
Age Restrictions	For narcolepsy, deny if less than 7 years of age. For idiopathic hypersomnia, deny if less than 18 years of age.
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	If diagnosis of narcolepsy without cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy, idiopathic hypersomnia and cataplexy (if applicable) is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Yonsa

Products Affected

- **YONSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) Alternatives tried/failed 2) Concomitant therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zavesca

Products Affected

- *miglustat*
- **ZAVESCA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of mild to moderate type 1 Gaucher disease confirmed by the following (A. or B.) A. (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm*3 -OR- 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B. Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Attestation enzyme replacement therapy (e.g. Cerezyme, Elelyso, or VPRIV) is not a therapeutic option. For brand Zavesca, documentation of failure on generic miglustat.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zavzpret

Products Affected

- **ZAVZPRET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute migraine headaches with or without aura -AND- Therapeutic failure, contraindication or intolerance to one generic triptan -AND- Inability to swallow capsules/tablets
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zejula

Products Affected

- **ZEJULA ORAL CAPSULE**
- **ZEJULA ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRCA status 2) Alternatives tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zelboraf

Products Affected

- **TAFINLAR ORAL CAPSULE**
- **TAFINLAR ORAL TABLET FOR SUSPENSION**
- **ZELBORAF**

PA Criteria	Criteria Details
Exclusion Criteria	Wild-type BRAF melanoma
Required Medical Information	Documentation of diagnosis -AND- both of the following. 1) BRAF mutations, if applicable to diagnosis. 2) Alternatives tried/failed and concomitant therapy, if applicable to diagnosis (e.g. diagnosis of V600K metastatic melanoma and drug regimen of Zelboraf and Cotellic)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Tafinlar tablets for oral suspension, attestation of inability to swallow Tafinlar capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zepatier

Products Affected

- **ZEPATIER**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zeposia

Products Affected

- **ZEPOSIA**
- **ZEPOSIA STARTER KIT (28-DAY)**
- **ZEPOSIA STARTER PACK (7-DAY)**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Zeposia and other disease modifying agents such as interferons, Copaxone, Tysabri.
Required Medical Information	Documentation of diagnosis. For moderate to severe active ulcerative colitis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Ulcerative Colitis: 12 months, Multiple Sclerosis: 24 months
Other Criteria	For moderate to severe active ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Xeljanz/Xeljanz XR and Stelara SC.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zokinvy

Products Affected

- **ZOKINVY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Hutchinson-Gilford Progeria Syndrome with mutation of the LMNA gene and BSA of 0.39 square meters or above -OR- Documentation of processing-deficient Progeroid Laminopathies with BSA of 0.39 square meters or above -AND- one of the following (1 or 2): 1) Heterozygous LMNA mutation and progerin-like protein accumulation 2.) Homozygous ZMPSTE24 mutations or compound heterozygous ZMPSTE23 mutations
Age Restrictions	Deny if less than 12 months of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zolinza

Products Affected

- **ZOLINZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following 2 systemic therapies. Systemic therapies include bexarotene, interferon alpha, extracorporeal photochemotherapy, PUVA, single agent or combination chemotherapies (e.g. cyclophosphamide, vinblastine, romidepsin)
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zolpidem Capsule

Products Affected

- *zolpidem*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of insomnia characterized by difficulties with sleep onset - AND- therapeutic failure or intolerance to 2 of the following (1-3): 1) eszopiclone, 2) zaleplon, 3) generic zolpidem tablets/zolpidem ER tablets. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
Age Restrictions	Deny if greater than 64 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zonisade

Products Affected

- **ZONISADE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of partial-onset seizures -AND- Documentation of adjunctive therapy -AND- Inability to swallow capsules -AND- Therapeutic failure/intolerance to 2 or contraindication to all of the following (1-3): 1) generic carbamazepine suspension/chewable tablet/extended-release capsule, 2) generic lacosamide solution, 3) generic oxcarbazepine suspension.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zoryve

Products Affected

- **ZORYVE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3). 1) Documentation of plaque psoriasis -AND- 2) trial and failure or intolerance to at least one generic, formulary medium, high, or ultrahigh potency topical corticosteroid (e.g. fluocinonide, triamcinolone, betamethasone) -OR- psoriasis on facial or intertriginous areas -AND- 3) trial and failure, contraindication, or intolerance to one generic, formulary vitamin D analog (e.g., calcipotriene, calcitriol)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Ztalmy

Products Affected

- **ZTALMY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures associated with CDKL5 deficiency confirmed by genetic testing -AND- therapeutic failure or intolerance to 2 previous antiepileptic therapies
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

ZTLido

Products Affected

- **ZTLIDO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of postherpetic neuralgia (PHN) -AND- One of the following (1,2 or 3): 1) trial and failure of 1 other agent used to treat PHN (e.g. gabapentin) 2) Inability to swallow oral medication 3) Unable to take an oral medication due to potential adverse events (e.g. sedation)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Patients must have therapeutic failure or contraindication to Lidoderm or lidocaine patch 5%.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zydelig

Products Affected

- **ZYDELIG**

PA Criteria	Criteria Details
Exclusion Criteria	First line treatment. Combination use with benadmustine and/or rituximab for the treatment of FL.
Required Medical Information	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Alternatives tried/failed 2) Concomitant therapy 3) Candidacy for use of rituximab alone
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zykadia

Products Affected

- **ZYKADIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- ALK mutations, as detected by an FDA approved test.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Zytiga

Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- **ZYTIGA ORAL TABLET 250 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- concomitant therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Zytiga, trial and failure of generic abiraterone is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Index of Drugs

ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET WITH SENSOR AND STRIP 15 MG, 2 MG, 20 MG, 30 MG, 5 MG 27
ABILIFY MYCITE STARTER KIT ORAL TABLET WITH SENSOR, STRIP, POD 10 MG 27
ABILIFY ORAL TABLET 27
abiraterone oral tablet 250 mg, 500 mg 474
acetaminophen-caff-dihydrocod oral capsule 296
acetaminophen-codeine oral solution 120-12 mg/5 ml 296
acetaminophen-codeine oral tablet 296
acitretin 1
ACTEMRA ACTPEN 2
ACTEMRA SUBCUTANEOUS 2
ACTHAR 3
ACTIMMUNE 5
adalimumab-fkjp 6
adapalene topical cream 400
adapalene topical gel 0.3 % 400
adapalene topical swab 400
adapalene-benzoyl peroxide 400
ADBRY 8
ADCIRCA 306
ADEMPAS 306
ADLARITY 10
AFINITOR 11
AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG 11
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML 12
AIRDUO DIGIHALER 13
AJOVY AUTOINJECTOR 14
AJOVY SYRINGE 14
AKLIEF 400
ALECENSA 15
ALKINDI SPRINKLE 16
alosetron oral tablet 0.5 mg, 1 mg 214
ALPRAZOLAM INTENSOL 296
alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg 296
alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg 296
alprazolam oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg 296
ALTRENO 400
ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG 18
ALUNBRIG ORAL TABLETS,DOSE PACK 18
ALYQ 306
AMBIEN 296
AMBIEN CR 296
ambrisentan 306
amitriptyline 154
amitriptyline-chlordiazepoxide 154
AMJEVITA(CF) AUTOINJECTOR 159
AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML 159
amphetamine sulfate 114
AMPYRA 20
ANAFRANIL 154
ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP 388
APOKYN 22
apomorphine 22
ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG 17
ARAZLO 382
ARCALYST 178
ARIKAYCE 23
aripiprazole 27
armodafinil 255
ARMONAIR DIGIHALER 24
ASCOMP WITH CODEINE 296
ASPRUZYO SPRINKLE 25
ATORVALIQ 355
ATRALIN 400
AUBAGIO 28
AURYXIA 29
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG 30
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 24 MG, 6 MG 30

AUSTEDO XR TITRATION KT(WK1-4) 30
AUVELITY 31
AVEED 388
AYVAKIT 32
baclofen oral suspension 128
BAFIERTAM 33
BALVERSA 34
BANZEL 35
BELBUCA 36
BENLYSTA SUBCUTANEOUS 38
benznidazole 40
benztropine oral 154
BERINERT INTRAVENOUS KIT 41
BESREMI 43
BETHKIS 64
bexarotene oral 375
bexarotene topical 375
BIVIGAM 166
BONJESTA 44
bosentan 306
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG 45
BRAFTOVI ORAL CAPSULE 75 MG 46
BRONCHITOL 47
BRUKINSA 48
BUPHENYL 49
buprenorphine 50
butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg 296
BUTRANS 50
BYDUREON BCISE 140
BYETTA 140
BYLVAY ORAL CAPSULE 1,200 MCG, 400 MCG 52
BYLVAY ORAL PELLET 200 MCG, 600 MCG 52
CABLIVI INJECTION KIT 53
CABOMETYX 54
CALQUENCE 55
CALQUENCE (ACALABRUTINIB MAL) 55
CAMZYOS 56
CAPLYTA 57
CAPRELSA ORAL TABLET 100 MG, 300 MG 58
CARAC 59
CARBAGLU 60
carbinoxamine maleate oral liquid 61
carbinoxamine maleate oral tablet 4 mg 61
carglumic acid 60
carisoprodol 154
CAYSTON 62
CERDELGA 63
CHENODAL 65
chlorzoxazone 154
CHOLBAM 66
CIALIS ORAL TABLET 2.5 MG, 5 MG 67
CIBINQO 68
CIMZIA 69
CIMZIA POWDER FOR RECONST 69
CINRYZE 71
citalopram oral capsule 73
clemastine oral syrup 74
clindamycin-tretinoin 400
clobazam oral suspension 263
clobazam oral tablet 263
clomipramine 154
clonidine hcl oral tablet extended release 12 hr 9
codeine sulfate 296
codeine-butalbital-asa-caff 296
COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY) 75
CONZIP 296
COPIKTRA 76
CORLANOR ORAL SOLUTION 77
CORLANOR ORAL TABLET 5 MG, 7.5 MG 77
CORTROPHIN GEL 309
COSENTYX (2 SYRINGES) 78
COSENTYX PEN (2 PENS) 78
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML 78
COSENTYX UNOREADY PEN 78
COTELLIC 79
CRINONE 80
CUVRIOR 81
CYLTEZO(CF) 159
CYLTEZO(CF) PEN 159

CYLTEZO(CF) PEN CROHN'S-UC-HS 159
CYLTEZO(CF) PEN PSORIASIS-UV .. 159
cyproheptadine 154
CYSTADROPS 82
CYSTARAN 82
dalfampridine 20
DARTISLA 84
DAURISMO ORAL TABLET 100 MG, 25 MG 85
DAYBUE 86
DAYTRANA 87
deferasirox 88
deferiprone 120
DEMEROL (PF) INJECTION SYRINGE 25 MG/ML 296
DEMEROL INJECTION SOLUTION 50 MG/ML 296
DEPO-TESTOSTERONE 388
DIACOMIT ORAL CAPSULE 250 MG, 500 MG 89
DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG 89
DIBENZYLINE 288
DICLEGIS 44
diclofenac epolamine 127
diclofenac sodium topical gel 3 % 350
DIFFERIN TOPICAL CREAM 400
DIFFERIN TOPICAL GEL WITH PUMP 400
DIFFERIN TOPICAL LOTION 400
dihydroergotamine nasal 90
DILAUDID ORAL LIQUID 296
DILAUDID ORAL TABLET 296
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg 385
DOJOLVI 91
DOPTELET (10 TAB PACK) 92
DOPTELET (15 TAB PACK) 92
DOPTELET (30 TAB PACK) 92
doxepin oral capsule 154
doxepin oral concentrate 154
doxepin oral tablet 154
doxepin topical 93
doxylamine-pyridoxine (vit b6) 44
droxidopa oral capsule 100 mg, 200 mg, 300 mg 247
DUEXIS 94
DUOBRII 96
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML 97
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML 97
EDLUAR 296
EGRIFTA SV 100
EMFLAZA 101
EMGALITY PEN 102
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3) 102
ENBREL MINI 104
ENBREL SUBCUTANEOUS SOLUTION 104
ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) 104
ENBREL SURECLICK 104
ENDARI 105
ENDOCET 296
ENSPRYNG 106
ENTADFI 107
EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG, 200-50 MG 108
EPCLUSA ORAL TABLET 108
EPIDIOLEX 109
EPIDUO FORTE 400
EPIDUO TOPICAL GEL WITH PUMP 400
EPRONTIA 110
ergoloid 154
ergotamine-caffeine 154
ERIVEDGE 111
ERLEADA ORAL TABLET 240 MG, 60 MG 112
erlotinib 99
ESBRIET ORAL CAPSULE 180
ESBRIET ORAL TABLET 267 MG, 801 MG 180

eszopiclone.....296
EUCRISA.....113
EVEKEO.....114
EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2).....115
everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg.....11
everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg.....11
EVRYSDI.....116
EXJADE.....88
EXKIVITY.....99
EXSERVAN.....117
FABIOR.....382
FASENRA.....118
FASENRA PEN.....118
febuxostat.....408
fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg.....398
fentanyl citrate buccal tablet, effervescent 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg.....398
fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour.....296
FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG.....398
FERRIPROX (2 TIMES A DAY).....120
FERRIPROX ORAL SOLUTION.....120
FERRIPROX ORAL TABLET 500 MG120
FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK.....121
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG.....121
FILSPARI.....122
fingolimod.....136
FINTEPLA.....123
FIORICET WITH CODEINE.....296
FIRAZYR.....124
FIRDAPSE.....126
FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %.....166
FLECTOR.....127
FLEQSUVY.....128
FORTEO.....129
FORTESTA.....388
FOTIVDA.....130
FUROSCIX.....131
gabapentin oral capsule 100 mg, 300 mg, 400 mg.....132
gabapentin oral solution 250 mg/5 ml.....132
gabapentin oral tablet 600 mg, 800 mg.....132
GALAFOLD.....133
GAMMAGARD LIQUID.....166
GAMMAGARD S-D (IGA < 1 MCG/ML).....166
GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %).....166
GAMMAPLEX.....166
GAMMAPLEX (WITH SORBITOL).....166
GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %).....166
GATTEX 30-VIAL.....134
GAVRETO.....135
gefitinib.....182
GENOTROPIN.....145
GENOTROPIN MINIQUICK.....145
GILENYA.....136
GILOTRIF.....99
GIMOTI.....137
GLASSIA.....17
GLEEVEC ORAL TABLET 100 MG, 400 MG.....138
GLEOSTINE.....139
GLYCATE.....141
glycopyrrolate oral tablet 1.5 mg.....141
GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG, 68.5 MG.....142
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG, 450 MG, 600 MG, 750 MG, 900 MG.....143
GRASTEK.....144
guanfacine oral tablet extended release 24 hr.....9
HADLIMA.....6

HADLIMA PUSHTOUCH 6
HADLIMA(CF) 6
HADLIMA(CF) PUSHTOUCH 6
HAEGARDA 147
HALCION ORAL TABLET 0.25 MG ... 296
HARVONI ORAL PELLETS IN PACKET 149
HARVONI ORAL TABLET 90-400 MG 149
HEMADY 150
HETLIOZ 151
HETLIOZ LQ 153
HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG, 600 MG 158
HULIO(CF) 6
HULIO(CF) PEN 6
HUMATROPE INJECTION CARTRIDGE 145
HUMIRA PEN 159
HUMIRA PEN CROHNS-UC-HS START 159
HUMIRA PEN PSOR-UVEITS-ADOL HS 159
HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML 159
HUMIRA(CF) 159
HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML 159
HUMIRA(CF) PEN 159
HUMIRA(CF) PEN CROHNS-UC-HS .. 159
HUMIRA(CF) PEN PEDIATRIC UC 159
HUMIRA(CF) PEN PSOR-UV-ADOL HS 159
hydrocodone bitartrate oral capsule, oral only, er 12hr 296
hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr 296
hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml 296
hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg 296
hydrocodone-ibuprofen 296
hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml 296
hydromorphone oral liquid 296
hydromorphone oral tablet 296
hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 32 mg, 8 mg ... 296
hydroxyzine hcl oral solution 10 mg/5 ml .. 154
hydroxyzine hcl oral tablet 154
hydroxyzine pamoate 154
HYFTOR 161
HYRIMOZ PEN CROHN'S-UC STARTER 159
HYRIMOZ PEN PSORIASIS STARTER 159
HYRIMOZ(CF) PEDI CROHN STARTER 159
HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML 159
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML 159
HYSINGLA ER 296
IBRANCE 162
IBSRELA 163
ibuprofen-famotidine 95
icatibant 124
ICLUSIG 164
IDHIFA ORAL TABLET 100 MG, 50 MG 165
ILUMYA 168
imatinib oral tablet 100 mg, 400 mg 138
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG 169
IMBRUVICA ORAL SUSPENSION 169
IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG 169
imipramine hcl 154
imipramine pamoate 154
INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE 170
INCRELEX 171
INGREZZA INITIATION PACK 173
INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG 173
INLYTA 174

INQOVI 175
INREBIC 176
INTRAROSA 179
INTUNIV ER 9
IRESSA 182
ISTURISA ORAL TABLET 1 MG, 10 MG, 5 MG 183
itraconazole 184
ivermectin oral 185
JADENU 88
JADENU SPRINKLE 88
JAKAFI 186
JATENZO ORAL CAPSULE 158 MG, 198 MG, 237 MG 388
JAVYGTOR 200
JAYPIRCA ORAL TABLET 100 MG, 50 MG 187
JUXTAPID 157
JYNARQUE ORAL TABLET 188
JYNARQUE ORAL TABLETS, SEQUENTIAL 188
KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 50 MG, 75 MG 189
KALYDECO ORAL TABLET 189
KAPVAY 9
KATERZIA 19
KERENDIA 190
KESIMPTA PEN 191
KEVEYIS 192
KEVZARA 193
KINERET 194
KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG 195
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3) 195
KITABIS PAK 64
KLISYRI 196
KORLYM 197
KOSELUGO ORAL CAPSULE 10 MG, 25 MG 198
KRAZATI 199
KUVAN 200
LAMPIT 201
lapatinib 404
LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG 202
ledipasvir-sofosbuvir 149
lenalidomide 327
LENVIMA 203
LETAIRIS 306
LEUKINE INJECTION RECON SOLN 204
levorphanol tartrate 296
LICART 127
lidocaine hcl mucous membrane solution 4 % (40 mg/ml) 397
lidocaine topical adhesive patch,medicated 5 % 206
lidocaine topical ointment 397
lidocaine-prilocaine topical cream 397
LIDODERM 206
LIQREV 306
LITFULO 207
LIVMARLI 208
LIVTENCITY 209
LODOCO 210
LOKELMA 211
LONSURF 212
LORBRENA ORAL TABLET 100 MG, 25 MG 213
LORZONE 154
LOTRONEX ORAL TABLET 0.5 MG, 1 MG 214
LOVAZA 215
LUMAKRAS ORAL TABLET 120 MG, 320 MG 216
LUMRYZ 217
LUNESTA 296
LUPKYNIS 218
LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG 219

LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED) 219
LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT.....219
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg.....202
LYBALVI.....220
LYNPARZA.....221
LYRICA CR.....222
LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG.....222
LYRICA ORAL SOLUTION.....222
LYTGOBI ORAL TABLET 4 MG, 4 MG (4X 4 MG TB), 4 MG (5X 4 MG TB)..... 223
LYVISPAH..... 224
MAVENCLAD (10 TABLET PACK).....225
MAVENCLAD (4 TABLET PACK).....225
MAVENCLAD (5 TABLET PACK).....225
MAVENCLAD (6 TABLET PACK).....225
MAVENCLAD (7 TABLET PACK).....225
MAVENCLAD (8 TABLET PACK).....225
MAVENCLAD (9 TABLET PACK).....225
MAVYRET ORAL PELLETS IN PACKET..... 226
MAVYRET ORAL TABLET.....226
MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG..... 227
MAYZENT STARTER(FOR 1MG MAINT).....227
MAYZENT STARTER(FOR 2MG MAINT).....227
megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml).....228
megestrol oral tablet.....228
MEKINIST ORAL RECON SOLN.....229
MEKINIST ORAL TABLET 0.5 MG, 2 MG..... 229
MEKTOVI..... 230
meloxicam submicronized.....426
meperidine (pf) injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml.....296
meperidine oral solution.....296
meperidine oral tablet 50 mg.....296
metaxalone.....154
methadone oral solution 10 mg/5 ml, 5 mg/5 ml.....296
methadone oral tablet 10 mg, 5 mg.....296
methamphetamine.....231
METHITEST..... 21
methyltestosterone oral capsule..... 21
miglustat..... 459
MIGRANAL.....90
modafinil.....304
morphine concentrate oral solution..... 296
morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg..... 296
morphine oral capsule,extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg.....296
morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml).....296
morphine oral tablet.....296
morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg.....296
MOTEGRITY.....232
MOUNJARO.....140
MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 15 MG, 200 MG, 30 MG, 60 MG.....296
MULPLETA..... 233
MYALEPT..... 234
MYCAPSSA.....235
MYFEMBREE.....236
NALOCET..... 296
NAMENDA ORAL TABLET..... 238
NAMENDA TITRATION PAK.....238
NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR 14 MG, 21 MG, 28 MG.....238
NAMZARIC.....239
naproxen-esomeprazole.....423
NATESTO..... 388
NATPARA.....240
NAYZILAM.....241
NERLYNX..... 242
NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG.....132
NEURONTIN ORAL SOLUTION..... 132

NEURONTIN ORAL TABLET 600 MG, 800 MG 132
NEXAVAR 243
NEXLETOL 244
NEXLIZET 244
NGENLA 145
NINLARO 246
NORDITROPIN FLEXPRO 145
NORGESIC 154
NORGESIC FORTE 154
NORLIQVA 19
NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG 247
NOURIANZ 248
NUBEQA 249
NUCALA SUBCUTANEOUS AUTO-INJECTOR 250
NUCALA SUBCUTANEOUS RECON SOLN 250
NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML 250
NUCYNTA 296
NUCYNTA ER 296
NUEDEXTA 252
NUPLAZID 253
NURTEC ODT 254
NUTROPIN AQ NUSPIN 145
NUVIGIL 255
OCALIVA 257
OCTAGAM 166
octreotide acetate injection solution 258
ODACTRA 259
ODOMZO 260
OFEV 180
OLPRUVA ORAL PELLETS IN PACKET 2 GRAM, 3 GRAM, 4 GRAM, 5 GRAM, 6 GRAM, 6.67 GRAM 261
OLUMIANT 262
OMNITROPE 145
ONFI ORAL SUSPENSION 263
ONFI ORAL TABLET 263
ONGENTYS 264
ONUREG 265
OPSUMIT 306
OPZELURA 266
ORALAIR SUBLINGUAL TABLET 300 INDX REACTIVITY 267
ORENCIA CLICKJECT 268
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML 268
ORENITRAM MONTH 1 TITRATION KT 306
ORENITRAM MONTH 2 TITRATION KT 306
ORENITRAM MONTH 3 TITRATION KT 306
ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG 306
ORGOVYX 269
ORIAHNN 270
ORILISSA ORAL TABLET 150 MG, 200 MG 271
ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG 273
ORKAMBI ORAL TABLET 272
ORLADEYO 274
orphenadrine citrate oral 154
orphenadrine-asa-caffeine oral tablet 25-385-30 mg 154
ORSERDU ORAL TABLET 345 MG, 86 MG 276
OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 193 MG 277
OSPHENA 278
OTEZLA 279
OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47) 279
OTREXUP (PF) 280
OXBRYTA ORAL TABLET 300 MG, 500 MG 281
OXBRYTA ORAL TABLET FOR SUSPENSION 282
OXERVATE 283
oxycodone oral capsule 296
oxycodone oral concentrate 296
oxycodone oral solution 296
oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg 296

oxycodone oral tablet,oral only,ext.rel.12 hr 10 mg, 20 mg 296
oxycodone-acetaminophen oral solution 5-325 mg/5 ml 296
oxycodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg 296
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG 296
oxymorphone oral tablet 296
oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg 296
OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) 140
PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML 284
PANRETIN 285
PANZYGA 166
PEGASYS 177
PEMAZYRE 286
PERCOCET 296
perphenazine-amitriptyline 154
PHEBURANE 287
phenobarbital 156
phenoxybenzamine 288
PHOSPHOLINE IODIDE 289
PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) 290
pirfenidone oral capsule 180
pirfenidone oral tablet 267 mg, 534 mg, 801 mg 180
PLIAGLIS 397
POMALYST 291
PONVORY 292
PONVORY 14-DAY STARTER PACK 292
PRALUENT PEN 293
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg 222
pregabalin oral solution 222
pregabalin oral tablet extended release 24 hr 222
PRENATAL VITAMIN PLUS LOW IRON 295
pretomanid 300
PRIVIGEN 166
PROAIR DIGIHALER 301
PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET 302
PROLASTIN-C INTRAVENOUS RECON SOLN 17
PROLATE ORAL SOLUTION 296
PROLATE ORAL TABLET 296
PROLIA 303
PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG 392
PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG 392
promethazine oral 154
PROVIGIL 304
PRUDOXIN 93
PULMOZYME 308
pyrimethamine 83
PYRUKYND ORAL TABLET 20 MG, 5 MG, 5 MG (4-WEEK PACK), 50 MG 311
PYRUKYND ORAL TABLETS,DOSE PACK 311
QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG 312
QINLOCK 313
QUALAQUIN 314
quinine sulfate 314
QULIPTA 315
RADICAVA ORS STARTER KIT SUSP 316
RASUVO (PF) 317
RAVICTI 318
RECORLEV 319
REGRANEX 320
RELISTOR ORAL 321
RELISTOR SUBCUTANEOUS SOLUTION 322

RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML 322
RELYVRIO 323
REPATHA PUSHTRONEX 324
REPATHA SURECLICK 324
REPATHA SYRINGE 324
RETEVMO ORAL CAPSULE 40 MG, 80 MG 326
RETIN-A 400
RETIN-A MICRO 400
RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 % 400
REVATIO ORAL SUSPENSION FOR RECONSTITUTION 306
REVATIO ORAL TABLET 306
REVLIMID 327
REXULTI ORAL TABLET 27
REZLIDHIA 328
REZUROCK 329
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG 330
ROXICODONE ORAL TABLET 15 MG, 30 MG 296
ROXYBOND 296
ROZLYTREK ORAL CAPSULE 100 MG, 200 MG 332
RUBRACA 333
RUCONEST 334
rufinamide 35
RYBELSUS 140
RYDAPT 336
RYVENT 61
SABRIL 337
SAIZEN 145
SAJAZIR 124
SAMSCA 338
SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML 258
sapropterin 200
SAVELLA 339
SCEMBLIX ORAL TABLET 20 MG, 40 MG 340
SEGLENTIS 296
SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG 145
sertraline oral capsule 341
SIGNIFOR 342
sildenafil (pulm.hypertension) oral suspension for reconstitution 306
sildenafil (pulm.hypertension) oral tablet 306
SILENOR 154
SILIQ 343
SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML 344
SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML 344
SKYCLARYS 346
SKYRIZI SUBCUTANEOUS PEN INJECTOR 347
SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML 347
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) 347
SKYTROFA 348
sodium oxybate 455
sodium phenylbutyrate 49
sofosbuvir-velpatasvir 108
SOGROYA 349
SOMA 154
SOMAVERT 351
sorafenib 243
SOTYKTU 352
SOVALDI 353
SPORANOX 184
SPRYCEL 354
STELARA SUBCUTANEOUS SOLUTION 356
STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML 356
STIVARGA 358
STROMECTOL 185
sunitinib malate 361
SUNOSI 359
SUTENT 361
SYMDEKO 362
SYMPAZAN 363

SYMPROIC 364
SYNAREL 365
SYNDROS 366
TABRECTA 367
tadalafil (pulm. hypertension) 306
tadalafil oral tablet 2.5 mg, 5 mg 67
TADLIQ 368
TAFINLAR ORAL CAPSULE 462
TAFINLAR ORAL TABLET FOR SUSPENSION 462
TAGRISSO 369
TAKHZYRO SUBCUTANEOUS SOLUTION 370
TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML (150 MG/ML) 370
TALTZ AUTOINJECTOR 372
TALTZ SYRINGE 372
TALZENNA 374
TARGRETIN ORAL 375
TARGRETIN TOPICAL 375
TARPEYO 376
TASCENSO ODT 377
TASIGNA 378
tasimelteon 379
TAVALISSE 380
TAVNEOS 381
tazarotene topical cream 383
tazarotene topical foam 382
tazarotene topical gel 383
TAZORAC TOPICAL CREAM 383
TAZORAC TOPICAL GEL 383
TAZVERIK 384
TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG, 120 MG (14)- 240 MG (46), 240 MG 385
TEGSEDI 386
TEPMETKO 387
teriflunomide 28
teriparatide 129
TESTIM 388
testosterone cypionate 388
testosterone enanthate 388
testosterone transdermal gel in metered-dose pump 388
testosterone transdermal gel in packet 388
testosterone transdermal solution in metered pump w/app 388
tetrabenazine oral tablet 12.5 mg, 25 mg 445
THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG 390
THIOLA 391
THIOLA EC 391
TIBSOVO 393
TIGLUTIK 395
tiopronin 391
TLANDO 388
TOBI 64
TOBI PODHALER 64
tobramycin in 0.225 % nacl 64
tobramycin inhalation 64
TOLSURA 396
tolvaptan 338
TRACLEER ORAL TABLET 306
TRACLEER ORAL TABLET FOR SUSPENSION 306
tramadol oral capsule,er biphase 24 hr 17-83 296
tramadol oral capsule,er biphase 24 hr 25-75 100 mg, 200 mg 296
tramadol oral solution 296
tramadol oral tablet 100 mg, 50 mg 296
tramadol oral tablet extended release 24 hr 296
tramadol oral tablet, er multiphase 24 hr 296
tramadol-acetaminophen 296
TREMFYA 399
tretinoin 400
tretinoin microspheres topical gel 400
tretinoin microspheres topical gel with pump 0.08 % 400
TREZIX 296
triazolam 296
TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 401
TRIKAFTA ORAL TABLETS, SEQUENTIAL 401
trimethobenzamide oral 394
trimipramine 154
TRUDHESA 90
TRULICITY 140

TUKYSA ORAL TABLET 150 MG, 50 MG ... 402
TURALIO ORAL CAPSULE 125 MG .. 403
TWYNEO ... 400
TYKERB ... 404
TYMLOS ... 405
TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 16 MCG (112)- 32 MCG (84), 16(112)-32(112) -48(28) MCG, 32 MCG, 32-48 MCG, 48 MCG, 64 MCG ... 406
UBRELVY ORAL TABLET 100 MG, 50 MG ... 407
ULORIC ... 408
UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG ... 306
UPTRAVI ORAL TABLETS,DOSE PACK ... 306
VALCHLOR ... 409
VALTOCO ... 410
VANCOCIN ORAL CAPSULE 125 MG, 250 MG ... 411
vancomycin oral capsule 125 mg, 250 mg . 411
VANFLYTA ... 412
VELTASSA ... 413
VELTIN ... 400
VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG ... 415
VENCLEXTA STARTING PACK ... 415
venlafaxine besylate ... 414
VENTAVIS ... 306
VEOZAH ... 416
VERKAZIA ... 417
VERQUVO ... 418
VERZENIO ... 419
VFEND IV ... 429
VIBERZI ... 420
VICTOZA 3-PAK ... 140
vigabatrin ... 337
VIGADRONE ... 337
VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50 MG ... 421
VIMOVO ... 422
VISTARIL ... 154
VITRAKVI ORAL CAPSULE 100 MG, 25 MG ... 424
VITRAKVI ORAL SOLUTION ... 424
VIVJOA ... 425
VIZIMPRO ... 427
VOGELXO TRANSDERMAL GEL ... 388
VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP ... 388
VONJO ... 428
voriconazole intravenous ... 429
VOSEVI ... 430
VOTRIENT ... 431
VOWST ... 119
VOXZOGO ... 432
VRAYLAR ORAL CAPSULE ... 433
VRAYLAR ORAL CAPSULE,DOSE PACK ... 433
VTAMA ... 434
VUITY ... 435
VUMERITY ... 436
VYNDAMAX ... 26
VYNDAQEL ... 26
WAKIX ... 437
WELIREG ... 439
WINLEVI ... 400
XALKORI ... 440
XANAX ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG ... 296
XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG, 2 MG, 3 MG ... 296
XCOPRI ... 441
XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) ... 441
XCOPRI TITRATION PACK ... 441
XDEMVY ... 442
XELJANZ ORAL SOLUTION ... 444
XELJANZ ORAL TABLET ... 443
XELJANZ XR ... 443
XENAZINE ORAL TABLET 12.5 MG, 25 MG ... 445
XERMELO ... 446
XGEVA ... 447

XIFAXAN ORAL TABLET 550 MG 448
XOLAIR 449
XOSPATA 451
XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK) 452
XTAMPZA ER 296
XTANDI ORAL CAPSULE 453
XTANDI ORAL TABLET 40 MG, 80 MG 453
XURIDEN 454
XYOSTED 388
XYREM 455
XYWAV 456
YONSA 458
YUFLYMA(CF) 6
YUFLYMA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML 6
YUSIMRY(CF) PEN 6
zaleplon oral capsule 10 mg, 5 mg 296
ZAVESCA 459
ZAVZPRET 460
ZEJULA ORAL CAPSULE 461
ZEJULA ORAL TABLET 461
ZELBORAF 462
ZEMAIRA 17
ZEPATIER 463
ZEPOSIA 464
ZEPOSIA STARTER KIT (28-DAY) 464
ZEPOSIA STARTER PACK (7-DAY) 464
ZIANA 400
zileuton 205
ZOKINVY 465
ZOLINZA 466
zolpidem 296, 467
ZOMACTON 145
ZONALON 93
ZONISADE 468
ZORBTIVE 145
ZORYVE 469
ZTALMY 470
ZTLIDO 471
ZYDELIG 472
ZYFLO 205
ZYKADIA 473
ZYTIGA ORAL TABLET 250 MG, 500 MG 474

Advair HFA AG

Products Affected

- *fluticasone propionate 115 mcg-salmeterol 21 mcg/actuation hfa inhaler*
- *fluticasone propionate 230 mcg-salmeterol 21 mcg/actuation hfa inhaler*
- *fluticasone propionate 45 mcg-salmeterol 21 mcg/actuation hfa inhaler*

Details

Criteria	Require a 1 month trial of Advair HFA (Step 1 drug) in the last 90 days

Brand ADHD

Products Affected

- **ADDERALL 20 MG TABLET**
- **ADDERALL 5 MG TABLET**
- **ADDERALL 7.5 MG TABLET**
- **ADDERALL XR 10 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 15 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 20 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 25 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 30 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 5 MG CAPSULE,EXTENDED RELEASE**
- **ADZENYS XR-ODT 12.5 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 15.7 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 18.8 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 3.1 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 6.3 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 9.4 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **APTENSIO XR 10 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 15 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 20 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 30 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 40 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 50 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 60 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **AZSTARYS 26.1 MG-5.2 MG CAPSULE**
- **AZSTARYS 39.2 MG-7.8 MG CAPSULE**
- **AZSTARYS 52.3 MG-10.4 MG CAPSULE**
- **CONCERTA 18 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 27 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 36 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 54 MG TABLET,EXTENDED RELEASE**
- **COTEMPLA XR-ODT 17.3 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **COTEMPLA XR-ODT 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE**
- **DEXEDRINE SPANSULE 15 MG CAPSULE,EXTENDED RELEASE**
- **DYANAVEL XR 10 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 15 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION**
- **DYANAVEL XR 20 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 5 MG TABLET,**

EXTENDED RELEASE

- **EVEKEO ODT 10 MG DISINTEGRATING TABLET**
- **EVEKEO ODT 15 MG DISINTEGRATING TABLET**
- **EVEKEO ODT 20 MG DISINTEGRATING TABLET**
- **EVEKEO ODT 5 MG DISINTEGRATING TABLET**
- **FOCALIN 10 MG TABLET**
- **FOCALIN 2.5 MG TABLET**
- **FOCALIN 5 MG TABLET**
- **FOCALIN XR 10 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 15 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 20 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 25 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 30 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 35 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 40 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 5 MG CAPSULE,EXTENDED RELEASE**
- **JORNAY PM 100 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 20 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 40 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 60 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 80 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- *lisdexamfetamine 10 mg capsule*
- *lisdexamfetamine 20 mg capsule*
- *lisdexamfetamine 30 mg capsule*
- *lisdexamfetamine 40 mg capsule*
- *lisdexamfetamine 50 mg capsule*
- *lisdexamfetamine 60 mg capsule*
- *lisdexamfetamine 70 mg capsule*
- **METHYLIN 10 MG/5 ML ORAL SOLUTION**
- **METHYLIN 5 MG/5 ML ORAL SOLUTION**
- *methylphenidate er 45 mg tablet,extended release 24 hr*
- *methylphenidate er 63 mg tablet,extended release 24 hr*
- *methylphenidate er 72 mg tablet,extended release 24 hr*
- **MYDAYIS 12.5 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 25 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 37.5 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 50 MG CAPSULE EXTENDED RELEASE 24 HR**
- **QUILLICHEW ER 20 MG CHEWABLE TABLET, EXTENDED RELEASE**
- **QUILLICHEW ER 30 MG CHEWABLE TABLET, EXTENDED RELEASE**
- **QUILLICHEW ER 40 MG CHEWABLE, EXTENDED RELEASE TABLET**
- **QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND RELEASE 24HR**
- **RELEXXII 45 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 63 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 72 MG TABLET,EXTENDED RELEASE**
- **RITALIN 10 MG TABLET**
- **RITALIN 20 MG TABLET**
- **RITALIN 5 MG TABLET**
- **RITALIN LA 10 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 20 MG**

CAPSULE,EXTENDED RELEASE

- **RITALIN LA 30 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 40 MG CAPSULE,EXTENDED RELEASE**
- **STRATTERA 10 MG CAPSULE**
- **STRATTERA 100 MG CAPSULE**
- **STRATTERA 18 MG CAPSULE**
- **STRATTERA 25 MG CAPSULE**
- **STRATTERA 40 MG CAPSULE**
- **STRATTERA 60 MG CAPSULE**
- **STRATTERA 80 MG CAPSULE**
- **VYVANSE 10 MG CAPSULE**
- **VYVANSE 10 MG CHEWABLE TABLET**
- **VYVANSE 20 MG CAPSULE**
- **VYVANSE 20 MG CHEWABLE TABLET**
- **VYVANSE 30 MG CAPSULE**
- **VYVANSE 30 MG CHEWABLE TABLET**
- **VYVANSE 40 MG CAPSULE**
- **VYVANSE 40 MG CHEWABLE TABLET**
- **VYVANSE 50 MG CAPSULE**
- **VYVANSE 50 MG CHEWABLE TABLET**
- **VYVANSE 60 MG CAPSULE**
- **VYVANSE 60 MG CHEWABLE TABLET**
- **VYVANSE 70 MG CAPSULE**
- **XELSTRYM 13.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 18 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 4.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 9 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH**

Details

Criteria	Require a 1 month trial of 2 of the following generic ADHD medications (Step 1 drug) when being utilized for the same medically accepted indication: methylphenidate, atomoxetine, dextroamphetamine/amphetamine or dexmethylphenidate in the last 180 days

Brand Albuterol

Products Affected

- *albuterol sulfate hfa 90 mcg/actuation aerosol inhaler (nda020983)*
- **PROAIR RESPICLICK 90 MCG/ACTUATION BREATH ACTIVATED**
- **PROVENTIL HFA 90 MCG/ACTUATION AEROSOL INHALER**

Details

Criteria	Require a 1 month trial of albuterol (generic Proair HFA) in the last 90 days

Brand Epinephrine

Products Affected

- **AUVI-Q 0.1 MG/0.1 ML INJECTION,AUTO-INJECTOR**
- **AUVI-Q 0.15 MG/0.15 ML AUTO-INJECTOR (FOR 33 LB TO 66 LB PATIENTS)**
- **AUVI-Q 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR**

Details

Criteria	Require a trial of 2 of the following (Step 1 drug): generic epinephrine injection, Epipen or Symjepi in the last 180 days

Brand Glaucoma

Products Affected

- **IYUZEH 0.005 % EYE DROPS IN A DROPPERETTE**
- **RHOPRESSA 0.02 % EYE DROPS**
- **ROCKLATAN 0.02 %-0.005 % EYE DROPS**
- **VYZULTA 0.024 % EYE DROPS**

Details

Criteria	Require a 1 month trial of generic latanoprost (Step 1 drug) plus one other preferred generic formulary glaucoma drug (Step 1 drug) in the last 180 days

Brand Levalbuterol

Products Affected

- **XOPENEX HFA 45 MCG/ACTUATION AEROSOL INHALER**

Details

Criteria	Require a 1 month trial of albuterol (generic Proair HFA) and generic levalbuterol in the last 180 days

Breo Ellipta AG

Products Affected

- *fluticasone furoate 100 mcg-vilanterol 25 mcg/dose inhalation powder*
- *fluticasone furoate 200 mcg-vilanterol 25 mcg/dose inhalation powder*

Details

Criteria	Require a 1 month trial of Breo Ellipta (Step 1 drug) in the last 90 days

Celecoxib

Products Affected

- **CELEBREX 100 MG CAPSULE**
- **CELEBREX 200 MG CAPSULE**
- **CELEBREX 400 MG CAPSULE**
- **CELEBREX 50 MG CAPSULE**
- *celecoxib 100 mg capsule*
- *celecoxib 200 mg capsule*
- *celecoxib 400 mg capsule*
- *celecoxib 50 mg capsule*

Details

Criteria	Require a 1 month trial of 2 formulary generic NSAIDs (Step 1 drug) in the last 180 days

Conjupri

Products Affected

- **CONJUPRI 2.5 MG TABLET**
- **CONJUPRI 5 MG TABLET**
- *levamlodipine 2.5 mg tablet*
- *levamlodipine 5 mg tablet*

Details

Criteria	Require a trial of 2 of the following generic medications (Step 1 drug): amlodipine tablet, felodipine extended-release tablet, or nifedipine 24hr extended-release tablet in the last 180 days

DPP4-SGLT2 Combo

Products Affected

- **STEGLUJAN 15 MG-100 MG TABLET**
- **STEGLUJAN 5 MG-100 MG TABLET**

Details

Criteria	Require a 1 month trial of 2 of the following (Step 1 drug): Glyxambi, Trijardy or Qtern in the last 180 days

Dry Eye

Products Affected

- **CEQUA 0.09 % EYE DROPS IN A DROPPERETTE**
- **MIEBO 100 % EYE DROPS**
- **TYRVAYA 0.03 MG/SPRAY NASAL SPRAY**

Details

Criteria	Require a 1 month trial of Xiidra and one of the following: Restasis or cyclosporine eye drop (i.e. generic Restasis), in the last 180 days

Dymista

Products Affected

- **DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY**
- **RYALTRIS 665 MCG-25 MCG/SPRAY NASAL SPRAY**

Details

Criteria	Require a 1 month trial of generic azelastine/fluticasone spray in the last 90 days

Flovent HFA AG

Products Affected

- *fluticasone propionate 110 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 220 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 44 mcg/actuation hfa aerosol inhaler*

Details

Criteria	Require a 1 month trial of Flovent HFA (Step 1 drug) in the last 90 days

Fortamet

Products Affected

- *metformin er 1,000 mg tablet,extended release 24hr*
- *metformin er 500 mg tablet,extended release 24hr*

Details

Criteria	Require a 1 month trial of generic metformin IR tablets and generic metformin ER (i.e. generic Glucophage XR) tablets in the last 180 days

Glumetza

Products Affected

- **GLUMETZA 1,000 MG TABLET,EXTENDED RELEASE**
- **GLUMETZA 500 MG TABLET,EXTENDED RELEASE**
- *metformin er 1,000 mg 24 hr tablet,extended release*
- *metformin er 500 mg 24 hr tablet,extended release*

Details

Criteria	Require a 1 month trial of generic metformin IR tablets and generic metformin ER (i.e. generic Glucophage XR) tablets in the last 180 days

GnRH Agonists

Products Affected

- *leuprolide 22.5 mg (3 month) intramuscular suspension*
- **LUPRON DEPOT 11.25 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 3.75 MG INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 45 MG (6 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT**
- **TRELSTAR 11.25 MG IM SUSPENSION**
- **TRELSTAR 22.5 MG IM SUSPENSION**
- **TRELSTAR 3.75 MG IM SUSPENSION**

Details

Criteria	Require a trial of Eligard (Step 1 drug) in the last 180 days when being utilized for the same medically accepted indication

Herpetic Keratitis

Products Affected

- **ZIRGAN 0.15 % EYE GEL**

Details

Criteria	Require a 1 month trial of generic trifluridine eye drops (Step 1 drug) in the last 90 days

Lactulose

Products Affected

- **KRISTALOSE 10 GRAM ORAL PACKET**
- **KRISTALOSE 20 GRAM ORAL PACKET**
- *lactulose 10 gram oral packet*

Details

Criteria	Require a 1 month trial of lactulose solution (Step 1 drug) in the last 90 days

Mupirocin

Products Affected

- *mupirocin calcium 2 % topical cream*

Details

Criteria	Require a 1 month trial of generic mupirocin ointment (Step 1 drug) in the last 90 days

Riomet

Products Affected

- *metformin 500 mg/5 ml oral solution*

Details

Criteria	Require a 1 month trial of generic metformin IR tablets in the last 90 days -OR- documentation supporting the inability to swallow or difficulty swallowing tablets containing metformin

Rytary

Products Affected

- **DHIVY 25 MG-100 MG TABLET**
- **RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE**

Details

Criteria	Require a trial of generic carbidopa/levodopa product (Step 1 drug) in the last 90 days

Sleeper Meds

Products Affected

- **BELSOMRA 10 MG TABLET**
- **BELSOMRA 15 MG TABLET**
- **BELSOMRA 20 MG TABLET**
- **BELSOMRA 5 MG TABLET**
- **DAYVIGO 10 MG TABLET**
- **DAYVIGO 5 MG TABLET**
- **QUVIVIQ 25 MG TABLET**
- **QUVIVIQ 50 MG TABLET**

Details

Criteria	Require a trial of 2 of the following (Step 1 drug): generic zolpidem tablet/zolpidem ER tablet, zaleplon or eszopiclone in the last 180 days

Soaanz

Products Affected

- **SOAANZ 20 MG TABLET**
- **SOAANZ 40 MG TABLET**
- **SOAANZ 60 MG TABLET**

Details

Criteria	Require a 1 month trial of generic furosemide tablets and generic torsemide tablets in the last 180 days

Suboxone

Products Affected

- **SUBOXONE 12 MG-3 MG SUBLINGUAL FILM**
- **SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM**
- **SUBOXONE 4 MG-1 MG SUBLINGUAL FILM**
- **SUBOXONE 8 MG-2 MG SUBLINGUAL FILM**

Details

Criteria	Require a 1 month trial of Zubsolv (Step 1 drug) in the last 90 days

Topical Antifungals

Products Affected

- **ERTACZO 2 % TOPICAL CREAM**
- **EXELDERM 1 % TOPICAL CREAM**
- **EXELDERM 1 % TOPICAL SOLUTION**
- **KETODAN 2 % TOPICAL FOAM**
- *naftifine 1 % topical cream*
- *naftifine 2 % topical cream*
- *naftifine 2 % topical gel*
- **NAFTIN 1 % TOPICAL GEL**
- **NAFTIN 2 % TOPICAL GEL**
- *oxiconazole 1 % topical cream*
- **OXISTAT 1 % LOTION**
- **OXISTAT 1 % TOPICAL CREAM**

Details

Criteria	Require a 1 month trial of generic econazole cream and one of the following: generic ketoconazole cream or ketoconazole shampoo (Step 1 drugs),when being utilized for the same medically accepted indication, in the last 180 days

Topical Psoriasis

Products Affected

- *calcipotriene 0.005 % topical foam*
- *calcipotriene-betamethasone 0.005 %-0.064 % topical ointment*
- *calcipotriene-betamethasone 0.005 %-0.064 % topical suspension*
- *calcitriol 3 mcg/gram topical ointment*
- **ENSTILAR 0.005 %-0.064 % TOPICAL FOAM**
- **SORILUX 0.005 % TOPICAL FOAM**
- **TACLONEX 0.005 %-0.064 % TOPICAL OINTMENT**
- **TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION**
- **VECTICAL 3 MCG/GRAM TOPICAL OINTMENT**

Details

Criteria	Require a 1 month trial of generic calcipotriene cream, ointment or solution (Step 1 drug) in the last 90 days

Ursodiol

Products Affected

- **RELTONE 200 MG CAPSULE**
- **RELTONE 400 MG CAPSULE**
- **URSO 250 250 MG TABLET**
- **URSO FORTE 500 MG TABLET**
- *ursodiol 200 mg capsule*
- *ursodiol 400 mg capsule*

Details

Criteria	Require a 1 month trial of generic ursodiol 250mg tablet, 300mg capsule or 500mg tablet (step 1 drug) in the last 90 days

Index of Drugs

ADDERALL 20 MG TABLET 2
ADDERALL 5 MG TABLET 2
ADDERALL 7.5 MG TABLET 2
ADDERALL XR 10 MG CAPSULE,EXTENDED RELEASE 2
ADDERALL XR 15 MG CAPSULE,EXTENDED RELEASE 2
ADDERALL XR 20 MG CAPSULE,EXTENDED RELEASE 2
ADDERALL XR 25 MG CAPSULE,EXTENDED RELEASE 2
ADDERALL XR 30 MG CAPSULE,EXTENDED RELEASE 2
ADDERALL XR 5 MG CAPSULE,EXTENDED RELEASE 2
ADZENYS XR-ODT 12.5 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
ADZENYS XR-ODT 15.7 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
ADZENYS XR-ODT 18.8 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
ADZENYS XR-ODT 3.1 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
ADZENYS XR-ODT 6.3 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
ADZENYS XR-ODT 9.4 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
albuterol sulfate hfa 90 mcg/actuation aerosol inhaler (nda020983) 5
APTENSIO XR 10 MG CAPSULE,EXTENDED RELEASE SPRINKLE 2
APTENSIO XR 15 MG CAPSULE,EXTENDED RELEASE SPRINKLE 2
APTENSIO XR 20 MG CAPSULE,EXTENDED RELEASE SPRINKLE 2
APTENSIO XR 30 MG CAPSULE,EXTENDED RELEASE SPRINKLE 2
APTENSIO XR 40 MG CAPSULE,EXTENDED RELEASE SPRINKLE 2
APTENSIO XR 50 MG CAPSULE,EXTENDED RELEASE SPRINKLE 2
APTENSIO XR 60 MG CAPSULE,EXTENDED RELEASE SPRINKLE 2
AUVI-Q 0.1 MG/0.1 ML INJECTION,AUTO-INJECTOR 6
AUVI-Q 0.15 MG/0.15 ML AUTO-INJECTOR (FOR 33 LB TO 66 LB PATIENTS) 6
AUVI-Q 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR 6
AZSTARYS 26.1 MG-5.2 MG CAPSULE 2
AZSTARYS 39.2 MG-7.8 MG CAPSULE 2
AZSTARYS 52.3 MG-10.4 MG CAPSULE 2
BELSOMRA 10 MG TABLET 24
BELSOMRA 15 MG TABLET 24
BELSOMRA 20 MG TABLET 24
BELSOMRA 5 MG TABLET 24
calcipotriene 0.005 % topical foam 28
calcipotriene-betamethasone 0.005 %-0.064 % topical ointment 28
calcipotriene-betamethasone 0.005 %-0.064 % topical suspension 28
calcitriol 3 mcg/gram topical ointment 28
CELEBREX 100 MG CAPSULE 10
CELEBREX 200 MG CAPSULE 10
CELEBREX 400 MG CAPSULE 10
CELEBREX 50 MG CAPSULE 10
celecoxib 100 mg capsule 10
celecoxib 200 mg capsule 10
celecoxib 400 mg capsule 10
celecoxib 50 mg capsule 10
CEQUA 0.09 % EYE DROPS IN A DROPPERETTE 13

CONCERTA 18 MG TABLET,EXTENDED RELEASE 2
CONCERTA 27 MG TABLET,EXTENDED RELEASE 2
CONCERTA 36 MG TABLET,EXTENDED RELEASE 2
CONCERTA 54 MG TABLET,EXTENDED RELEASE 2
CONJUPRI 2.5 MG TABLET 11
CONJUPRI 5 MG TABLET 11
COTEMPLA XR-ODT 17.3 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
COTEMPLA XR-ODT 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET 2
DAYVIGO 10 MG TABLET 24
DAYVIGO 5 MG TABLET 24
DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE 2
DEXEDRINE SPANSULE 15 MG CAPSULE,EXTENDED RELEASE 2
DHIVY 25 MG-100 MG TABLET 23
DYANAVEL XR 10 MG TABLET, EXTENDED RELEASE 2
DYANAVEL XR 15 MG TABLET, EXTENDED RELEASE 2
DYANAVEL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION 2
DYANAVEL XR 20 MG TABLET, EXTENDED RELEASE 2
DYANAVEL XR 5 MG TABLET, EXTENDED RELEASE 2
DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY 14
ENSTILAR 0.005 %-0.064 % TOPICAL FOAM 28
ERTACZO 2 % TOPICAL CREAM 27
EVEKEO ODT 10 MG DISINTEGRATING TABLET 2
EVEKEO ODT 15 MG DISINTEGRATING TABLET 2
EVEKEO ODT 20 MG DISINTEGRATING TABLET 2
EVEKEO ODT 5 MG DISINTEGRATING TABLET 2
EXELDERM 1 % TOPICAL CREAM 27
EXELDERM 1 % TOPICAL SOLUTION 27
fluticasone furoate 100 mcg-vilanterol 25 mcg/dose inhalation powder 9
fluticasone furoate 200 mcg-vilanterol 25 mcg/dose inhalation powder 9
fluticasone propionate 110 mcg/actuation hfa aerosol inhaler 15
fluticasone propionate 115 mcg-salmeterol 21 mcg/actuation hfa inhaler 1
fluticasone propionate 220 mcg/actuation hfa aerosol inhaler 15
fluticasone propionate 230 mcg-salmeterol 21 mcg/actuation hfa inhaler 1
fluticasone propionate 44 mcg/actuation hfa aerosol inhaler 15
fluticasone propionate 45 mcg-salmeterol 21 mcg/actuation hfa inhaler 1
FOCALIN 10 MG TABLET 2
FOCALIN 2.5 MG TABLET 2
FOCALIN 5 MG TABLET 2
FOCALIN XR 10 MG CAPSULE,EXTENDED RELEASE 2
FOCALIN XR 15 MG CAPSULE,EXTENDED RELEASE 2
FOCALIN XR 20 MG CAPSULE,EXTENDED RELEASE 2
FOCALIN XR 25 MG CAPSULE,EXTENDED RELEASE 2
FOCALIN XR 30 MG CAPSULE,EXTENDED RELEASE 2
FOCALIN XR 35 MG CAPSULE,EXTENDED RELEASE 2
FOCALIN XR 40 MG CAPSULE,EXTENDED RELEASE 2
FOCALIN XR 5 MG CAPSULE,EXTENDED RELEASE 2
GLUMETZA 1,000 MG TABLET,EXTENDED RELEASE 17
GLUMETZA 500 MG TABLET,EXTENDED RELEASE 17

IYUZEH 0.005 % EYE DROPS IN A DROPPERETTE 7
JORNAY PM 100 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 2
JORNAY PM 20 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 2
JORNAY PM 40 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 2
JORNAY PM 60 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 2
JORNAY PM 80 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 2
KETODAN 2 % TOPICAL FOAM 27
KRISTALOSE 10 GRAM ORAL PACKET 20
KRISTALOSE 20 GRAM ORAL PACKET 20
lactulose 10 gram oral packet 20
leuprolide 22.5 mg (3 month) intramuscular suspension 18
levamlodipine 2.5 mg tablet 11
levamlodipine 5 mg tablet 11
lisdexamfetamine 10 mg capsule 2
lisdexamfetamine 20 mg capsule 2
lisdexamfetamine 30 mg capsule 2
lisdexamfetamine 40 mg capsule 2
lisdexamfetamine 50 mg capsule 2
lisdexamfetamine 60 mg capsule 2
lisdexamfetamine 70 mg capsule 2
LUPRON DEPOT 11.25 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT 18
LUPRON DEPOT 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT 18
LUPRON DEPOT 3.75 MG INTRAMUSCULAR SYRINGE KIT 18
LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT 18
LUPRON DEPOT 45 MG (6 MONTH) INTRAMUSCULAR SYRINGE KIT 18
LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT 18
metformin 500 mg/5 ml oral solution 22
metformin er 1,000 mg 24 hr tablet,extended release 17
metformin er 1,000 mg tablet,extended release 24hr 16
metformin er 500 mg 24 hr tablet,extended release 17
metformin er 500 mg tablet,extended release 24hr 16
METHYLIN 10 MG/5 ML ORAL SOLUTION 2
METHYLIN 5 MG/5 ML ORAL SOLUTION 2
methylphenidate er 45 mg tablet,extended release 24 hr 2
methylphenidate er 63 mg tablet,extended release 24 hr 2
methylphenidate er 72 mg tablet,extended release 24 hr 2
MIEBO 100 % EYE DROPS 13
mupirocin calcium 2 % topical cream 21
MYDAYIS 12.5 MG CAPSULE EXTENDED RELEASE 24 HR 2
MYDAYIS 25 MG CAPSULE EXTENDED RELEASE 24 HR 2
MYDAYIS 37.5 MG CAPSULE EXTENDED RELEASE 24 HR 2
MYDAYIS 50 MG CAPSULE EXTENDED RELEASE 24 HR 2
naftifine 1 % topical cream 27
naftifine 2 % topical cream 27
naftifine 2 % topical gel 27
NAFTIN 1 % TOPICAL GEL 27
NAFTIN 2 % TOPICAL GEL 27
oxiconazole 1 % topical cream 27
OXISTAT 1 % LOTION 27
OXISTAT 1 % TOPICAL CREAM 27
PROAIR RESPICLICK 90 MCG/ACTUATION BREATH ACTIVATED 5

PROVENTIL HFA 90 MCG/ACTUATION AEROSOL INHALER 5
QUILLICHEW ER 20 MG CHEWABLE TABLET, EXTENDED RELEASE 2
QUILLICHEW ER 30 MG CHEWABLE TABLET, EXTENDED RELEASE 2
QUILLICHEW ER 40 MG CHEWABLE, EXTENDED RELEASE TABLET 2
QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND RELEASE 24HR 2
QUVIVIQ 25 MG TABLET 24
QUVIVIQ 50 MG TABLET 24
RELEXXII 45 MG TABLET,EXTENDED RELEASE 2
RELEXXII 63 MG TABLET,EXTENDED RELEASE 2
RELEXXII 72 MG TABLET,EXTENDED RELEASE 2
RELTONE 200 MG CAPSULE 29
RELTONE 400 MG CAPSULE 29
RHOPRESSA 0.02 % EYE DROPS 7
RITALIN 10 MG TABLET 2
RITALIN 20 MG TABLET 2
RITALIN 5 MG TABLET 2
RITALIN LA 10 MG CAPSULE,EXTENDED RELEASE 2
RITALIN LA 20 MG CAPSULE,EXTENDED RELEASE 2
RITALIN LA 30 MG CAPSULE,EXTENDED RELEASE 2
RITALIN LA 40 MG CAPSULE,EXTENDED RELEASE 2
ROCKLATAN 0.02 %-0.005 % EYE DROPS 7
RYALTRIS 665 MCG-25 MCG/SPRAY NASAL SPRAY 14
RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE 23
RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE 23
RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE 23
RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE 23
SOAANZ 20 MG TABLET 25
SOAANZ 40 MG TABLET 25
SOAANZ 60 MG TABLET 25
SORILUX 0.005 % TOPICAL FOAM 28
STEGLUJAN 15 MG-100 MG TABLET 12
STEGLUJAN 5 MG-100 MG TABLET 12
STRATTERA 10 MG CAPSULE 2
STRATTERA 100 MG CAPSULE 2
STRATTERA 18 MG CAPSULE 2
STRATTERA 25 MG CAPSULE 2
STRATTERA 40 MG CAPSULE 2
STRATTERA 60 MG CAPSULE 2
STRATTERA 80 MG CAPSULE 2
SUBOXONE 12 MG-3 MG SUBLINGUAL FILM 26
SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM 26
SUBOXONE 4 MG-1 MG SUBLINGUAL FILM 26
SUBOXONE 8 MG-2 MG SUBLINGUAL FILM 26
TACLONEX 0.005 %-0.064 % TOPICAL OINTMENT 28
TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION 28
TRELSTAR 11.25 MG IM SUSPENSION 18
TRELSTAR 22.5 MG IM SUSPENSION 18
TRELSTAR 3.75 MG IM SUSPENSION 18
TYRVAYA 0.03 MG/SPRAY NASAL SPRAY 13
URSO 250 250 MG TABLET 29
URSO FORTE 500 MG TABLET 29
ursodiol 200 mg capsule 29
ursodiol 400 mg capsule 29
VECTICAL 3 MCG/GRAM TOPICAL OINTMENT 28
VYVANSE 10 MG CAPSULE 2
VYVANSE 10 MG CHEWABLE TABLET 2
VYVANSE 20 MG CAPSULE 2

VYVANSE 20 MG CHEWABLE TABLET.....2
VYVANSE 30 MG CAPSULE..... 2
VYVANSE 30 MG CHEWABLE TABLET.....2
VYVANSE 40 MG CAPSULE..... 2
VYVANSE 40 MG CHEWABLE TABLET.....2
VYVANSE 50 MG CAPSULE..... 2
VYVANSE 50 MG CHEWABLE TABLET.....2
VYVANSE 60 MG CAPSULE..... 2
VYVANSE 60 MG CHEWABLE TABLET.....2
VYVANSE 70 MG CAPSULE..... 2
VYZULTA 0.024 % EYE DROPS.....7
XELSTRYM 13.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH.....2
XELSTRYM 18 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH.....2
XELSTRYM 4.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH.....2
XELSTRYM 9 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH.....2
XOPENEX HFA 45 MCG/ACTUATION AEROSOL INHALER..... 8
ZIRGAN 0.15 % EYE GEL..... 19